"date","Open","High","Low","Close","AdjClose","Volume","Positive","Negative","Polarity","Subjectivity","news_tag","news_title","news_link","trends","year","month","vol","vary","jump","win","return","release","positive","negative","tag","half","tag_n"
2018-01-02,34.5161285400391,34.6489562988281,34.38330078125,34.573055267334,28.8219718933105,17059833,NA,NA,NA,NA,NA,NA,NA,1.41,2018,1,16.652237369617,0.265655517578125,0.0569267272949219,1,NA,0,NA,NA,NA,0,NA
2018-01-03,34.5825424194336,34.8861465454102,34.3738136291504,34.8292236328125,29.0355224609375,14183151,199,51,0.591999997632,0.266808964496469,"Partnerships","Sangamo and Pfizer announce collaboration for development of zinc finger protein gene therapy for ALS","https://www.pfizer.com//news/press-release/press-release-detail/sangamo_and_pfizer_announce_collaboration_for_development_of_zinc_finger_protein_gene_therapy_for_als",1.47,2018,1,16.4675653392749,0.512332916259766,0.246681213378906,1,0.213550567626953,1,1.99,0.51,"Management",0,1
2018-01-04,34.8292236328125,35.0284614562988,34.7248573303223,34.9051246643066,29.0988063812256,13046517,61,3,0.906249985839844,0.2176870740895,"Partnerships","Berkeley Lights Announces Research Collaboration and License Agreement with Pfizer","https://www.pfizer.com//news/press-release/press-release-detail/berkeley-lights-announces-research-collaboration-and",1.86,2018,1,16.3840318362068,0.303604125976562,0.0759010314941406,1,0.0632839202880824,1,0.61,0.03,"Management",0,1
2018-01-05,34.9335861206055,34.9905128479004,34.7343444824219,34.9715385437012,29.1541690826416,13167517,57,12,0.652173903591683,0.246428570548469,"Partnerships","Distributed Bio Announces SuperHuman  Platform License Agreement with Pfizer Inc.","https://www.pfizer.com//news/press-release/press-release-detail/distributed-bio-announces-superhuman-platform-license-0",1.41,2018,1,16.3932635973408,0.256168365478516,0.0379524230957031,1,0.0553627014160192,1,0.57,0.12,"Management",0,1
2018-01-08,34.8387107849121,34.9146118164062,34.468692779541,34.5825424194336,28.8298759460449,19964341,328,47,0.749333331335111,0.288906009022414,"Partnerships","Regeneron Forms Consortium of Leading Life Sciences Companies to  Accelerate Largest Widely-Available ‘Big Data’ Human Sequencing Resource with UK Biobank","https://www.pfizer.com//news/press-release/press-release-detail/regeneron-forms-consortium-leading-life-sciences-companies",2.13,2018,1,16.8094583402604,0.445919036865234,-0.256168365478516,0,-0.324293136596683,1,3.28,0.47,"Management",0,1
2018-01-09,34.573055267334,34.762809753418,34.4971542358398,34.5445938110352,28.7982425689697,16876226,79,6,0.858823519307959,0.251479289196807,"Partnerships","Adapsyn Bioscience Completes Financing to Advance its Small Molecule Natural Products  Platform and Pipeline; Announces Research Collaboration with Pfizer Inc.","https://www.pfizer.com//news/press-release/press-release-detail/adapsyn-bioscience-completes-financing-advance-its-small",2.34,2018,1,16.6414165031907,0.265655517578125,-0.0284614562988281,0,-0.0316333770751918,1,0.79,0.06,"Management",0,1
2018-01-10,34.4781761169434,34.7343444824219,34.4497146606445,34.6015167236328,28.8456954956055,18755825,NA,NA,NA,NA,NA,NA,NA,2.31,2018,1,16.7470149821172,0.284629821777344,0.123340606689453,1,0.0474529266357422,0,NA,NA,NA,0,NA
2018-01-11,34.762809753418,34.8197326660156,34.5540809631348,34.6869087219238,28.9168834686279,15102555,NA,NA,NA,NA,NA,NA,NA,2.34,2018,1,16.5303745589835,0.265651702880859,-0.0759010314941406,0,0.0711879730224609,0,NA,NA,NA,0,NA
2018-01-12,34.7533226013184,34.9146118164062,34.5920295715332,34.6679306030273,28.9010639190674,20240700,NA,NA,NA,NA,NA,NA,NA,1.47,2018,1,16.8232060361711,0.322582244873047,-0.0853919982910156,0,-0.0158195495605469,0,NA,NA,NA,0,NA
2018-01-16,34.6963958740234,35.0853881835938,34.6015167236328,34.7248573303223,28.9485244750977,30536699,NA,NA,NA,NA,NA,NA,NA,1.68,2018,1,17.2344397969066,0.483871459960938,0.0284614562988281,1,0.0474605560302734,0,NA,NA,NA,0,NA
2018-01-17,34.9335861206055,35.4554061889648,34.8861465454102,35.2751426696777,29.4072704315186,25332363,64,26,0.422222217530864,0.243243242585829,"Partnerships","Circle Pharma announces publication in Journal of Medicinal Chemistry of results from  collaboration with Pfizer Inc.","https://www.pfizer.com//news/press-release/press-release-detail/circle-pharma-announces-publication-journal-medicinal",1.71,2018,1,17.0475933456925,0.569259643554688,0.341556549072266,1,0.458745956420898,1,0.64,0.26,"Management",0,1
2018-01-18,35.2656555175781,35.2656555175781,34.8197326660156,35.0948753356934,29.2569885253906,19946528,NA,NA,NA,NA,NA,NA,NA,1.5,2018,1,16.8085657012006,0.4459228515625,-0.170780181884766,0,-0.15028190612793,0,NA,NA,NA,0,NA
2018-01-19,35.2846298217773,35.3700180053711,34.6299819946289,35.0474395751953,29.2174472808838,31133684,238,64,0.57615893848954,0.268206038838183,"Research","Survey of Ulcerative Colitis Patients and Gastroenterologists Indicates that Symptoms May Create a New Reality for Patients","https://www.pfizer.com//news/press-release/press-release-detail/survey_of_ulcerative_colitis_patients_and_gastroenterologists_indicates_that_symptoms_may_create_a_new_reality_for_patients",1.5,2018,1,17.2538009099704,0.740036010742188,-0.237190246582031,0,-0.0395412445068359,1,2.38,0.64,"Research",0,2
2018-01-22,35,35.1707763671875,34.8481979370117,35.0379524230957,29.2095317840576,21380495,27,15,0.285714278911565,0.217616579183334,"Partnerships","MINDIMMUNE THERAPEUTICS TO CONDUCT RESEARCH ON SPECIALIZED IMMUNE CELLS WITH PFIZER INC.","https://www.pfizer.com//news/press-release/press-release-detail/mindimmune-therapeutics-conduct-research-specialized-immune",1.71,2018,1,16.8779896625437,0.322578430175781,0.0379524230957031,1,-0.00791549682617188,1,0.27,0.15,"Management",0,1
2018-01-23,34.9335861206055,35.1802673339844,34.6679306030273,34.9335861206055,29.1225299835205,18527212,NA,NA,NA,NA,NA,NA,NA,1.68,2018,1,16.7347511822006,0.512336730957031,0,0,-0.0870018005371094,0,NA,NA,NA,0,NA
2018-01-24,35.0948753356934,35.1707763671875,34.8481979370117,35.0379524230957,29.2095317840576,18673191,126,23,0.691275163145804,0.271402549596717,"Medicines","Pfizer Announces Positive Top-Line Results For Potential Biosimilar To Rituxan®/MabThera®","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_positive_top_line_results_for_potential_biosimilar_to_rituxan_mabthera",1.89,2018,1,16.742599470374,0.322578430175781,-0.0569229125976562,0,0.0870018005371094,1,1.26,0.23,"Research",0,2
2018-01-25,35.0759010314941,35.426944732666,35.0094871520996,35.322582244873,29.4468173980713,18988232,NA,NA,NA,NA,NA,NA,NA,1.5,2018,1,16.759330029486,0.417457580566406,0.246681213378906,1,0.237285614013672,0,NA,NA,NA,0,NA
2018-01-26,35.3889923095703,37.087287902832,35.3889923095703,37.0113868713379,30.8546886444092,51441419,NA,NA,NA,NA,NA,NA,NA,1.92,2018,1,17.7559542424893,1.69829559326172,1.62239456176758,1,1.40787124633789,0,NA,NA,NA,0,NA
2018-01-29,37.0018997192383,37.4098663330078,36.7836799621582,37.0208740234375,30.862606048584,36779014,NA,NA,NA,NA,NA,NA,NA,1.77,2018,1,17.4204379959227,0.626186370849609,0.0189743041992188,1,0.00791740417480469,0,NA,NA,NA,0,NA
2018-01-30,36.2523727416992,36.764705657959,35.4364318847656,35.8633766174316,29.8976459503174,48483684,9,1,0.799999920000008,0.24999999375,"Finance","Pfizer Reports Fourth-Quarter and Full-Year 2017 Results","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_reports_fourth_quarter_and_full_year_2017_results",2.46,2018,1,17.6967379075627,1.32827377319336,-0.388996124267578,0,-0.964960098266602,1,0.09,0.01,"Finance",0,3
2018-01-31,35.9772300720215,36.043643951416,34.9430732727051,35.1423149108887,29.2965354919434,35859926,NA,NA,NA,NA,NA,NA,NA,2.25,2018,1,17.3951309904448,1.10057067871094,-0.834915161132812,0,-0.601110458374023,0,NA,NA,NA,0,NA
2018-02-01,34.7343444824219,35.4838714599609,34.7343444824219,34.9430732727051,29.4003143310547,29697926,NA,NA,NA,NA,NA,NA,NA,2.04,2018,2,17.2065878033571,0.749526977539062,0.208728790283203,1,0.103778839111328,0,NA,NA,NA,0,NA
2018-02-02,34.7248573303223,35.3415565490723,34.6394691467285,34.7343444824219,29.2246952056885,25588907,NA,NA,NA,NA,NA,NA,NA,1.71,2018,2,17.0576695343063,0.70208740234375,0.00948715209960938,1,-0.175619125366211,0,NA,NA,NA,0,NA
2018-02-05,34.6110076904297,34.8197326660156,32.2580642700195,32.8937377929688,27.6760501861572,42463657,291,149,0.322727271993802,0.271940667322657,"Research","Phase 3 PROSPER Trial Shows XTANDI® (enzalutamide) Significantly Reduced the Risk of Metastasis or Death by 71 Percent in Men with Non-Metastatic Castration-Resistant Prostate Cancer","https://www.pfizer.com//news/press-release/press-release-detail/phase_3_prosper_trial_shows_xtandi_enzalutamide_significantly_reduced_the_risk_of_metastasis_or_death_by_71_percent_in_men_with_non_metastatic_castration_resistant_prostate_cancer",1.86,2018,2,17.5641591622007,2.56166839599609,-1.71726989746094,0,-1.54864501953125,1,2.91,1.49,"Research",0,2
2018-02-06,32.4098663330078,33.662239074707,32.2580642700195,33.472484588623,28.1629943847656,56035067,NA,NA,NA,NA,NA,NA,NA,2.16,2018,2,17.8414882669948,1.4041748046875,1.06261825561523,1,0.486944198608398,0,NA,NA,NA,0,NA
2018-02-07,33.3301696777344,33.8235282897949,33.1783676147461,33.1878547668457,27.9235134124756,30955980,NA,NA,NA,NA,NA,NA,NA,1.77,2018,2,17.2480767855979,0.645160675048828,-0.142314910888672,0,-0.239480972290043,0,NA,NA,NA,0,NA
2018-02-08,33.2068328857422,33.3681221008301,31.8785572052002,31.9070205688477,26.8458461761475,45850792,NA,NA,NA,NA,NA,NA,NA,1.92,2018,2,17.6409030520461,1.48956489562988,-1.29981231689453,0,-1.07766723632812,0,NA,NA,NA,0,NA
2018-02-09,32.4383316040039,32.6660346984863,31.4990501403809,32.4098663330078,27.2689304351807,49851776,NA,NA,NA,NA,NA,NA,NA,1.74,2018,2,17.7245647006776,1.16698455810547,-0.0284652709960938,0,0.423084259033203,0,NA,NA,NA,0,NA
2018-02-12,32.6850090026855,33.0834922790527,32.2865295410156,32.8842506408691,27.668062210083,38743670,208,70,0.49640287591222,0.298924730861371,"Research","U.S., EU and Japan Health Authorities Accept Regulatory Submissions for Review of Pfizer’s Third-Generation ALK Inhibitor Lorlatinib","https://www.pfizer.com//news/press-release/press-release-detail/u_s_eu_and_japan_health_authorities_accept_regulatory_submissions_for_review_of_pfizer_s_third_generation_alk_inhibitor_lorlatinib",1.56,2018,2,17.4724779713917,0.796962738037109,0.199241638183594,1,0.399131774902344,1,2.08,0.7,"Research",0,2
2018-02-13,32.7988624572754,33.235294342041,32.6470603942871,33.1499061584473,27.8915824890137,21559570,NA,NA,NA,NA,NA,NA,NA,1.95,2018,2,16.8863304058479,0.588233947753906,0.351043701171875,1,0.223520278930664,0,NA,NA,NA,0,NA
2018-02-14,32.9221992492676,33.529411315918,32.7893753051758,33.3870964050293,28.0911483764648,24494749,132,19,0.748344365905004,0.252086810931408,"Medicines","Pfizer Receives Breakthrough Therapy Designation from FDA for PF-04965842, an oral JAK1 Inhibitor, for the Treatment of Patients with Moderate-to-Severe Atopic Dermatitis","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_receives_breakthrough_therapy_designation_from_fda_for_pf_04965842_an_oral_jak1_inhibitor_for_the_treatment_of_patients_with_moderate_to_severe_atopic_dermatitis",1.53,2018,2,17.0139693668382,0.740036010742188,0.464897155761719,1,0.199565887451172,1,1.32,0.19,"Research",0,2
2018-02-15,33.5578765869141,33.8994293212891,33.2827301025391,33.8804550170898,28.5062427520752,22588379,NA,NA,NA,NA,NA,NA,NA,1.71,2018,2,16.9329461727253,0.61669921875,0.322578430175781,1,0.415094375610352,0,NA,NA,NA,0,NA
2018-02-16,33.9278945922852,34.7817840576172,33.851993560791,34.4022789001465,28.9453010559082,27659595,NA,NA,NA,NA,NA,NA,NA,1.68,2018,2,17.1354832781651,0.929790496826172,0.474384307861328,1,0.439058303833008,0,NA,NA,NA,0,NA
2018-02-20,34.1745719909668,34.6204948425293,34.0417442321777,34.1650848388672,28.7457332611084,27202370,NA,NA,NA,NA,NA,NA,NA,1.83,2018,2,17.1188146965849,0.578750610351562,-0.00948715209960938,0,-0.199567794799805,0,NA,NA,NA,0,NA
2018-02-21,34.1271362304688,34.7153701782227,33.8994293212891,33.9278945922852,28.5461654663086,25872327,NA,NA,NA,NA,NA,NA,NA,1.62,2018,2,17.0686845385171,0.815940856933594,-0.199241638183594,0,-0.199567794799805,0,NA,NA,NA,0,NA
2018-02-22,34.0322570800781,34.2979125976562,33.7855796813965,33.9089164733887,28.5301971435547,23983454,NA,NA,NA,NA,NA,NA,NA,1.77,2018,2,16.992874775584,0.512332916259766,-0.123340606689453,0,-0.0159683227539062,0,NA,NA,NA,0,NA
2018-02-23,34.089183807373,34.4402275085449,33.9943084716797,34.4022789001465,28.9453010559082,17940029,353,137,0.440816325630987,0.256813417056177,"Medicines","Pfizer Receives Positive CHMP Opinion for Two Hematology Medicines, MYLOTARG™ and BOSULIF®","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_receives_positive_chmp_opinion_for_two_hematology_medicines_mylotarg_and_bosulif",1.5,2018,2,16.7025450868343,0.445919036865234,0.313095092773438,1,0.415103912353516,1,3.53,1.37,"Research",0,2
2018-02-26,34.4307403564453,35.3036041259766,34.3548393249512,35.189754486084,29.6078605651855,25407302,NA,NA,NA,NA,NA,NA,NA,1.12,2018,2,17.0505472103479,0.948764801025391,0.759014129638672,1,0.662559509277344,0,NA,NA,NA,0,NA
2018-02-27,35.1707763671875,35.3320693969727,34.8576850891113,34.9146118164062,29.3763694763184,23543093,NA,NA,NA,NA,NA,NA,NA,1.14,2018,2,16.9743430870133,0.474384307861328,-0.25616455078125,0,-0.231491088867188,0,NA,NA,NA,0,NA
2018-02-28,35.1328277587891,35.3700180053711,34.4497146606445,34.4497146606445,28.9852123260498,28360927,65,21,0.511627901027583,0.233695651538871,"Partnerships","Inserm announces research agreement with Pfizer Inc. to study rare neuromuscular  disease","https://www.pfizer.com//news/press-release/press-release-detail/inserm-announces-research-agreement-pfizer-inc-study-rare",1.18,2018,2,17.1605229812367,0.920303344726562,-0.683113098144531,0,-0.391157150268555,1,0.65,0.21,"Management",0,1
2018-03-01,34.2694511413574,34.4117660522461,33.3965835571289,33.8045539855957,28.4423923492432,30282896,NA,NA,NA,NA,NA,NA,NA,1.04,2018,3,17.2260936556691,1.01518249511719,-0.464897155761719,0,-0.542819976806641,0,NA,NA,NA,0,NA
2018-03-02,33.7286529541016,34.2220115661621,33.5863380432129,34.1081581115723,28.6978340148926,22271336,43,11,0.592592581618656,0.305084744039069,"Partnerships","Neofluidics Announces Collaboration with Pfizer Inc.","https://www.pfizer.com//news/press-release/press-release-detail/neofluidics-announces-collaboration-pfizer-inc",1.04,2018,3,16.9188110733542,0.635673522949219,0.379505157470703,1,0.255441665649411,1,0.43,0.11,"Management",0,1
2018-03-05,33.9848213195801,34.4212532043457,33.9373817443848,34.2694511413574,28.8335399627686,22319609,74,18,0.608695645557656,0.194503170836146,"Medicines","Hospira Issues A Voluntary Nationwide Recall For Hydromorphone  HCL Injection, USP CII Due To The Potential For Empty Or Cracked  Glass Vials","https://www.pfizer.com//news/announcements/hospira-issues-voluntary-nationwide-recall-hydromorphone-hcl-injection-usp-cii",1.44,2018,3,16.9209762222064,0.483871459960938,0.284629821777344,1,0.13570594787598,1,0.74,0.18,"Research",0,2
2018-03-06,34.38330078125,34.38330078125,33.9184074401855,34.0417442321777,28.6419563293457,18003479,NA,NA,NA,NA,NA,NA,NA,1.71,2018,3,16.7060756305073,0.464893341064453,-0.341556549072266,0,-0.191583633422852,0,NA,NA,NA,0,NA
2018-03-07,33.7760925292969,34.2314987182617,33.7286529541016,34.089183807373,28.6818714141846,23440328,30,2,0.874999972656251,0.165803107949207,"Finance","Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_invites_public_to_view_and_listen_to_webcast_of_pfizer_presentation_at_healthcare_conference-22",1.41,2018,3,16.9699685584108,0.502845764160156,0.313091278076172,1,0.0399150848388672,1,0.3,0.02,"Finance",0,3
2018-03-08,34.146110534668,34.6299819946289,34.089183807373,34.6299819946289,29.1368827819824,21646630,313,153,0.343347638748181,0.265981735008001,"Medicines","Pfizer Announces Favorable Outcome of FDA Advisory Committee Meeting on XELJANZ® (tofacitinib) for Moderately to Severely Active Ulcerative Colitis","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_favorable_outcome_of_fda_advisory_committee_meeting_on_xeljanz_tofacitinib_for_moderately_to_severely_active_ulcerative_colitis",1.74,2018,3,16.8903603882947,0.540798187255859,0.483871459960938,1,0.455011367797855,1,3.13,1.53,"Research",0,2
2018-03-09,34.7343444824219,35.0284614562988,34.6584434509277,34.8861465454102,29.3524169921875,19300743,123,47,0.447058820899654,0.303571428029337,"Partnerships","AM‐Pharma announces Phase II study results of recAP in sepsis‐associated Acute  Kidney Injury","https://www.pfizer.com//news/press-release/press-release-detail/am-pharma-announces-phase-ii-study-results-recap-sepsis",1.59,2018,3,16.7756542023549,0.370018005371094,0.151802062988281,1,0.215534210205075,1,1.23,0.47,"Management",0,1
2018-03-12,35.0284614562988,35.104362487793,34.6299819946289,34.7343444824219,29.2246952056885,26571656,91,48,0.309352515760054,0.259813083626518,"Partnerships","BIOGEN TO ACQUIRE FROM PFIZER FIRST-IN-CLASS PHASE 2b READY ASSET  FOR COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA","https://www.pfizer.com//news/press-release/press-release-detail/biogen-acquire-pfizer-first-class-phase-2b-ready-asset",1.53,2018,3,17.0953556793594,0.474380493164062,-0.294116973876953,0,-0.127721786499023,1,0.91,0.48,"Management",0,1
2018-03-13,34.9146118164062,35.0664138793945,34.5635681152344,34.8671722412109,29.3364486694336,29560695,NA,NA,NA,NA,NA,NA,NA,1.68,2018,3,17.2019561990986,0.502845764160156,-0.0474395751953125,0,0.111753463745117,0,NA,NA,NA,0,NA
2018-03-14,34.9525604248047,35.0948753356934,34.3263778686523,34.4876670837402,29.0171432495117,23378458,NA,NA,NA,NA,NA,NA,NA,1.62,2018,3,16.9673256008009,0.768497467041016,-0.464893341064453,0,-0.319305419921875,0,NA,NA,NA,0,NA
2018-03-15,34.4876670837402,34.9240989685059,34.4876670837402,34.705883026123,29.2007446289062,20508310,NA,NA,NA,NA,NA,NA,NA,1.56,2018,3,16.8363407765845,0.436431884765625,0.218215942382812,1,0.183601379394531,0,NA,NA,NA,0,NA
2018-03-16,34.762809753418,35.1423149108887,34.7438316345215,34.895637512207,29.3604030609131,34125253,NA,NA,NA,NA,NA,NA,NA,1.56,2018,3,17.3455482546651,0.398483276367188,0.132827758789062,1,0.159658432006839,0,NA,NA,NA,0,NA
2018-03-19,34.9146118164062,34.9146118164062,34.2314987182617,34.468692779541,29.0011768341064,20003761,271,130,0.351620946754062,0.26626826011536,"Medicines","U.S. FDA Grants Priority Review for a Supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) in Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)","https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_grants_priority_review_for_a_supplemental_new_drug_application_snda_for_xtandi_enzalutamide_in_non_metastatic_castration_resistant_prostate_cancer_crpc",0.98,2018,3,16.8114309138297,0.683113098144531,-0.445919036865234,0,-0.359226226806644,1,2.71,1.3,"Research",0,2
2018-03-20,34.5066413879395,34.677417755127,34.2694511413574,34.468692779541,29.0011768341064,20295824,NA,NA,NA,NA,NA,NA,NA,1.28,2018,3,16.8259257578354,0.407966613769531,-0.0379486083984375,0,0,0,NA,NA,NA,0,NA
2018-03-21,34.6204948425293,34.8481979370117,34.3453521728516,34.4117660522461,28.9532794952393,19071392,NA,NA,NA,NA,NA,NA,NA,1.16,2018,3,16.763700021579,0.502845764160156,-0.208728790283203,0,-0.0478973388671911,0,NA,NA,NA,0,NA
2018-03-22,34.1840591430664,34.2884254455566,33.6527519226074,33.7760925292969,28.4184379577637,22094686,NA,NA,NA,NA,NA,NA,NA,1.24,2018,3,16.9108477303457,0.635673522949219,-0.407966613769531,0,-0.534841537475582,0,NA,NA,NA,0,NA
2018-03-23,33.6717262268066,33.6812133789062,32.6755218505859,32.7229614257812,27.532356262207,29385731,160,77,0.350210968986452,0.324657533801839,"Research","Pfizer Reports Top-Line Results from a Study of CHANTIX®/CHAMPIX® (varenicline) in Adolescent Smokers","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_reports_top_line_results_from_a_study_of_chantix_champix_varenicline_in_adolescent_smokers",1.12,2018,3,17.1960198083873,1.00569152832031,-0.948764801025391,0,-0.886081695556641,1,1.6,0.77,"Research",0,2
2018-03-26,33.1404151916504,33.3491477966309,32.5616683959961,33.2447814941406,27.9714050292969,24926468,NA,NA,NA,NA,NA,NA,NA,1.77,2018,3,17.0314408088859,0.787479400634766,0.104366302490234,1,0.439048767089844,0,NA,NA,NA,0,NA
2018-03-27,33.3776092529297,33.7381401062012,32.9981002807617,33.2163200378418,27.9474601745605,28835227,NA,NA,NA,NA,NA,NA,NA,1.77,2018,3,17.1771083920578,0.740039825439453,-0.161289215087891,0,-0.0239448547363281,0,NA,NA,NA,0,NA
2018-03-28,33.3776092529297,33.9753303527832,33.3206825256348,33.4914627075195,28.1789627075195,26349684,NA,NA,NA,NA,NA,NA,NA,1.5,2018,3,17.086966878421,0.654647827148438,0.113853454589844,1,0.231502532958984,0,NA,NA,NA,0,NA
2018-03-29,33.7001914978027,33.8425064086914,33.2732467651367,33.6717262268066,28.3306274414062,24804731,182,60,0.504132229321768,0.281722933315806,"Research","Pfizer Announces Positive Topline Results From Phase 3 ATTR-ACT Study Of Tafamidis In Patients With Transthyretin Cardiomyopathy","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_positive_topline_results_from_phase_3_attr_act_study_of_tafamidis_in_patients_with_transthyretin_cardiomyopathy",1.59,2018,3,17.0265449993856,0.569259643554688,-0.0284652709960938,0,0.151664733886719,1,1.82,0.6,"Research",0,2
2018-04-02,33.6053123474121,33.9089164733887,32.9791259765625,33.2542686462402,27.9793872833252,28323299,NA,NA,NA,NA,NA,NA,NA,1.12,2018,4,17.159195345425,0.929790496826172,-0.351043701171875,0,-0.351240158081055,0,NA,NA,NA,0,NA
2018-04-03,33.3111953735352,33.9089164733887,33.130931854248,33.851993560791,28.4823036193848,21347927,295,56,0.680911678971762,0.274647887109039,"Research","Pfizer and Allogene Therapeutics Enter into Asset Contribution Agreement for Pfizer’s Allogeneic CAR T Immuno-oncology Portfolio","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_and_allogene_therapeutics_enter_into_asset_contribution_agreement_for_pfizer_s_allogeneic_car_t_immuno_oncology_portfolio",1.12,2018,4,16.876465243749,0.777984619140625,0.540798187255859,1,0.502916336059574,1,2.95,0.56,"Research",0,2
2018-04-04,33.5104370117188,34.3738136291504,33.4345359802246,34.278938293457,28.84153175354,22010682,223,79,0.476821190474102,0.307535641234689,"Medicines","U.S. FDA and European Medicines Agency Accept Regulatory Submissions for Review of Dacomitinib to Treat Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mutations","https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_and_european_medicines_agency_accept_regulatory_submissions_for_review_of_dacomitinib_to_treat_metastatic_non_small_cell_lung_cancer_with_egfr_activating_mutations",1.16,2018,4,16.9070384843706,0.939277648925781,0.768501281738281,1,0.35922813415527,1,2.23,0.79,"Research",0,2
2018-04-05,33.8425064086914,34.1555976867676,33.7096786499023,33.8994293212891,28.5222129821777,25781789,NA,NA,NA,NA,NA,NA,NA,1.04,2018,4,17.0651789867344,0.445919036865234,0.0569229125976562,1,-0.319318771362305,0,NA,NA,NA,0,NA
2018-04-06,33.7381401062012,34.0322570800781,33.102466583252,33.3681221008301,28.0751838684082,22288200,NA,NA,NA,NA,NA,NA,NA,1.04,2018,4,16.9195679932669,0.929790496826172,-0.370018005371094,0,-0.447029113769531,0,NA,NA,NA,0,NA
2018-04-09,33.4914627075195,34.089183807373,33.4155616760254,33.6432647705078,28.3066825866699,20457297,NA,NA,NA,NA,NA,NA,NA,1.53,2018,4,16.8338502472056,0.673622131347656,0.151802062988281,1,0.231498718261715,0,NA,NA,NA,0,NA
2018-04-10,34.1555976867676,34.2504730224609,33.8899421691895,34.1081581115723,28.6978340148926,20667254,210,107,0.3249211346217,0.264607679244902,"Research","Pfizer Provides Update on Phase 3 Trial of Axitinib as Adjuvant Treatment for Patients at High Risk of Renal Cell Carcinoma Recurrence After Surgery","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_provides_update_on_phase_3_trial_of_axitinib_as_adjuvant_treatment_for_patients_at_high_risk_of_renal_cell_carcinoma_recurrence_after_surgery",1.74,2018,4,16.844061121678,0.360530853271484,-0.0474395751953125,0,0.391151428222656,1,2.1,1.07,"Research",0,2
2018-04-11,33.8994293212891,34.2220115661621,33.7666015625,33.956356048584,28.5701122283936,13879915,NA,NA,NA,NA,NA,NA,NA,1.56,2018,4,16.4459534611514,0.455410003662109,0.0569267272949219,1,-0.12772178649902,0,NA,NA,NA,0,NA
2018-04-12,34.1840591430664,34.6299819946289,34.1271362304688,34.4592018127441,28.9931888580322,23817976,211,55,0.586466163208774,0.278825995514857,"Research","Pfizer Doses First Patient Using Investigational Mini-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_doses_first_patient_using_investigational_mini_dystrophin_gene_therapy_for_the_treatment_of_duchenne_muscular_dystrophy",1.59,2018,4,16.9859511896534,0.502845764160156,0.275142669677734,1,0.423076629638672,1,2.11,0.55,"Research",0,2
2018-04-13,34.5445938110352,34.6299819946289,34.278938293457,34.4592018127441,28.9931888580322,17774340,NA,NA,NA,NA,NA,NA,NA,1.5,2018,4,16.6932664584234,0.351043701171875,-0.0853919982910156,0,0,0,NA,NA,NA,0,NA
2018-04-16,34.6299819946289,34.8481979370117,34.5256156921387,34.6584434509277,29.1608352661133,15932369,NA,NA,NA,NA,NA,NA,NA,0.96,2018,4,16.5838634467147,0.322582244873047,0.0284614562988281,1,0.167646408081055,0,NA,NA,NA,0,NA
2018-04-17,34.8671722412109,34.895637512207,34.4117660522461,34.468692779541,29.0011768341064,17675580,NA,NA,NA,NA,NA,NA,NA,1.2,2018,4,16.6876946404938,0.483871459960938,-0.398479461669922,0,-0.159658432006836,0,NA,NA,NA,0,NA
2018-04-18,34.5161285400391,34.7153701782227,34.4212532043457,34.6204948425293,29.12890625,14652497,NA,NA,NA,NA,NA,NA,NA,1.08,2018,4,16.5001213908372,0.294116973876953,0.104366302490234,1,0.127729415893555,0,NA,NA,NA,0,NA
2018-04-19,34.5256156921387,34.810245513916,34.4117660522461,34.6584434509277,29.1608352661133,16636652,48,4,0.846153829881657,0.319018402950807,"Finance","Pfizer Invites Public to Listen to Webcast of April 26 Annual Meeting of Shareholders","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_invites_public_to_listen_to_webcast_of_april_26_annual_meeting_of_shareholders-0",1.1,2018,4,16.6271188312987,0.398479461669922,0.132827758789062,1,0.0319290161132812,1,0.48,0.04,"Finance",0,3
2018-04-20,34.6299819946289,34.9051246643066,34.6015167236328,34.7533226013184,29.2406558990479,22371993,NA,NA,NA,NA,NA,NA,NA,1.06,2018,4,16.9233204667312,0.303607940673828,0.123340606689453,1,0.0798206329345703,0,NA,NA,NA,0,NA
2018-04-23,34.7912712097168,35,34.7248573303223,34.9146118164062,29.3763694763184,25381058,207,69,0.499999998188406,0.270323212271965,"Medicines","MYLOTARG™ Approved In The EU For The Treatment Of Previously Untreated, De Novo, CD33-positive Acute Myeloid Leukemia In Combination With Chemotherapy","https://www.pfizer.com//news/press-release/press-release-detail/mylotarg_approved_in_the_eu_for_the_treatment_of_previously_untreated_de_novo_cd33_positive_acute_myeloid_leukemia_in_combination_with_chemotherapy",1.04,2018,4,17.0495137451483,0.275142669677734,0.123340606689453,1,0.135713577270508,1,2.07,0.69,"Research",0,2
2018-04-24,35.0189743041992,35.3605308532715,34.8861465454102,35.1612892150879,29.583911895752,27106350,NA,NA,NA,NA,NA,NA,NA,1.12,2018,4,17.1152786126368,0.474384307861328,0.142314910888672,1,0.207542419433594,0,NA,NA,NA,0,NA
2018-04-25,35.0284614562988,35.1423149108887,34.6394691467285,34.8007583618164,29.2805728912354,27730213,NA,NA,NA,NA,NA,NA,NA,1.02,2018,4,17.1380331348359,0.502845764160156,-0.227703094482422,0,-0.303339004516602,0,NA,NA,NA,0,NA
2018-04-26,34.9146118164062,35.1992416381836,34.8671722412109,34.9620475769043,29.4162788391113,20405651,101,16,0.726495720286361,0.295454544708448,"Finance","Pfizer Hosts Annual Meeting of Shareholders","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_hosts_annual_meeting_of_shareholders-5",1.1,2018,4,16.8313224792643,0.332069396972656,0.0474357604980469,1,0.135705947875977,1,1.01,0.16,"Finance",0,3
2018-04-27,34.895637512207,35.2087287902832,34.8197326660156,35.104362487793,29.536018371582,14425149,NA,NA,NA,NA,NA,NA,NA,1.04,2018,4,16.4844837689179,0.388996124267578,0.208724975585938,1,0.119739532470703,0,NA,NA,NA,0,NA
2018-04-30,35.2277030944824,35.2751426696777,34.5351028442383,34.7343444824219,29.2246952056885,28295789,54,7,0.770491790647676,0.268722465776553,"Leadership","Dawn Rogers Appointed Executive Vice President of Pfizer Worldwide Human Resources","https://www.pfizer.com//news/announcements/dawn-rogers-appointed-executive-vice-president-pfizer-worldwide-human-resources",0.88,2018,4,17.1582235882962,0.740039825439453,-0.493358612060547,0,-0.311323165893555,1,0.54,0.07,"Management",0,1
2018-05-01,33.7571144104004,34.2030372619629,32.8652763366699,33.5863380432129,28.2587909698486,51278154,39,13,0.499999990384616,0.222222221272555,"Partnerships","HUB Announces Collaboration with Pfizer Inc. on Human Gut Organoids for  IBD","https://www.pfizer.com//news/press-release/press-release-detail/hub-announces-collaboration-pfizer-inc-human-gut-organoids",1.08,2018,5,17.7527753909903,1.33776092529297,-0.1707763671875,0,-0.965904235839844,1,0.39,0.13,"Management",0,1
2018-05-02,33.3681221008301,33.5578765869141,32.9601516723633,33.102466583252,27.8516693115234,29550260,NA,NA,NA,NA,NA,NA,NA,1.1,2018,5,17.2016031342647,0.597724914550781,-0.265655517578125,0,-0.407121658325192,0,NA,NA,NA,0,NA
2018-05-03,33.0360527038574,33.0929794311523,32.6565475463867,32.9791259765625,27.7478885650635,23517902,NA,NA,NA,NA,NA,NA,NA,0.98,2018,5,16.9732725188566,0.436431884765625,-0.0569267272949219,0,-0.103780746459964,0,NA,NA,NA,0,NA
2018-05-04,32.7893753051758,33.1973419189453,32.6091079711914,33.0550270080566,27.8117580413818,19795912,NA,NA,NA,NA,NA,NA,NA,0.92,2018,5,16.800986060217,0.588233947753906,0.265651702880859,1,0.0638694763183594,0,NA,NA,NA,0,NA
2018-05-07,33.0075912475586,33.3301696777344,32.9316902160645,33.1404151916504,27.8835964202881,21580018,107,18,0.711999994304,0.268817203722974,"Partnerships","Wave Life Sciences Highlights Progress on Hepatic Collaboration with Pfizer","https://www.pfizer.com//news/press-release/press-release-detail/wave-life-sciences-highlights-progress-hepatic",1.04,2018,5,16.8872783982387,0.398479461669922,0.132823944091797,1,0.0718383789062536,1,1.07,0.18,"Management",0,1
2018-05-08,33.1214408874512,33.2922210693359,32.9316902160645,33.1878547668457,27.9235134124756,28269650,109,10,0.831932766118212,0.269841269229385,"Partnerships","New project to enhance nanomedicine development","https://www.pfizer.com//news/press-release/press-release-detail/new-project-enhance-nanomedicine-development",0.92,2018,5,17.1572993843513,0.360530853271484,0.0664138793945312,1,0.0399169921874929,1,1.09,0.1,"Management",0,1
2018-05-09,33.2258071899414,33.5958251953125,33.0834922790527,33.3681221008301,28.0751838684082,20430209,52,6,0.793103434601665,0.25892857027264,"Medicines","Important Notice Regarding EpiPen auto-injector supply","https://www.pfizer.com//news/announcements/important-notice-regarding-epipen-auto-injector-supply",1.06,2018,5,16.8325252457424,0.512332916259766,0.142314910888672,1,0.151670455932621,1,0.52,0.06,"Research",0,2
2018-05-10,33.2068328857422,33.5009498596191,33.102466583252,33.2447814941406,28.2444534301758,30906653,NA,NA,NA,NA,NA,NA,NA,0.98,2018,5,17.2464820584915,0.398483276367188,0.0379486083984375,1,0.169269561767578,0,NA,NA,NA,0,NA
2018-05-11,33.3301696777344,33.7381401062012,33.2732467651367,33.6812133789062,28.6152496337891,21619964,NA,NA,NA,NA,NA,NA,NA,0.84,2018,5,16.8891277513026,0.464893341064453,0.351043701171875,1,0.370796203613281,0,NA,NA,NA,0,NA
2018-05-14,33.6907005310059,34.0796966552734,33.6717262268066,34.0227699279785,28.9054298400879,21485052,NA,NA,NA,NA,NA,NA,NA,1.12,2018,5,16.8828680420255,0.407970428466797,0.332069396972656,1,0.290180206298828,0,NA,NA,NA,0,NA
2018-05-15,33.6907005310059,33.9468688964844,33.662239074707,33.8614807128906,28.7683944702148,19345643,272,95,0.482288827023736,0.271650628962509,"Medicines","Pfizer’s Biosimilar RETACRIT® (epoetin alfa-epbx) Approved by U.S. FDA","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_s_biosimilar_retacrit_epoetin_alfa_epbx_approved_by_u_s_fda",1.06,2018,5,16.7779778358185,0.284629821777344,0.170780181884766,1,-0.137035369873047,1,2.72,0.95,"Research",0,2
2018-05-16,33.8994293212891,34.0417442321777,33.7476272583008,33.851993560791,28.7603397369385,21870711,193,39,0.663793100587099,0.241918665024068,"Research","Pfizer Oncology to Showcase Clinical Advances from its Growing Portfolio and Research Pipeline at ASCO","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_oncology_to_showcase_clinical_advances_from_its_growing_portfolio_and_research_pipeline_at_asco",0.98,2018,5,16.9006589481358,0.294116973876953,-0.0474357604980469,0,-0.00805473327636719,1,1.93,0.39,"Research",0,2
2018-05-17,33.8045539855957,33.9468688964844,33.6242866516113,33.8804550170898,28.7845153808594,13021432,165,79,0.352459014948938,0.287396937235104,"Medicines","LYRICA® (pregabalin) Oral Solution CV Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint","https://www.pfizer.com//news/press-release/press-release-detail/lyrica_pregabalin_oral_solution_cv_phase_3_trial_in_pediatric_epilepsy_meets_primary_endpoint-0",1.1,2018,5,16.3821072501323,0.322582244873047,0.0759010314941406,1,0.0241756439208984,1,1.65,0.79,"Research",0,2
2018-05-18,33.7855796813965,33.9184074401855,33.6147994995117,33.8140411376953,28.7280960083008,15734639,NA,NA,NA,NA,NA,NA,NA,0.98,2018,5,16.5713752092866,0.303607940673828,0.0284614562988281,1,-0.0564193725585938,0,NA,NA,NA,0,NA
2018-05-21,33.8804550170898,34.0322570800781,33.7001914978027,33.9658432006836,28.857063293457,17802903,218,62,0.557142855153061,0.260950605534995,"Research","Spark Therapeutics and Pfizer Announce Data from 15 Participants with Hemophilia B Showing Persistent and Sustained Factor IX Levels with No Serious Adverse Events","https://www.pfizer.com//news/press-release/press-release-detail/spark_therapeutics_and_pfizer_announce_data_from_15_participants_with_hemophilia_b_showing_persistent_and_sustained_factor_ix_levels_with_no_serious_adverse_events",1.04,2018,5,16.6948721480229,0.332065582275391,0.08538818359375,1,0.12896728515625,1,2.18,0.62,"Research",0,2
2018-05-22,33.9658432006836,34.2409858703613,33.8614807128906,33.8899421691895,28.792573928833,14477322,255,94,0.461318050254103,0.281678772976853,"Research","A Study Analyzing Observational Data Shows Real-World Effectiveness of Prevnar® 13 in Adults Age 65+","https://www.pfizer.com//news/press-release/press-release-detail/a_study_analyzing_observational_data_shows_real_world_effectiveness_of_prevnar_13_in_adults_age_65-0",1.08,2018,5,16.4880940521396,0.379505157470703,-0.0759010314941406,0,-0.0644893646240234,1,2.55,0.94,"Research",0,2
2018-05-23,33.851993560791,34.1840591430664,33.8045539855957,34.1271362304688,28.9940948486328,20358642,168,46,0.570093455279937,0.275064266998632,"Research","FDA Grants Breakthrough Therapy Designation for Tafamidis for the Treatment of Patients with Transthyretin Cardiomyopathy","https://www.pfizer.com//news/press-release/press-release-detail/fda_grants_breakthrough_therapy_designation_for_tafamidis_for_the_treatment_of_patients_with_transthyretin_cardiomyopathy-1",0.98,2018,5,16.8290160971307,0.379505157470703,0.275142669677734,1,0.201520919799805,1,1.68,0.46,"Research",0,2
2018-05-24,34.1176452636719,34.2409858703613,33.9373817443848,34.0512313842773,28.9296092987061,17523066,94,11,0.790476182947846,0.355932202183281,"Finance","Pfizer Reaches $23.85 Million Settlement Agreement To Resolve  Allegations Related To Patient Assistance Charities","https://www.pfizer.com//news/announcements/pfizer-reaches-2385-million-settlement-agreement-resolve-allegations-related",1.12,2018,5,16.6790286852294,0.303604125976562,-0.0664138793945312,0,-0.0644855499267578,1,0.94,0.11,"Finance",0,3
2018-05-25,33.9848213195801,34.0796966552734,33.719165802002,33.851993560791,28.7603397369385,15005376,NA,NA,NA,NA,NA,NA,NA,0.94,2018,5,16.5239191614993,0.360530853271484,-0.132827758789062,0,-0.169269561767578,0,NA,NA,NA,0,NA
2018-05-29,33.5578765869141,33.8994293212891,33.5104370117188,33.8709678649902,28.7764625549316,28179639,359,153,0.402343749214172,0.268203247633209,"Medicines","Pfizer’s XALKORI® (crizotinib) Receives FDA Breakthrough Therapy Designation in Two New Indications","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_s_xalkori_crizotinib_receives_fda_breakthrough_therapy_designation_in_two_new_indications-0",1.02,2018,5,17.1541102893355,0.388992309570312,0.313091278076172,1,0.0161228179931641,1,3.59,1.53,"Research",0,2
2018-05-30,34.1081581115723,34.3927879333496,34.0607223510742,34.2030372619629,29.0585784912109,29093773,334,154,0.368852458260548,0.268574573324945,"Medicines","Pfizer Announces U.S. FDA Approves XELJANZ® (tofacitinib) for the Treatment of Moderately to Severely Active Ulcerative Colitis","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_u_s_fda_approves_xeljanz_tofacitinib_for_the_treatment_of_moderately_to_severely_active_ulcerative_colitis-0",0.98,2018,5,17.1860347573607,0.332065582275391,0.094879150390625,1,0.282115936279297,1,3.34,1.54,"Research",0,2
2018-05-31,34.1081581115723,34.3453521728516,34.0512313842773,34.089183807373,28.9618549346924,30926468,66,20,0.534883714710655,0.231805929294324,"Partnerships","Cortexyme Completes $76 Million Series B Financing and Provides Update on Clinical Development Progress","https://www.pfizer.com//news/press-release/press-release-detail/cortexyme-completes-76-million-series-b-financing-and",1.14,2018,5,17.2471229771357,0.294120788574219,-0.0189743041992188,0,-0.0967235565185547,1,0.66,0.2,"Management",0,1
2018-06-01,34.4022789001465,34.4212532043457,34.2599601745605,34.3927879333496,29.2197875976562,22345011,165,42,0.594202895680179,0.262025316124019,"Medicines","Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, TRAZIMERA™ (trastuzumab)","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_receives_positive_chmp_opinion_for_oncology_biosimilar_trazimera_trastuzumab-0",0.82,2018,6,16.9221136773824,0.161293029785156,-0.009490966796875,0,0.257932662963867,1,1.65,0.42,"Research",0,2
2018-06-04,34.5445938110352,34.6869087219238,34.3738136291504,34.5825424194336,29.3809986114502,19015319,368,126,0.489878541518464,0.263747997723573,"Medicines","Two-Year Update of Pivotal JAVELIN Merkel 200 Trial Shows Continued Durable Responses with BAVENCIO® (avelumab)","https://www.pfizer.com//news/press-release/press-release-detail/two_year_update_of_pivotal_javelin_merkel_200_trial_shows_continued_durable_responses_with_bavencio_avelumab",0.98,2018,6,16.7607555280222,0.313095092773438,0.0379486083984375,1,0.161211013793945,1,3.68,1.26,"Research",0,2
2018-06-05,34.6394691467285,34.762809753418,34.4781761169434,34.573055267334,29.3729457855225,21476093,NA,NA,NA,NA,NA,NA,NA,1.06,2018,6,16.882450967494,0.284633636474609,-0.0664138793945312,0,-0.00805282592773438,0,NA,NA,NA,0,NA
2018-06-06,34.5351028442383,34.6963958740234,34.3358612060547,34.5161285400391,29.3245792388916,19368093,NA,NA,NA,NA,NA,NA,NA,1.06,2018,6,16.7791376309546,0.36053466796875,-0.0189743041992188,0,-0.0483665466308594,0,NA,NA,NA,0,NA
2018-06-07,34.6204948425293,34.7153701782227,34.5066413879395,34.6204948425293,29.4132499694824,17083337,178,75,0.40711462289678,0.272043010460169,"Medicines","U.S. FDA and European Medicines Agency Accept Regulatory Submissions for Review of Talazoparib for Metastatic Breast Cancer Patients with an Inherited BRCA Mutation","https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_and_european_medicines_agency_accept_regulatory_submissions_for_review_of_talazoparib_for_metastatic_breast_cancer_patients_with_an_inherited_brca_mutation-1",0.98,2018,6,16.6536141604854,0.208728790283203,0,0,0.0886707305908239,1,1.78,0.75,"Research",0,2
2018-06-08,34.6584434509277,34.8292236328125,34.5825424194336,34.7912712097168,29.5583438873291,16453783,NA,NA,NA,NA,NA,NA,NA,0.98,2018,6,16.6160660391179,0.246681213378906,0.132827758789062,1,0.145093917846676,0,NA,NA,NA,0,NA
2018-06-11,34.9146118164062,34.9146118164062,34.4212532043457,34.4402275085449,29.2600955963135,19505640,NA,NA,NA,NA,NA,NA,NA,1,2018,6,16.7862142637513,0.493358612060547,-0.474384307861328,0,-0.298248291015625,0,NA,NA,NA,0,NA
2018-06-12,34.5256156921387,34.5351028442383,34.2979125976562,34.4402275085449,29.2600955963135,16371887,192,65,0.494163422201699,0.336387434114676,"Responsibility","Pfizer Announces Extension of Zithromax® Antibiotic Donation Program through 2025 to Help Eliminate World’s Leading Infectious Cause of Blindness","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_extension_of_zithromax_antibiotic_donation_program_through_2025_to_help_eliminate_world_s_leading_infectious_cause_of_blindness-0",1.16,2018,6,16.6110762756231,0.237190246582031,-0.08538818359375,0,0,1,1.92,0.65,"Management",0,1
2018-06-13,34.5066413879395,34.6394691467285,34.3453521728516,34.3643264770508,29.1956157684326,16029232,NA,NA,NA,NA,NA,NA,NA,0.96,2018,6,16.5899246756556,0.294116973876953,-0.142314910888672,0,-0.0644798278808594,0,NA,NA,NA,0,NA
2018-06-14,34.3643264770508,34.5256156921387,34.2030372619629,34.3073997497559,29.1472434997559,19959387,NA,NA,NA,NA,NA,NA,NA,1.04,2018,6,16.8092101670549,0.322578430175781,-0.0569267272949219,0,-0.0483722686767578,0,NA,NA,NA,0,NA
2018-06-15,34.3358612060547,34.5256156921387,34.1840591430664,34.4971542358398,29.3084564208984,49156979,NA,NA,NA,NA,NA,NA,NA,0.84,2018,6,17.7105294087165,0.341556549072266,0.161293029785156,1,0.161212921142582,0,NA,NA,NA,0,NA
2018-06-18,34.278938293457,34.3643264770508,33.8994293212891,34.3073997497559,29.1472434997559,24143451,NA,NA,NA,NA,NA,NA,NA,0.96,2018,6,16.9995237625818,0.464897155761719,0.0284614562988281,1,-0.161212921142582,0,NA,NA,NA,0,NA
2018-06-19,34.0512313842773,34.4971542358398,34.0322570800781,34.3643264770508,29.1956157684326,18484630,16,1,0.882352889273359,0.186813184760295,"Finance","Pfizer Invites Public To View And Listen To Webcast Of July 31 Conference Call With Analysts","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_invites_public_to_view_and_listen_to_webcast_of_july_31_conference_call_with_analysts-1",0.96,2018,6,16.7324501880222,0.464897155761719,0.313095092773438,1,0.0483722686767578,1,0.16,0.01,"Finance",0,3
2018-06-20,34.4307403564453,34.705883026123,34.3548393249512,34.5920295715332,29.3890628814697,21354251,NA,NA,NA,NA,NA,NA,NA,1.04,2018,6,16.8767614347185,0.351043701171875,0.161289215087891,1,0.193447113037109,0,NA,NA,NA,0,NA
2018-06-21,34.4117660522461,34.4971542358398,34.2979125976562,34.4402275085449,29.2600955963135,16893090,NA,NA,NA,NA,NA,NA,NA,0.94,2018,6,16.642415279737,0.199241638183594,0.0284614562988281,1,-0.12896728515625,0,NA,NA,NA,0,NA
2018-06-22,34.6204948425293,34.762809753418,34.5351028442383,34.6394691467285,29.4293670654297,27018447,NA,NA,NA,NA,NA,NA,NA,0.8,2018,6,17.1120304499125,0.227706909179688,0.0189743041992188,1,0.169271469116211,0,NA,NA,NA,0,NA
2018-06-25,34.4592018127441,34.5920295715332,34.2884254455566,34.5161285400391,29.3245792388916,20424517,217,87,0.427631577540686,0.250618301524635,"Medicines","Pfizer Announces Overall Survival Results from Phase 3 PALOMA-3 Trial of IBRANCE® (Palbociclib) in HR+, HER2- Metastatic Breast Cancer","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_overall_survival_results_from_phase_3_paloma_3_trial_of_ibrance_palbociclib_in_hr_her2_metastatic_breast_cancer-0",0.86,2018,6,16.8322465999007,0.303604125976562,0.0569267272949219,1,-0.104787826538086,1,2.17,0.87,"Research",0,2
2018-06-26,34.5351028442383,34.7153701782227,34.4402275085449,34.5161285400391,29.3245792388916,25435023,NA,NA,NA,NA,NA,NA,NA,0.92,2018,6,17.0516376798202,0.275142669677734,-0.0189743041992188,0,0,0,NA,NA,NA,0,NA
2018-06-27,34.4402275085449,34.677417755127,34.3263778686523,34.3548393249512,29.1875457763672,29396165,173,48,0.565610857169182,0.271165643839061,"Research","U.S. FDA Grants Priority Review for Pfizer’s New Drug Application for Glasdegib in Patients with Previously Untreated Acute Myeloid Leukemia","https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_grants_priority_review_for_pfizer_s_new_drug_application_for_glasdegib_in_patients_with_previously_untreated_acute_myeloid_leukemia-0",0.82,2018,6,17.1963748156418,0.351039886474609,-0.08538818359375,0,-0.137033462524414,1,1.73,0.48,"Research",0,2
2018-06-28,34.2599601745605,34.6204948425293,34.2599601745605,34.4971542358398,29.3084564208984,16506167,312,135,0.39597315347657,0.264653641051123,"Medicines","XELJANZ® (tofacitinib citrate) Receives Marketing Authorisation in the European Union for Active Psoriatic Arthritis","https://www.pfizer.com//news/press-release/press-release-detail/xeljanz_tofacitinib_citrate_receives_marketing_authorisation_in_the_european_union_for_active_psoriatic_arthritis-0",0.96,2018,6,16.6192446872,0.36053466796875,0.237194061279297,1,0.120910644531254,1,3.12,1.35,"Research",0,2
2018-06-29,34.5825424194336,34.705883026123,34.4212532043457,34.4212532043457,29.2439746856689,20974705,NA,NA,NA,NA,NA,NA,NA,0.82,2018,6,16.8588277935328,0.284629821777344,-0.161289215087891,0,-0.0644817352294957,0,NA,NA,NA,0,NA
2018-07-02,34.1555976867676,34.5066413879395,34.1555976867676,34.468692779541,29.2842769622803,14556372,NA,NA,NA,NA,NA,NA,NA,0,2018,7,16.4935394625576,0.351043701171875,0.313095092773438,1,0.0403022766113281,0,NA,NA,NA,1,NA
2018-07-03,34.5256156921387,34.705883026123,34.38330078125,34.4876670837402,29.3004035949707,9608159,NA,NA,NA,NA,NA,NA,NA,0,2018,7,16.0781232953926,0.322582244873047,-0.0379486083984375,0,0.0161266326904297,0,NA,NA,NA,1,NA
2018-07-05,34.6679306030273,35.0189743041992,34.6394691467285,34.9810256958008,29.719554901123,20391106,NA,NA,NA,NA,NA,NA,NA,0,2018,7,16.8306094323962,0.379505157470703,0.313095092773438,1,0.419151306152344,0,NA,NA,NA,1,NA
2018-07-06,35.104362487793,35.3320693969727,34.9905128479004,35.2087287902832,29.9130039215088,18955452,NA,NA,NA,NA,NA,NA,NA,0,2018,7,16.7576022053545,0.341556549072266,0.104366302490234,1,0.193449020385742,0,NA,NA,NA,1,NA
2018-07-09,35.3605308532715,35.5502853393555,35.1138534545898,35.2561683654785,29.9533138275146,22329412,NA,NA,NA,NA,NA,NA,NA,0,2018,7,16.9214153359652,0.436431884765625,-0.104362487792969,0,0.0403099060058594,0,NA,NA,NA,1,NA
2018-07-10,35.3889923095703,35.5787467956543,35.294116973877,35.5123329162598,30.1709499359131,20253875,NA,NA,NA,NA,NA,NA,NA,0,2018,7,16.8238567406082,0.284629821777344,0.123340606689453,1,0.217636108398441,0,NA,NA,NA,1,NA
2018-07-11,35.3415565490723,35.4933586120605,35.2561683654785,35.3036041259766,29.9936141967773,17795314,202,33,0.719148933110004,0.281437125411453,"Leadership","Pfizer to Organize for Future Growth","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_to_organize_for_future_growth-0",0,2018,7,16.6944457783713,0.237190246582031,-0.0379524230957031,0,-0.177335739135746,1,2.02,0.33,"Management",1,1
2018-07-12,35.4933586120605,35.6356735229492,35.3036041259766,35.5977210998535,30.2434978485107,16974881,NA,NA,NA,NA,NA,NA,NA,0,2018,7,16.6472452799858,0.332069396972656,0.104362487792969,1,0.249883651733402,0,NA,NA,NA,1,NA
2018-07-13,35.5787467956543,35.6641387939453,35.3130912780762,35.6072120666504,30.2515563964844,15227243,320,162,0.327800829195434,0.270179372045864,"Medicines","U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)","https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_approves_xtandi_enzalutamide_for_the_treatment_of_men_with_non_metastatic_castration_resistant_prostate_cancer_crpc-0",0,2018,7,16.5385967498621,0.351047515869141,0.0284652709960938,1,0.00805854797362926,1,3.2,1.62,"Research",1,2
2018-07-16,35.5597724914551,35.6261863708496,35.3795051574707,35.4648971557617,30.1306457519531,17888699,226,77,0.491749173294557,0.294460641113255,"Research","Pfizer Initiates Pivotal Phase 3 Program for Investigational Hemophilia B Gene Therapy","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_initiates_pivotal_phase_3_program_for_investigational_hemophilia_b_gene_therapy-0",0,2018,7,16.6996797865506,0.246681213378906,-0.0948753356933594,0,-0.12091064453125,1,2.26,0.77,"Research",1,2
2018-07-17,35.5407981872559,35.8349151611328,35.531307220459,35.721061706543,30.3482799530029,15740014,NA,NA,NA,NA,NA,NA,NA,0,2018,7,16.5717167539391,0.303607940673828,0.180263519287109,1,0.217634201049805,0,NA,NA,NA,1,NA
2018-07-18,35.6641387939453,35.7969627380371,35.5597724914551,35.7305488586426,30.3563385009766,20803430,190,54,0.557377046895996,0.283391405013483,"Research","Pfizer And Lilly Announce Positive Top-Line Results From Phase 3 Trial Of Tanezumab For The Treatment Of Osteoarthritis (OA) Pain","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_and_lilly_announce_positive_top_line_results_from_phase_3_trial_of_tanezumab_for_the_treatment_of_osteoarthritis_oa_pain",0,2018,7,16.8506284829915,0.237190246582031,0.0664100646972656,1,0.00805854797362926,1,1.9,0.54,"Research",1,2
2018-07-19,35.531307220459,35.6736221313477,35.3984832763672,35.4459190368652,30.1145172119141,16596811,NA,NA,NA,NA,NA,NA,NA,0,2018,7,16.6247211866904,0.275138854980469,-0.08538818359375,0,-0.241821289062496,0,NA,NA,NA,1,NA
2018-07-20,35.294116973877,35.4174575805664,35.2182159423828,35.4174575805664,30.0903491973877,15532798,186,51,0.569620250761096,0.259583789419952,"Medicines","U.S. FDA Approves Pfizer’s Biosimilar NIVESTYM™ (filgrastim-aafi)","https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_approves_pfizer_s_biosimilar_nivestym_filgrastim_aafi-0",0,2018,7,16.5584644106945,0.199241638183594,0.123340606689453,1,-0.0241680145263672,1,1.86,0.51,"Research",1,2
2018-07-23,35.426944732666,35.5882339477539,35.237190246582,35.3036041259766,29.9936141967773,20853074,NA,NA,NA,NA,NA,NA,NA,0,2018,7,16.8530119773491,0.351043701171875,-0.123340606689453,0,-0.0967350006103516,0,NA,NA,NA,1,NA
2018-07-24,35.4554061889648,35.8159408569336,35.3605308532715,35.7685012817383,30.3885879516602,17804800,134,21,0.729032253361082,0.268630848754539,"Finance","Pfizer to Build Cutting-Edge Sterile Injectable Facility in Michigan, Investing Nearly Half a Billion Dollars in U.S. Manufacturing, Creating More than 450 Jobs","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_to_build_cutting_edge_sterile_injectable_facility_in_michigan_investing_nearly_half_a_billion_dollars_in_u_s_manufacturing_creating_more_than_450_jobs-0",0,2018,7,16.6949786979958,0.455410003662109,0.313095092773438,1,0.394973754882812,1,1.34,0.21,"Finance",1,3
2018-07-25,35.7400398254395,36.1195449829102,35.6356735229492,36.043643951416,30.6223468780518,17171030,NA,NA,NA,NA,NA,NA,NA,0,2018,7,16.6587342776638,0.483871459960945,0.303604125976562,1,0.233758926391605,0,NA,NA,NA,1,NA
2018-07-26,36.0910835266113,36.4041748046875,36.0910835266113,36.2049331665039,30.759370803833,24840567,NA,NA,NA,NA,NA,NA,NA,0,2018,7,17.0279886811127,0.313091278076172,0.113849639892578,1,0.137023925781246,0,NA,NA,NA,1,NA
2018-07-27,36.148006439209,36.5085372924805,36.1195449829102,36.4421234130859,30.9608840942383,22111971,NA,NA,NA,NA,NA,NA,NA,0,2018,7,16.911629739268,0.388992309570305,0.294116973876953,1,0.201513290405273,0,NA,NA,NA,1,NA
2018-07-30,36.3946876525879,36.6982917785645,36.2239074707031,36.6129035949707,31.1059818267822,21981486,NA,NA,NA,NA,NA,NA,NA,0,2018,7,16.9057111570627,0.474384307861328,0.218215942382812,1,0.145097732543945,0,NA,NA,NA,1,NA
2018-07-31,36.2523727416992,37.9411773681641,36.1859588623047,37.8842506408691,32.1861038208008,50837371,878,305,0.484361791644665,0.272832103258111,"Finance","PFIZER REPORTS SECOND-QUARTER 2018 RESULTS","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_reports_second_quarter_2018_results-0",0,2018,7,17.744142311368,1.75521850585938,1.63187789916992,1,1.08012199401855,1,8.78,3.05,"Finance",1,3
2018-08-01,37.5996208190918,38.2542686462402,37.514232635498,38.2068328857422,32.4601707458496,32734605,337,142,0.407098120235703,0.271234427932483,"Medicines","XELJANZ® (tofacitinib citrate) Receives Marketing Authorization in the European Union for Moderately to Severely Active Ulcerative Colitis","https://www.pfizer.com//news/press-release/press-release-detail/xeljanz_tofacitinib_citrate_receives_marketing_authorization_in_the_european_union_for_moderately_to_severely_active_ulcerative_colitis-0",0,2018,8,17.3039433637379,0.740036010742188,0.607212066650391,1,0.274066925048828,1,3.37,1.42,"Research",1,2
2018-08-02,37.5901336669922,38.1593933105469,37.5047454833984,37.618595123291,32.2325439453125,31879284,NA,NA,NA,NA,NA,NA,NA,0,2018,8,17.2774669837803,0.654647827148438,0.0284614562988281,1,-0.227626800537109,0,NA,NA,NA,1,NA
2018-08-03,37.5901336669922,38.5768508911133,37.4667930603027,38.4629974365234,32.9560546875,27368375,NA,NA,NA,NA,NA,NA,NA,0,2018,8,17.1248987442181,1.11005783081055,0.87286376953125,1,0.7235107421875,0,NA,NA,NA,1,NA
2018-08-06,38.2922210693359,39.1081581115723,38.2637557983398,38.9373817443848,33.3625183105469,27479572,NA,NA,NA,NA,NA,NA,NA,0,2018,8,17.1289534866242,0.844402313232429,0.645160675048828,1,0.406463623046875,0,NA,NA,NA,1,NA
2018-08-07,38.7571144104004,39.1366233825684,38.7001914978027,38.7476272583008,33.1999320983887,18928575,NA,NA,NA,NA,NA,NA,NA,0,2018,8,16.7561832958446,0.436431884765625,-0.00948715209960938,0,-0.162586212158203,0,NA,NA,NA,1,NA
2018-08-08,38.6242866516113,39.5066413879395,38.5009498596191,39.2884254455566,33.6632957458496,25837440,91,31,0.49180327465735,0.271714921443842,"Partnerships","SANGAMO ANNOUNCES POSITIVE PRELIMINARY DATA FROM THE PHASE 1/2  ALTA STUDY EVALUATING SB-525 GENE THERAPY FOR HEMOPHILIA A","https://www.pfizer.com//news/press-release/press-release-detail/sangamo-announces-positive-preliminary-data-phase-12-alta",0,2018,8,17.0673351994669,1.00569152832031,0.664138793945312,1,0.463363647460938,1,0.91,0.31,"Management",1,1
2018-08-09,39.1840591430664,39.2504730224609,38.719165802002,38.8994293212891,33.330005645752,20121282,NA,NA,NA,NA,NA,NA,NA,0,2018,8,16.8172886685584,0.531307220458984,-0.284629821777344,0,-0.333290100097656,0,NA,NA,NA,1,NA
2018-08-10,38.719165802002,39.193546295166,38.6147994995117,38.8330154418945,33.2730941772461,18194148,NA,NA,NA,NA,NA,NA,NA,0,2018,8,16.7166106168436,0.578746795654297,0.113849639892578,1,-0.0569114685058594,0,NA,NA,NA,1,NA
2018-08-13,38.851993560791,39.0986709594727,38.719165802002,38.719165802002,33.1755409240723,19860627,NA,NA,NA,NA,NA,NA,NA,0,2018,8,16.8042498374308,0.379505157470703,-0.132827758789062,0,-0.0975532531738281,0,NA,NA,NA,1,NA
2018-08-14,38.7476272583008,38.9373817443848,38.4629974365234,38.6242866516113,33.0942459106445,17336824,NA,NA,NA,NA,NA,NA,NA,0,2018,8,16.6683434098985,0.474384307861328,-0.123340606689453,0,-0.0812950134277344,0,NA,NA,NA,1,NA
2018-08-15,38.7096786499023,39.1271362304688,38.5673637390137,39.0512313842773,33.4600677490234,22428488,NA,NA,NA,NA,NA,NA,NA,0,2018,8,16.9258425390913,0.559772491455078,0.341552734375,1,0.365821838378906,0,NA,NA,NA,1,NA
2018-08-16,39.1176452636719,39.3453521728516,38.9658432006836,39.2979125976562,33.6714324951172,16457472,162,31,0.678756473167065,0.264383561281666,"Partnerships","BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza","https://www.pfizer.com//news/press-release/press-release-detail/biontech-signs-collaboration-agreement-pfizer-develop-mrna",0,2018,8,16.6162902177334,0.379508972167969,0.180267333984375,1,0.21136474609375,1,1.62,0.31,"Management",1,1
2018-08-17,39.3548393249512,40.0284614562988,39.3453521728516,39.9335861206055,34.2160949707031,25910693,NA,NA,NA,NA,NA,NA,NA,0,2018,8,17.0701663372047,0.683109283447266,0.578746795654297,1,0.544662475585938,0,NA,NA,NA,1,NA
2018-08-20,40.0379524230957,40.5787467956543,39.9335861206055,40.1612892150879,34.4111938476562,22521029,79,11,0.755555547160494,0.251396647342467,"Finance","Pfizer Invites Public To View And Listen To Webcast Of August 27 Conference Call With Analysts And Investors To Review Tafamidis Data Presentation At ESC Congress 2018","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_invites_public_to_view_and_listen_to_webcast_of_august_27_conference_call_with_analysts_and_investors_to_review_tafamidis_data_presentation_at_esc_congress_2018",0,2018,8,16.9299600973124,0.645160675048828,0.123336791992188,1,0.195098876953125,1,0.79,0.11,"Finance",1,3
2018-08-21,40.1612892150879,40.2656555175781,39.8387107849121,40,34.2729949951172,18633244,NA,NA,NA,NA,NA,NA,NA,0,2018,8,16.7404579088378,0.426944732666016,-0.161289215087891,0,-0.138198852539062,0,NA,NA,NA,1,NA
2018-08-22,39.9905128479004,40.1707763671875,39.6679306030273,39.9146118164062,34.1998329162598,15001687,257,112,0.39295392847438,0.270527859039202,"Research","Pfizer and Astellas Amend Clinical Research Protocols for Two Phase 3 Trials of Enzalutamide in Patients with Hormone-Sensitive Prostate Cancer","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_and_astellas_amend_clinical_research_protocols_for_two_phase_3_trials_of_enzalutamide_in_patients_with_hormone_sensitive_prostate_cancer",0,2018,8,16.5236732860684,0.502845764160156,-0.0759010314941406,0,-0.0731620788574219,1,2.57,1.12,"Research",1,2
2018-08-23,39.9525604248047,40.1518020629883,39.810245513916,40.0379524230957,34.3055152893066,21032148,NA,NA,NA,NA,NA,NA,NA,0,2018,8,16.8615627298095,0.341556549072266,0.0853919982910156,1,0.105682373046875,0,NA,NA,NA,1,NA
2018-08-24,40.2561683654785,40.3130912780762,39.8481979370117,40.2277030944824,34.4680976867676,21661703,NA,NA,NA,NA,NA,NA,NA,0,2018,8,16.8910564668029,0.464893341064453,-0.0284652709960866,0,0.162582397460938,0,NA,NA,NA,1,NA
2018-08-27,40.3415565490723,40.4364318847656,39.193546295166,39.4497146606445,33.8014984130859,24485896,NA,NA,NA,NA,NA,NA,NA,0,2018,8,17.0136078771218,1.24288558959961,-0.891841888427734,0,-0.666599273681641,0,NA,NA,NA,1,NA
2018-08-28,39.4781761169434,39.6394691467285,39.2030372619629,39.3738136291504,33.7364654541016,19871694,NA,NA,NA,NA,NA,NA,NA,0,2018,8,16.8048069153689,0.436431884765618,-0.104362487792969,0,-0.065032958984375,0,NA,NA,NA,1,NA
2018-08-29,39.3738136291504,39.4876670837402,39.0607223510742,39.3738136291504,33.7364654541016,15785020,NA,NA,NA,NA,NA,NA,NA,0,2018,8,16.5745720103503,0.426944732666016,0,0,0,0,NA,NA,NA,1,NA
2018-08-30,39.1176452636719,39.762809753418,39.089183807373,39.3738136291504,33.7364654541016,16015425,182,66,0.467741933597815,0.313131312735945,"Research","Pfizer Terminates Domagrozumab (PF-06252616) Clinical Studies for the Treatment of Duchenne Muscular Dystrophy","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_terminates_domagrozumab_pf_06252616_clinical_studies_for_the_treatment_of_duchenne_muscular_dystrophy",0,2018,8,16.5890629407341,0.673625946044922,0.256168365478516,1,0,1,1.82,0.66,"Research",1,2
2018-08-31,39.1745719909668,39.4497146606445,38.9848213195801,39.3927879333496,33.7527198791504,20983559,NA,NA,NA,NA,NA,NA,NA,0,2018,8,16.8592498319522,0.464893341064453,0.218215942382812,1,0.0162544250488281,0,NA,NA,NA,1,NA
2018-09-04,39.3548393249512,39.4212532043457,39.1081581115723,39.2504730224609,33.6307792663574,15274779,113,14,0.779527552917106,0.323155215462709,"Finance","Pfizer Prices $5,000,000,000 Debt Offering","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_prices_5_000_000_000_debt_offering",0,2018,9,16.5417136602996,0.313095092773438,-0.104366302490234,0,-0.121940612792969,1,1.13,0.14,"Finance",1,3
2018-09-05,39.1745719909668,39.7722969055176,39.146110534668,39.705883026123,34.0209884643555,21819908,158,41,0.587939695537992,0.230324073807495,"Medicines","Pfizer Receives Breakthrough Therapy Designation from FDA for PF-06651600, an oral JAK3 Inhibitor, for the Treatment of Patients with Alopecia Areata","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_receives_breakthrough_therapy_designation_from_fda_for_pf_06651600_an_oral_jak3_inhibitor_for_the_treatment_of_patients_with_alopecia_areata",0,2018,9,16.8983333678747,0.626186370849609,0.53131103515625,1,0.390209197998047,1,1.58,0.41,"Research",1,2
2018-09-06,39.705883026123,39.762809753418,39.3263778686523,39.6394691467285,33.9640846252441,18356780,127,25,0.671052627164128,0.264808361907999,"Partnerships","CYTOO enters into Research and Option Agreement with Pfizer to develop a  target discovery platform for Duchenne Muscular Dystrophy","https://www.pfizer.com//news/press-release/press-release-detail/cytoo-enters-research-and-option-agreement-pfizer-develop",0,2018,9,16.7255096009877,0.436431884765625,-0.0664138793945384,0,-0.0569038391113281,1,1.27,0.25,"Management",1,1
2018-09-07,39.4592018127441,40.1802673339844,39.3358612060547,40.0379524230957,34.3055152893066,21221658,NA,NA,NA,NA,NA,NA,NA,0,2018,9,16.8705328690555,0.844406127929688,0.578750610351562,1,0.3414306640625,0,NA,NA,NA,1,NA
2018-09-10,40.2087287902832,40.531307220459,39.895637512207,39.9051246643066,34.1916999816895,21482206,NA,NA,NA,NA,NA,NA,NA,0,2018,9,16.882735569068,0.635669708251953,-0.303604125976562,0,-0.113815307617188,0,NA,NA,NA,1,NA
2018-09-11,39.8481979370117,40.2561683654785,39.8007583618164,40.1423149108887,34.3949356079102,19658786,532,265,0.335006273105387,0.231888274590664,"Research","BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Significantly Improved Progression-Free Survival in Previously Untreated Patients with Advanced Renal Cell Carcinoma in Phase III Study","https://www.pfizer.com//news/press-release/press-release-detail/bavencio_avelumab_plus_inlyta_axitinib_significantly_improved_progression_free_survival_in_previously_untreated_patients_with_advanced_renal_cell_carcinoma_in_phase_iii_study",0,2018,9,16.7940349718989,0.455410003662102,0.294116973876953,1,0.203235626220703,1,5.32,2.65,"Research",1,2
2018-09-12,40.1328277587891,40.5977210998535,40.1138534545898,40.237190246582,34.4762229919434,17508205,59,21,0.4749999940625,0.242424241689624,"Partnerships","System1 Announces a $25 Million Series A Funding to Advance  Integrated Technology Platform for Neurotherapeutics Discovery","https://www.pfizer.com//news/press-release/press-release-detail/system1-announces-25-million-series-funding-advance",0,2018,9,16.6781802432735,0.483867645263686,0.104362487792969,1,0.0812873840332031,1,0.59,0.21,"Management",1,1
2018-09-13,40.322582244873,40.721061706543,40.2561683654785,40.6546478271484,34.833911895752,18666129,NA,NA,NA,NA,NA,NA,NA,0,2018,9,16.742221209618,0.46489334106446,0.332065582275391,1,0.357688903808594,0,NA,NA,NA,1,NA
2018-09-14,40.5597724914551,40.7969627380371,40.322582244873,40.7590141296387,34.9233360290527,16800655,163,53,0.509259256901577,0.260240963541878,"Research","Pfizer Presents Positive Phase 2 Data in Alopecia Areata During Late-Breaker Session at the 27th European Academy of Dermatology and Venereology (EADV) Congress","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_presents_positive_phase_2_data_in_alopecia_areata_during_late_breaker_session_at_the_27th_european_academy_of_dermatology_and_venereology_eadv_congress",0,2018,9,16.6369284912302,0.474380493164062,0.199241638183594,1,0.0894241333007812,1,1.63,0.53,"Research",1,2
2018-09-17,40.8159408569336,40.9677429199219,40.5502853393555,40.806453704834,34.9639930725098,16904263,52,11,0.650793640463593,0.258196720253292,"Partnerships","ATOMWISE ENTERS INTO AN EVALUATION AGREEMENT WITH PFIZER","https://www.pfizer.com//news/press-release/press-release-detail/atomwise-enters-evaluation-agreement-pfizer",0,2018,9,16.6430764557614,0.417457580566406,-0.00948715209960938,0,0.0406570434570312,1,0.52,0.11,"Management",1,1
2018-09-18,40.7969627380371,41.4421234130859,40.6356735229492,41.280834197998,35.3704414367676,20464991,224,66,0.544827584328181,0.257548845241964,"Research","New Sub-group Analyses from the Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) Study Presented at 2018 HFSA Annual Scientific Meeting","https://www.pfizer.com//news/press-release/press-release-detail/new_sub_group_analyses_from_the_tafamidis_phase_3_transthyretin_amyloid_cardiomyopathy_attr_act_study_presented_at_2018_hfsa_annual_scientific_meeting",0,2018,9,16.8342262769973,0.806449890136719,0.483871459960938,1,0.406448364257812,1,2.24,0.66,"Research",1,2
2018-09-19,41.1954460144043,41.4421234130859,40.7874755859375,41.043643951416,35.1672096252441,23783088,NA,NA,NA,NA,NA,NA,NA,0,2018,9,16.9844853398656,0.654647827148438,-0.151802062988281,0,-0.203231811523438,0,NA,NA,NA,1,NA
2018-09-20,41.148006439209,41.6318778991699,41.1290321350098,41.5085372924805,35.5655517578125,18419809,138,23,0.714285709849157,0.25515055427076,"Vaccines","Pfizer Granted FDA Breakthrough Therapy Designation for 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_granted_fda_breakthrough_therapy_designation_for_20_valent_pneumococcal_conjugate_vaccine_for_the_prevention_of_invasive_disease_and_pneumonia_in_adults_aged_18_years_and_older",0,2018,9,16.7289372738631,0.502845764160156,0.360530853271484,1,0.398342132568359,1,1.38,0.23,"Pandemic",1,4
2018-09-21,41.5370025634766,41.9354858398438,41.3757133483887,41.8026580810547,35.8175621032715,37092579,NA,NA,NA,NA,NA,NA,NA,0,2018,9,17.428927507575,0.559772491455078,0.265655517578125,1,0.252010345458984,0,NA,NA,NA,1,NA
2018-09-24,41.6888046264649,42.1821632385254,41.5844383239746,41.6793174743652,35.7118759155273,18089591,NA,NA,NA,NA,NA,NA,NA,0,2018,9,16.71084730322,0.597724914550781,-0.00948715209961648,0,-0.105686187744141,0,NA,NA,NA,1,NA
2018-09-25,41.869068145752,42.0208740234375,41.5180282592773,41.5464897155762,35.5980644226074,15318520,NA,NA,NA,NA,NA,NA,NA,0,2018,9,16.5445731771464,0.502845764160156,-0.322578430175781,0,-0.113811492919922,0,NA,NA,NA,1,NA
2018-09-26,41.5939292907715,42.0398483276367,41.4041748046875,41.4421234130859,35.5086441040039,18384817,NA,NA,NA,NA,NA,NA,NA,0,2018,9,16.727035773294,0.635673522949219,-0.151805877685554,0,-0.0894203186035156,0,NA,NA,NA,1,NA
2018-09-27,41.5464897155762,41.9165077209473,41.4421234130859,41.6508522033691,35.6874847412109,14887434,450,194,0.39751552733305,0.27663230228667,"Medicines","U.S. FDA Approves VIZIMPRO® (dacomitinib) for the First-Line Treatment of Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer","https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_approves_vizimpro_dacomitinib_for_the_first_line_treatment_of_patients_with_egfr_mutated_metastatic_non_small_cell_lung_cancer",0,2018,9,16.5160281265572,0.474384307861328,0.104362487792969,1,0.178840637207031,1,4.5,1.94,"Research",1,2
2018-09-28,41.6793174743652,41.8785591125488,41.4895629882812,41.8121452331543,35.8256797790527,15454591,NA,NA,NA,NA,NA,NA,NA,0,2018,9,16.5534167339763,0.388996124267578,0.132827758789062,1,0.138195037841797,0,NA,NA,NA,1,NA
2018-10-01,41.7741928100586,42.2390899658203,41.660343170166,42.0018997192383,35.9882736206055,16872537,186,33,0.698630133796209,0.323964496562183,"Leadership","Pfizer Announces CEO Succession","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_ceo_succession",0,2018,10,16.6411978877827,0.578746795654297,0.227706909179688,1,0.162593841552734,1,1.86,0.33,"Management",1,1
2018-10-02,41.9449729919434,42.1157493591309,41.869068145752,41.954460144043,35.9476280212402,18167693,NA,NA,NA,NA,NA,NA,NA,0,2018,10,16.7151555198252,0.246681213378906,0.00948715209960938,1,-0.0406455993652344,0,NA,NA,NA,1,NA
2018-10-03,42.0113868713379,42.5426940917969,42.0113868713379,42.514232635498,36.4272575378418,23957631,NA,NA,NA,NA,NA,NA,NA,0,2018,10,16.9917974949417,0.531307220458984,0.502845764160156,1,0.479629516601562,0,NA,NA,NA,1,NA
2018-10-04,42.2485771179199,42.4952545166016,42.0208740234375,42.4098663330078,36.3378295898438,18960406,154,81,0.310638296550475,0.260243632048457,"Finance","Pfizer to Award More Than $3 Million in Grants to Further Breast Cancer Research","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_to_award_more_than_3_million_in_grants_to_further_breast_cancer_research",0,2018,10,16.7578635208055,0.474380493164062,0.161289215087891,1,-0.0894279479980469,1,1.54,0.81,"Finance",1,3
2018-10-05,42.4193534851074,42.6944961547851,42.3149909973145,42.6091079711914,36.5085372924805,18112568,NA,NA,NA,NA,NA,NA,NA,0,2018,10,16.7121166751276,0.379505157470696,0.189754486083984,1,0.170707702636719,0,NA,NA,NA,1,NA
2018-10-08,42.4573059082031,42.9981002807617,42.4098663330078,42.9601516723633,36.8093185424805,24679621,NA,NA,NA,NA,NA,NA,NA,0,2018,10,17.0214884408388,0.588233947753906,0.502845764160156,1,0.30078125,0,NA,NA,NA,1,NA
2018-10-09,42.6850090026855,43.4629974365234,42.4952545166016,43.1404151916504,36.9637794494629,21486844,123,27,0.639999995733333,0.288461537906805,"Leadership","Pfizer Announces Executive Leadership Team","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_executive_leadership_team",0,2018,10,16.8829514453698,0.967742919921875,0.455406188964844,1,0.154460906982422,1,1.23,0.27,"Management",1,1
2018-10-10,43.1214408874512,43.3870964050293,42.2011375427246,42.2296028137207,36.1833801269531,33746234,NA,NA,NA,NA,NA,NA,NA,0,2018,10,17.3343794135045,1.18595886230469,-0.891838073730469,0,-0.780399322509766,0,NA,NA,NA,1,NA
2018-10-11,42.087287902832,42.2106246948242,40.2277030944824,40.61669921875,34.8013954162598,44299198,NA,NA,NA,NA,NA,NA,NA,0,2018,10,17.6064771535878,1.9829216003418,-1.47058868408203,0,-1.38198471069336,0,NA,NA,NA,1,NA
2018-10-12,40.5787467956543,41.7077789306641,40.4554061889649,41.5370025634766,35.5899391174316,30417070,NA,NA,NA,NA,NA,NA,NA,0,2018,10,17.2305145548211,1.25237274169921,0.958255767822266,1,0.788543701171875,0,NA,NA,NA,1,NA
2018-10-15,41.4136619567871,41.470588684082,40.7779884338379,40.910816192627,35.0534057617188,24002742,NA,NA,NA,NA,NA,NA,NA,0,2018,10,16.9936786734481,0.692600250244141,-0.502845764160156,0,-0.536533355712891,0,NA,NA,NA,1,NA
2018-10-16,41.1290321350098,41.7267532348633,40.8349151611328,41.6793174743652,35.7118759155273,22353654,59,8,0.761194018489642,0.345360822962058,"Medicines","U.S. FDA Approves TALZENNA® (talazoparib)","https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_approves_talzenna_talazoparib",0,2018,10,16.9225004003291,0.891838073730469,0.550285339355469,1,0.658470153808594,1,0.59,0.08,"Research",1,2
2018-10-17,41.527515411377,42.5047454833984,41.5085372924805,42.2865295410156,36.2321472167969,23154167,NA,NA,NA,NA,NA,NA,NA,0,2018,10,16.9576853654872,0.996208190917969,0.759014129638672,1,0.520271301269531,0,NA,NA,NA,1,NA
2018-10-18,42.0683097839355,42.2201156616211,41.470588684082,41.7457313537598,35.7687797546387,22498368,NA,NA,NA,NA,NA,NA,NA,0,2018,10,16.9289533756583,0.749526977539062,-0.322578430175781,0,-0.463367462158203,0,NA,NA,NA,1,NA
2018-10-19,41.7931671142578,42.5332069396973,41.7267532348633,42.2201156616211,36.1752433776855,19564875,NA,NA,NA,NA,NA,NA,NA,0,2018,10,16.7892464757584,0.806453704833984,0.426948547363281,1,0.406463623046875,0,NA,NA,NA,1,NA
2018-10-22,42.1631889343262,42.2296028137207,41.764705657959,42.0967750549316,36.0695571899414,18026878,NA,NA,NA,NA,NA,NA,NA,0,2018,10,16.7073744798077,0.464897155761719,-0.0664138793945312,0,-0.105686187744141,0,NA,NA,NA,1,NA
2018-10-23,41.6413650512695,42.0493354797363,41.4516143798828,41.8406066894531,35.8500747680664,23073114,233,44,0.682310466850865,0.33054892561987,"Partnerships","Bain Capital and Pfizer Create Cerevel Therapeutics, New CNS Company","https://www.pfizer.com//news/press-release/press-release-detail/bain_capital_and_pfizer_create_cerevel_therapeutics_new_cns_company",0,2018,10,16.9541786448755,0.597721099853516,0.199241638183594,1,-0.219482421875,1,2.33,0.44,"Management",1,1
2018-10-24,41.5654640197754,42.0208740234375,40.189754486084,40.3036041259766,34.533130645752,36927206,NA,NA,NA,NA,NA,NA,NA,0,2018,10,17.4244591543992,1.83111953735352,-1.26185989379883,0,-1.31694412231445,0,NA,NA,NA,1,NA
2018-10-25,40.2182159423828,41.6888046264649,39.5256156921387,41.1859588623047,35.2891578674316,38600642,54,16,0.542857135102041,0.269230768195266,"Partnerships","CANCER THERAPEUTICS CRC SIGNS AGREEMENT TO ENABLE PFIZER TO DEVELOP NOVEL  CANCER DRUGS","https://www.pfizer.com//news/press-release/press-release-detail/cancer-therapeutics-crc-signs-agreement-enable-pfizer",0,2018,10,17.4687794923274,2.16318893432618,0.967742919921875,1,0.756027221679688,1,0.54,0.16,"Management",1,1
2018-10-26,40.8444023132324,41.0626182556152,40.0189743041992,40.4174575805664,34.6306800842285,30295333,NA,NA,NA,NA,NA,NA,NA,0,2018,10,17.2265042652221,1.04364395141602,-0.426944732666016,0,-0.658477783203125,0,NA,NA,NA,1,NA
2018-10-29,40.7495269775391,41.4421234130859,40.3795051574707,41.0151786804199,35.142822265625,31847559,NA,NA,NA,NA,NA,NA,NA,0,2018,10,17.2764713279426,1.06261825561523,0.265651702880859,1,0.512142181396484,0,NA,NA,NA,1,NA
2018-10-30,39.8007583618164,40.8823547363281,39.6394691467285,40.6926002502441,34.8664321899414,35424202,NA,NA,NA,NA,NA,NA,NA,0,2018,10,17.3829058450522,1.24288558959962,0.891841888427734,1,-0.276390075683594,0,NA,NA,NA,1,NA
2018-10-31,40.806453704834,41.4231491088867,40.5218238830566,40.853889465332,35.0046234130859,28193235,NA,NA,NA,NA,NA,NA,NA,0,2018,10,17.1545926489817,0.901325225830078,0.0474357604980469,1,0.138191223144531,0,NA,NA,NA,1,NA
2018-11-01,40.9867172241211,41.5844383239746,40.8823547363281,41.4326362609863,35.5005149841309,24278152,NA,NA,NA,NA,NA,NA,NA,0,2018,11,17.0050874504218,0.702083587646484,0.445919036865234,1,0.495891571044922,0,NA,NA,NA,1,NA
2018-11-02,41.5180282592773,41.5939292907715,40.3036041259766,40.7305488586426,34.8989486694336,24223028,473,205,0.395280235405191,0.273607748073605,"Medicines","U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC","https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_approves_lorbrena_lorlatinib_for_previously_treated_alk_positive_metastatic_nsclc",0,2018,11,17.0028143502019,1.29032516479493,-0.787479400634766,0,-0.601566314697266,1,4.73,2.05,"Research",1,2
2018-11-05,40.6356735229492,41.3852005004883,40.6356735229492,41.2903213500977,35.3785820007324,21628396,NA,NA,NA,NA,NA,NA,NA,0,2018,11,16.8895176851506,0.749526977539062,0.654647827148438,1,0.479633331298828,0,NA,NA,NA,1,NA
2018-11-06,41.3472480773926,41.3567352294922,40.5028457641602,40.806453704834,34.9639930725098,22194183,NA,NA,NA,NA,NA,NA,NA,0,2018,11,16.9153408305373,0.853889465332024,-0.540794372558594,0,-0.414588928222656,0,NA,NA,NA,1,NA
2018-11-07,41.1574935913086,42.2770385742188,41.0721054077149,42.1252365112305,36.0939559936523,36794929,NA,NA,NA,NA,NA,NA,NA,0,2018,11,17.4208706219086,1.2049331665039,0.967742919921875,1,1.12996292114258,0,NA,NA,NA,1,NA
2018-11-08,41.6129035949707,41.9354858398438,41.2428855895996,41.6034164428711,35.9219169616699,25696520,NA,NA,NA,NA,NA,NA,NA,0,2018,11,17.0618661710523,0.692600250244141,-0.00948715209960938,0,-0.172039031982422,0,NA,NA,NA,1,NA
2018-11-09,41.4800758361816,42.3244781494141,41.4800758361816,42.0113868713379,36.2741775512695,26042654,NA,NA,NA,NA,NA,NA,NA,0,2018,11,17.0752463286326,0.844402313232422,0.53131103515625,1,0.352260589599609,0,NA,NA,NA,1,NA
2018-11-12,42.0113868713379,42.2675514221191,41.6508522033691,41.8500938415527,36.1349105834961,21853847,NA,NA,NA,NA,NA,NA,NA,0,2018,11,16.8998875738402,0.61669921875,-0.161293029785156,0,-0.139266967773438,0,NA,NA,NA,1,NA
2018-11-13,42.0588226318359,42.1821632385254,41.1290321350098,41.2903213500977,35.6515884399414,20159015,NA,NA,NA,NA,NA,NA,NA,0,2018,11,16.8191621904524,1.05313110351562,-0.768501281738281,0,-0.483322143554688,0,NA,NA,NA,1,NA
2018-11-14,41.5180282592773,41.6034164428711,40.5218238830566,40.7115745544434,35.1518630981445,28398871,NA,NA,NA,NA,NA,NA,NA,0,2018,11,17.1618599840328,1.08159255981445,-0.806453704833984,0,-0.499725341796875,0,NA,NA,NA,1,NA
2018-11-15,40.5123329162598,41.1669845581055,40.1802673339844,40.9962043762207,35.3976287841797,25936305,NA,NA,NA,NA,NA,NA,NA,0,2018,11,17.0711543211607,0.986717224121094,0.483871459960938,1,0.245765686035156,0,NA,NA,NA,1,NA
2018-11-16,40.8918418884277,41.5370025634766,40.7115745544434,41.280834197998,35.6433868408203,24604576,NA,NA,NA,NA,NA,NA,NA,0,2018,11,17.0184430405067,0.825428009033203,0.388992309570312,1,0.245758056640625,0,NA,NA,NA,1,NA
2018-11-19,41.3852005004883,42.0018997192383,41.280834197998,41.9165077209473,36.192253112793,23671575,357,185,0.31734317284623,0.257237778710376,"Research","Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer","https://www.pfizer.com//news/press-release/press-release-detail/merck_kgaa_darmstadt_germany_and_pfizer_provide_update_on_avelumab_in_platinum_resistant_refractory_ovarian_cancer",0,2018,11,16.9797855614452,0.721065521240234,0.531307220458984,1,0.548866271972656,1,3.57,1.85,"Research",1,2
2018-11-20,41.7552185058594,42.1157493591309,41.1764717102051,41.2998085021973,35.6597785949707,22968557,NA,NA,NA,NA,NA,NA,NA,0,2018,11,16.9496367951588,0.939277648925781,-0.455410003662109,0,-0.532474517822266,0,NA,NA,NA,1,NA
2018-11-21,41.2713470458984,41.2713470458984,40.5787467956543,40.8918418884277,35.3075256347656,19665848,281,86,0.531335148415981,0.264218862300778,"Medicines","U.S. FDA Approves DAURISMO™ (glasdegib) for Adult Patients with Newly-Diagnosed Acute Myeloid Leukemia (AML) for Whom Intensive Chemotherapy is Not an Option","https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_approves_daurismo_glasdegib_for_adult_patients_with_newly_diagnosed_acute_myeloid_leukemia_aml_for_whom_intensive_chemotherapy_is_not_an_option",0,2018,11,16.7943941360664,0.692600250244141,-0.379505157470703,0,-0.352252960205078,1,2.81,0.86,"Research",1,2
2018-11-23,40.7495269775391,41.3187866210938,40.6072120666504,40.9297904968262,35.3402862548828,8844009,NA,NA,NA,NA,NA,NA,NA,0,2018,11,15.9952509516689,0.711574554443359,0.180263519287109,1,0.0327606201171875,0,NA,NA,NA,1,NA
2018-11-26,41.1005706787109,41.2618598937988,40.6831130981445,41.1195449829102,35.5041275024414,20147948,NA,NA,NA,NA,NA,NA,NA,0,2018,11,16.8186130545759,0.578746795654297,0.0189743041992259,1,0.163841247558594,0,NA,NA,NA,1,NA
2018-11-27,40.9867172241211,41.8880462646484,40.7685012817383,41.8121452331543,36.1021347045898,19765873,108,50,0.367088605271591,0.288848262726054,"Medicines","Pfizer Receives Six Months Pediatric Exclusivity for LYRICA® (pregabalin)","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_receives_six_months_pediatric_exclusivity_for_lyrica_pregabalin",0,2018,11,16.7994674733153,1.11954498291016,0.825428009033203,1,0.59800720214843,1,1.08,0.5,"Research",1,2
2018-11-28,42.0208740234375,42.618595123291,41.8406066894531,42.5996208190918,36.7820892333984,19892669,NA,NA,NA,NA,NA,NA,NA,0,2018,11,16.8058618801317,0.777988433837891,0.578746795654297,1,0.679954528808601,0,NA,NA,NA,1,NA
2018-11-29,42.4667930603027,43.4819717407227,42.4098663330078,43.1783676147461,37.2817802429199,26065315,NA,NA,NA,NA,NA,NA,NA,0,2018,11,17.0761160996482,1.07210540771484,0.711574554443359,1,0.499691009521484,0,NA,NA,NA,1,NA
2018-11-30,43.0265655517578,43.8899421691895,42.9601516723633,43.8614807128906,37.8716125488281,45054495,109,14,0.772357717297905,0.297101448557726,"Partnerships","Pfizer Reaches a Global Agreement with AbbVie","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_reaches_a_global_agreement_with_abbvie",0,2018,11,17.6233833372609,0.929790496826172,0.834915161132812,1,0.589832305908203,1,1.09,0.14,"Management",1,1
2018-12-03,43.9943084716797,44.0037956237793,43.4155616760254,43.6337776184082,37.6750106811523,26771178,NA,NA,NA,NA,NA,NA,NA,0,2018,12,17.1028364563646,0.588233947753906,-0.360530853271484,0,-0.196601867675781,0,NA,NA,NA,1,NA
2018-12-04,43.8614807128906,44.089183807373,42.7988624572754,42.8273239135742,36.9786834716797,28703898,NA,NA,NA,NA,NA,NA,NA,0,2018,12,17.1725435251611,1.29032135009766,-1.03415679931641,0,-0.696327209472656,0,NA,NA,NA,1,NA
2018-12-06,42.2960166931152,42.6850090026855,41.3852005004883,42.6755218505859,36.8476142883301,32188528,NA,NA,NA,NA,NA,NA,NA,0,2018,12,17.2871207048093,1.29980850219727,0.379505157470703,1,-0.131069183349609,0,NA,NA,NA,1,NA
2018-12-07,42.5237197875977,42.6375694274902,41.4421234130859,41.6698303222656,35.9792594909668,27963885,NA,NA,NA,NA,NA,NA,NA,0,2018,12,17.1464244499357,1.1954460144043,-0.853889465332031,0,-0.868354797363281,0,NA,NA,NA,1,NA
2018-12-10,41.8785591125488,42.2770385742188,40.8633766174316,42.1252365112305,36.3724822998047,26187895,NA,NA,NA,NA,NA,NA,NA,0,2018,12,17.0808078772507,1.41366195678711,0.246677398681641,1,0.393222808837891,0,NA,NA,NA,1,NA
2018-12-11,41.8216323852539,42.2296028137207,41.337760925293,41.7552185058594,36.0529899597168,23904931,NA,NA,NA,NA,NA,NA,NA,0,2018,12,16.9895953554451,0.891841888427734,-0.0664138793945312,0,-0.319492340087891,0,NA,NA,NA,1,NA
2018-12-12,42.0778007507324,42.5521812438965,41.8880462646484,41.897533416748,36.1758651733398,20180938,NA,NA,NA,NA,NA,NA,NA,0,2018,12,16.8202491030262,0.66413497924804,-0.180267333984375,0,0.12287521362304,0,NA,NA,NA,1,NA
2018-12-13,42.1821632385254,42.5996208190918,41.9449729919434,42.2865295410156,36.5117454528809,23613921,NA,NA,NA,NA,NA,NA,NA,0,2018,12,16.9773470113185,0.654647827148438,0.104366302490234,1,0.335880279541023,0,NA,NA,NA,1,NA
2018-12-14,41.8216323852539,41.8595848083496,41.2049331665039,41.5559768676758,35.8809661865234,33024982,152,36,0.617021273313717,0.286585365416791,"Medicines","Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, ZIRABEV™ (bevacizumab)","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_receives_positive_chmp_opinion_for_oncology_biosimilar_zirabev_bevacizumab",0,2018,12,17.312774893611,0.654651641845703,-0.265655517578125,0,-0.630779266357422,1,1.52,0.36,"Research",1,2
2018-12-17,41.2713470458984,41.7172698974609,40.7779884338379,40.9013290405273,35.3157081604004,38651866,77,21,0.571428565597668,0.214442012659864,"Partnerships","Kineta Enters Research Collaboration and License Agreement  with Pfizer to Develop New Cancer Immunotherapies","https://www.pfizer.com//news/press-release/press-release-detail/kineta-enters-research-collaboration-and-license-agreement",0,2018,12,17.4701056371351,0.939281463623047,-0.370018005371094,0,-0.565258026123047,1,0.77,0.21,"Management",1,1
2018-12-18,41.2428855895996,41.2713470458984,39.8861465454102,40.2277030944824,34.7340774536133,31125779,149,28,0.683615815346803,0.221804511000245,"Partnerships","Pfizer and GlaxoSmithKline Announce Joint Venture to Create a Premier Global Consumer Healthcare Company","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_and_glaxosmithkline_announce_joint_venture_to_create_a_premier_global_consumer_healthcare_company",0,2018,12,17.2535469726761,1.38520050048827,-1.01518249511719,0,-0.581630706787109,1,1.49,0.28,"Management",1,1
2018-12-19,40.6356735229492,40.7874755859375,39.4307403564453,39.8197326660156,34.3818130493164,36937957,NA,NA,NA,NA,NA,NA,NA,0,2018,12,17.4247502523769,1.35673522949219,-0.815940856933594,0,-0.352264404296875,0,NA,NA,NA,1,NA
2018-12-20,39.573055267334,40.237190246582,39.4022789001465,39.8007583618164,34.3654365539551,34494680,277,133,0.351219511338489,0.276094275908354,"Research","Astellas and Pfizer Announce Positive Top-Line Results from Phase 3 ARCHES Trial of XTANDI® (enzalutamide) in Men with Metastatic Hormone-Sensitive Prostate Cancer","https://www.pfizer.com//news/press-release/press-release-detail/astellas_and_pfizer_announce_positive_top_line_results_from_phase_3_arches_trial_of_xtandi_enzalutamide_in_men_with_metastatic_hormone_sensitive_prostate_cancer",0,2018,12,17.3563156962025,0.834911346435554,0.227703094482422,1,-0.0163764953613281,1,2.77,1.33,"Research",1,2
2018-12-21,39.5066413879395,40.6736221313477,39.3263778686523,39.7817840576172,34.3490524291992,61928192,313,159,0.326271185749425,0.265765765616123,"Research","Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on JAVELIN Ovarian 100 Trial of Avelumab in Previously Untreated Advanced Ovarian Cancer","https://www.pfizer.com//news/press-release/press-release-detail/merck_kgaa_darmstadt_germany_and_pfizer_provide_update_on_javelin_ovarian_100_trial_of_avelumab_in_previously_untreated_advanced_ovarian_cancer",0,2018,12,17.9414860943842,1.34724426269531,0.275142669677734,1,-0.0163841247558594,1,3.13,1.59,"Research",1,2
2018-12-24,39.6679306030273,39.810245513916,38.4440231323242,38.472484588623,33.2185592651367,19778205,NA,NA,NA,NA,NA,NA,NA,0,2018,12,16.8000911823711,1.3662223815918,-1.1954460144043,0,-1.1304931640625,0,NA,NA,NA,1,NA
2018-12-26,38.5768508911133,40.0379524230957,38.3491477966309,40.0284614562988,34.5620422363281,25437131,NA,NA,NA,NA,NA,NA,NA,0,2018,12,17.051720554232,1.68880462646484,1.45161056518555,1,1.34348297119141,0,NA,NA,NA,1,NA
2018-12-27,39.6679306030273,40.6546478271484,39.146110534668,40.6546478271484,35.1027183532715,28894672,NA,NA,NA,NA,NA,NA,NA,0,2018,12,17.1791678108332,1.50853729248047,0.986717224121094,1,0.540676116943359,0,NA,NA,NA,1,NA
2018-12-28,40.8159408569336,41.3092994689941,40.61669921875,40.7590141296387,35.1928329467773,25480977,NA,NA,NA,NA,NA,NA,NA,0,2018,12,17.0534427709772,0.692600250244141,-0.0569267272949219,0,0.0901145935058594,0,NA,NA,NA,1,NA
2018-12-31,40.9962043762207,41.4895629882812,40.8918418884277,41.4136619567871,35.7580757141113,20534028,NA,NA,NA,NA,NA,NA,NA,0,2018,12,16.8375940191319,0.597721099853516,0.417457580566406,1,0.565242767333984,0,NA,NA,NA,1,NA
2019-01-02,40.910816192627,41.2713470458984,40.4554061889649,41.0341567993164,35.4303970336914,26430315,NA,NA,NA,NA,NA,NA,NA,0.27,2019,1,17.0900222426195,0.815940856933587,0.123340606689453,1,-0.327678680419922,0,NA,NA,NA,0,NA
2019-01-03,41.0246696472168,41.1195449829102,39.8007583618164,39.8861465454102,34.4391632080078,28503533,153,51,0.49999999754902,0.242857142568027,"Research","Pfizer Initiates Phase 2b/3 Clinical Trial for PF-06651600, an Oral JAK3 Inhibitor, for the Treatment of Patients with Moderate to Severe Alopecia Areata","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_initiates_phase_2b_3_clinical_trial_for_pf_06651600_an_oral_jak3_inhibitor_for_the_treatment_of_patients_with_moderate_to_severe_alopecia_areata",0.32,2019,1,17.1655386375515,1.31878662109376,-1.13852310180663,0,-0.991233825683594,1,1.53,0.51,"Research",0,2
2019-01-04,40.2656555175781,41.1290321350098,40.0948753356934,40.7969627380371,35.2255935668945,27145348,NA,NA,NA,NA,NA,NA,NA,0.32,2019,1,17.1167162821188,1.03415679931641,0.531307220458984,1,0.786430358886719,0,NA,NA,NA,0,NA
2019-01-07,40.8633766174316,41.3852005004883,40.6641387939453,41.0151786804199,35.4140090942383,20995469,70,10,0.749999990625,0.294117645977509,"Partnerships","CytoReason Signs Collaboration Agreement with Pfizer Inc. To Utilize CytoReason’s Machine Learning Model  of the Immune System for Drug Discovery","https://www.pfizer.com//news/press-release/press-release-detail/cytoreason-signs-collaboration-agreement-pfizer-inc-utilize",0.35,2019,1,16.8598172581323,0.721061706542969,0.151802062988281,1,0.18841552734375,1,0.7,0.1,"Management",0,1
2019-01-08,41.3282737731934,41.4611015319824,40.9392776489258,41.2049331665039,35.5778541564941,19677231,NA,NA,NA,NA,NA,NA,NA,0.48,2019,1,16.7949727892897,0.521823883056641,-0.123340606689453,0,0.163845062255859,0,NA,NA,NA,0,NA
2019-01-09,41.2333984375,41.4326362609863,40.9867172241211,41.1195449829102,35.5041275024414,20107580,55,19,0.486486479912345,0.216374268373175,"Partnerships","eFFECTOR Enters Into Agreement with Pfizer Inc. to Develop Novel First-inClass Inhibitors of eIF4E to Treat Multiple Cancer Types","https://www.pfizer.com//news/press-release/press-release-detail/effector-enters-agreement-pfizer-inc-develop-novel-first-",0.45,2019,1,16.8166074660999,0.445919036865234,-0.113853454589837,0,-0.0737266540527344,1,0.55,0.19,"Management",0,1
2019-01-10,41.0056915283203,41.0151786804199,39.8766593933105,40.1423149108887,34.6603507995605,39731162,NA,NA,NA,NA,NA,NA,NA,0.36,2019,1,17.4976463999523,1.13851928710938,-0.863376617431641,0,-0.843776702880859,0,NA,NA,NA,0,NA
2019-01-11,40.1612892150879,40.6831130981445,39.9905128479004,40.6831130981445,35.1272926330566,21064506,NA,NA,NA,NA,NA,NA,NA,0.39,2019,1,16.8631000493711,0.692600250244141,0.521823883056641,1,0.466941833496094,0,NA,NA,NA,0,NA
2019-01-14,40.3700180053711,40.4459190368652,40.0094871520996,40.1992416381836,34.7095069885254,17605173,192,60,0.523809521730915,0.256619144341528,"Medicines","US FDA Accepts Regulatory Submissions for Review of Tafamidis to Treat Transthyretin Amyloid Cardiomyopathy","https://www.pfizer.com//news/press-release/press-release-detail/us_fda_accepts_regulatory_submissions_for_review_of_tafamidis_to_treat_transthyretin_amyloid_cardiomyopathy",0.39,2019,1,16.6837033940783,0.436431884765625,-0.1707763671875,0,-0.41778564453125,1,1.92,0.6,"Research",0,2
2019-01-15,40.4174575805664,41.0246696472168,40.2561683654785,40.5407981872559,35.0044097900391,25865371,NA,NA,NA,NA,NA,NA,NA,0.34,2019,1,17.0684156436863,0.768501281738288,0.123340606689453,1,0.294902801513672,0,NA,NA,NA,0,NA
2019-01-16,40.4079704284668,40.5977210998535,39.8766593933105,39.9525604248047,34.4965057373047,30169380,NA,NA,NA,NA,NA,NA,NA,0.38,2019,1,17.2223380938548,0.721061706542976,-0.455410003662109,0,-0.507904052734375,0,NA,NA,NA,0,NA
2019-01-17,39.8007583618164,40.4743843078613,39.6869087219238,40.294116973877,34.7914199829102,24177284,NA,NA,NA,NA,NA,NA,NA,0.38,2019,1,17.0009241139683,0.7874755859375,0.493358612060547,1,0.294914245605469,0,NA,NA,NA,0,NA
2019-01-18,40.6641387939453,40.6831130981445,40.0948753356934,40.3510437011719,34.8405685424805,38618455,NA,NA,NA,NA,NA,NA,NA,0.32,2019,1,17.4692408548801,0.588237762451172,-0.313095092773438,0,0.0491485595703125,0,NA,NA,NA,0,NA
2019-01-22,40.237190246582,40.5028457641602,39.7817840576172,40.104362487793,34.6275825500488,29444122,NA,NA,NA,NA,NA,NA,NA,0.34,2019,1,17.1980048895736,0.721061706542976,-0.132827758789062,0,-0.212985992431641,0,NA,NA,NA,0,NA
2019-01-23,39.8387107849121,40.0379524230957,39.4212532043457,40,34.537467956543,24462813,NA,NA,NA,NA,NA,NA,NA,0.32,2019,1,17.0126647265775,0.61669921875,0.161289215087891,1,-0.0901145935058594,0,NA,NA,NA,0,NA
2019-01-24,39.6394691467285,39.6489562988281,38.5388984680176,38.851993560791,33.5462379455566,34394023,NA,NA,NA,NA,NA,NA,NA,0.34,2019,1,17.3533933863222,1.11005783081055,-0.787475585937493,0,-0.991230010986328,0,NA,NA,NA,0,NA
2019-01-25,38.9943084716797,39.1366233825684,38.4345359802246,38.5578765869141,33.2922859191895,35862455,NA,NA,NA,NA,NA,NA,NA,0.33,2019,1,17.3952015123627,0.70208740234375,-0.436431884765625,0,-0.253952026367188,0,NA,NA,NA,0,NA
2019-01-28,38.425048828125,38.4535102844238,37.4573059082031,37.5047454833984,32.3829803466797,39329694,NA,NA,NA,NA,NA,NA,NA,0.37,2019,1,17.4874903894834,0.996204376220703,-0.920303344726562,0,-0.909305572509766,0,NA,NA,NA,0,NA
2019-01-29,37.4762802124023,38.7571144104004,37.4478187561035,38.6812133789062,33.3987808227539,51376808,214,72,0.49650349476747,0.273946359890856,"Research","Pfizer and Lilly Announce Top-Line Results From Second Phase 3 Study of Tanezumab in Osteoarthritis Pain","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_and_lilly_announce_top_line_results_from_second_phase_3_study_of_tanezumab_in_osteoarthritis_pain",0.41,2019,1,17.7546974418396,1.30929565429687,1.20493316650391,1,1.01580047607422,1,2.14,0.72,"Research",0,2
2019-01-30,38.6812133789062,39.6110076904297,38.6432647705078,39.4497146606445,34.0623359680176,36067880,NA,NA,NA,NA,NA,NA,NA,0.38,2019,1,17.400913304273,0.967742919921875,0.768501281738281,1,0.663555145263672,0,NA,NA,NA,0,NA
2019-01-31,39.2599601745605,40.4364318847656,39.2314987182617,40.2751426696777,35.0787506103516,40927452,NA,NA,NA,NA,NA,NA,NA,0.32,2019,1,17.5273116183379,1.20493316650391,1.01518249511719,1,1.01641464233398,0,NA,NA,NA,0,NA
2019-02-01,40.6736221313477,40.910816192627,40.3700180053711,40.6831130981445,35.43408203125,27239681,276,101,0.464190980201085,0.286474163916053,"Medicines","Pfizer Receives Positive CHMP Opinion for Vizimpro® (dacomitinib) for the First-line Treatment of Adult Patients with Locally Advanced Or Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mutations","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_receives_positive_chmp_opinion_for_vizimpro_dacomitinib_for_the_first_line_treatment_of_adult_patients_with_locally_advanced_or_metastatic_non_small_cell_lung_cancer_with_egfr_activating_mutations",0.35,2019,2,17.1201853651686,0.540798187255859,0.009490966796875,1,0.355331420898438,1,2.76,1.01,"Research",0,2
2019-02-04,40.6451606750488,40.6451606750488,39.810245513916,40.2656555175781,35.070484161377,19426485,190,59,0.526104415557814,0.372197308860692,"Responsibility","The Union For International Cancer Control And Pfizer Announce New Phase Of Global Grants Initiative Supporting Metastatic Breast Cancer Patients","https://www.pfizer.com//news/press-release/press-release-detail/the_union_for_international_cancer_control_and_pfizer_announce_new_phase_of_global_grants_initiative_supporting_metastatic_breast_cancer_patients",0.36,2019,2,16.7821479506486,0.834915161132812,-0.379505157470703,0,-0.363597869873047,1,1.9,0.59,"Management",0,1
2019-02-05,40.2561683654785,40.5407981872559,39.9051246643066,39.9525604248047,34.7977905273438,21127641,NA,NA,NA,NA,NA,NA,NA,0.35,2019,2,16.8660927884763,0.635673522949219,-0.303607940673821,0,-0.272693634033203,0,NA,NA,NA,0,NA
2019-02-06,39.7722969055176,40.1992416381836,39.6489562988281,40.1612892150879,34.9795875549316,16450410,NA,NA,NA,NA,NA,NA,NA,0.36,2019,2,16.615861019666,0.550285339355469,0.388992309570312,1,0.181797027587891,0,NA,NA,NA,0,NA
2019-02-07,39.9525604248047,39.9905128479004,39.0986709594727,39.5635681152344,34.4589805603027,24248008,NA,NA,NA,NA,NA,NA,NA,0.31,2019,2,17.0038450688843,0.891841888427734,-0.388992309570312,0,-0.520606994628906,0,NA,NA,NA,0,NA
2019-02-08,39.4022789001465,40.0759010314941,39.3643264770508,40.0664138793945,34.8969573974609,27500125,NA,NA,NA,NA,NA,NA,NA,0.36,2019,2,17.1297011444445,0.711574554443359,0.664134979248054,1,0.437976837158203,0,NA,NA,NA,0,NA
2019-02-11,40.1138534545898,40.1423149108887,39.38330078125,39.5445938110351,34.4424591064453,27102134,514,261,0.326451612481998,0.229697688135834,"Medicines","FDA Accepts sBLA and Grants Priority Review for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma","https://www.pfizer.com//news/press-release/press-release-detail/fda_accepts_sbla_and_grants_priority_review_for_bavencio_avelumab_plus_inlyta_axitinib_for_the_treatment_of_advanced_renal_cell_carcinoma",0.32,2019,2,17.1151230650346,0.759014129638672,-0.569259643554688,0,-0.454498291015625,1,5.14,2.61,"Research",0,2
2019-02-12,39.573055267334,39.8576850891113,39.2694511413574,39.7248573303223,34.5994644165039,30540177,73,5,0.871794860618015,0.224137930390408,"Partnerships","G-CON Manufacturing Delivers New PCMM POD® With Tablet Coating Capability to Pfizer Inc.’s  Groton, Conn. Site","https://www.pfizer.com//news/press-release/press-release-detail/g-con-manufacturing-delivers-new-pcmm-podr-tablet-coating",0.35,2019,2,17.2345536861595,0.588233947753906,0.151802062988281,1,0.157005310058594,1,0.73,0.05,"Management",0,1
2019-02-13,39.7722969055176,39.9051246643066,39.2694511413574,39.5635681152344,34.4589805603027,24757195,NA,NA,NA,NA,NA,NA,NA,0.36,2019,2,17.0246267521949,0.635673522949219,-0.208728790283203,0,-0.140483856201172,0,NA,NA,NA,0,NA
2019-02-14,39.5635681152344,39.9620475769043,39.4876670837402,39.8197326660156,34.6820945739746,19864949,NA,NA,NA,NA,NA,NA,NA,0.3,2019,2,16.804467430238,0.474380493164062,0.25616455078125,1,0.223114013671875,0,NA,NA,NA,0,NA
2019-02-15,40.2087287902832,40.3320693969727,39.9240989685059,40.2277030944824,35.037425994873,19168993,NA,NA,NA,NA,NA,NA,NA,0.3,2019,2,16.7688046358149,0.407970428466797,0.0189743041992188,1,0.355331420898438,0,NA,NA,NA,0,NA
2019-02-19,40.0759010314941,40.6641387939453,40.0284614562988,40.4174575805664,35.2027015686035,24432985,228,78,0.490196076829425,0.27592425583776,"Medicines","Pfizer Receives European Approval for ZIRABEV™ (bevacizumab), a Biosimilar to Avastin®*","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_receives_european_approval_for_zirabev_bevacizumab_a_biosimilar_to_avastin",0.34,2019,2,17.0114446625352,0.635677337646484,0.341556549072266,1,0.165275573730469,1,2.28,0.78,"Research",0,2
2019-02-20,40.3510437011719,40.3795051574707,39.7817840576172,40.0379524230957,34.8721656799316,27354884,NA,NA,NA,NA,NA,NA,NA,0.42,2019,2,17.1244056814866,0.597721099853516,-0.313091278076172,0,-0.330535888671875,0,NA,NA,NA,0,NA
2019-02-21,39.8671722412109,40.1518020629883,39.7153701782227,39.9810256958008,34.8225708007812,19611883,NA,NA,NA,NA,NA,NA,NA,0.37,2019,2,16.7916462669897,0.436431884765625,0.113853454589844,1,-0.0495948791503906,0,NA,NA,NA,0,NA
2019-02-22,40.1328277587891,40.9203033447266,40.0569267272949,40.7590141296387,35.5001907348633,24779329,NA,NA,NA,NA,NA,NA,NA,0.34,2019,2,17.0255203958659,0.863376617431641,0.626186370849609,1,0.677619934082031,0,NA,NA,NA,0,NA
2019-02-25,40.8349151611328,41.148006439209,40.7400398254395,40.8728637695312,35.5993461608887,25274815,NA,NA,NA,NA,NA,NA,NA,0.34,2019,2,17.0453190429234,0.407966613769531,0.0379486083984375,1,0.0991554260253906,0,NA,NA,NA,0,NA
2019-02-26,40.7590141296387,41.0151786804199,40.6072120666504,40.8159408569336,35.5497703552246,16548959,NA,NA,NA,NA,NA,NA,NA,0.34,2019,2,16.6218338179337,0.407966613769531,0.0569267272949219,1,-0.0495758056640625,0,NA,NA,NA,0,NA
2019-02-27,40.7779884338379,41.0056915283203,40.61669921875,40.7305488586426,35.475399017334,16475074,NA,NA,NA,NA,NA,NA,NA,0.36,2019,2,16.6173591906945,0.388992309570312,-0.0474395751953125,0,-0.074371337890625,0,NA,NA,NA,0,NA
2019-02-28,40.7495269775391,41.5370025634766,40.6736221313477,41.1290321350098,35.8224639892578,39002427,176,58,0.504273502118489,0.207263064475409,"Research","Pfizer Announces Serotypes Included in 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_serotypes_included_in_20_valent_pneumococcal_conjugate_vaccine_candidate_being_investigated_for_the_prevention_of_invasive_disease_and_pneumonia_in_adults_aged_18_years_and_older",0.36,2019,2,17.4791344585663,0.863380432128906,0.379505157470703,1,0.347064971923828,1,1.76,0.58,"Research",0,2
2019-03-01,41.3757133483887,41.5464897155762,41.0721054077149,41.1385192871094,35.8307342529297,26667781,264,101,0.446575341242259,0.27693474941052,"Medicines","Pfizer Receives Positive CHMP Opinion for LORVIQUA® (lorlatinib) for Certain Adult Patients with Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_receives_positive_chmp_opinion_for_lorviqua_lorlatinib_for_certain_adult_patients_with_previously_treated_alk_positive_advanced_non_small_cell_lung_cancer",0.34,2019,3,17.0989667280954,0.474384307861321,-0.237194061279297,0,0.008270263671875,1,2.64,1.01,"Research",0,2
2019-03-04,41.2144203186035,41.3567352294922,40.6831130981445,40.8633766174316,35.5910873413086,22805820,115,14,0.782945730364762,0.320099254788836,"Finance","Pfizer Prices $5,000,000,000 Debt Offering","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_prices_5_000_000_000_debt_offering-0",0.31,2019,3,16.9425263683569,0.673622131347656,-0.351043701171882,0,-0.239646911621094,1,1.15,0.14,"Finance",0,3
2019-03-05,40.8823547363281,41.0341567993164,40.6546478271484,40.6926002502441,35.4423446655273,26529812,41,5,0.782608678638942,0.208144795438259,"Finance","Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_invites_public_to_view_and_listen_to_webcast_of_pfizer_presentation_at_healthcare_conference-23",0.37,2019,3,17.0937796774649,0.379508972167969,-0.189754486083984,0,-0.14874267578125,1,0.41,0.05,"Finance",0,3
2019-03-06,40.6261863708496,40.6736221313477,39.4876670837402,39.7153701782227,34.5911979675293,22410359,NA,NA,NA,NA,NA,NA,NA,0.35,2019,3,16.9250339099051,1.18595504760742,-0.910816192626953,0,-0.851146697998047,0,NA,NA,NA,0,NA
2019-03-07,39.7153701782227,39.7438316345215,39.1366233825684,39.2694511413574,34.2028160095215,29046132,NA,NA,NA,NA,NA,NA,NA,0.28,2019,3,17.1843959170831,0.607208251953132,-0.445919036865234,0,-0.388381958007812,0,NA,NA,NA,0,NA
2019-03-08,39.2125244140625,39.3168869018555,38.2732467651367,38.7950668334961,33.7896385192871,31306119,343,166,0.34774066729324,0.248292682805711,"Medicines","European Medicines Agency Validates Application for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma","https://www.pfizer.com//news/press-release/press-release-detail/european_medicines_agency_validates_application_for_bavencio_avelumab_plus_inlyta_axitinib_for_the_treatment_of_advanced_renal_cell_carcinoma",0.28,2019,3,17.259324163554,1.04364013671875,-0.417457580566406,0,-0.413177490234375,1,3.43,1.66,"Research",0,2
2019-03-11,38.9943084716797,39.3927879333496,38.7096786499023,39.3738136291504,34.2937126159668,29161545,209,85,0.421768706048406,0.260176990920197,"Medicines","U.S. FDA Approves Pfizer’s Oncology Biosimilar TRAZIMERA™ (trastuzumab-qyyp), a Biosimilar to Herceptin®1","https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_approves_pfizer_s_oncology_biosimilar_trazimera_trastuzumab_qyyp_a_biosimilar_to_herceptin_1",0.33,2019,3,17.188361481532,0.683109283447266,0.379505157470703,1,0.504074096679688,1,2.09,0.85,"Research",0,2
2019-03-12,39.5635681152344,39.7722969055176,39.2504730224609,39.5920295715332,34.483772277832,24170539,NA,NA,NA,NA,NA,NA,NA,0.34,2019,3,17.0006450941761,0.521823883056641,0.0284614562988281,1,0.190059661865234,0,NA,NA,NA,0,NA
2019-03-13,39.7248573303223,39.9715385437012,39.4212532043457,39.8576850891113,34.715160369873,23715316,NA,NA,NA,NA,NA,NA,NA,0.33,2019,3,16.9816316842717,0.550285339355469,0.132827758789062,1,0.231388092041016,0,NA,NA,NA,0,NA
2019-03-14,39.8481979370117,39.9240989685059,39.0227699279785,39.0796966552734,34.0375480651855,32119596,NA,NA,NA,NA,NA,NA,NA,0.34,2019,3,17.2849769002642,0.901329040527351,-0.768501281738281,0,-0.6776123046875,0,NA,NA,NA,0,NA
2019-03-15,39.1176452636719,39.7343444824219,38.7666015625,39.6394691467285,34.5250930786133,74768652,NA,NA,NA,NA,NA,NA,NA,0.32,2019,3,18.1299092775671,0.967742919921875,0.521823883056634,1,0.487545013427734,0,NA,NA,NA,0,NA
2019-03-18,39.6299819946289,39.9146118164062,39.5161285400391,39.6679306030273,34.5498847961426,18994345,NA,NA,NA,NA,NA,NA,NA,0.33,2019,3,16.7596519138979,0.398483276367188,0.0379486083984375,1,0.0247917175292969,0,NA,NA,NA,0,NA
2019-03-19,39.8197326660156,40.2561683654785,39.6110076904297,40.1328277587891,34.9547996520996,26403227,347,153,0.387999999224,0.248015872892849,"Research","Merck KGaA, Darmstadt, Germany, and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer","https://www.pfizer.com//news/press-release/press-release-detail/merck_kgaa_darmstadt_germany_and_pfizer_announce_discontinuation_of_phase_iii_javelin_ovarian_parp_100_trial_in_previously_untreated_advanced_ovarian_cancer",0.33,2019,3,17.0889968333691,0.645160675048821,0.313095092773438,1,0.404914855957031,1,3.47,1.53,"Research",0,2
2019-03-20,40.0379524230957,40.2277030944824,39.6394691467285,40.0094871520996,34.8473701477051,23499035,183,59,0.512396692097534,0.295482295121511,"Finance","Pfizer Secures Exclusive Option to Acquire Gene Therapy Company Vivet Therapeutics","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_secures_exclusive_option_to_acquire_gene_therapy_company_vivet_therapeutics",0.33,2019,3,16.9724699569964,0.588233947753913,-0.0284652709960938,0,-0.107429504394531,1,1.83,0.59,"Finance",0,3
2019-03-21,39.7817840576172,40.4554061889649,39.7248573303223,40.1802673339844,34.9961166381836,24262553,NA,NA,NA,NA,NA,NA,NA,0.39,2019,3,17.0044447321138,0.730548858642585,0.398483276367188,1,0.148746490478516,0,NA,NA,NA,0,NA
2019-03-22,40.0379524230957,40.4364318847656,39.6869087219238,39.705883026123,34.582935333252,19620105,NA,NA,NA,NA,NA,NA,NA,0.33,2019,3,16.7920654147373,0.749523162841797,-0.332069396972656,0,-0.413181304931641,0,NA,NA,NA,0,NA
2019-03-25,39.6679306030273,39.9905128479004,39.5351028442383,39.7438316345215,34.6159858703613,19823316,NA,NA,NA,NA,NA,NA,NA,0.29,2019,3,16.8023694290695,0.455410003662109,0.0759010314941477,1,0.033050537109375,0,NA,NA,NA,0,NA
2019-03-26,40.0379524230957,40.5123329162598,39.9715385437012,40.2466773986816,35.0539627075195,20849279,NA,NA,NA,NA,NA,NA,NA,0.35,2019,3,16.8528299732387,0.540794372558594,0.208724975585938,1,0.437976837158203,0,NA,NA,NA,0,NA
2019-03-27,40.1707763671875,40.4554061889649,39.7722969055176,39.8671722412109,34.7234153747559,19455048,NA,NA,NA,NA,NA,NA,NA,0.36,2019,3,16.7836171830304,0.683109283447273,-0.303604125976562,0,-0.330547332763672,0,NA,NA,NA,0,NA
2019-03-28,40.0189743041992,40.1992416381836,39.9051246643066,40.1233406066895,34.946533203125,16915541,NA,NA,NA,NA,NA,NA,NA,0.33,2019,3,16.6437434022494,0.294116973876953,0.104366302490234,1,0.223117828369141,0,NA,NA,NA,0,NA
2019-03-29,40.2277030944824,40.3984832763672,40.0284614562988,40.294116973877,35.095272064209,21681834,NA,NA,NA,NA,NA,NA,NA,0.36,2019,3,16.8919853711753,0.370021820068359,0.0664138793945312,1,0.148738861083984,0,NA,NA,NA,0,NA
2019-04-01,40.3984832763672,40.7400398254395,40.3700180053711,40.6451606750488,35.4010200500488,20345046,NA,NA,NA,NA,NA,NA,NA,0.3,2019,4,16.8283480495652,0.370021820068359,0.246677398681641,1,0.305747985839844,0,NA,NA,NA,0,NA
2019-04-02,40.7495269775391,40.9677429199219,40.5502853393555,40.7115745544434,35.4588737487793,18625129,234,45,0.677419352410683,0.258333333094136,"Research","Sangamo and Pfizer Announce Phase 1/2 Interim Data for Investigational Hemophilia A Gene Therapy","https://www.pfizer.com//news/press-release/press-release-detail/sangamo_and_pfizer_announce_phase_1_2_interim_data_for_investigational_hemophilia_a_gene_therapy",0.32,2019,4,16.7400223020713,0.417457580566406,-0.0379524230957031,0,0.0578536987304688,1,2.34,0.45,"Research",0,2
2019-04-03,40.7874755859375,40.8633766174316,40.3700180053711,40.6451606750488,35.4010200500488,16200402,307,111,0.468899520409331,0.29210342397477,"Medicines","VIZIMPRO® (dacomitinib) Receives Marketing Authorization in European Union (EU) for the First-Line Treatment of Adult Patients with EGFR-Mutated Non-Small Cell Lung Cancer","https://www.pfizer.com//news/press-release/press-release-detail/vizimpro_dacomitinib_receives_marketing_authorization_in_european_union_eu_for_the_first_line_treatment_of_adult_patients_with_egfr_mutated_non_small_cell_lung_cancer",0.34,2019,4,16.6005466764364,0.493358612060547,-0.142314910888672,0,-0.0578536987304688,1,3.07,1.11,"Research",0,2
2019-04-04,40.5977210998535,40.721061706543,40.322582244873,40.5502853393555,35.3183975219727,12990972,248,93,0.454545453212477,0.273895582109321,"Medicines","U.S. FDA Approves IBRANCE® (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer","https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_approves_ibrance_palbociclib_for_the_treatment_of_men_with_hr_her2_metastatic_breast_cancer",0.34,2019,4,16.3797652896138,0.398479461669922,-0.047435760498054,0,-0.0826225280761719,1,2.48,0.93,"Research",0,2
2019-04-05,40.7779884338379,41.0626182556152,40.6926002502441,40.7874755859375,35.5249786376953,15559043,NA,NA,NA,NA,NA,NA,NA,0.34,2019,4,16.5601526352383,0.370018005371094,0.00948715209960938,1,0.206581115722656,0,NA,NA,NA,0,NA
2019-04-08,40.8633766174316,41.0626182556152,40.7115745544434,40.9297904968262,35.6489334106445,15410323,NA,NA,NA,NA,NA,NA,NA,0.33,2019,4,16.5505482323835,0.351043701171875,0.0664138793945312,1,0.123954772949219,0,NA,NA,NA,0,NA
2019-04-09,40.7779884338379,40.7969627380371,40.3984832763672,40.6451606750488,35.4010200500488,18825072,NA,NA,NA,NA,NA,NA,NA,0.33,2019,4,16.7507002094648,0.398479461669922,-0.132827758789062,0,-0.247913360595703,0,NA,NA,NA,0,NA
2019-04-10,40.721061706543,40.721061706543,40.4648971557617,40.5407981872559,35.3101234436035,13202615,NA,NA,NA,NA,NA,NA,NA,0.31,2019,4,16.3959255497394,0.25616455078125,-0.180263519287109,0,-0.0908966064453125,0,NA,NA,NA,0,NA
2019-04-11,40.5977210998535,40.6356735229492,39.8387107849121,40.104362487793,34.930004119873,20214877,NA,NA,NA,NA,NA,NA,NA,0.31,2019,4,16.8219294259164,0.796962738037109,-0.493358612060554,0,-0.380119323730469,0,NA,NA,NA,0,NA
2019-04-12,40.1707763671875,40.1707763671875,39.4497146606445,39.573055267334,34.4672393798828,21338546,NA,NA,NA,NA,NA,NA,NA,0.3,2019,4,16.8760257134223,0.721061706542969,-0.597721099853516,0,-0.462764739990234,0,NA,NA,NA,0,NA
2019-04-15,39.7153701782227,39.9620475769043,39.3453521728516,39.9335861206055,34.7812652587891,18362788,NA,NA,NA,NA,NA,NA,NA,0.31,2019,4,16.7258368379381,0.616695404052734,0.218215942382812,1,0.31402587890625,0,NA,NA,NA,0,NA
2019-04-16,40.0569267272949,40.1328277587891,38.7381401062012,38.8235282897949,33.8144264221191,27506976,NA,NA,NA,NA,NA,NA,NA,0.34,2019,4,17.129950239549,1.39468765258789,-1.2333984375,0,-0.966838836669922,0,NA,NA,NA,0,NA
2019-04-17,38.8045539855957,38.8994293212891,37.3719177246094,37.8368110656738,32.9550170898438,42412117,NA,NA,NA,NA,NA,NA,NA,0.37,2019,4,17.5629446812554,1.52751159667969,-0.967742919921875,0,-0.859409332275391,0,NA,NA,NA,0,NA
2019-04-18,37.8842506408691,37.8842506408691,36.4516143798828,37.3624305725098,32.5418395996094,50579774,194,78,0.426470586667388,0.262801932113235,"Research","Pfizer and Lilly Announce Top-Line Results From Long-Term Phase 3 Study of Tanezumab in Patients With Osteoarthritis","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_and_lilly_announce_top_line_results_from_long_term_phase_3_study_of_tanezumab_in_patients_with_osteoarthritis",0.37,2019,4,17.7390623507976,1.43263626098633,-0.521820068359375,0,-0.413177490234375,1,1.94,0.78,"Research",0,2
2019-04-22,37.0303611755371,37.4762802124023,36.8216323852539,36.9829216003418,32.2112998962402,31018904,NA,NA,NA,NA,NA,NA,NA,0.3,2019,4,17.250107415283,0.654647827148438,-0.0474395751953125,0,-0.330539703369141,0,NA,NA,NA,0,NA
2019-04-23,37.087287902832,37.6091079711914,36.8880462646484,37.4003791809082,32.5748977661133,26672102,NA,NA,NA,NA,NA,NA,NA,0.3,2019,4,17.0991287456929,0.721061706542969,0.313091278076172,1,0.363597869873047,0,NA,NA,NA,0,NA
2019-04-24,37.4762802124023,37.6091079711914,37.1537017822266,37.3529396057129,32.5335807800293,21196994,NA,NA,NA,NA,NA,NA,NA,0.31,2019,4,16.8693699843124,0.455406188964844,-0.123340606689453,0,-0.0413169860839844,0,NA,NA,NA,0,NA
2019-04-25,37.2390899658203,37.7893753051758,37.1631889343262,37.5806465148926,32.7319068908691,18130065,109,18,0.716535427428855,0.296037295347232,"Finance","Pfizer Hosts Annual Meeting of Shareholders","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_hosts_annual_meeting_of_shareholders-6",0.35,2019,4,16.7130822230995,0.626186370849609,0.341556549072266,1,0.198326110839844,1,1.09,0.18,"Finance",0,3
2019-04-26,37.6375694274902,37.9411773681641,37.4288444519043,37.9221992492676,33.0293846130371,20053193,216,75,0.484536080809154,0.271455223627374,"Medicines","Pfizer Receives Positive CHMP Opinion for TALZENNA® (talazoparib) for Patients with Inherited (Germline) BRCA-Mutated Locally Advanced or Metastatic Breast Cancer","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_receives_positive_chmp_opinion_for_talzenna_talazoparib_for_patients_with_inherited_germline_brca_mutated_locally_advanced_or_metastatic_breast_cancer",0.3,2019,4,16.8138990007753,0.512332916259766,0.284629821777344,1,0.297477722167969,1,2.16,0.75,"Research",0,2
2019-04-29,37.9221992492676,37.9696388244629,37.5616683959961,37.5616683959961,32.7153663635254,23229001,NA,NA,NA,NA,NA,NA,NA,0.3,2019,4,16.9609121421362,0.407970428466797,-0.360530853271484,0,-0.314018249511719,0,NA,NA,NA,0,NA
2019-04-30,38.3301696777344,39.0702095031738,37.7609100341797,38.529411315918,33.5582618713379,34360400,NA,NA,NA,NA,NA,NA,NA,0.43,2019,4,17.3524153255594,1.30929946899414,0.199241638183594,1,0.8428955078125,0,NA,NA,NA,0,NA
2019-05-01,38.5104370117188,38.8235282897949,38.1119537353516,38.6812133789062,33.6904716491699,20703406,NA,NA,NA,NA,NA,NA,NA,0.32,2019,5,16.8458088340642,0.711574554443359,0.1707763671875,1,0.132209777832031,0,NA,NA,NA,0,NA
2019-05-02,38.719165802002,38.9184074401855,38.5009498596191,38.9089164733887,33.8888092041016,20471210,NA,NA,NA,NA,NA,NA,NA,0.32,2019,5,16.8345301156336,0.417457580566406,0.189750671386719,1,0.198337554931641,0,NA,NA,NA,0,NA
2019-05-03,39.1081581115723,39.3738136291504,38.9278945922851,39.2694511413574,34.2028160095215,18664759,NA,NA,NA,NA,NA,NA,NA,0.29,2019,5,16.7421478119572,0.445919036865241,0.161293029785156,1,0.314006805419922,0,NA,NA,NA,0,NA
2019-05-06,38.8140411376953,39.6299819946289,38.7476272583008,39.5161285400391,34.4176597595215,25973406,250,77,0.529051986149688,0.274559193724132,"Medicines","U.S. FDA Approves VYNDAQEL® and VYNDAMAX™ for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease","https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_approves_vyndaqel_and_vyndamax_for_use_in_patients_with_transthyretin_amyloid_cardiomyopathy_a_rare_and_fatal_disease",0.28,2019,5,17.0725837648687,0.882354736328125,0.70208740234375,1,0.21484375,1,2.5,0.77,"Research",0,2
2019-05-07,39.2694511413574,39.573055267334,38.425048828125,38.7381401062012,33.7400512695312,27603838,317,109,0.488262909651965,0.283244680662736,"Medicines","European Commission Approves LORVIQUA® (lorlatinib) for Certain Adult Patients with Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer","https://www.pfizer.com//news/press-release/press-release-detail/european_commission_approves_lorviqua_lorlatinib_for_certain_adult_patients_with_previously_treated_alk_positive_advanced_non_small_cell_lung_cancer",0.34,2019,5,17.1334654152176,1.14800643920898,-0.53131103515625,0,-0.677608489990234,1,3.17,1.09,"Research",0,2
2019-05-08,38.7096786499023,38.9278945922851,38.3681221008301,38.851993560791,33.8392181396484,23811968,165,38,0.625615760464947,0.256962024991187,"Finance","Pfizer Acquires Clinical-Stage Biotech Therachon","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_acquires_clinical_stage_biotech_therachon",0.35,2019,5,16.98569891139,0.559772491455071,0.142314910888672,1,0.0991668701171875,1,1.65,0.38,"Finance",0,3
2019-05-09,38.235294342041,38.7476272583008,38.1688804626465,38.5578765869141,33.8809013366699,19732461,137,18,0.767741930530697,0.298651251833042,"Finance","Pfizer Opens New State-Of-The-Art Biologics Clinical Manufacturing Facility In Andover, Massachusetts","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_opens_new_state_of_the_art_biologics_clinical_manufacturing_facility_in_andover_massachusetts",0.34,2019,5,16.7977756548058,0.578746795654304,0.322582244873047,1,0.0416831970214844,1,1.37,0.18,"Finance",0,3
2019-05-10,38.5483856201172,38.7286529541016,37.8273239135742,38.6337776184082,33.9476013183594,17391527,NA,NA,NA,NA,NA,NA,NA,0.3,2019,5,16.6714937490604,0.901329040527344,0.0853919982910156,1,0.0666999816894531,0,NA,NA,NA,0,NA
2019-05-13,38.1688804626465,38.5673637390137,38.0929794311523,38.4914627075195,33.8225479125977,28010788,NA,NA,NA,NA,NA,NA,NA,0.3,2019,5,17.1481003153508,0.474384307861328,0.322582244873054,1,-0.125053405761719,0,NA,NA,NA,0,NA
2019-05-14,38.5104370117188,38.7760925292969,38.4819717407227,38.5768508911133,33.8975791931152,26772759,467,214,0.371512481099101,0.243736578295012,"Medicines","FDA Approves BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Combination for Patients with Advanced Renal Cell Carcinoma","https://www.pfizer.com//news/press-release/press-release-detail/fda_approves_bavencio_avelumab_plus_inlyta_axitinib_combination_for_patients_with_advanced_renal_cell_carcinoma",0.38,2019,5,17.1028955106677,0.294120788574219,0.0664138793945312,1,0.0750312805175781,1,4.67,2.14,"Research",0,2
2019-05-15,38.7666015625,39.1745719909668,38.6147994995117,39.0417442321777,34.3060760498047,33520678,200,45,0.632653058642232,0.264293419348119,"Research","Pfizer Oncology to Showcase New Data from Innovative Science That Address Patient Needs at ASCO 2019 Annual Meeting","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_oncology_to_showcase_new_data_from_innovative_science_that_address_patient_needs_at_asco_2019_annual_meeting",0.3,2019,5,17.3276730899362,0.559772491455078,0.275142669677734,1,0.408496856689453,1,2,0.45,"Research",0,2
2019-05-16,39.0417442321777,39.8292236328125,39.0417442321777,39.5066413879395,34.7145843505859,25508486,NA,NA,NA,NA,NA,NA,NA,0.32,2019,5,17.0545217782846,0.787479400634766,0.464897155761719,1,0.40850830078125,0,NA,NA,NA,0,NA
2019-05-17,39.1840591430664,39.6679306030273,39.1366233825684,39.3453521728516,34.5728569030762,29187684,NA,NA,NA,NA,NA,NA,NA,0.33,2019,5,17.1892574317031,0.531307220458984,0.161293029785156,1,-0.141727447509766,0,NA,NA,NA,0,NA
2019-05-20,39.278938293457,39.573055267334,39.1650848388672,39.4592018127441,34.6729049682617,24251591,NA,NA,NA,NA,NA,NA,NA,0.3,2019,5,17.0039928226775,0.407970428466797,0.180263519287109,1,0.100048065185547,0,NA,NA,NA,0,NA
2019-05-21,39.573055267334,39.6679306030273,39.3643264770508,39.5351028442383,34.7395896911621,28785056,NA,NA,NA,NA,NA,NA,NA,0.32,2019,5,17.1753669562881,0.303604125976562,-0.0379524230957031,0,0.0666847229003906,0,NA,NA,NA,0,NA
2019-05-22,39.5540809631348,40.0474395751953,39.4212532043457,39.8387107849121,35.0063743591309,25274604,NA,NA,NA,NA,NA,NA,NA,0.36,2019,5,17.0453106946577,0.626186370849609,0.284629821777344,1,0.26678466796875,0,NA,NA,NA,0,NA
2019-05-23,39.6963958740234,39.8292236328125,39.5161285400391,39.7722969055176,34.9480171203613,25495944,NA,NA,NA,NA,NA,NA,NA,0.29,2019,5,17.0540299778759,0.313095092773438,0.0759010314941406,1,-0.0583572387695312,0,NA,NA,NA,0,NA
2019-05-24,39.9051246643066,40.1423149108887,39.7248573303223,39.8007583618164,34.973030090332,15383341,157,73,0.365217389716446,0.29003783065569,"Medicines","Pfizer Announces Top-Line Results from Phase 3 Trial of LYRICA® (pregabalin) in Primary Generalized Tonic-Clonic Seizures","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_top_line_results_from_phase_3_trial_of_lyrica_pregabalin_in_primary_generalized_tonic_clonic_seizures",0.29,2019,5,16.5487957936251,0.417457580566406,-0.104366302490234,0,0.0250129699707031,1,1.57,0.73,"Research",0,2
2019-05-28,39.9905128479004,40.3036041259766,39.7438316345215,39.7533226013184,34.9313430786133,49440610,NA,NA,NA,NA,NA,NA,NA,0.66,2019,5,17.7162827294516,0.559772491455071,-0.237190246582031,0,-0.04168701171875,0,NA,NA,NA,0,NA
2019-05-29,39.5635681152344,39.6963958740234,39.1650848388672,39.5825424194336,34.7812881469727,26895761,NA,NA,NA,NA,NA,NA,NA,0.68,2019,5,17.1074792856919,0.53131103515625,0.0189743041992188,1,-0.150054931640625,0,NA,NA,NA,0,NA
2019-05-30,39.5445938110351,39.8007583618164,39.4497146606445,39.7533226013184,34.9313430786133,17344308,NA,NA,NA,NA,NA,NA,NA,0.76,2019,5,16.6687749990222,0.351043701171875,0.20872879028321,1,0.150054931640625,0,NA,NA,NA,0,NA
2019-05-31,39.5540809631348,39.8292236328125,39.3263778686523,39.3927879333496,34.6145401000977,22639288,NA,NA,NA,NA,NA,NA,NA,0.56,2019,5,16.9351974062125,0.502845764160156,-0.161293029785156,0,-0.316802978515625,0,NA,NA,NA,0,NA
2019-06-03,39.4971542358398,40.0284614562988,39.4402275085449,39.7722969055176,34.9480171203613,22643082,NA,NA,NA,NA,NA,NA,NA,0.31,2019,6,16.93536497694,0.588233947753906,0.275142669677741,1,0.333477020263672,0,NA,NA,NA,0,NA
2019-06-04,40.3036041259766,40.5597724914551,39.8861465454102,40.0664138793945,35.2064666748047,18453537,NA,NA,NA,NA,NA,NA,NA,0.33,2019,6,16.7307666715845,0.673625946044915,-0.237190246582031,0,0.258449554443359,0,NA,NA,NA,0,NA
2019-06-05,40.4174575805664,40.6451606750488,40.237190246582,40.3036041259766,35.4148712158203,21418861,138,31,0.633136090928189,0.273462782729025,"Leadership","Jeff Settleman, Ph.D., Joins Pfizer to Lead Oncology Research & Development","https://www.pfizer.com//news/press-release/press-release-detail/jeff_settleman_ph_d_joins_pfizer_to_lead_oncology_research_development",0.53,2019,6,16.8797824936547,0.407970428466797,-0.113853454589844,0,0.208404541015625,1,1.38,0.31,"Management",0,1
2019-06-06,40.6072120666504,40.8823547363281,40.3036041259766,40.5218238830566,35.6066284179688,24494222,NA,NA,NA,NA,NA,NA,NA,0.62,2019,6,17.0139478517924,0.578750610351562,-0.08538818359375,0,0.191757202148438,0,NA,NA,NA,0,NA
2019-06-07,40.7779884338379,41.0341567993164,40.6641387939453,40.721061706543,35.7817039489746,20023470,NA,NA,NA,NA,NA,NA,NA,0.51,2019,6,16.8124156934467,0.370018005371094,-0.0569267272949219,0,0.175075531005859,0,NA,NA,NA,0,NA
2019-06-10,41.0246696472168,41.0246696472168,40.4838714599609,40.8633766174316,35.9067497253418,15275727,NA,NA,NA,NA,NA,NA,NA,0.33,2019,6,16.5417757214607,0.540798187255859,-0.161293029785156,0,0.125045776367188,0,NA,NA,NA,0,NA
2019-06-11,40.9867172241211,41.0815925598145,40.3700180053711,40.4838714599609,35.5732803344727,18813162,NA,NA,NA,NA,NA,NA,NA,0.38,2019,6,16.7500673423773,0.711574554443359,-0.502845764160156,0,-0.333469390869141,0,NA,NA,NA,0,NA
2019-06-12,40.294116973877,40.9582557678223,40.2846298217773,40.8728637695312,35.9150848388672,16296843,315,169,0.301652891938734,0.26021505362354,"Medicines","Pfizer Announces Results from XELJANZ® XR (tofacitinib) ORAL Shift Study, The First Phase 3b/4 Study to Evaluate Methotrexate Withdrawal with a JAK Inhibitor","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_results_from_xeljanz_xr_tofacitinib_oral_shift_study_the_first_phase_3b_4_study_to_evaluate_methotrexate_withdrawal_with_a_jak_inhibitor",0.37,2019,6,16.6064820273984,0.673625946044922,0.578746795654297,1,0.341804504394531,1,3.15,1.69,"Research",0,2
2019-06-13,40.8633766174316,40.9297904968262,40.1992416381836,40.322582244873,35.4315528869629,14464042,NA,NA,NA,NA,NA,NA,NA,0.32,2019,6,16.4871763345079,0.730548858642578,-0.540794372558594,0,-0.483531951904297,0,NA,NA,NA,0,NA
2019-06-14,40.3415565490723,40.6736221313477,40.3036041259766,40.5692596435547,35.648307800293,13197872,NA,NA,NA,NA,NA,NA,NA,0.34,2019,6,16.3955662382091,0.370018005371094,0.227703094482422,1,0.216754913330078,0,NA,NA,NA,0,NA
2019-06-17,40.5123329162598,40.7020874023438,40.1802673339844,40.6831130981445,35.748348236084,14094931,362,87,0.612472158992267,0.264428739538028,"Finance","Pfizer to Acquire Array BioPharma","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_to_acquire_array_biopharma",0.47,2019,6,16.4613258581129,0.521820068359375,0.170780181884766,1,0.100040435791016,1,3.62,0.87,"Finance",0,3
2019-06-18,40.6261863708496,41.1100578308105,40.6261863708496,40.8633766174316,35.9067497253418,22833434,16,1,0.882352889273359,0.191011233808863,"Finance","Pfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_invites_public_to_view_and_listen_to_webcast_of_july_30_conference_call_with_analysts-0",0.39,2019,6,16.9437364671092,0.483871459960938,0.237190246582031,1,0.158401489257812,1,0.16,0.01,"Finance",0,3
2019-06-19,40.9582557678223,41.3567352294922,40.8823547363281,41.2713470458984,36.2652397155762,21753611,NA,NA,NA,NA,NA,NA,NA,0.36,2019,6,16.8952903706766,0.474380493164062,0.313091278076172,1,0.358489990234375,0,NA,NA,NA,0,NA
2019-06-20,41.5844383239746,41.8500938415527,41.280834197998,41.3662223815918,36.3486022949219,23500300,NA,NA,NA,NA,NA,NA,NA,0.42,2019,6,16.972523787543,0.569259643554688,-0.218215942382812,0,0.0833625793457031,0,NA,NA,NA,0,NA
2019-06-21,41.3187866210938,41.7457313537598,41.0910835266113,41.4326362609863,36.4069595336914,38141203,295,133,0.378504672012839,0.252805670258236,"Medicines","European Commission Approves TALZENNA® (talazoparib) for Patients with Inherited (Germline) BRCA-Mutated Locally Advanced or Metastatic Breast Cancer","https://www.pfizer.com//news/press-release/press-release-detail/european_commission_approves_talzenna_talazoparib_for_patients_with_inherited_germline_brca_mutated_locally_advanced_or_metastatic_breast_cancer",0.31,2019,6,17.456805725546,0.654647827148438,0.113849639892578,1,0.0583572387695312,1,2.95,1.33,"Research",0,2
2019-06-24,41.4516143798828,41.6508522033691,41.2428855895996,41.5180282592773,36.4819946289062,24624075,NA,NA,NA,NA,NA,NA,NA,0.33,2019,6,17.0192352214758,0.407966613769531,0.0664138793945312,1,0.0750350952148438,0,NA,NA,NA,0,NA
2019-06-25,41.6034164428711,42.0208740234375,41.5180282592773,41.5180282592773,36.4819946289062,28429015,NA,NA,NA,NA,NA,NA,NA,0.32,2019,6,17.1629208717021,0.502845764160156,-0.08538818359375,0,0,0,NA,NA,NA,0,NA
2019-06-26,41.4421234130859,41.5559768676758,40.322582244873,40.7874755859375,35.8400573730469,41009348,NA,NA,NA,NA,NA,NA,NA,0.35,2019,6,17.5293106230652,1.23339462280273,-0.654647827148438,0,-0.641937255859375,0,NA,NA,NA,0,NA
2019-06-27,40.8159408569336,41.3282737731934,40.806453704834,41.2049331665039,36.2068786621094,21994977,73,11,0.73809522930839,0.302158272294395,"Leadership","Scott Gottlieb Elected to Pfizer’s Board of Directors","https://www.pfizer.com//news/press-release/press-release-detail/scott_gottlieb_elected_to_pfizer_s_board_of_directors",0.34,2019,6,16.9063247125371,0.521820068359375,0.388992309570312,1,0.3668212890625,1,0.73,0.11,"Management",0,1
2019-06-28,41.2239074707031,41.4800758361816,40.7779884338379,41.1005706787109,36.115177154541,39726209,278,133,0.352798052669591,0.254017305158209,"Medicines","Pfizer Receives U.S. FDA Approval for Its Oncology Biosimilar, ZIRABEV™ (bevacizumab-bvzr)","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_receives_u_s_fda_approval_for_its_oncology_biosimilar_zirabev_bevacizumab_bvzr",0.33,2019,6,17.4975217293316,0.70208740234375,-0.123336791992188,0,-0.0917015075683594,1,2.78,1.33,"Research",0,2
2019-07-01,41.280834197998,41.6318778991699,41.1195449829102,41.527515411377,36.4903335571289,21341392,187,41,0.640350874384426,0.280788176994103,"Research","Pfizer Announces Positive Top-Line Results from Phase 4 Study of Crisaborole Ointment, 2%, in Children Aged 3 Months to Less Than 24 Months with Mild to Moderate Atopic Dermatitis","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_positive_top_line_results_from_phase_4_study_of_crisaborole_ointment_2_in_children_aged_3_months_to_less_than_24_months_with_mild_to_moderate_atopic_dermatitis",0.41,2019,7,16.8761590781836,0.512332916259759,0.246681213378906,1,0.375156402587891,1,1.87,0.41,"Research",1,2
2019-07-02,41.4421234130859,41.954460144043,41.4231491088867,41.954460144043,36.8654899597168,16541898,NA,NA,NA,NA,NA,NA,NA,0.48,2019,7,16.6214070535449,0.53131103515625,0.512336730957031,1,0.375156402587891,0,NA,NA,NA,1,NA
2019-07-03,42.0967750549316,42.2770385742188,41.7267532348633,42.1252365112305,37.015552520752,10297580,NA,NA,NA,NA,NA,NA,NA,0.44,2019,7,16.1474195712483,0.550285339355469,0.0284614562988281,1,0.150062561035156,0,NA,NA,NA,1,NA
2019-07-05,42.0398483276367,42.0778007507324,41.5370025634766,41.6698303222656,36.6153755187988,18295227,291,73,0.598901097255766,0.255080588468759,"Research","Sangamo and Pfizer Announce Updated Phase 1/2 Results for SB-525 Investigational Hemophilia A Gene Therapy Showing Sustained Increased Factor VIII Levels","https://www.pfizer.com//news/press-release/press-release-detail/sangamo_and_pfizer_announce_updated_phase_1_2_results_for_sb_525_investigational_hemophilia_a_gene_therapy_showing_sustained_increased_factor_viii_levels",0.26,2019,7,16.7221508187792,0.540798187255859,-0.370018005371094,0,-0.400177001953125,1,2.91,0.73,"Research",1,2
2019-07-08,41.5559768676758,41.6223907470703,40.7779884338379,41.0815925598145,36.0984992980957,23955312,NA,NA,NA,NA,NA,NA,NA,0.38,2019,7,16.9917006943797,0.844402313232422,-0.474384307861328,0,-0.516876220703125,0,NA,NA,NA,1,NA
2019-07-09,41.1954460144043,41.5559768676758,41.0815925598145,41.148006439209,36.1568565368652,14223308,NA,NA,NA,NA,NA,NA,NA,0.37,2019,7,16.4703926556908,0.474384307861328,-0.0474395751953125,0,0.0583572387695312,0,NA,NA,NA,1,NA
2019-07-10,41.4136619567871,41.8500938415527,41.2144203186035,41.8026580810547,36.7321014404297,15298599,NA,NA,NA,NA,NA,NA,NA,0.42,2019,7,16.543271878908,0.635673522949212,0.388996124267578,1,0.575244903564453,0,NA,NA,NA,1,NA
2019-07-11,41.1005706787109,41.3282737731934,40.2087287902832,40.7779884338379,35.8317222595215,38383518,NA,NA,NA,NA,NA,NA,NA,0.48,2019,7,17.4631387327201,1.11954498291016,-0.322582244873047,0,-0.900379180908203,0,NA,NA,NA,1,NA
2019-07-12,40.7115745544434,40.7874755859375,39.8576850891113,40.2277030944824,35.3481788635254,33580967,NA,NA,NA,NA,NA,NA,NA,0.36,2019,7,17.3294700358807,0.929790496826172,-0.483871459960938,0,-0.483543395996094,0,NA,NA,NA,1,NA
2019-07-15,40.104362487793,40.5787467956543,40.0759010314941,40.5597724914551,35.6399803161621,20363912,NA,NA,NA,NA,NA,NA,NA,0.4,2019,7,16.8292749217501,0.502845764160156,0.455410003662109,1,0.291801452636719,0,NA,NA,NA,1,NA
2019-07-16,40.5977210998535,40.7685012817383,40.3036041259766,40.6546478271484,35.7233428955078,19553386,NA,NA,NA,NA,NA,NA,NA,0.38,2019,7,16.7886590774718,0.464897155761719,0.0569267272949148,1,0.0833625793457031,0,NA,NA,NA,1,NA
2019-07-17,40.8823547363281,40.9772300720215,40.5407981872559,40.5502853393555,35.6316375732422,16341532,NA,NA,NA,NA,NA,NA,NA,0.42,2019,7,16.6092204618449,0.436431884765632,-0.332069396972656,0,-0.091705322265625,0,NA,NA,NA,1,NA
2019-07-18,40.6641387939453,40.853889465332,40.3700180053711,40.853889465332,35.8984107971191,13728877,NA,NA,NA,NA,NA,NA,NA,0.41,2019,7,16.4350120555412,0.483871459960938,0.189750671386719,1,0.266773223876953,0,NA,NA,NA,1,NA
2019-07-19,40.9772300720215,40.9962043762207,40.5787467956543,40.5787467956543,35.6566390991211,23552579,NA,NA,NA,NA,NA,NA,NA,0.37,2019,7,16.9747459265662,0.417457580566406,-0.398483276367195,0,-0.241771697998047,0,NA,NA,NA,1,NA
2019-07-22,40.6356735229492,40.8159408569336,40.3700180053711,40.6261863708496,35.6983299255371,12552086,NA,NA,NA,NA,NA,NA,NA,0.68,2019,7,16.3453975045373,0.4459228515625,-0.00948715209960938,0,0.0416908264160156,0,NA,NA,NA,1,NA
2019-07-23,40.6546478271484,41.0151786804199,40.5597724914551,40.8823547363281,35.9234313964844,19586904,382,171,0.381555153017079,0.270283479828796,"Medicines","FDA Approves Pfizer’s Biosimilar, RUXIENCE™ (rituximab-pvvr), for Certain Cancers and Autoimmune Conditions","https://www.pfizer.com//news/press-release/press-release-detail/fda_approves_pfizer_s_biosimilar_ruxience_rituximab_pvvr_for_certain_cancers_and_autoimmune_conditions",0.86,2019,7,16.7903717886694,0.455406188964844,0.227706909179688,1,0.225101470947266,1,3.82,1.71,"Research",1,2
2019-07-24,40.7969627380371,40.7969627380371,40.1992416381836,40.6926002502441,35.7566871643066,18117838,NA,NA,NA,NA,NA,NA,NA,0.78,2019,7,16.7124075909814,0.597721099853516,-0.104362487792969,0,-0.166744232177734,0,NA,NA,NA,1,NA
2019-07-25,40.6356735229492,40.7969627380371,40.3510437011719,40.4838714599609,35.5732803344727,17514634,NA,NA,NA,NA,NA,NA,NA,0.72,2019,7,16.678547375116,0.445919036865234,-0.151802062988281,0,-0.183406829833984,0,NA,NA,NA,1,NA
2019-07-26,40.4743843078613,40.9582557678223,40.2561683654785,40.8823547363281,35.9234313964844,21062187,NA,NA,NA,NA,NA,NA,NA,0.7,2019,7,16.8629899529108,0.702087402343757,0.407970428466797,1,0.350151062011719,0,NA,NA,NA,1,NA
2019-07-29,40.0094871520996,40.7969627380371,39.2220115661621,39.3263778686523,34.5561828613281,64559186,524,99,0.682182984458775,0.288961038827013,"Finance","Mylan and Upjohn, a Division of Pfizer, to Combine, Creating a New Champion for Global Health Uniquely Positioned to Fulfill the World’s Need for Medicine","https://www.pfizer.com//news/press-release/press-release-detail/mylan_and_upjohn_a_division_of_pfizer_to_combine_creating_a_new_champion_for_global_health_uniquely_positioned_to_fulfill_the_world_s_need_for_medicine",1,2019,7,17.9830929889099,1.574951171875,-0.683109283447266,0,-1.36724853515625,1,5.24,0.99,"Finance",1,3
2019-07-30,37.7893753051758,38.1783676147461,36.6223907470703,36.8026580810547,32.3385887145996,95739668,205,47,0.626984124496095,0.268370606742949,"Finance","Pfizer Completes Acquisition of Array Biopharma","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_completes_acquisition_of_array_biopharma",0.82,2019,7,18.3771432846425,1.55597686767578,-0.986717224121094,0,-2.21759414672852,1,2.05,0.47,"Finance",1,3
2019-07-31,36.6223907470703,37.6375694274902,36.5370025634766,36.8500938415527,32.3802680969238,56309423,55,10,0.692307681656805,0.228873238630728,"Partnerships","BioInvent announces selection of first target discovered by BioInvent’s  proprietary F.I.R.S.TTM technology platform under collaboration with Pfizer Inc.","https://www.pfizer.com//news/press-release/press-release-detail/bioinvent-announces-selection-first-target-discovered",0.56,2019,7,17.8463724680895,1.10056686401367,0.227703094482422,1,0.0416793823242188,1,0.55,0.1,"Management",1,1
2019-08-01,36.3472480773926,36.6413650512695,35.7495269775391,36.2903213500977,32.1867294311523,51624920,132,18,0.759999994933333,0.253807106169531,"Partnerships","Pfizer Announces Closing of Joint Venture With GlaxoSmithKline to Create a Premier Global Consumer Healthcare Company","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_closing_of_joint_venture_with_glaxosmithkline_to_create_a_premier_global_consumer_healthcare_company",0.46,2019,8,17.759515078978,0.891838073730469,-0.0569267272949219,0,-0.193538665771484,1,1.32,0.18,"Management",1,1
2019-08-02,36.2903213500977,36.5654640197754,35.8159408569336,36.0531311035156,31.9763641357422,29153640,198,74,0.455882351265138,0.311569300903128,"Research","Pfizer Announces Phase 3 Top-Line Results for Rivipansel in Patients with Sickle Cell Disease Experiencing a Vaso-Occlusive Crisis","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_phase_3_top_line_results_for_rivipansel_in_patients_with_sickle_cell_disease_experiencing_a_vaso_occlusive_crisis",0.43,2019,8,17.1880903686211,0.749523162841797,-0.237190246582031,0,-0.210365295410156,1,1.98,0.74,"Research",1,2
2019-08-05,35.8254280090332,35.8918418884277,34.5445938110352,35.0664138793945,31.1012172698975,46030183,NA,NA,NA,NA,NA,NA,NA,0.41,2019,8,17.6448079131784,1.34724807739258,-0.759014129638672,0,-0.875146865844727,0,NA,NA,NA,1,NA
2019-08-06,35.2846298217773,35.3984832763672,34.6015167236328,35.0569267272949,31.0928077697754,31985843,NA,NA,NA,NA,NA,NA,NA,0.43,2019,8,17.2808039878873,0.796966552734375,-0.227703094482422,0,-0.00840950012207031,0,NA,NA,NA,1,NA
2019-08-07,34.7722969055176,34.895637512207,34.0227699279785,34.705883026123,30.781457901001,32017253,NA,NA,NA,NA,NA,NA,NA,0.37,2019,8,17.2817855029547,0.872867584228516,-0.0664138793945312,0,-0.311349868774414,0,NA,NA,NA,1,NA
2019-08-08,34.8197326660156,35.0569267272949,34.7248573303223,34.9810256958008,31.0254821777344,23356429,NA,NA,NA,NA,NA,NA,NA,0.4,2019,8,16.9663828789029,0.332069396972656,0.161293029785156,1,0.244024276733398,0,NA,NA,NA,1,NA
2019-08-09,34.8861465454102,34.9430732727051,34.2599601745605,34.4876670837402,30.5879154205322,25391703,NA,NA,NA,NA,NA,NA,NA,0.36,2019,8,17.0499330644655,0.683113098144531,-0.398479461669922,0,-0.437566757202148,0,NA,NA,NA,1,NA
2019-08-12,34.4497146606445,34.4592018127441,32.9981002807617,33.5768508911133,29.7800846099854,44212665,NA,NA,NA,NA,NA,NA,NA,0.38,2019,8,17.6045218670831,1.46110153198242,-0.87286376953125,0,-0.807830810546875,0,NA,NA,NA,1,NA
2019-08-13,33.6147994995117,33.9753303527832,33.3491477966309,33.3965835571289,29.6202068328857,45549453,NA,NA,NA,NA,NA,NA,NA,0.47,2019,8,17.6343091947707,0.626182556152344,-0.218215942382812,0,-0.159877777099606,0,NA,NA,NA,1,NA
2019-08-14,33.1404151916504,33.1878547668457,32.4478187561035,32.485767364502,28.8123817443848,38633421,NA,NA,NA,NA,NA,NA,NA,0.41,2019,8,17.4696283147212,0.740036010742188,-0.654647827148438,0,-0.807825088500977,0,NA,NA,NA,1,NA
2019-08-15,32.5426940917969,32.808349609375,32.2296028137207,32.7134704589844,29.0143375396729,30713665,NA,NA,NA,NA,NA,NA,NA,0.37,2019,8,17.2402182600889,0.578746795654297,0.1707763671875,1,0.201955795288082,0,NA,NA,NA,1,NA
2019-08-16,32.9411773681641,33.2163200378418,32.7229614257812,32.8747634887695,29.1573963165283,30012334,NA,NA,NA,NA,NA,NA,NA,0.37,2019,8,17.2171190217872,0.493358612060547,-0.0664138793945312,0,0.143058776855469,0,NA,NA,NA,1,NA
2019-08-19,33.0929794311523,33.5104370117188,33.045539855957,33.3776092529297,29.6033782958984,21997296,NA,NA,NA,NA,NA,NA,NA,0.43,2019,8,16.9064301401379,0.464897155761719,0.284629821777344,1,0.445981979370121,0,NA,NA,NA,1,NA
2019-08-20,33.3017082214355,33.3586349487305,32.7988624572754,32.8368110656738,29.1237297058105,19932510,159,45,0.558823526672434,0.354782608078639,"Research","The Pfizer Foundation Invests in 20 Organizations Tackling Infectious Diseases and Antimicrobial Resistance","https://www.pfizer.com//news/press-release/press-release-detail/the_pfizer_foundation_invests_in_20_organizations_tackling_infectious_diseases_and_antimicrobial_resistance",0.43,2019,8,16.8078626752212,0.559772491455078,-0.464897155761719,0,-0.479648590087894,1,1.59,0.45,"Research",1,2
2019-08-21,33.1499061584473,33.3206825256348,33.0360527038574,33.0834922790527,29.3425159454346,19208728,268,133,0.336658353275166,0.265036351444127,"Medicines","U.S. FDA Grants XTANDI® (enzalutamide) Application Priority Review for the Treatment of Men with Metastatic Hormone-Sensitive Prostate Cancer","https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_grants_xtandi_enzalutamide_application_priority_review_for_the_treatment_of_men_with_metastatic_hormone_sensitive_prostate_cancer",0.49,2019,8,16.7708753690993,0.284629821777344,-0.0664138793945312,0,0.218786239624023,1,2.68,1.33,"Research",1,2
2019-08-22,33.1688804626465,33.425048828125,33.0170783996582,33.2827301025391,29.5192279815674,16933142,NA,NA,NA,NA,NA,NA,NA,0.43,2019,8,16.6447833836599,0.407970428466797,0.113849639892578,1,0.176712036132812,0,NA,NA,NA,1,NA
2019-08-23,33.4060707092285,33.5388984680176,32.4193534851074,32.5806465148926,28.8965358734131,27765311,NA,NA,NA,NA,NA,NA,NA,0.37,2019,8,17.1392980297638,1.11954498291016,-0.825424194335938,0,-0.622692108154293,0,NA,NA,NA,1,NA
2019-08-26,32.8462982177734,33.0740051269531,32.7134704589844,33.0550270080566,29.3172740936279,17468680,NA,NA,NA,NA,NA,NA,NA,0.4,2019,8,16.6759201784013,0.36053466796875,0.208728790283203,1,0.42073822021484,0,NA,NA,NA,1,NA
2019-08-27,33.2163200378418,33.2922210693359,32.5521812438965,32.5806465148926,28.8965358734131,24715351,NA,NA,NA,NA,NA,NA,NA,0.39,2019,8,17.0229351469847,0.740039825439453,-0.635673522949219,0,-0.42073822021484,0,NA,NA,NA,1,NA
2019-08-28,32.5996208190918,33.3491477966309,32.5237197875977,33.2827301025391,29.5192279815674,26047924,NA,NA,NA,NA,NA,NA,NA,0.43,2019,8,17.0754486684805,0.825428009033203,0.683109283447266,1,0.622692108154293,0,NA,NA,NA,1,NA
2019-08-29,33.956356048584,33.956356048584,33.425048828125,33.5199241638184,29.7295970916748,19610302,NA,NA,NA,NA,NA,NA,NA,0.44,2019,8,16.7915656493535,0.531307220458984,-0.436431884765625,0,0.210369110107422,0,NA,NA,NA,1,NA
2019-08-30,33.7950668334961,33.8899421691895,33.472484588623,33.7286529541016,29.9147319793701,18873346,NA,NA,NA,NA,NA,NA,NA,0.38,2019,8,16.7532612731054,0.417457580566406,-0.0664138793945312,0,0.185134887695312,0,NA,NA,NA,1,NA
2019-09-03,33.7855796813965,34.4212532043457,33.6907005310059,34.2694511413574,30.3943691253662,26624989,NA,NA,NA,NA,NA,NA,NA,0.38,2019,9,17.0973608064069,0.730552673339844,0.483871459960938,1,0.479637145996094,0,NA,NA,NA,1,NA
2019-09-04,34.4402275085449,34.5351028442383,33.8709678649902,33.9943084716797,30.1503467559814,20649441,NA,NA,NA,NA,NA,NA,NA,0.44,2019,9,16.8431988552145,0.664134979248047,-0.445919036865234,0,-0.244022369384766,0,NA,NA,NA,1,NA
2019-09-05,34.2599601745605,34.6110076904297,34.0512313842773,34.4781761169434,30.5794925689697,22096794,NA,NA,NA,NA,NA,NA,NA,0.4,2019,9,16.9109431333467,0.559776306152344,0.218215942382812,1,0.429145812988281,0,NA,NA,NA,1,NA
2019-09-06,34.4971542358398,34.6963958740234,34.2599601745605,34.6299819946289,30.7141380310059,20873416,NA,NA,NA,NA,NA,NA,NA,0.43,2019,9,16.8539869934904,0.436435699462891,0.132827758789062,1,0.134645462036133,0,NA,NA,NA,1,NA
2019-09-09,34.7153701782227,34.9525604248047,34.278938293457,34.9430732727051,30.9918270111084,24675616,202,80,0.432624111941049,0.222573006927725,"Research","Pfizer Announces Positive Preliminary Results from a Proof-of-Concept Phase 2 Study (B7471003) of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Otitis Media in Healthy Infants","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_positive_preliminary_results_from_a_proof_of_concept_phase_2_study_b7471003_of_its_20_valent_pneumococcal_conjugate_vaccine_candidate_being_investigated_for_the_prevention_of_invasive_disease_and",0.43,2019,9,17.0213261480371,0.673622131347656,0.227703094482422,1,0.277688980102539,1,2.02,0.8,"Research",1,2
2019-09-10,34.7153701782227,35.4648971557617,34.1745719909668,35.4648971557617,31.4546489715576,32250397,NA,NA,NA,NA,NA,NA,NA,0.45,2019,9,17.2890409422152,1.29032516479492,0.749526977539062,1,0.462821960449219,0,NA,NA,NA,1,NA
2019-09-11,35.806453704834,35.8254280090332,35.0094871520996,35.4933586120605,31.4798889160156,16963181,NA,NA,NA,NA,NA,NA,NA,0.42,2019,9,16.6465557886545,0.815940856933594,-0.313095092773438,0,0.0252399444580078,0,NA,NA,NA,1,NA
2019-09-12,35.6451606750488,35.6926002502441,35.1612892150879,35.3700180053711,31.3704872131348,16692303,NA,NA,NA,NA,NA,NA,NA,0.53,2019,9,16.630458332845,0.53131103515625,-0.275142669677734,0,-0.109401702880856,0,NA,NA,NA,1,NA
2019-09-13,35.4743843078613,35.6736221313477,34.7343444824219,35.0189743041992,31.0591411590576,24099605,NA,NA,NA,NA,NA,NA,NA,0.41,2019,9,16.9977060497795,0.939277648925781,-0.455410003662109,0,-0.311346054077152,0,NA,NA,NA,1,NA
2019-09-16,34.5920295715332,35.1233406066895,34.4876670837402,34.9430732727051,30.9918270111084,19877070,NA,NA,NA,NA,NA,NA,NA,0.39,2019,9,16.805077414334,0.635673522949219,0.351043701171875,1,-0.0673141479492188,0,NA,NA,NA,1,NA
2019-09-17,34.9051246643066,34.9146118164062,34.4876670837402,34.6299819946289,30.7141380310059,22091945,130,33,0.595092020889006,0.296363635824793,"Vaccines","Terry Bradshaw and Pfizer Educate Boomers About the Risks of Pneumococcal  Pneumonia and the Importance of Vaccination","https://www.pfizer.com//news/announcements/terry-bradshaw-and-pfizer-educate-boomers-about-risks-pneumococcal-pneumonia-and",0.45,2019,9,16.9107236656765,0.426944732666016,-0.275142669677734,0,-0.277688980102539,1,1.3,0.33,"Pandemic",1,4
2019-09-18,34.6963958740234,34.8387107849121,34.4022789001465,34.5161285400391,30.6131534576416,19679550,NA,NA,NA,NA,NA,NA,NA,0.45,2019,9,16.7950906342875,0.436431884765625,-0.180267333984375,0,-0.100984573364258,0,NA,NA,NA,1,NA
2019-09-19,34.5540809631348,34.8861465454102,34.4781761169434,34.6394691467285,30.7225494384766,17746409,701,375,0.302973977413593,0.23932384336314,"Research","Pfizer Presents Scientific Advancements in Cancer Care at the ESMO Congress 2019 Highlighting Expanded Portfolio","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_presents_scientific_advancements_in_cancer_care_at_the_esmo_congress_2019_highlighting_expanded_portfolio",0.42,2019,9,16.6916937999086,0.407970428466797,0.08538818359375,1,0.109395980834957,1,7.01,3.75,"Research",1,2
2019-09-20,35,35.3415565490723,34.6110076904297,34.810245513916,30.8740158081055,45990658,384,184,0.352112675436421,0.23183673459925,"Medicines","CHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma","https://www.pfizer.com//news/press-release/press-release-detail/chmp_adopts_positive_opinion_for_bavencio_avelumab_plus_axitinib_for_first_line_treatment_of_patients_with_advanced_renal_cell_carcinoma",0.39,2019,9,17.6439488686154,0.730548858642578,-0.189754486083984,0,0.15146636962891,1,3.84,1.84,"Research",1,2
2019-09-23,34.5161285400391,34.7153701782227,34.3738136291504,34.38330078125,30.4953479766846,17295191,NA,NA,NA,NA,NA,NA,NA,0.44,2019,9,16.6659391017662,0.341556549072266,-0.132827758789062,0,-0.378667831420898,0,NA,NA,NA,1,NA
2019-09-24,34.4117660522461,34.705883026123,34.1366233825684,34.1650848388672,30.3018093109131,24186560,261,97,0.458100557379607,0.261313868422399,"Medicines","Pfizer Presents New Evidence of IBRANCE® (palbociclib) Effectiveness in HR+, HER2- Metastatic Breast Cancer Patients in Four Real-World Studies at ESMO Congress 2019","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_presents_new_evidence_of_ibrance_palbociclib_effectiveness_in_hr_her2_metastatic_breast_cancer_patients_in_four_real_world_studies_at_esmo_congress_2019",0.4,2019,9,17.0013077062953,0.569259643554688,-0.246681213378906,0,-0.193538665771481,1,2.61,0.97,"Research",1,2
2019-09-25,34.0702095031738,34.4876670837402,33.8709678649902,34.0607223510742,30.2092456817627,20269685,NA,NA,NA,NA,NA,NA,NA,0.43,2019,9,16.824637027435,0.61669921875,-0.00948715209960938,0,-0.0925636291503942,0,NA,NA,NA,1,NA
2019-09-26,34.2220115661621,34.38330078125,33.7476272583008,33.9468688964844,30.1082668304443,17059728,NA,NA,NA,NA,NA,NA,NA,0.43,2019,9,16.6522312147903,0.635673522949219,-0.275142669677734,0,-0.100978851318359,0,NA,NA,NA,1,NA
2019-09-27,34.0227699279785,34.4781761169434,33.8899421691895,34.3643264770508,30.4785194396973,17583671,444,202,0.374613002516079,0.231956911945437,"Research","New Data for BAVENCIO® (avelumab) for Advanced Cancers to Be Presented at ESMO 2019","https://www.pfizer.com//news/press-release/press-release-detail/new_data_for_bavencio_avelumab_for_advanced_cancers_to_be_presented_at_esmo_2019",0.38,2019,9,16.6824813021304,0.588233947753906,0.341556549072266,1,0.37025260925293,1,4.44,2.02,"Research",1,2
2019-09-30,34.4212532043457,34.4497146606445,34.0796966552734,34.089183807373,30.2344856262207,17205391,NA,NA,NA,NA,NA,NA,NA,0.35,2019,9,16.6607333810286,0.370018005371094,-0.332069396972656,0,-0.244033813476562,0,NA,NA,NA,1,NA
2019-10-01,34.089183807373,34.1745719909668,33.6147994995117,33.6147994995117,29.8137435913086,22013001,NA,NA,NA,NA,NA,NA,NA,0.38,2019,10,16.9071438367509,0.559772491455078,-0.474384307861328,0,-0.420742034912109,0,NA,NA,NA,1,NA
2019-10-02,33.4535102844238,33.4629974365234,32.8842506408691,32.9221992492676,29.199462890625,22458000,NA,NA,NA,NA,NA,NA,NA,0.41,2019,10,16.9271575006422,0.578746795654297,-0.53131103515625,0,-0.614280700683594,0,NA,NA,NA,1,NA
2019-10-03,32.9316902160645,33.6527519226074,32.8273239135742,33.6337776184082,29.8305816650391,22076135,NA,NA,NA,NA,NA,NA,NA,0.45,2019,10,16.9100077640589,0.825428009033203,0.70208740234375,1,0.631118774414062,0,NA,NA,NA,1,NA
2019-10-04,33.6717262268066,34.1366233825684,33.6337776184082,34.089183807373,30.2344856262207,18065349,NA,NA,NA,NA,NA,NA,NA,0.39,2019,10,16.7095062968572,0.502845764160156,0.417457580566406,1,0.403903961181641,0,NA,NA,NA,1,NA
2019-10-07,33.9848213195801,34.4022789001465,33.9658432006836,33.9943084716797,30.1503467559814,11759373,186,50,0.576271183998851,0.240570845830203,"Partnerships","Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-LRx","https://www.pfizer.com//news/press-release/press-release-detail/akcea_and_pfizer_inc_announce_licensing_agreement_for_investigative_antisense_therapy_akcea_angptl3_lrx",0.34,2019,10,16.2801612677254,0.436435699462891,0.00948715209960938,1,-0.0841388702392578,1,1.86,0.5,"Management",1,1
2019-10-08,33.8235282897949,34.0417442321777,33.6053123474121,33.6147994995117,29.8137435913086,14761270,NA,NA,NA,NA,NA,NA,NA,0.42,2019,10,16.5075174845404,0.436431884765625,-0.208728790283203,0,-0.336603164672852,0,NA,NA,NA,1,NA
2019-10-09,33.8235282897949,34.0512313842773,33.7096786499023,33.8614807128906,30.0325298309326,13634333,NA,NA,NA,NA,NA,NA,NA,0.44,2019,10,16.4281017281844,0.341552734375,0.0379524230957031,1,0.218786239624023,0,NA,NA,NA,1,NA
2019-10-10,33.8425064086914,34.1650848388672,33.7760925292969,33.956356048584,30.1166801452637,12198680,NA,NA,NA,NA,NA,NA,NA,0.41,2019,10,16.3168383891046,0.388992309570312,0.113849639892578,1,0.0841503143310547,0,NA,NA,NA,1,NA
2019-10-11,34.2884254455566,34.705883026123,34.2220115661621,34.2599601745605,30.3859558105469,18446054,NA,NA,NA,NA,NA,NA,NA,0.34,2019,10,16.7303610844496,0.483871459960938,-0.0284652709960938,0,0.269275665283203,0,NA,NA,NA,1,NA
2019-10-14,34.3073997497559,34.4876670837402,34.1366233825684,34.4402275085449,30.5458431243896,8700981,89,16,0.69523808861678,0.248226949767785,"Partnerships","ImaginAb signs multi-party collaboration agreement with three global  pharmaceutical companies to help further develop company’s CD8  ImmunoPET technology","https://www.pfizer.com//news/press-release/press-release-detail/imaginab-signs-multi-party-collaboration-agreement-three",0.37,2019,10,15.9789464508183,0.351043701171875,0.132827758789062,1,0.159887313842773,1,0.89,0.16,"Management",1,1
2019-10-15,34.5825424194336,34.8576850891113,34.5445938110352,34.6299819946289,30.7141380310059,15178232,NA,NA,NA,NA,NA,NA,NA,0.42,2019,10,16.5353729199943,0.313091278076172,0.0474395751953125,1,0.168294906616211,0,NA,NA,NA,1,NA
2019-10-16,34.7533226013184,34.8671722412109,34.4592018127441,34.4781761169434,30.5794925689697,14435795,NA,NA,NA,NA,NA,NA,NA,0.46,2019,10,16.4852215133066,0.407970428466797,-0.275146484375,0,-0.134645462036133,0,NA,NA,NA,1,NA
2019-10-17,34.6204948425293,34.9240989685059,34.5066413879395,34.5920295715332,30.6804752349854,15312090,284,48,0.710843371352881,0.27829002491342,"Partnerships","The Bristol-Myers Squibb-Pfizer Alliance and Fitbit Collaborate to Address Gaps in Atrial Fibrillation Detection with the Aim of Accelerating Diagnosis","https://www.pfizer.com//news/press-release/press-release-detail/the_bristol_myers_squibb_pfizer_alliance_and_fitbit_collaborate_to_address_gaps_in_atrial_fibrillation_detection_with_the_aim_of_accelerating_diagnosis",0.41,2019,10,16.5441533357084,0.417457580566406,-0.0284652709960938,0,0.100982666015625,1,2.84,0.48,"Management",1,1
2019-10-18,34.5635681152344,34.8197326660156,34.4876670837402,34.5920295715332,30.6804752349854,14219198,NA,NA,NA,NA,NA,NA,NA,0.43,2019,10,16.4701036516389,0.332065582275391,0.0284614562988281,1,0,0,NA,NA,NA,1,NA
2019-10-21,34.7722969055176,34.8007583618164,34.4971542358398,34.5920295715332,30.6804752349854,13237081,285,130,0.373493975003629,0.273026315609851,"Research","OPKO and Pfizer Announce Positive Phase 3 Top-Line Results for Somatrogon, an Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency","https://www.pfizer.com//news/press-release/press-release-detail/opko_and_pfizer_announce_positive_phase_3_top_line_results_for_somatrogon_an_investigational_long_acting_human_growth_hormone_to_treat_children_with_growth_hormone_deficiency",0.37,2019,10,16.3985326914338,0.303604125976562,-0.180267333984375,0,0,1,2.85,1.3,"Research",1,2
2019-10-22,34.5445938110352,34.8197326660156,34.3927879333496,34.5635681152344,30.6552352905273,14549416,NA,NA,NA,NA,NA,NA,NA,0.46,2019,10,16.4930614820505,0.426944732666016,0.0189743041992188,1,-0.0252399444580078,0,NA,NA,NA,1,NA
2019-10-23,34.4497146606445,34.895637512207,34.3643264770508,34.8861465454102,30.9413356781006,14000598,NA,NA,NA,NA,NA,NA,NA,0.44,2019,10,16.4546106723785,0.53131103515625,0.436431884765625,1,0.286100387573239,0,NA,NA,NA,1,NA
2019-10-24,34.8671722412109,34.9525604248047,34.4022789001465,34.5256156921387,30.6215744018555,19998385,NA,NA,NA,NA,NA,NA,NA,0.41,2019,10,16.8111621282618,0.550281524658203,-0.341556549072266,0,-0.319761276245114,0,NA,NA,NA,1,NA
2019-10-25,34.5351028442383,34.9905128479004,34.4497146606445,34.8861465454102,30.9413356781006,17497665,NA,NA,NA,NA,NA,NA,NA,0.41,2019,10,16.6775780585704,0.540798187255859,0.351043701171875,1,0.319761276245114,0,NA,NA,NA,1,NA
2019-10-28,34.9715385437012,35.5597724914551,34.9335861206055,35.3700180053711,31.3704872131348,25800339,438,216,0.339449540765368,0.235082674250509,"Medicines","European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma","https://www.pfizer.com//news/press-release/press-release-detail/european_commission_approves_bavencio_avelumab_plus_axitinib_combination_for_first_line_treatment_of_patients_with_advanced_renal_cell_carcinoma",0.36,2019,10,17.0658982280996,0.626186370849609,0.398479461669922,1,0.429151535034187,1,4.38,2.16,"Research",1,2
2019-10-29,36.0531311035156,36.7741928100586,35.9772300720215,36.2523727416992,32.153076171875,32212032,NA,NA,NA,NA,NA,NA,NA,0.53,2019,10,17.28785063636,0.796962738037109,0.199241638183594,1,0.782588958740231,0,NA,NA,NA,1,NA
2019-10-30,36.4421234130859,36.8311195373535,36.337760925293,36.5085372924805,32.3802680969238,22019430,NA,NA,NA,NA,NA,NA,NA,0.43,2019,10,16.9074358487796,0.493358612060554,0.0664138793945312,1,0.227191925048828,0,NA,NA,NA,1,NA
2019-10-31,36.4231491088867,36.6034164428711,36.2239074707031,36.4041748046875,32.2877044677734,24539860,NA,NA,NA,NA,NA,NA,NA,0.39,2019,10,17.0158093330093,0.379508972167969,-0.0189743041992188,0,-0.0925636291503906,0,NA,NA,NA,1,NA
2019-11-01,36.7077789306641,36.9449729919434,36.4231491088867,36.4231491088867,32.3045387268066,19263220,NA,NA,NA,NA,NA,NA,NA,0.38,2019,11,16.7737081881501,0.521823883056641,-0.284629821777344,0,0.0168342590332031,0,NA,NA,NA,1,NA
2019-11-04,36.7267532348633,36.7552185058594,36.0815925598145,36.0815925598145,32.0016021728516,17709730,NA,NA,NA,NA,NA,NA,NA,0.39,2019,11,16.689624820485,0.673625946044922,-0.645160675048828,0,-0.302936553955078,0,NA,NA,NA,1,NA
2019-11-05,36.0815925598145,36.148006439209,35.5502853393555,35.5597724914551,31.5387840270996,21688474,NA,NA,NA,NA,NA,NA,NA,0.41,2019,11,16.8922915714332,0.597721099853516,-0.521820068359375,0,-0.462818145751953,0,NA,NA,NA,1,NA
2019-11-06,35.6831130981445,35.7969627380371,35.4364318847656,35.6831130981445,31.6481876373291,18757722,NA,NA,NA,NA,NA,NA,NA,0.42,2019,11,16.7471161189093,0.360530853271484,0,0,0.109403610229492,0,NA,NA,NA,1,NA
2019-11-07,35.4838714599609,35.6546478271484,34.9905128479004,35.0189743041992,31.3593120574951,22727297,NA,NA,NA,NA,NA,NA,NA,0.4,2019,11,16.9390773150275,0.664134979248047,-0.464897155761719,0,-0.288875579833984,0,NA,NA,NA,1,NA
2019-11-08,34.9905128479004,35.2561683654785,34.9430732727051,35.1518020629883,31.4782600402832,26626886,356,163,0.371868978088884,0.254536537393557,"Research","EMD Serono and Pfizer Provide Update on Phase III JAVELIN Gastric 100 Trial","https://www.pfizer.com//news/press-release/press-release-detail/emd_serono_and_pfizer_provide_update_on_phase_iii_javelin_gastric_100_trial",0.4,2019,11,17.0974320527219,0.313095092773438,0.161289215087891,1,0.118947982788086,1,3.56,1.63,"Research",1,2
2019-11-11,35.0189743041992,35.1138534545898,34.8671722412109,35.0379524230957,31.3763065338135,12542916,NA,NA,NA,NA,NA,NA,NA,0.39,2019,11,16.3446666817482,0.246681213378906,0.0189781188964844,1,-0.101953506469727,0,NA,NA,NA,1,NA
2019-11-12,34.9430732727051,35.189754486084,34.8197326660156,35.0759010314941,31.4102878570557,13338370,325,48,0.742627343853546,0.298161470585003,"Finance","Mylan and Pfizer Announce Viatris as the New Company Name in the Planned Mylan-Upjohn Combination","https://www.pfizer.com//news/press-release/press-release-detail/mylan_and_pfizer_announce_viatris_as_the_new_company_name_in_the_planned_mylan_upjohn_combination",0.4,2019,11,16.4061554770522,0.370021820068359,0.132827758789062,1,0.0339813232421875,1,3.25,0.48,"Finance",1,3
2019-11-13,35.0569267272949,35.0569267272949,34.4402275085449,34.7248573303223,31.0959339141846,25855252,76,21,0.567010303432884,0.326599325499666,"Partnerships","CENTOGENE Signs Data Access and Collaboration Agreement with Pfizer Inc.","https://www.pfizer.com//news/press-release/press-release-detail/centogene-signs-data-access-and-collaboration-agreement",0.46,2019,11,17.0680243491059,0.61669921875,-0.332069396972656,0,-0.314353942871094,1,0.76,0.21,"Management",1,1
2019-11-14,34.6869087219238,34.8766593933105,34.4592018127441,34.677417755127,31.0534439086914,25190600,NA,NA,NA,NA,NA,NA,NA,0.44,2019,11,17.0419815067183,0.417457580566406,-0.009490966796875,0,-0.0424900054931641,0,NA,NA,NA,1,NA
2019-11-15,34.7533226013184,35.5502853393555,34.6489562988281,35.3700180053711,31.6736640930176,36378810,356,152,0.401574802359105,0.253873063341393,"Medicines","Pfizer Announces CHMP Opinion for XELJANZ® (tofacitinib) in the  European Union Related to Ongoing Review of the Product","https://www.pfizer.com//news/announcements/pfizer-announces-chmp-opinion-xeljanzr-tofacitinib-european-union-related",0.39,2019,11,17.4094970477274,0.901329040527344,0.616695404052734,1,0.620220184326168,1,3.56,1.52,"Research",1,2
2019-11-18,35.4743843078613,35.5218238830566,35.0664138793945,35.3130912780762,31.6226940155029,18084532,287,117,0.420792078166356,0.288777698149551,"Medicines","FDA Approves Pfizer’s Biosimilar, ABRILADA™ (adalimumab-afzb) for Multiple Inflammatory Conditions","https://www.pfizer.com//news/press-release/press-release-detail/fda_approves_pfizer_s_biosimilar_abrilada_adalimumab_afzb_for_multiple_inflammatory_conditions",0.41,2019,11,16.7105676005301,0.455410003662109,-0.161293029785156,0,-0.0509700775146449,1,2.87,1.17,"Research",1,2
2019-11-19,35.5123329162598,35.7495269775391,35.4079704284668,35.7305488586426,31.9965209960938,26475110,NA,NA,NA,NA,NA,NA,NA,0.42,2019,11,17.0917156420775,0.341556549072266,0.218215942382812,1,0.37382698059082,0,NA,NA,NA,1,NA
2019-11-20,35.6451606750488,35.7590141296387,35.1138534545898,35.1518020629883,31.4782600402832,19947582,NA,NA,NA,NA,NA,NA,NA,0.51,2019,11,16.8086185410783,0.645160675048828,-0.493358612060547,0,-0.518260955810547,0,NA,NA,NA,1,NA
2019-11-21,35.3036041259766,35.9962043762207,35.1423149108887,35.806453704834,32.0644950866699,20942664,NA,NA,NA,NA,NA,NA,NA,0.44,2019,11,16.8572990236946,0.853889465332031,0.502849578857422,1,0.586235046386719,0,NA,NA,NA,1,NA
2019-11-22,35.853889465332,36.4421234130859,35.7590141296387,36.3662223815918,32.5657653808594,25544006,49,10,0.661016937948866,0.220149252909891,"Partnerships","CeMM enters into research collaboration on expanding the druggable proteome  with Pfizer Inc.","https://www.pfizer.com//news/press-release/press-release-detail/cemm-enters-research-collaboration-expanding-druggable",0.38,2019,11,17.0559132874137,0.683109283447266,0.512332916259766,1,0.501270294189453,1,0.49,0.1,"Management",1,1
2019-11-25,36.5085372924805,36.8880462646484,36.4800758361816,36.6982917785645,32.8631286621094,31592385,NA,NA,NA,NA,NA,NA,NA,0.4,2019,11,17.2684267001571,0.407970428466797,0.189754486083984,1,0.29736328125,0,NA,NA,NA,1,NA
2019-11-26,36.5654640197754,36.6129035949707,36.1005706787109,36.3282737731934,32.5317840576172,34620633,NA,NA,NA,NA,NA,NA,NA,0.45,2019,11,17.3599604206585,0.512332916259766,-0.237190246582031,0,-0.331344604492188,0,NA,NA,NA,1,NA
2019-11-27,36.4136619567871,36.7267532348633,36.3662223815918,36.6508522033691,32.8206405639648,19201034,NA,NA,NA,NA,NA,NA,NA,0.37,2019,11,16.7704747417951,0.360530853271484,0.237190246582031,1,0.288856506347656,0,NA,NA,NA,1,NA
2019-11-29,36.5654640197754,36.8880462646484,36.5370025634766,36.5464897155762,32.7271919250488,9793873,NA,NA,NA,NA,NA,NA,NA,0.31,2019,11,16.0972676461422,0.351043701171875,-0.0189743041992188,0,-0.0934486389160156,0,NA,NA,NA,1,NA
2019-12-02,36.8026580810547,36.8121452331543,36.2903213500977,36.3282737731934,32.5317840576172,15645998,NA,NA,NA,NA,NA,NA,NA,0.41,2019,12,16.5657257873131,0.521823883056641,-0.474384307861328,0,-0.195407867431641,0,NA,NA,NA,1,NA
2019-12-03,36.0151786804199,36.2428855895996,35.9013290405273,36.1005706787109,32.3278732299805,20869832,NA,NA,NA,NA,NA,NA,NA,0.46,2019,12,16.8538152771047,0.341556549072266,0.0853919982910156,1,-0.203910827636719,0,NA,NA,NA,1,NA
2019-12-04,36.2713470458984,36.2998085021973,35.9487686157227,36.1859588623047,32.4043388366699,14501248,79,23,0.549019602460592,0.202783299795659,"Partnerships","ImCheck Raises $53 Million Series B to Advance Clinical Pipeline of Novel  Gamma Delta T-Cell-Focused Antibodies for Cancer and Autoimmune Diseases","https://www.pfizer.com//news/press-release/press-release-detail/imcheck-raises-53-million-series-b-advance-clinical",0.45,2019,12,16.4897453416122,0.351039886474609,-0.08538818359375,0,0.0764656066894531,1,0.79,0.23,"Management",1,1
2019-12-05,36.4041748046875,36.4041748046875,35.853889465332,36.0815925598145,32.3108787536621,13098058,NA,NA,NA,NA,NA,NA,NA,0.37,2019,12,16.3879746092545,0.550285339355469,-0.322582244873047,0,-0.0934600830078125,0,NA,NA,NA,1,NA
2019-12-06,36.3187866210938,36.5464897155762,36.2618598937988,36.3282737731934,32.5317840576172,12868708,NA,NA,NA,NA,NA,NA,NA,0.39,2019,12,16.3703092637405,0.284629821777344,0.00948715209960938,1,0.220905303955078,0,NA,NA,NA,1,NA
2019-12-09,36.148006439209,36.4136619567871,36.148006439209,36.3567352294922,32.5572700500488,15641571,NA,NA,NA,NA,NA,NA,NA,0.37,2019,12,16.5654427995394,0.265655517578125,0.208728790283203,1,0.0254859924316406,0,NA,NA,NA,1,NA
2019-12-10,36.3092994689941,36.6034164428711,36.2333984375,36.5085372924805,32.6932029724121,19171311,81,18,0.636363629935721,0.274999999236111,"Partnerships","ImmunOs Therapeutics AG raises CHF 15M in Series A Financing, co-led by Pfizer Ventures and  BioMedPartners, to Advance a Novel Immunotherapy Agent For Cancer Into Human Trials","https://www.pfizer.com//news/press-release/press-release-detail/immunos-therapeutics-ag-raises-chf-15m-series-financing-co",0.36,2019,12,16.7689255529512,0.370018005371094,0.199237823486328,1,0.135932922363281,1,0.81,0.18,"Management",1,1
2019-12-11,36.4041748046875,36.5939292907715,36.2428855895996,36.2618598937988,32.4723052978516,15569372,NA,NA,NA,NA,NA,NA,NA,0.41,2019,12,16.5608162732498,0.351043701171882,-0.142314910888672,0,-0.220897674560547,0,NA,NA,NA,1,NA
2019-12-12,36.2144203186035,36.6413650512695,36.2144203186035,36.5654640197754,32.7441864013672,13414469,333,149,0.381742737797214,0.269574943920819,"Medicines","FDA Approves XELJANZ® XR (tofacitinib) Extended-Release Tablets for the Treatment of Ulcerative Colitis","https://www.pfizer.com//news/press-release/press-release-detail/fda_approves_xeljanz_xr_tofacitinib_extended_release_tablets_for_the_treatment_of_ulcerative_colitis",0.38,2019,12,16.411844533048,0.426944732666009,0.351043701171868,1,0.271881103515625,1,3.33,1.49,"Research",1,2
2019-12-13,36.5464897155762,36.6982917785645,36.1195449829102,36.3662223815918,32.5657653808594,16678496,227,77,0.493421051008483,0.258723404035129,"Medicines","Pfizer Receives Positive CHMP Opinion for VYNDAQEL® for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_receives_positive_chmp_opinion_for_vyndaqel_for_use_in_patients_with_transthyretin_amyloid_cardiomyopathy_a_rare_and_fatal_disease",0.39,2019,12,16.6296308429212,0.57874679565429,-0.180267333984375,0,-0.178421020507812,1,2.27,0.77,"Research",1,2
2019-12-16,36.7172698974609,37.381404876709,36.6793174743652,37.1347236633301,33.2539520263672,24187824,312,144,0.368421051823638,0.276699028958314,"Medicines","XTANDI® (enzalutamide) Approved by U.S. FDA for the Treatment of Metastatic Castration-Sensitive Prostate Cancer","https://www.pfizer.com//news/press-release/press-release-detail/xtandi_enzalutamide_approved_by_u_s_fda_for_the_treatment_of_metastatic_castration_sensitive_prostate_cancer",0.4,2019,12,17.0013599653565,0.70208740234375,0.417453765869141,1,0.688186645507812,1,3.12,1.44,"Research",1,2
2019-12-17,37.4193534851074,37.4193534851074,36.8500938415527,36.9070205688477,33.0500450134277,29038016,121,48,0.431952660165961,0.237026647633904,"Partnerships","Triplet Therapeutics Launches with $59 Million in Financing to Further its Development of  Transformative Treatments for Triplet Repeat Disorders","https://www.pfizer.com//news/press-release/press-release-detail/triplet-therapeutics-launches-59-million-financing-further",0.43,2019,12,17.1841164604654,0.569259643554688,-0.512332916259766,0,-0.203907012939453,1,1.21,0.48,"Management",1,1
2019-12-18,37.0113868713379,37.0778007507324,36.660343170166,36.897533416748,33.0415458679199,27339390,309,112,0.46793349057498,0.224773091177377,"Medicines","U.S. FDA Accepts and Grants Priority Review to sNDA for BRAFTOVI® (encorafenib) in Combination with ERBITUX® (cetuximab) (BRAFTOVI Doublet) for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer After Prior Therapy","https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_accepts_and_grants_priority_review_to_snda_for_braftovi_encorafenib_in_combination_with_erbitux_cetuximab_braftovi_doublet_for_the_treatment_of_brafv600e_mutant_metastatic_colorectal_cancer_after_prior",0.34,2019,12,17.1238391139571,0.417457580566406,-0.113853454589844,0,-0.0084991455078125,1,3.09,1.12,"Research",1,2
2019-12-19,37.0018997192383,37.144214630127,36.8216323852539,36.9734344482422,33.1095199584961,22022276,NA,NA,NA,NA,NA,NA,NA,0.37,2019,12,16.9075650899073,0.322582244873047,-0.0284652709960938,0,0.0679740905761719,0,NA,NA,NA,1,NA
2019-12-20,37.3339653015137,37.514232635498,36.9734344482422,37.2201156616211,33.3304214477539,58199772,NA,NA,NA,NA,NA,NA,NA,0.39,2019,12,17.8793920123504,0.540798187255859,-0.113849639892578,0,0.220901489257812,0,NA,NA,NA,1,NA
2019-12-23,37.4003791809082,37.4952545166016,37.1252365112305,37.3055038452149,33.4068870544434,17454345,246,57,0.623762374179002,0.291066282141147,"Partnerships","Theravance Biopharma and Pfizer Inc. Enter Global License Agreement for Skin-Targeted, Locally-Acting Pan-Janus Kinase (JAK) Inhibitor Program","https://www.pfizer.com//news/press-release/press-release-detail/theravance_biopharma_and_pfizer_inc_enter_global_license_agreement_for_skin_targeted_locally_acting_pan_janus_kinase_jak_inhibitor_program",0.3,2019,12,16.6750992300451,0.370018005371094,-0.0948753356933523,0,0.0764656066894531,1,2.46,0.57,"Management",1,1
2019-12-24,37.3149909973145,37.4193534851074,37.191650390625,37.2770385742188,33.3813896179199,5187683,NA,NA,NA,NA,NA,NA,NA,0.25,2019,12,15.4617979127716,0.227703094482422,-0.0379524230957031,0,-0.0254974365234375,0,NA,NA,NA,1,NA
2019-12-26,37.2865295410156,37.5426940917969,37.191650390625,37.3624305725098,33.4578552246094,9384078,NA,NA,NA,NA,NA,NA,NA,0.26,2019,12,16.0545250878648,0.351043701171875,0.0759010314941406,1,0.0764656066894531,0,NA,NA,NA,1,NA
2019-12-27,37.4098663330078,37.5901336669922,37.2390899658203,37.3055038452149,33.4068870544434,10117662,NA,NA,NA,NA,NA,NA,NA,0.3,2019,12,16.1297932663017,0.351043701171875,-0.104362487792962,0,-0.0509681701660156,0,NA,NA,NA,1,NA
2019-12-30,37.2865295410156,37.4003791809082,36.897533416748,36.9165077209473,33.0585441589355,11554264,NA,NA,NA,NA,NA,NA,NA,0.3,2019,12,16.2625651908401,0.502845764160156,-0.370021820068359,0,-0.348342895507812,0,NA,NA,NA,1,NA
2019-12-31,36.8026580810547,37.191650390625,36.7267532348633,37.1726760864258,33.2879371643066,15175703,NA,NA,NA,NA,NA,NA,NA,0.26,2019,12,16.535206285926,0.464897155761719,0.370018005371094,1,0.229393005371094,0,NA,NA,NA,1,NA
2020-01-02,37.2865295410156,37.3339653015137,36.8880462646484,37.1347236633301,33.2539520263672,16514072,NA,NA,NA,NA,NA,NA,NA,0.01,2020,1,16.6197234844414,0.445919036865234,-0.151805877685547,0,-0.0339851379394531,0,NA,NA,NA,0,NA
2020-01-03,36.7362442016602,37.2296028137207,36.6888046264649,36.9354858398438,33.0755386352539,14922848,NA,NA,NA,NA,NA,NA,NA,0,2020,1,16.5184040862536,0.540798187255852,0.199241638183587,1,-0.178413391113281,0,NA,NA,NA,0,NA
2020-01-06,36.8311195373535,37.0018997192383,36.7172698974609,36.8880462646484,33.0330581665039,15771951,406,176,0.395189002757407,0.258093126271356,"Research","BAVENCIO Significantly Improved Overall Survival in Patients With Locally Advanced or Metastatic Urothelial Carcinoma","https://www.pfizer.com//news/press-release/press-release-detail/bavencio-significantly-improved-overall-survival-patients",0.01,2020,1,16.573743730607,0.284629821777344,0.0569267272949148,1,-0.04248046875,1,4.06,1.76,"Research",0,2
2020-01-07,37.1157493591309,37.1252365112305,36.6982917785645,36.764705657959,32.922607421875,20108107,142,15,0.80891719229989,0.240797545642949,"Finance","Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-0",0.01,2020,1,16.8166336747768,0.426944732666016,-0.351043701171875,0,-0.110450744628906,1,1.42,0.15,"Finance",0,3
2020-01-08,36.7741928100586,37.2106246948242,36.764705657959,37.0588226318359,33.1859931945801,16403507,NA,NA,NA,NA,NA,NA,NA,0.01,2020,1,16.6130057723596,0.445919036865234,0.284629821777344,1,0.263385772705078,0,NA,NA,NA,0,NA
2020-01-09,37.2580642700195,37.2580642700195,36.8026580810547,36.897533416748,33.0415458679199,21971895,NA,NA,NA,NA,NA,NA,NA,0.01,2020,1,16.9052747401365,0.455406188964844,-0.360530853271484,0,-0.144447326660156,0,NA,NA,NA,0,NA
2020-01-10,36.9829216003418,37.5996208190918,36.9734344482422,37.4667930603027,33.5513153076172,21557357,NA,NA,NA,NA,NA,NA,NA,0.01,2020,1,16.8862277547522,0.626186370849609,0.483871459960938,1,0.509769439697266,0,NA,NA,NA,0,NA
2020-01-13,37.5901336669922,37.7324485778809,37.2011375427246,37.3908920288086,33.4833526611328,15392405,241,145,0.248704662568123,0.296466973658628,"Partnerships","Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc. for Pfizer’s Reboxetine  Clinical and Nonclinical Data and for New Phase 3 Esreboxetine Product Candidate","https://www.pfizer.com//news/press-release/press-release-detail/axsome-therapeutics-enters-exclusive-license-agreement",0.01,2020,1,16.5493848288786,0.53131103515625,-0.199241638183594,0,-0.067962646484375,1,2.41,1.45,"Management",0,1
2020-01-14,37.4098663330078,38.0265655517578,37.2865295410156,38.0170783996582,34.0440902709961,20919160,41,6,0.744680835219557,0.255434781220463,"Partnerships","Insilico enters into research collaboration with Pfizer Inc. to explore novel data  and artificial intelligence system for potential therapeutic targets","https://www.pfizer.com//news/press-release/press-release-detail/insilico-enters-research-collaboration-pfizer-inc-explore",0.01,2020,1,16.8561760911942,0.740036010742188,0.607212066650391,1,0.560737609863281,1,0.41,0.06,"Management",0,1
2020-01-15,38.130931854248,38.7760925292969,38.1119537353516,38.5863380432129,34.5538635253906,23925800,NA,NA,NA,NA,NA,NA,NA,0.01,2020,1,16.9904679743667,0.664138793945312,0.455406188964844,1,0.509773254394531,0,NA,NA,NA,0,NA
2020-01-16,38.7001914978027,38.7096786499023,38.2542686462402,38.529411315918,34.5028991699219,16216422,NA,NA,NA,NA,NA,NA,NA,0.01,2020,1,16.6015350521216,0.455410003662109,-0.170780181884766,0,-0.05096435546875,0,NA,NA,NA,0,NA
2020-01-17,38.4914627075195,38.719165802002,38.3491477966309,38.4345359802246,34.4179267883301,23083970,NA,NA,NA,NA,NA,NA,NA,0.01,2020,1,16.9546490385308,0.370018005371094,-0.0569267272949219,0,-0.0849723815917969,0,NA,NA,NA,0,NA
2020-01-21,38.3111953735351,38.5768508911133,38.130931854248,38.2732467651367,34.2734985351562,23115696,NA,NA,NA,NA,NA,NA,NA,0.01,2020,1,16.9560224685298,0.445919036865234,-0.0379486083984304,0,-0.144428253173828,0,NA,NA,NA,0,NA
2020-01-22,38.2542686462402,38.339656829834,37.9221992492676,38.130931854248,34.1460571289062,18097812,NA,NA,NA,NA,NA,NA,NA,0.01,2020,1,16.7113016602064,0.417457580566406,-0.123336791992188,0,-0.12744140625,0,NA,NA,NA,0,NA
2020-01-23,38.130931854248,38.7381401062012,38.0740051269531,38.6242866516113,34.5878486633301,27148510,595,331,0.285097191916742,0.238046272432379,"Medicines","Pfizer Brings Three New Biosimilars to U.S. Patients at Substantial  Discounts","https://www.pfizer.com//news/announcements/pfizer-brings-three-new-biosimilars-us-patients-substantial-discounts",0.01,2020,1,17.116832759378,0.664134979248047,0.493354797363281,1,0.441791534423828,1,5.95,3.31,"Research",0,2
2020-01-24,38.8425064086914,38.8709678649902,37.6091079711914,37.7798843383789,33.8316955566406,34143698,NA,NA,NA,NA,NA,NA,NA,0.01,2020,1,17.3460886174403,1.26185989379883,-1.0626220703125,0,-0.756153106689453,0,NA,NA,NA,0,NA
2020-01-27,37.3908920288086,38.3586349487305,37.2390899658203,38.102466583252,34.1205596923828,31964026,NA,NA,NA,NA,NA,NA,NA,0.01,2020,1,17.2801216721764,1.11954498291016,0.711574554443359,1,0.288864135742188,0,NA,NA,NA,0,NA
2020-01-28,37.3055038452149,37.4667930603027,36.0056915283203,36.1859588623047,32.4043388366699,70202408,1097,409,0.456839309125605,0.263747810811953,"Finance","PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2019 RESULTS","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-reports-fourth-quarter-and-full-year-2019-results",0.01,2020,1,18.0668931846466,1.46110153198242,-1.11954498291016,0,-1.71622085571289,1,10.97,4.09,"Finance",0,3
2020-01-29,36.1669845581055,36.4136619567871,35.6261863708496,35.6546478271484,31.9285526275635,34165726,NA,NA,NA,NA,NA,NA,NA,0.01,2020,1,17.3467335650574,0.7874755859375,-0.512336730957031,0,-0.475786209106445,0,NA,NA,NA,0,NA
2020-01-30,35.1992416381836,35.2656555175781,34.810245513916,35.1707763671875,31.8169708251953,32316589,NA,NA,NA,NA,NA,NA,NA,0.01,2020,1,17.2910912786251,0.455410003662109,-0.0284652709960938,0,-0.111581802368164,0,NA,NA,NA,0,NA
2020-01-31,35.0474395751953,35.531307220459,35.0094871520996,35.3320693969727,31.9628868103027,33894005,166,35,0.651741290289844,0.301349324885533,"Medicines","Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, RUXIENCE™ (rituximab)","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-receives-positive-chmp-opinion-oncology-biosimilar",0.01,2020,1,17.3387487425579,0.521820068359375,0.284629821777344,1,0.145915985107422,1,1.66,0.35,"Research",0,2
2020-02-03,35.5407981872559,36.0910835266113,35.3889923095703,35.5882339477539,32.1946220397949,20875735,NA,NA,NA,NA,NA,NA,NA,0.01,2020,2,16.8540980855647,0.702091217041016,0.0474357604980469,1,0.231735229492188,0,NA,NA,NA,0,NA
2020-02-04,36.1290321350098,36.280834197998,35.7020874023438,35.7590141296387,32.3491172790527,31150865,NA,NA,NA,NA,NA,NA,NA,0.01,2020,2,17.2543526037744,0.578746795654297,-0.370018005371094,0,0.154495239257812,0,NA,NA,NA,0,NA
2020-02-05,35.910816192627,36.5939292907715,35.8823547363281,36.2144203186035,32.761100769043,29443490,NA,NA,NA,NA,NA,NA,NA,0.01,2020,2,17.1979834249579,0.711574554443366,0.30360412597657,1,0.411983489990234,0,NA,NA,NA,0,NA
2020-02-06,36.470588684082,36.527515411377,36.0815925598145,36.2998085021973,32.8383407592773,21047748,NA,NA,NA,NA,NA,NA,NA,0.01,2020,2,16.8623041765076,0.4459228515625,-0.170780181884766,0,0.077239990234375,0,NA,NA,NA,0,NA
2020-02-07,36.3946876525879,36.4326362609863,35.9867172241211,36.1005706787109,32.6581115722656,21903596,NA,NA,NA,NA,NA,NA,NA,0.01,2020,2,16.9021614278751,0.445919036865234,-0.294116973876953,0,-0.180229187011719,0,NA,NA,NA,0,NA
2020-02-10,36.2523727416992,36.2618598937988,35.7874755859375,35.8728637695312,32.4521141052246,19998385,NA,NA,NA,NA,NA,NA,NA,0.01,2020,2,16.8111621282618,0.474384307861328,-0.379508972167969,0,-0.205997467041016,0,NA,NA,NA,0,NA
2020-02-11,35.9487686157227,36.1764717102051,35.8254280090332,36.1385192871094,32.6924324035645,16027335,241,108,0.381088824122955,0.258902076959271,"Research","XTANDI® (enzalutamide) Demonstrates Significant Improvement in Overall Survival in Phase 3 PROSPER Trial of Patients with nmCRPC","https://www.pfizer.com//news/press-release/press-release-detail/xtandir-enzalutamide-demonstrates-significant-improvement",0.01,2020,2,16.5898063223782,0.351043701171875,0.189750671386719,1,0.240318298339844,1,2.41,1.08,"Research",0,2
2020-02-12,36.1385192871094,36.2333984375,35.7874755859375,35.806453704834,32.3920364379883,22944315,NA,NA,NA,NA,NA,NA,NA,0.01,2020,2,16.9485807949505,0.4459228515625,-0.332065582275391,0,-0.300395965576172,0,NA,NA,NA,0,NA
2020-02-13,35.6546478271484,35.6546478271484,35,35.0379524230957,31.6968193054199,22099745,NA,NA,NA,NA,NA,NA,NA,0.01,2020,2,16.9110766732093,0.654647827148438,-0.616695404052734,0,-0.695217132568363,0,NA,NA,NA,0,NA
2020-02-14,35.0759010314941,35.1423149108887,34.5540809631348,34.6394691467285,31.3363285064697,21006747,NA,NA,NA,NA,NA,NA,NA,0.01,2020,2,16.8603542774045,0.588233947753906,-0.436431884765625,0,-0.360490798950192,0,NA,NA,NA,0,NA
2020-02-18,34.677417755127,34.7912712097168,34.4117660522461,34.4592018127441,31.1732521057129,17988513,233,66,0.558528426225657,0.257536606151993,"Medicines","European Commission Approves VYNDAQEL®, the First Treatment in the EU for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)","https://www.pfizer.com//news/press-release/press-release-detail/european-commission-approves-vyndaqelr-first-treatment-eu",0.01,2020,2,16.7052440010698,0.379505157470703,-0.218215942382812,0,-0.163076400756836,1,2.33,0.66,"Research",0,2
2020-02-19,34.5351028442383,34.6299819946289,34.3548393249512,34.3738136291504,31.0960063934326,17750941,NA,NA,NA,NA,NA,NA,NA,0.01,2020,2,16.6919491429001,0.275142669677734,-0.161289215087891,0,-0.0772457122802734,0,NA,NA,NA,0,NA
2020-02-20,33.8804550170898,34.2125244140625,33.5958251953125,34.0132827758789,30.7698554992676,42953135,64,15,0.620253156705656,0.221288514786307,"Partnerships","Montis Biosciences launched with €8,4 million seed financing and a novel  approach to immune-oncology","https://www.pfizer.com//news/press-release/press-release-detail/montis-biosciences-launched-eu84-million-seed-financing-and",0.01,2020,2,17.5756202188629,0.61669921875,0.132827758789062,1,-0.326150894165043,1,0.64,0.15,"Management",0,1
2020-02-21,33.9278945922852,33.9848213195801,33.7096786499023,33.8899421691895,30.658275604248,32425256,NA,NA,NA,NA,NA,NA,NA,0.01,2020,2,17.2944482141184,0.275142669677734,-0.0379524230957031,0,-0.111579895019528,0,NA,NA,NA,0,NA
2020-02-24,33.2447814941406,33.5863380432129,32.8273239135742,32.8937377929688,29.7570686340332,37969296,NA,NA,NA,NA,NA,NA,NA,0.01,2020,2,17.4522884174198,0.759014129638672,-0.351043701171875,0,-0.901206970214844,0,NA,NA,NA,0,NA
2020-02-25,32.9032249450684,32.9601516723633,31.9829216003418,32.191650390625,29.1219310760498,41878898,142,14,0.820512815253123,0.240369799321464,"Finance","Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_invites_public_to_listen_to_webcast_of_pfizer_discussion_at_healthcare_conference-26",0.01,2020,2,17.5502926542228,0.977230072021484,-0.711574554443359,0,-0.635137557983398,1,1.42,0.14,"Finance",0,3
2020-02-26,32.485767364502,33.4060707092285,32.2770385742188,32.9411773681641,29.7999858856201,47920005,NA,NA,NA,NA,NA,NA,NA,0.01,2020,2,17.6850436369801,1.12903213500977,0.455410003662109,1,0.678054809570312,0,NA,NA,NA,0,NA
2020-02-27,32.6755218505859,33.8804550170898,32.3529396057129,32.3529396057129,29.2678375244141,55444827,479,152,0.518225038798376,0.268168295678637,"Finance","Mylan and Pfizer Finalize Appointments to Viatris Board of Directors","https://www.pfizer.com//news/press-release/press-release-detail/mylan-and-pfizer-finalize-appointments-viatris-board",0.01,2020,2,17.8308989941913,1.52751541137695,-0.322582244873047,0,-0.532148361206055,1,4.79,1.52,"Finance",0,3
2020-02-28,31.7741947174072,32.2011375427246,30.8633785247803,31.7077808380127,28.6842002868652,66057447,NA,NA,NA,NA,NA,NA,NA,0.01,2020,2,18.0060353456336,1.33775901794434,-0.0664138793945312,0,-0.583637237548832,0,NA,NA,NA,0,NA
2020-03-02,32.1726760864258,33.1593933105469,31.7362422943115,33.0929794311523,29.937313079834,42034469,188,49,0.586497887820684,0.305806451218314,"Medicines","U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis","https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_accepts_regulatory_submission_for_tanezumab_a_potential_first_in_class_treatment_for_patients_with_chronic_pain_due_to_moderate_to_severe_osteoarthritis",0.01,2020,3,17.5540005539315,1.42315101623535,0.920303344726562,1,1.25311279296875,1,1.88,0.49,"Research",0,2
2020-03-03,33.3776092529297,33.9468688964844,32.1252365112305,32.5426940917969,29.4395008087158,46174475,NA,NA,NA,NA,NA,NA,NA,0.01,2020,3,17.6479377358531,1.82163238525391,-0.834915161132812,0,-0.497812271118164,0,NA,NA,NA,0,NA
2020-03-04,33.3017082214355,34.5920295715332,33.1593933105469,34.5351028442383,31.2419185638428,38712155,62,10,0.722222212191358,0.25806451520407,"Leadership","Susan Hockfield Elected to Pfizer’s Board of Directors","https://www.pfizer.com//news/press-release/press-release-detail/susan-hockfield-elected-pfizers-board-directors",0.01,2020,3,17.4716642172054,1.43263626098633,1.23339462280273,1,1.80241775512695,1,0.62,0.1,"Management",0,1
2020-03-05,33.8235282897949,34.3263778686523,33.3586349487305,33.6432647705078,30.4351234436035,35096303,NA,NA,NA,NA,NA,NA,NA,0.01,2020,3,17.3736063837465,0.967742919921875,-0.180263519287109,0,-0.806795120239258,0,NA,NA,NA,0,NA
2020-03-06,32.9221992492676,33.3681221008301,32.3719177246094,33.2258071899414,30.0574741363525,40931036,NA,NA,NA,NA,NA,NA,NA,0.01,2020,3,17.527399184087,0.996204376220703,0.303607940673828,1,-0.377649307250977,0,NA,NA,NA,0,NA
2020-03-09,31.7457313537598,32.912712097168,31.4611015319824,32.0303611755371,28.9760208129883,43183856,NA,NA,NA,NA,NA,NA,NA,0.01,2020,3,17.5809773028228,1.45161056518554,0.28462982177734,1,-1.08145332336426,0,NA,NA,NA,0,NA
2020-03-10,32.7988624572754,32.8842506408691,31.3187866210938,32.8178367614746,29.6884059906006,40548329,NA,NA,NA,NA,NA,NA,NA,0.01,2020,3,17.5180051539538,1.56546401977539,0.0189743041992188,1,0.712385177612301,0,NA,NA,NA,0,NA
2020-03-11,32.0303611755371,32.144214630127,30.0379505157471,30.521821975708,27.6113319396973,65350213,NA,NA,NA,NA,NA,NA,NA,0.01,2020,3,17.995271272704,2.10626411437988,-1.5085391998291,0,-2.07707405090332,0,NA,NA,NA,0,NA
2020-03-12,28.9184055328369,30.3605308532715,28.4629974365234,28.4819736480713,25.765998840332,62731445,NA,NA,NA,NA,NA,NA,NA,0.01,2020,3,17.9543734109789,1.89753341674804,-0.436431884765621,0,-1.84533309936523,0,NA,NA,NA,0,NA
2020-03-13,29.667932510376,31.1954460144043,28.6812133789062,31.0341567993164,28.0748119354248,60553038,330,149,0.377870562885448,0.244263130931023,"Research","EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study","https://www.pfizer.com//news/press-release/press-release-detail/emd_serono_and_pfizer_provide_update_on_phase_iii_javelin_head_and_neck_100_study",0.01,2020,3,17.9190302166296,2.51423263549805,1.36622428894043,1,2.30881309509277,1,3.3,1.49,"Research",0,2
2020-03-16,28.4060726165771,30.6261863708496,28.1309299468994,28.6337757110596,25.9033260345459,50995050,NA,NA,NA,NA,NA,NA,NA,0.01,2020,3,17.7472391467643,2.49525642395019,0.227703094482422,1,-2.17148590087891,0,NA,NA,NA,0,NA
2020-03-17,30.0189743041992,30.9772300720215,29.0227699279785,30.5123348236084,27.6027507781982,54220606,187,42,0.633187770160752,0.259637187914244,"COVID-19","Pfizer and BioNTech to Co-Develop Potential COVID-19 Vaccine","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-co-develop-potential-covid-19-vaccine",0.01,2020,3,17.8085715971031,1.95446014404297,0.49336051940918,1,1.69942474365234,1,1.87,0.42,"Pandemic",0,4
2020-03-18,29.1935482025146,30.9392795562744,28.757116317749,30.7020874023438,27.7744083404541,43884976,232,97,0.410334345257342,0.221399730672006,"Research","Pfizer Announces Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults Aged 18 Years or Older","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-top-line-results-phase-3-study-20-valent",0.01,2020,3,17.5970826099111,2.18216323852539,1.5085391998291,1,0.171657562255863,1,2.32,0.97,"Research",0,2
2020-03-19,30.5692596435547,30.5977230072021,28.4724864959717,28.8614807128906,26.109317779541,59820929,NA,NA,NA,NA,NA,NA,NA,0.01,2020,3,17.9068661576851,2.12523651123047,-1.70777893066406,0,-1.66509056091309,0,NA,NA,NA,0,NA
2020-03-20,28.7286529541016,29.0986728668213,27.4288425445557,27.5237197875977,24.8991241455078,52488989,NA,NA,NA,NA,NA,NA,NA,0.01,2020,3,17.776113991283,1.66983032226562,-1.2049331665039,0,-1.2101936340332,0,NA,NA,NA,0,NA
2020-03-23,27.286527633667,28.0645160675049,26.4516124725342,27.0303611755371,24.4528121948242,52853041,NA,NA,NA,NA,NA,NA,NA,0.01,2020,3,17.7830258277537,1.6129035949707,-0.256166458129883,0,-0.446311950683594,0,NA,NA,NA,0,NA
2020-03-24,27.9981021881104,28.5104351043701,27.4193553924561,28.1783676147461,25.4913463592529,44466784,220,41,0.685823752161595,0.272727272442291,"Medicines","U.S. FDA Approves Supplemental New Drug Application (sNDA) for Expanded Indication of EUCRISA® (Crisaborole) Ointment, 2%, in Children as Young as 3 Months of Age With Mild-to-Moderate Atopic Dermatitis","https://www.pfizer.com//news/press-release/press-release-detail/us-fda-approves-supplemental-new-drug-application-snda",0.01,2020,3,17.6102530639436,1.09107971191406,0.180265426635746,1,1.03853416442871,1,2.2,0.41,"Research",0,2
2020-03-25,27.9886150360107,29.146110534668,27.5142307281494,28.2258052825928,25.5342597961426,44601275,NA,NA,NA,NA,NA,NA,NA,0.01,2020,3,17.6132730264465,1.63187980651855,0.237190246582028,1,0.0429134368896449,0,NA,NA,NA,0,NA
2020-03-26,28.3586349487305,30.3510437011719,28.3491458892822,30.1233406066895,27.2508487701416,43269967,314,49,0.730027546198271,0.279230769015976,"Finance","Mylan and Pfizer Provide Update Regarding Proposed Combination of Mylan and Upjohn","https://www.pfizer.com//news/press-release/press-release-detail/mylan-and-pfizer-provide-update-regarding-proposed",0.01,2020,3,17.5829693726584,2.00189781188965,1.76470565795898,1,1.71658897399903,1,3.14,0.49,"Finance",0,3
2020-03-27,29.2220115661621,30.1138515472412,29.089183807373,29.3168888092041,26.5212993621826,38290344,157,23,0.744444440308642,0.292207791733429,"Responsibility","Pfizer Completes $1.25 Billion Sustainability Bond for Social and Environmental Impact","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-completes-125-billion-sustainability-bond-social-and",0.01,2020,3,17.4607083335983,1.02466773986816,0.0948772430419922,1,-0.729549407958984,1,1.57,0.23,"Management",0,1
2020-03-30,29.4592037200928,31.1669826507568,29.4592037200928,30.9962043762207,28.0404796600342,29943508,NA,NA,NA,NA,NA,NA,NA,0.01,2020,3,17.2148231311571,1.70777893066406,1.53700065612793,1,1.51918029785156,0,NA,NA,NA,0,NA
2020-03-31,30.7400379180908,31.3092975616455,30.5882358551025,30.9677429199219,28.0147323608398,29466151,NA,NA,NA,NA,NA,NA,NA,0.01,2020,3,17.1987527727239,0.721061706542969,0.227705001831055,1,-0.0257472991943359,0,NA,NA,NA,0,NA
2020-04-01,30.2846298217773,30.6261863708496,29.9146118164062,30.1233406066895,27.2508487701416,26709625,303,76,0.598944589448695,0.360266159353359,"COVID-19","Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic","https://www.pfizer.com//news/press-release/press-release-detail/medical-professionals-across-merck-co-inc-pfizer-inc-and",0.01,2020,4,17.1005345827418,0.711574554443359,-0.161289215087891,0,-0.763883590698242,1,3.03,0.76,"Pandemic",0,4
2020-04-02,30.2656555175781,31.3092975616455,30.1233406066895,31.1859588623047,28.2121391296387,27186876,235,102,0.394658752538105,0.290517241128864,"Medicines","Pfizer Receives European Approval for Oncology Biosimilar, RUXIENCE™ (rituximab)","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-receives-european-approval-oncology-biosimilar",0.01,2020,4,17.1182449516081,1.18595695495605,0.920303344726562,1,0.96129035949707,1,2.35,1.02,"Research",0,2
2020-04-03,30.9582538604736,32.1537017822266,30.9582538604736,31.9165096282959,28.8730278015137,32837370,NA,NA,NA,NA,NA,NA,NA,0.01,2020,4,17.3070777845327,1.19544792175293,0.958255767822266,1,0.660888671875,0,NA,NA,NA,0,NA
2020-04-06,32.1821632385254,33.1119537353516,32.0493354797363,32.7988624572754,29.6712398529053,40503217,256,48,0.684210524065097,0.373923738777462,"Responsibility","Pfizer and The Pfizer Foundation Donate $40 Million in Charitable Grants, Expand Product Access and Mobilize Colleagues to Combat COVID-19 Pandemic","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-pfizer-foundation-donate-40-million-charitable",0.01,2020,4,17.5168919857104,1.06261825561523,0.61669921875,1,0.798212051391602,1,2.56,0.48,"Management",0,1
2020-04-07,33.2068328857422,33.3681221008301,31.8690700531006,31.8880462646484,28.8472766876221,24226295,55,7,0.774193535900104,0.273127752100759,"Finance","Pfizer to Hold Virtual-Only 2020 Annual Meeting of Shareholders","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-hold-virtual-only-2020-annual-meeting-shareholders",0.01,2020,4,17.0029492127621,1.4990520477295,-1.31878662109375,0,-0.823963165283203,1,0.55,0.07,"Finance",0,3
2020-04-08,32.2485771179199,33.0170783996582,31.7267551422119,32.8273239135742,29.696985244751,25523980,286,108,0.451776648599552,0.237206501964355,"Medicines","U.S. FDA Approves BRAFTOVI® (Encorafenib) in Combination with Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer (CRC) After Prior Therapy","https://www.pfizer.com//news/press-release/press-release-detail/us-fda-approves-braftovir-encorafenib-combination-cetuximab",0.01,2020,4,17.0551289995727,1.29032325744629,0.578746795654297,1,0.849708557128906,1,2.86,1.08,"Research",0,2
2020-04-09,33.235294342041,33.9373817443848,33.0645141601562,33.5768508911133,30.3750438690186,30648107,223,69,0.527397258467818,0.291708291416875,"COVID-19","Pfizer Advances Battle Against COVID-19 on Multiple Fronts","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-advances-battle-against-covid-19-multiple-fronts",0.01,2020,4,17.2380814892405,0.872867584228516,0.341556549072266,1,0.678058624267578,1,2.23,0.69,"Pandemic",0,4
2020-04-13,34.1176452636719,34.1366233825684,32.9411773681641,33.339656829834,30.1604690551758,18270141,NA,NA,NA,NA,NA,NA,NA,0.01,2020,4,16.7207787006283,1.1954460144043,-0.777988433837891,0,-0.214574813842773,0,NA,NA,NA,0,NA
2020-04-14,34.089183807373,34.7533226013184,33.529411315918,34.573055267334,31.2762508392334,21845309,NA,NA,NA,NA,NA,NA,NA,0.01,2020,4,16.8994968111573,1.22391128540039,0.483871459960938,1,1.11578178405762,0,NA,NA,NA,0,NA
2020-04-15,34.2125244140625,34.3738136291504,33.7571144104004,34.1271362304688,30.8728542327881,21312196,NA,NA,NA,NA,NA,NA,NA,0.01,2020,4,16.8747900958981,0.61669921875,-0.08538818359375,0,-0.403396606445309,0,NA,NA,NA,0,NA
2020-04-16,34.2694511413574,34.4022789001465,33.7571144104004,34.0417442321777,30.7956027984619,20657451,NA,NA,NA,NA,NA,NA,NA,0.01,2020,4,16.8435866839435,0.645164489746094,-0.227706909179688,0,-0.077251434326179,0,NA,NA,NA,0,NA
2020-04-17,34.6299819946289,35.104362487793,34.2599601745605,35.0189743041992,31.6796455383301,24404843,NA,NA,NA,NA,NA,NA,NA,0.01,2020,4,17.0102921951502,0.844402313232422,0.388992309570312,1,0.884042739868171,0,NA,NA,NA,0,NA
2020-04-20,34.5161285400391,35.0189743041992,34.2314987182617,34.2314987182617,30.9672622680664,22530620,147,63,0.399999998095238,0.283783783400292,"Partnerships","Valneva Receives FDA Fast Track Designation for its Lyme Disease  Vaccine Candidate VLA15","https://www.pfizer.com//news/press-release/press-release-detail/valneva-receives-fda-fast-track-designation-its-lyme",0.01,2020,4,16.9303858752776,0.7874755859375,-0.284629821777344,0,-0.712383270263675,1,1.47,0.63,"Management",0,1
2020-04-21,33.9468688964844,34.089183807373,33.5578765869141,33.7950668334961,30.5724487304688,23975233,NA,NA,NA,NA,NA,NA,NA,0.01,2020,4,16.992531938853,0.531307220458984,-0.151802062988281,0,-0.394813537597656,0,NA,NA,NA,0,NA
2020-04-22,35.0664138793945,35.104362487793,34.2694511413574,34.3927879333496,31.1131687164307,20182624,195,45,0.624999997395833,0.248190278957404,"Research","BioNTech and Pfizer announce regulatory approval from German authority Paul-Ehrlich-Institut to commence first clinical trial of COVID-19 vaccine candidates","https://www.pfizer.com//news/press-release/press-release-detail/biontech_and_pfizer_announce_regulatory_approval_from_german_authority_paul_ehrlich_institut_to_commence_first_clinical_trial_of_covid_19_vaccine_candidates",0.01,2020,4,16.8203326437166,0.834911346435547,-0.673625946044922,0,0.540719985961914,1,1.95,0.45,"Research",0,2
2020-04-23,34.4212532043457,35.4838714599609,34.4212532043457,34.810245513916,31.4908275604248,20185365,99,15,0.736842098799631,0.262672810454671,"Finance","Pfizer Hosts Virtual-Only Annual Meeting of Shareholders","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-hosts-virtual-only-annual-meeting-shareholders",0.01,2020,4,16.8204684443812,1.06261825561523,0.388992309570312,1,0.377658843994141,1,0.99,0.15,"Finance",0,3
2020-04-24,34.9525604248047,35.5123329162598,34.895637512207,35.4648971557617,32.0830535888672,17353794,NA,NA,NA,NA,NA,NA,NA,0.01,2020,4,16.6693217724273,0.616695404052734,0.512336730957031,1,0.592226028442383,0,NA,NA,NA,0,NA
2020-04-27,35.6641387939453,36.5654640197754,35.6451606750488,36.3662223815918,32.8984260559082,23394057,NA,NA,NA,NA,NA,NA,NA,0.01,2020,4,16.9679926164579,0.920303344726562,0.702083587646484,1,0.815372467041016,0,NA,NA,NA,0,NA
2020-04-28,37.0493354797363,37.2106246948242,35.4648971557617,35.9677429199219,32.5379447937012,35666728,1379,487,0.478027866839213,0.277802590400804,"Finance","PFIZER REPORTS FIRST-QUARTER 2020 RESULTS","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-reports-first-quarter-2020-results",0.01,2020,4,17.3897288514201,1.7457275390625,-1.08159255981445,0,-0.360481262207031,1,13.79,4.87,"Finance",0,3
2020-04-29,36.4895629882812,36.574951171875,35.7779884338379,36.1669845581055,32.7181930541992,26518535,160,38,0.616161613049689,0.260526315446676,"Research","BioNTech and Pfizer announce completion of dosing for first cohort of Phase 1/2 trial of COVID-19 vaccine candidates in Germany","https://www.pfizer.com//news/press-release/press-release-detail/biontech-and-pfizer-announce-completion-dosing-first-cohort",0.02,2020,4,17.0933545181383,0.796962738037109,-0.322578430175781,0,0.180248260498047,1,1.6,0.38,"Research",0,2
2020-04-30,36.0531311035156,36.5370025634766,35.4459190368652,36.3946876525879,32.9241790771484,29450973,207,79,0.447552445987579,0.282888229195956,"Partnerships","Valneva and Pfizer Announce Collaboration to Co-Develop and Commercialize Lyme Disease Vaccine, VLA15","https://www.pfizer.com//news/press-release/press-release-detail/valneva_and_pfizer_announce_collaboration_to_co_develop_and_commercialize_lyme_disease_vaccine_vla15",0.02,2020,4,17.1982375405201,1.09108352661133,0.341556549072266,1,0.205986022949219,1,2.07,0.79,"Management",0,1
2020-05-01,35.910816192627,35.9962043762207,35.4743843078613,35.7115745544434,32.3062019348145,22679867,192,55,0.554655868199774,0.250507099137417,"Medicines","Pfizer Receives Positive CHMP Opinion for DAURISMOTM (glasdegib)for  Certain Adult Patients with Newly Diagnosed Acute Myeloid Leukemia  (AML)","https://www.pfizer.com//news/announcements/pfizer-receives-positive-chmp-opinion-daurismotm-glasdegibfor-certain-adult",0.01,2020,5,16.9369882167011,0.521820068359375,-0.199241638183594,0,-0.617977142333984,1,1.92,0.55,"Research",0,2
2020-05-04,35.6736221313477,35.9772300720215,35.4933586120605,35.6926002502441,32.2890396118164,19893512,204,113,0.287066245151211,0.299056603491456,"Research","New Data Suggest Burden of Group B Streptococcus (GBS) Infection in U.S. Adults Greater Than Previously Recognized","https://www.pfizer.com//news/press-release/press-release-detail/new-data-suggest-burden-group-b-streptococcus-gbs-infection",0.01,2020,5,16.8059042566522,0.483871459960938,0.0189781188964844,1,-0.0171623229980469,1,2.04,1.13,"Research",0,2
2020-05-05,36.8216323852539,36.869068145752,36.3092994689941,36.5370025634766,33.0529174804688,24123952,208,45,0.64426877215704,0.249999999752964,"Research","Pfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID-19 mRNA Vaccine Development Program","https://www.pfizer.com//news/press-release/press-release-detail/pfizer_and_biontech_dose_first_participants_in_the_u_s_as_part_of_global_covid_19_mrna_vaccine_development_program",0.02,2020,5,16.9987158052838,0.559768676757812,-0.284629821777344,0,0.763877868652344,1,2.08,0.45,"Research",0,2
2020-05-06,36.9734344482422,37.0113868713379,36.5370025634766,36.5370025634766,33.0529174804688,24047432,NA,NA,NA,NA,NA,NA,NA,0.02,2020,5,16.9955388128526,0.474384307861328,-0.436431884765625,0,0,0,NA,NA,NA,0,NA
2020-05-07,36.4421234130859,36.5180282592773,35,35.0664138793945,32.0387077331543,33546080,NA,NA,NA,NA,NA,NA,NA,0.01,2020,5,17.3284306038288,1.51802825927734,-1.37570953369141,0,-1.01420974731445,0,NA,NA,NA,0,NA
2020-05-08,35.3415565490723,35.4648971557617,35.1423149108887,35.3130912780762,32.2640838623047,19893618,71,7,0.820512809993426,0.249201277159101,"Research","Pfizer Invites Public to View and Listen to Webcast of May 15 Conference Call with Analysts to Review Duchenne Muscular Dystrophy (DMD) Data Presentation at ASGCT 2020 Annual Meeting","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-may-15",0.01,2020,5,16.8059095850081,0.322582244873047,-0.0284652709960938,0,0.225376129150391,1,0.71,0.07,"Research",0,2
2020-05-11,35.3415565490723,36.2523727416992,35.2561683654785,36.148006439209,33.0269088745117,25620421,NA,NA,NA,NA,NA,NA,NA,0.01,2020,5,17.0589003258038,0.996204376220703,0.806449890136719,1,0.762825012207031,0,NA,NA,NA,0,NA
2020-05-12,36.1669845581055,36.280834197998,35.426944732666,35.4459190368652,32.385440826416,19335314,186,42,0.631578944598338,0.243850267118877,"Research","New Data from 18 Approved and Investigational Pfizer Medicines to be Showcased at ASCO20 Virtual Scientific Program","https://www.pfizer.com//news/press-release/press-release-detail/new-data-18-approved-and-investigational-pfizer-medicines",0.01,2020,5,16.7774437745898,0.853889465332031,-0.721065521240234,0,-0.641468048095703,1,1.86,0.42,"Research",0,2
2020-05-13,35.3984832763672,35.5028457641602,34.7153701782227,35.1518020629883,32.1167221069336,24596882,88,10,0.795918359225323,0.258575197206926,"Finance","Save the Date: Pfizer Announces New Date of September 14, 2020 for Rescheduled Investor Day","https://www.pfizer.com//news/press-release/press-release-detail/save-date-pfizer-announces-new-date-september-14-2020",0.01,2020,5,17.0181302855575,0.7874755859375,-0.246681213378906,0,-0.268718719482422,1,0.88,0.1,"Finance",0,3
2020-05-14,34.9146118164062,36.0151786804199,34.895637512207,35.9772300720215,32.8708763122559,22362507,221,91,0.416666665331197,0.225596529121044,"Research","Pfizer Announces Positive Top-Line Results From Phase 3 Lot Consistency Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naive Adults 18 Through 49 Years of Age","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-phase-3-lot",0.01,2020,5,16.9228963645408,1.11954116821289,1.06261825561523,1,0.754154205322266,1,2.21,0.91,"Research",0,2
2020-05-15,36.0151786804199,36.2144203186035,35.4743843078613,35.8254280090332,32.7321929931641,25460002,272,84,0.528089886157051,0.276612276397349,"Research","Pfizer’s New Phase 1b Results of Gene Therapy in Ambulatory Boys with Duchenne Muscular Dystrophy (DMD) Support Advancement into Pivotal Phase 3 Study","https://www.pfizer.com//news/press-release/press-release-detail/pfizers-new-phase-1b-results-gene-therapy-ambulatory-boys",0.01,2020,5,17.0526192689254,0.740036010742195,-0.189750671386719,0,-0.138683319091797,1,2.72,0.84,"Research",0,2
2020-05-18,36.3757133483887,36.4895629882812,35.7020874023438,36.1195449829102,33.0009078979492,22635177,116,14,0.784615378579882,0.3073286044744,"Finance","Pfizer Prices $4,000,000,000 Debt Offering","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-prices-4000000000-debt-offering",0.01,2020,5,16.9350158027488,0.7874755859375,-0.256168365478509,0,0.268714904785156,1,1.16,0.14,"Finance",0,3
2020-05-19,35.910816192627,36.0721054077149,35.3984832763672,35.7495269775391,32.6628379821777,19476234,NA,NA,NA,NA,NA,NA,NA,0.01,2020,5,16.7847055623446,0.673622131347663,-0.161289215087891,0,-0.338069915771484,0,NA,NA,NA,0,NA
2020-05-20,36.0056915283203,36.2428855895996,35.6261863708496,35.7020874023438,32.6194953918457,17504200,NA,NA,NA,NA,NA,NA,NA,0.01,2020,5,16.6779514672275,0.61669921875,-0.303604125976562,0,-0.0433425903320312,0,NA,NA,NA,0,NA
2020-05-21,35.6451606750488,35.721061706543,35.1518020629883,35.3510437011719,32.2987594604492,17652181,80,32,0.428571424744898,0.312849161137293,"Hiring & Recruitment","Interviews: How To Upskill In A Lockdown","https://www.pfizer.com//news/announcements/interviews-how-upskill-lockdown",0.01,2020,5,16.6863699597648,0.569259643554688,-0.294116973876953,0,-0.320735931396484,1,0.8,0.32,"Management",0,1
2020-05-22,35.2087287902832,35.6072120666504,35.0664138793945,35.5787467956543,32.5068054199219,15781226,114,11,0.823999993408,0.316455695401378,"Finance","Pfizer Inc. Recommends Rejection of Unsolicited Note Tender Offer by Huguenot Bond Liquidity, LLC","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-inc-recommends-rejection-unsolicited-note-tender",0.01,2020,5,16.5743316270131,0.540798187255859,0.370018005371094,1,0.208045959472656,1,1.14,0.11,"Finance",0,3
2020-05-26,35.721061706543,35.9297904968262,35.531307220459,35.5692596435547,32.4981346130371,23260094,NA,NA,NA,NA,NA,NA,NA,0.01,2020,5,16.9622497893113,0.398483276367188,-0.151802062988281,0,-0.00867080688476562,0,NA,NA,NA,0,NA
2020-05-27,35.4933586120605,35.61669921875,35.0759010314941,35.4933586120605,32.4287910461426,25904158,NA,NA,NA,NA,NA,NA,NA,0.01,2020,5,17.0699140929289,0.540798187255859,0,0,-0.0693435668945312,0,NA,NA,NA,0,NA
2020-05-28,35.9013290405273,36.470588684082,35.7874755859375,36.2239074707031,33.0962562561035,22521767,NA,NA,NA,NA,NA,NA,NA,0.01,2020,5,16.9299928661471,0.683113098144531,0.322578430175781,1,0.667465209960938,0,NA,NA,NA,0,NA
2020-05-29,36.3092994689941,36.4611015319824,35.6546478271484,36.2333984375,33.1049346923828,48333067,240,123,0.322314048698859,0.245602164921785,"Medicines","Final PROSPER Results Show XTANDI® (enzalutamide) Significantly Extends Overall Survival in Men with Non-Metastatic Castration-Resistant Prostate Cancer","https://www.pfizer.com//news/press-release/press-release-detail/final-prosper-results-show-xtandir-enzalutamide",0.01,2020,5,17.6936265220465,0.806453704833984,-0.0759010314941406,0,0.00867843627929688,1,2.4,1.23,"Research",0,2
2020-06-01,33.6812133789062,33.8994293212891,33.1214408874512,33.6432647705078,30.7384357452393,76884979,166,27,0.720207250154367,0.271067415349624,"Leadership","Annaliesa Anderson, Ph.D., Will Lead Pfizer’s Vaccine Research & Development","https://www.pfizer.com//news/announcements/annaliesa-anderson-phd-will-lead-pfizers-vaccine-research-development",0.01,2020,6,18.1578210968031,0.777988433837891,-0.0379486083984375,0,-2.36649894714356,1,1.66,0.27,"Management",0,1
2020-06-02,33.7096786499023,34.3073997497559,33.4440231323242,34.3073997497559,31.3452243804932,42690900,133,15,0.797297291910153,0.237560192235056,"Finance","Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-2",0.01,2020,6,17.5694963641568,0.863376617431641,0.597721099853516,1,0.60678863525391,1,1.33,0.15,"Finance",0,3
2020-06-03,34.4307403564453,34.5445938110352,33.719165802002,34.3073997497559,31.3452243804932,38751996,224,76,0.493333331688889,0.239808153285525,"Research","Complete Results from Second Pivotal Monotherapy Study of Abrocitinib Published in JAMA Dermatology","https://www.pfizer.com//news/press-release/press-release-detail/complete-results-second-pivotal-monotherapy-study",0.01,2020,6,17.4726928479196,0.825428009033203,-0.123340606689453,0,0,1,2.24,0.76,"Research",0,2
2020-06-04,33.8804550170898,34.4307403564453,33.8709678649902,34.1650848388672,31.2152042388916,27013388,NA,NA,NA,NA,NA,NA,NA,0.01,2020,6,17.1118431899452,0.559772491455078,0.284629821777344,1,-0.130020141601562,0,NA,NA,NA,0,NA
2020-06-05,34.38330078125,34.6204948425293,34.0417442321777,34.146110534668,31.1978626251221,36705655,NA,NA,NA,NA,NA,NA,NA,0.01,2020,6,17.4184414155918,0.578750610351562,-0.237190246582031,0,-0.0173416137695312,0,NA,NA,NA,0,NA
2020-06-08,33.9658432006836,34.7248573303223,33.851993560791,34.7153701782227,31.7179737091064,30194149,NA,NA,NA,NA,NA,NA,NA,0.01,2020,6,17.2231587549719,0.87286376953125,0.749526977539062,1,0.520111083984375,0,NA,NA,NA,0,NA
2020-06-09,34.6299819946289,34.7817840576172,34.3168869018555,34.3548393249512,31.3885688781738,21675088,NA,NA,NA,NA,NA,NA,NA,0.01,2020,6,16.8916741867355,0.464897155761719,-0.275142669677734,0,-0.329404830932617,0,NA,NA,NA,0,NA
2020-06-10,34.4971542358398,34.5825424194336,34.0512313842773,34.0796966552734,31.137186050415,29557217,196,63,0.513513511530836,0.232286995307366,"Research","Pfizer Announces Positive Top-Line Results from JADE TEEN Trial of Abrocitinib in Adolescents with Moderate-to-Severe Atopic Dermatitis","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-jade-teen-trial",0.01,2020,6,17.2018385359482,0.53131103515625,-0.417457580566406,0,-0.251382827758789,1,1.96,0.63,"Research",0,2
2020-06-11,33.7760925292969,33.851993560791,31.5749530792236,31.5939273834229,28.866039276123,63166642,255,72,0.55963302581152,0.311132254699208,"Medicines","FDA Approves Pfizer’s Oncology Supportive Care Biosimilar, NYVEPRIA™ (pegfilgrastim-apgf)","https://www.pfizer.com//news/press-release/press-release-detail/fda-approves-pfizers-oncology-supportive-care-biosimilar",0.01,2020,6,17.9612869191484,2.27704048156738,-2.18216514587402,0,-2.27114677429199,1,2.55,0.72,"Research",0,2
2020-06-12,32.3339653015137,32.3529396057129,31.3567352294922,32.0208740234375,29.25612449646,37902472,75,9,0.785714276360544,0.252252251494738,"Finance","Pfizer Invites Public to View and Listen to Webcast of June 18 Conference Call with Analysts to Review Data Presentations at Scientific Conferences during the Week of June 15th","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-june-18",0.01,2020,6,17.4505269185836,0.996204376220703,-0.313091278076172,0,0.390085220336914,1,0.75,0.09,"Finance",0,3
2020-06-15,31.5939273834229,31.99241065979,31.0815944671631,31.6508541107178,28.9180564880371,36247482,NA,NA,NA,NA,NA,NA,NA,0.01,2020,6,17.4058805023715,0.91081619262695,0.0569267272949219,1,-0.338068008422852,0,NA,NA,NA,0,NA
2020-06-16,31.8690700531006,32.2201156616211,31.043643951416,31.6888046264648,28.9527263641357,55616945,326,144,0.387234041729289,0.264639639490631,"Medicines","Merck and Pfizer’s SGLT2 Inhibitor STEGLATROTM (ertugliflozin) Meets Primary  Endpoint in VERTIS CV Trial for Patients with Type 2 Diabetes and  Atherosclerotic Cardiovascular Disease","https://www.pfizer.com//news/announcements/merck-and-pfizers-sglt2-inhibitor-steglatrotm-ertugliflozin-meets-primary",0.01,2020,6,17.8339984969562,1.17647171020508,-0.180265426635739,0,0.0346698760986364,1,3.26,1.44,"Research",0,2
2020-06-17,31.8690700531006,32.0398483276367,31.6129035949707,31.8406066894531,29.0914249420166,27509822,NA,NA,NA,NA,NA,NA,NA,0.01,2020,6,17.1300536988561,0.426944732666016,-0.0284633636474574,0,0.138698577880856,0,NA,NA,NA,0,NA
2020-06-18,31.565465927124,31.7552185058594,31.2903232574463,31.5370025634766,28.8140354156494,32278855,359,53,0.742718444799227,0.263090676715779,"Finance","Upjohn Announces Pricing of Senior Notes in Connection with the Proposed Combination of Mylan and Upjohn","https://www.pfizer.com//news/press-release/press-release-detail/upjohn-announces-pricing-senior-notes-connection-proposed",0.01,2020,6,17.2899229608371,0.464895248413086,-0.0284633636474645,0,-0.277389526367184,1,3.59,0.53,"Finance",0,3
2020-06-19,31.9639472961426,32.0113868713379,31.4231491088867,31.7077808380127,28.970064163208,43986266,NA,NA,NA,NA,NA,NA,NA,0.01,2020,6,17.5993880295286,0.588237762451172,-0.256166458129879,0,0.15602874755859,0,NA,NA,NA,0,NA
2020-06-22,31.6223907470703,31.6508541107178,31.2239093780518,31.4136619567871,28.7013416290283,23332503,312,136,0.39285714198023,0.241249326741384,"Medicines","European Medicines Agency Validates Application for BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma","https://www.pfizer.com//news/press-release/press-release-detail/european-medicines-agency-validates-application-bavencior",0.02,2020,6,16.9653579678567,0.426944732666012,-0.208728790283203,0,-0.268722534179688,1,3.12,1.36,"Research",0,2
2020-06-23,31.4990501403809,31.5464897155762,31.0626182556152,31.0910816192627,28.4066143035889,37690408,208,65,0.523809521890808,0.221770917772729,"Research","NEW DATA ON THE BURDEN OF EMERGING S. PNEUMONIAE SEROTYPES  PUBLISHED IN ISPPD 2020 ONLINE DIGITAL LIBRARY","https://www.pfizer.com//news/announcements/new-data-burden-emerging-s-pneumoniae-serotypes-published-isppd-2020-online",0.02,2020,6,17.4449162168692,0.483871459960941,-0.407968521118164,0,-0.294727325439453,1,2.08,0.65,"Research",0,2
2020-06-24,31.0341567993164,31.0531311035156,30.3605308532715,30.5407962799072,27.9038410186768,30817695,211,71,0.496453898948745,0.294979079189352,"Responsibility","Pfizer and Wellcome Launch Surveillance Program to Combat Growing Threat of Antimicrobial Resistance in Sub-Saharan Africa","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-wellcome-launch-surveillance-program-combat",0.02,2020,6,17.2435996284103,0.692600250244141,-0.49336051940918,0,-0.502773284912106,1,2.11,0.71,"Management",0,1
2020-06-25,30.4648952484131,30.7210636138916,30.1992416381836,30.6641368865967,28.0165328979492,27418651,44,4,0.833333315972223,0.298136644110953,"Finance","Pfizer Declares Third-Quarter 2020 Dividend","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-declares-third-quarter-2020-dividend",0.02,2020,6,17.1267340696938,0.521821975708008,0.19924163818359,1,0.112691879272457,1,0.44,0.04,"Finance",0,3
2020-06-26,30.5977230072021,30.6261863708496,29.9905128479004,30.3984813690186,27.7738132476807,42153992,NA,NA,NA,NA,NA,NA,NA,0.02,2020,6,17.5568399710213,0.635673522949219,-0.199241638183594,0,-0.242719650268555,0,NA,NA,NA,0,NA
2020-06-29,30.7969646453857,30.9962043762207,30.5502853393555,30.9677429199219,28.293924331665,23956261,75,9,0.785714276360544,0.297872339369247,"Responsibility","Pfizer Statement on Facebook Advertising Boycott","https://www.pfizer.com//news/announcements/pfizer-statement-facebook-advertising-boycott",0.01,2020,6,16.991740309024,0.445919036865234,0.170778274536129,1,0.520111083984375,1,0.75,0.09,"Management",0,1
2020-06-30,30.8633785247803,31.1954460144043,30.5787487030029,31.0246677398682,28.3459358215332,25451676,473,195,0.416167664047653,0.258914728581816,"Medicines","FDA Approves BAVENCIO as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma","https://www.pfizer.com//news/press-release/press-release-detail/fda-approves-bavencio-first-line-maintenance-treatment",0.01,2020,6,17.0522921926995,0.616697311401367,0.161289215087891,1,0.0520114898681641,1,4.73,1.95,"Research",0,2
2020-06-30,30.8633785247803,31.1954460144043,30.5787487030029,31.0246677398682,28.3459358215332,25451676,473,195,0.416167664047653,0.258914728581816,"Medicines","FDA Approves BAVENCIO as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma","https://www.pfizer.com//news/press-release/press-release-detail/fda-approves-bavencio-first-line-maintenance-treatment",0,2020,6,17.0522921926995,0.616697311401367,0.161289215087891,1,0,1,4.73,1.95,"Research",0,2
2020-07-01,32.7703971862793,32.7703971862793,31.99241065979,32.0113868713379,29.2474613189697,73503009,252,70,0.565217389549014,0.226760563220591,"Research","Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 study of mRNA-based Vaccine Candidate Against SARS-CoV-2","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-early-positive-data-ongoing",0.01,2020,7,18.1128369157255,0.777986526489258,-0.759010314941406,0,0.901525497436523,1,2.52,0.7,"Research",1,2
2020-07-02,32.8462982177734,33.0645141601562,32.2960166931152,32.7419357299805,29.9149265289307,45270881,59,23,0.439024384889947,0.302583024713716,"Hiring & Recruitment","How to deal with negative emotions","https://www.pfizer.com//news/announcements/how-deal-negative-emotions",0.01,2020,7,17.6281746023237,0.768497467041016,-0.104362487792969,0,0.667465209960938,1,0.59,0.23,"Management",1,1
2020-07-06,33.1593933105469,33.1973419189453,32.618595123291,32.7419357299805,29.9149265289307,27150935,NA,NA,NA,NA,NA,NA,NA,0,2020,7,17.1169220788881,0.578746795654297,-0.417457580566406,0,0,0,NA,NA,NA,1,NA
2020-07-07,32.3055038452148,32.5901336669922,32.2201156616211,32.2865295410156,29.4988460540771,25148018,83,28,0.495495491031572,0.34796238135435,"Hiring & Recruitment","Being your authentic self – why it takes courage to be vulnerable","https://www.pfizer.com//news/announcements/being-your-authentic-self-why-it-takes-courage-be-vulnerable",0,2020,7,17.0402896840121,0.370018005371094,-0.0189743041992188,0,-0.416080474853516,1,0.83,0.28,"Management",1,1
2020-07-08,32.2675514221191,32.6091079711914,31.8500957489014,32.0208740234375,29.25612449646,24256545,NA,NA,NA,NA,NA,NA,NA,0,2020,7,17.0041970770653,0.759012222290039,-0.246677398681641,0,-0.242721557617188,0,NA,NA,NA,1,NA
2020-07-09,32.0018997192383,32.144214630127,31.4041748046875,31.7457313537598,29.0047378540039,20363702,133,41,0.528735629145198,0.298969071651256,"Finance","Pfizer Pledges $100 Million to New Industry Fund to Help Fight Growing Threat of Antimicrobial Resistance","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-pledges-100-million-new-industry-fund-help-fight",0,2020,7,16.829264609337,0.740039825439453,-0.256168365478512,0,-0.251386642456058,1,1.33,0.41,"Finance",1,3
2020-07-10,31.9354839324951,32.2960166931152,31.7741947174072,32.0967750549316,29.3254718780518,24459019,NA,NA,NA,NA,NA,NA,NA,0,2020,7,17.0125096220077,0.521821975708008,0.161291122436523,1,0.320734024047859,0,NA,NA,NA,1,NA
2020-07-13,32.9506645202637,33.8899421691895,32.7514228820801,33.4060707092285,30.5217247009277,56569129,190,42,0.637931031733056,0.23269809404945,"Vaccines","Pfizer and BioNTech Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV-2","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-granted-fda-fast-track-designation-two",0.03,2020,7,17.8509739880248,1.13851928710938,0.455406188964844,1,1.19625282287597,1,1.9,0.42,"Pandemic",1,4
2020-07-14,33.5578765869141,33.6053123474121,33.0929794311523,33.425048828125,30.5390605926514,32854129,NA,NA,NA,NA,NA,NA,NA,0,2020,7,17.3075880179757,0.512332916259766,-0.132827758789062,0,0.0173358917236328,0,NA,NA,NA,1,NA
2020-07-15,34.146110534668,34.1555976867676,33.6527519226074,33.8899421691895,30.9638118743896,26294454,NA,NA,NA,NA,NA,NA,NA,0,2020,7,17.084868638417,0.502845764160156,-0.256168365478516,0,0.424751281738281,0,NA,NA,NA,1,NA
2020-07-16,33.7760925292969,33.8140411376953,33.4535102844238,33.7760925292969,30.8597946166992,18421812,NA,NA,NA,NA,NA,NA,NA,0,2020,7,16.7290460095723,0.360530853271484,0,0,-0.10401725769043,0,NA,NA,NA,1,NA
2020-07-17,34.0227699279785,34.468692779541,33.8994293212891,34.3927879333496,31.4232387542725,23347365,NA,NA,NA,NA,NA,NA,NA,0,2020,7,16.965994730577,0.569263458251953,0.370018005371094,1,0.563444137573242,0,NA,NA,NA,1,NA
2020-07-20,35.5692596435547,35.6926002502441,34.4592018127441,34.6299819946289,31.6399555206299,36815693,260,50,0.677419352653486,0.266781411130136,"Vaccines","Pfizer and BioNTech Announce Agreement with the United Kingdom for 30 Million Doses of mRNA-based Vaccine Candidate against SARS-CoV-2","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-agreement-united-kingdom-30",0,2020,7,17.4214347796191,1.2333984375,-0.939277648925781,0,0.216716766357422,1,2.6,0.5,"Pandemic",1,4
2020-07-21,35.0474395751953,35.1802673339844,34.6489562988281,34.810245513916,31.8046607971191,23588520,NA,NA,NA,NA,NA,NA,NA,0,2020,7,16.9762707533607,0.53131103515625,-0.237194061279297,0,0.164705276489258,0,NA,NA,NA,1,NA
2020-07-22,36.2713470458984,36.7457313537598,35.5977210998535,36.5844383239746,33.4256591796875,90705554,279,58,0.655786348202414,0.273983739614647,"Vaccines","Pfizer and BioNTech Announce an Agreement with U.S. Government for up to 600 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-agreement-us-government-600",0.04,2020,7,18.3231291590754,1.14801025390625,0.313091278076172,1,1.62099838256836,1,2.79,0.58,"Pandemic",1,4
2020-07-23,37.2201156616211,37.4003791809082,36.2239074707031,36.4421234130859,33.2956390380859,59639536,102,20,0.672131142031712,0.391025639772354,"Hiring & Recruitment","The value of trust","https://www.pfizer.com//news/announcements/value-trust",0.02,2020,7,17.9038292845845,1.17647171020508,-0.777992248535156,0,-0.130020141601562,1,1.02,0.2,"Management",1,1
2020-07-24,36.0815925598145,36.1954460144043,35.4174575805664,35.7305488586426,32.6455001831055,33870501,NA,NA,NA,NA,NA,NA,NA,0.02,2020,7,17.33805504606,0.777988433837891,-0.351043701171875,0,-0.650138854980469,0,NA,NA,NA,1,NA
2020-07-27,35.4459190368652,35.8159408569336,35.322582244873,35.61669921875,32.5414733886719,27640307,291,90,0.527559053733441,0.249836065409944,"Research","Pfizer and BioNTech Choose Lead mRNA Vaccine Candidate Against COVID-19 and Commence Pivotal Phase 2/3 Global Study","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-choose-lead-mrna-vaccine-candidate",0.01,2020,7,17.1347857000723,0.493358612060547,0.170780181884766,1,-0.104026794433594,1,2.91,0.9,"Research",1,2
2020-07-28,36.5654640197754,37.3244781494141,36.1100578308105,37.0208740234375,33.8244132995605,56393954,NA,NA,NA,NA,NA,NA,NA,0.01,2020,7,17.8478725298729,1.21442031860352,0.455410003662109,1,1.28293991088867,0,NA,NA,NA,1,NA
2020-07-29,37.2865295410156,37.4288444519043,36.4800758361816,37.2485771179199,34.0324516296387,37033660,NA,NA,NA,NA,NA,NA,NA,0.01,2020,7,17.4273378137874,0.948768615722656,-0.0379524230957031,0,0.208038330078125,0,NA,NA,NA,1,NA
2020-07-30,36.3187866210938,36.9449729919434,36.2428855895996,36.7552185058594,33.909912109375,32273796,70,25,0.473684205540166,0.346715327201769,"Hiring & Recruitment","How to be resilient","https://www.pfizer.com//news/announcements/how-be-resilient",0.01,2020,7,17.2897662205709,0.70208740234375,0.436431884765625,1,-0.122539520263672,1,0.7,0.25,"Management",1,1
2020-07-31,36.3187866210938,36.764705657959,35.9203033447266,36.5085372924805,33.6823272705078,28472124,240,55,0.627118641941971,0.259454705136803,"COVID-19","Pfizer and BioNTech to Supply Japan with 120 Million Doses of their BNT162 mRNA-based Vaccine Candidate","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-supply-japan-120-million-doses-their",0,2020,7,17.1644360964407,0.844402313232422,0.189750671386719,1,-0.227584838867188,1,2.4,0.55,"Pandemic",1,4
2020-08-03,36.6318778991699,36.6793174743652,36.2618598937988,36.3852005004883,33.568531036377,31036400,NA,NA,NA,NA,NA,NA,NA,0,2020,8,17.2506712993919,0.417457580566406,-0.246677398681641,0,-0.113796234130859,0,NA,NA,NA,1,NA
2020-08-04,36.3472480773926,36.6982917785645,36.1385192871094,36.4231491088867,33.6035499572754,29448549,NA,NA,NA,NA,NA,NA,NA,0,2020,8,17.1981552308565,0.559772491455078,0.0759010314941406,1,0.0350189208984375,0,NA,NA,NA,1,NA
2020-08-05,36.4990501403809,36.5559768676758,36.1764717102051,36.4800758361816,33.6560668945312,24292697,394,165,0.409660106601681,0.261826697769636,"Medicines","LORBRENA® (lorlatinib) Significantly Improves Progression-Free Survival in First-Line ALK-Positive Lung Cancer","https://www.pfizer.com//news/press-release/press-release-detail/lorbrenar-lorlatinib-significantly-improves-progression",0,2020,8,17.0056863693263,0.379505157470703,-0.0189743041992188,0,0.0525169372558594,1,3.94,1.65,"Research",1,2
2020-08-06,36.7836799621582,37.0967750549316,36.1954460144043,36.3092994689941,33.4985160827637,20922111,89,10,0.797979789919396,0.242053789139233,"Finance","Pfizer Announces Times for Rescheduled Virtual Investor Day on September 14 and September 15, 2020","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-times-rescheduled-virtual-investor-day",0,2020,8,16.8563171480882,0.901329040527344,-0.474380493164062,0,-0.157550811767578,1,0.89,0.1,"Finance",1,3
2020-08-07,36.337760925293,36.6413650512695,36.2049331665039,36.4800758361816,33.6560668945312,23097251,101,14,0.756521732551985,0.28325123082943,"COVID-19","Pfizer Announces Agreement with Gilead to Manufacture Remdesivir for Treatment of COVID-19","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-agreement-gilead-manufacture-remdesivir",0,2020,8,16.9552242073766,0.436431884765625,0.142314910888672,1,0.157550811767578,1,1.01,0.14,"Pandemic",1,4
2020-08-10,36.574951171875,36.6793174743652,36.2998085021973,36.4231491088867,33.6035499572754,19964552,NA,NA,NA,NA,NA,NA,NA,0,2020,8,16.8094689090478,0.379508972167969,-0.151802062988281,0,-0.0525169372558594,0,NA,NA,NA,1,NA
2020-08-11,36.5844383239746,36.6034164428711,35.7400398254395,35.853889465332,33.0783653259277,21326847,NA,NA,NA,NA,NA,NA,NA,0,2020,8,16.8754773064385,0.863376617431641,-0.730548858642578,0,-0.525184631347656,0,NA,NA,NA,1,NA
2020-08-12,35.8918418884277,36.574951171875,35.8728637695312,36.3662223815918,33.551025390625,19957595,NA,NA,NA,NA,NA,NA,NA,0,2020,8,16.8091203807122,0.70208740234375,0.474380493164062,1,0.472660064697266,0,NA,NA,NA,1,NA
2020-08-13,36.1195449829102,36.2239074707031,35.9392776489258,36.2144203186035,33.4109802246094,15340021,NA,NA,NA,NA,NA,NA,NA,0,2020,8,16.5459757880614,0.284629821777344,0.0948753356933594,1,-0.140045166015625,0,NA,NA,NA,1,NA
2020-08-14,36.0626182556152,36.4231491088867,35.9867172241211,36.1100578308105,33.314697265625,12901276,NA,NA,NA,NA,NA,NA,NA,0,2020,8,16.3728368566806,0.436431884765625,0.0474395751953125,1,-0.096282958984375,0,NA,NA,NA,1,NA
2020-08-17,36.0910835266113,36.4421234130859,36.0056915283203,36.3852005004883,33.568531036377,17494187,NA,NA,NA,NA,NA,NA,NA,0,2020,8,16.6773792694459,0.436431884765625,0.294116973876953,1,0.253833770751953,0,NA,NA,NA,1,NA
2020-08-18,36.4800758361816,36.4895629882812,36.2144203186035,36.3946876525879,33.5772895812988,10846398,78,17,0.642105256398892,0.372549018146867,"Health Equity","Improving Access to Cures Through Innovation","https://www.pfizer.com//news/announcements/improving-access-cures-through-innovation",0,2020,8,16.1993436934623,0.275142669677727,-0.08538818359375,0,0.008758544921875,1,0.78,0.17,"Management",1,1
2020-08-19,36.5085372924805,36.6318778991699,36.1669845581055,36.2998085021973,33.4897575378418,15690055,NA,NA,NA,NA,NA,NA,NA,0,2020,8,16.5685376938552,0.464893341064453,-0.208728790283203,0,-0.0875320434570312,0,NA,NA,NA,1,NA
2020-08-20,36.2239074707031,36.8026580810547,36.1764717102051,36.7362442016602,33.892406463623,21957455,283,72,0.594366195508828,0.236194277953297,"COVID-19","Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-share-positive-early-data-lead-mrna",0,2020,8,16.9046173209003,0.626186370849609,0.512336730957038,1,0.40264892578125,1,2.83,0.72,"Pandemic",1,4
2020-08-21,36.9165077209473,37.0018997192383,36.5939292907715,36.8880462646484,34.0324554443359,25467170,NA,NA,NA,NA,NA,NA,NA,0,2020,8,17.0529007689375,0.40797042846679,-0.0284614562988281,0,0.140048980712891,0,NA,NA,NA,1,NA
2020-08-24,37.0208740234375,37.0398483276367,36.5654640197754,36.8500938415527,33.9974479675293,25011947,NA,NA,NA,NA,NA,NA,NA,0,2020,8,17.0348641886651,0.474384307861328,-0.170780181884766,0,-0.0350074768066406,0,NA,NA,NA,1,NA
2020-08-25,36.5370025634766,36.5844383239746,36.0056915283203,36.4421234130859,33.6210594177246,26221201,NA,NA,NA,NA,NA,NA,NA,0,2020,8,17.0820788781171,0.578746795654297,-0.094879150390625,0,-0.376388549804688,0,NA,NA,NA,1,NA
2020-08-26,36.2333984375,36.3092994689941,35.7305488586426,36.1005706787109,33.3059425354004,24083689,NA,NA,NA,NA,NA,NA,NA,0,2020,8,16.9970454058676,0.578750610351562,-0.132827758789062,0,-0.315116882324219,0,NA,NA,NA,1,NA
2020-08-27,36.0151786804199,36.0531311035156,35.7495269775391,35.9203033447266,33.1396217346191,22156556,NA,NA,NA,NA,NA,NA,NA,0,2020,8,16.9136440377361,0.303604125976562,-0.0948753356933594,0,-0.16632080078125,0,NA,NA,NA,1,NA
2020-08-28,35.9297904968262,36.1100578308105,35.4838714599609,35.9677429199219,33.1833992004395,32830519,NA,NA,NA,NA,NA,NA,NA,0,2020,8,17.3068691285238,0.626186370849609,0.0379524230957031,1,0.0437774658203125,0,NA,NA,NA,1,NA
2020-08-31,35.9013290405273,36.0721054077149,35.5787467956543,35.853889465332,33.0783653259277,30032465,NA,NA,NA,NA,NA,NA,NA,0,2020,8,17.2177895544701,0.493358612060554,-0.0474395751953125,0,-0.105033874511719,0,NA,NA,NA,1,NA
2020-09-01,35.853889465332,35.8823547363281,34.6394691467285,34.9905128479004,32.2818145751953,36145560,NA,NA,NA,NA,NA,NA,NA,0,2020,9,17.403064705115,1.24288558959961,-0.863376617431641,0,-0.796550750732422,0,NA,NA,NA,1,NA
2020-09-02,34.8861465454102,35.3889923095703,34.5351028442383,35.294116973877,32.5619163513184,29068688,NA,NA,NA,NA,NA,NA,NA,0,2020,9,17.1851721734789,0.853889465332031,0.407970428466797,1,0.280101776123047,0,NA,NA,NA,1,NA
2020-09-03,35.4554061889648,35.5692596435547,34.2504730224609,34.5351028442383,31.8616619110107,35956788,94,13,0.757009338719539,0.255980860631625,"Finance","Pfizer Invites Public to Register for Webcast of Virtual Investor Day on September 14 and 15, 2020","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-register-webcast-virtual-investor-day",0,2020,9,17.3978284699212,1.31878662109375,-0.920303344726562,0,-0.700254440307614,1,0.94,0.13,"Finance",1,3
2020-09-04,34.6204948425293,34.7533226013184,34.0322570800781,34.4971542358398,31.8266506195068,26872257,NA,NA,NA,NA,NA,NA,NA,0,2020,9,17.1066050112999,0.721065521240234,-0.123340606689453,0,-0.0350112915039098,0,NA,NA,NA,1,NA
2020-09-08,34.6584434509277,34.7343444824219,33.851993560791,34.089183807373,31.4502620697021,26736818,565,125,0.637681158496114,0.291754756747672,"Vaccines","Biopharma Leaders Unite To Stand With Science","https://www.pfizer.com//news/press-release/press-release-detail/biopharma-leaders-unite-stand-science",0,2020,9,17.1015521622027,0.882350921630859,-0.569259643554688,0,-0.376388549804688,1,5.65,1.25,"Pandemic",1,4
2020-09-09,34.4307403564453,34.7722969055176,34.2884254455566,34.3263778686523,31.6690979003906,27490533,263,53,0.664556959922288,0.257748776298737,"COVID-19","Pfizer and BioNTech to Potentially Supply the EU with 200 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-potentially-supply-eu-200-million-doses",0,2020,9,17.1293522851983,0.483871459960938,-0.104362487792969,0,0.218835830688477,1,2.63,0.53,"Pandemic",1,4
2020-09-10,34.3453521728516,34.4592018127441,33.7571144104004,33.8235282897949,31.2051734924316,21650741,190,35,0.688888885827161,0.260718423799863,"Research","Pfizer to Present Latest Scientific Advancements from Its Industry-Leading Portfolio at the ESMO Virtual Congress 2020","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-present-latest-scientific-advancements-its-industry",0,2020,9,16.8905502843428,0.70208740234375,-0.521823883056641,0,-0.463924407958984,1,1.9,0.35,"Research",1,2
2020-09-11,33.9089164733887,34.2599601745605,33.6337776184082,34.2220115661621,31.5728073120117,24109301,82,10,0.782608687145558,0.255555554845679,"Finance","Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-3",0,2020,9,16.9981082990954,0.626182556152344,0.313095092773438,1,0.367633819580078,1,0.82,0.1,"Finance",1,3
2020-09-14,34.4971542358398,35.61669921875,34.4212532043457,35.1138534545898,32.3956108093262,29565543,92,20,0.642857137117347,0.208566107619058,"Finance","Pfizer Hosts Virtual Investor Day","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-hosts-virtual-investor-day",0.01,2020,9,17.2021201872031,1.1954460144043,0.61669921875,1,0.822803497314453,1,0.92,0.2,"Finance",1,3
2020-09-15,35.2846298217773,35.4364318847656,34.9240989685059,35.0664138793945,32.3518409729004,22003726,331,99,0.539534882466198,0.221079691403044,"COVID-19","Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-investor-day-features-significant-number-pipeline",0,2020,9,16.9067224060654,0.512332916259766,-0.218215942382812,0,-0.0437698364257812,1,3.31,0.99,"Pandemic",1,4
2020-09-16,35.3700180053711,35.3984832763672,34.8387107849121,34.895637512207,32.1942863464355,22208412,NA,NA,NA,NA,NA,NA,NA,0,2020,9,16.9159817390178,0.559772491455078,-0.474380493164062,0,-0.157554626464844,0,NA,NA,NA,1,NA
2020-09-17,34.895637512207,35.0759010314941,34.677417755127,34.9335861206055,32.229305267334,17894390,NA,NA,NA,NA,NA,NA,NA,0,2020,9,16.6999978697507,0.398483276367188,0.0379486083984375,1,0.0350189208984375,0,NA,NA,NA,1,NA
2020-09-18,34.895637512207,35.1707763671875,34.6963958740234,34.7533226013184,32.06298828125,31694623,417,188,0.378512396068575,0.237907982604047,"Research","BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published in The New England Journal of Medicine","https://www.pfizer.com//news/press-release/press-release-detail/bavencio-pivotal-phase-iii-javelin-bladder-100-results",0,2020,9,17.2716576345602,0.474380493164062,-0.142314910888672,0,-0.166316986083984,1,4.17,1.88,"Research",1,2
2020-09-21,34.5066413879395,34.6110076904297,33.5673637390137,34.1745719909668,31.5290374755859,26608968,NA,NA,NA,NA,NA,NA,NA,0,2020,9,17.0967588973705,1.04364395141602,-0.332069396972656,0,-0.533950805664062,0,NA,NA,NA,1,NA
2020-09-22,33.9753303527832,34.468692779541,33.9089164733887,34.3927879333496,31.7303581237793,22727297,88,10,0.795918359225323,0.258575197206926,"Finance","Pfizer Invites Public to View and Listen to Webcast of October 27 Conference Call with Analysts","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-october-27",0,2020,9,16.9390773150275,0.559776306152344,0.417457580566406,1,0.201320648193359,1,0.88,0.1,"Finance",1,3
2020-09-23,34.4781761169434,34.5161285400391,34.1271362304688,34.1555976867676,31.5115337371826,23102521,283,129,0.373786406859742,0.264951768318359,"Medicines","FDA Accepts Supplemental New Drug Application for Pfizer’s XALKORI® (crizotinib) for the Treatment of Pediatric ALK-positive Anaplastic Large Cell Lymphoma","https://www.pfizer.com//news/press-release/press-release-detail/fda-accepts-supplemental-new-drug-application-pfizers",0,2020,9,16.9554523470218,0.388992309570312,-0.322578430175781,0,-0.21882438659668,1,2.83,1.29,"Research",1,2
2020-09-24,34.1081581115723,34.193546295166,33.719165802002,33.9278945922852,31.301456451416,20859925,46,4,0.8399999832,0.304878046921475,"Finance","Pfizer Declares Fourth-Quarter 2020 Dividend","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-declares-fourth-quarter-2020-dividend",0,2020,9,16.8533404600714,0.474380493164062,-0.180263519287109,0,-0.210077285766602,1,0.46,0.04,"Finance",1,3
2020-09-25,33.719165802002,34.2979125976562,33.7001914978027,34.2030372619629,31.555305480957,14365598,NA,NA,NA,NA,NA,NA,NA,0,2020,9,16.4803469480991,0.597721099853516,0.483871459960938,1,0.253849029541016,0,NA,NA,NA,1,NA
2020-09-28,34.3073997497559,34.705883026123,34.3073997497559,34.5256156921387,31.8529109954834,15044269,388,166,0.400722020937325,0.251589464009269,"Medicines","U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis","https://www.pfizer.com//news/press-release/press-release-detail/us-fda-approves-pfizers-xeljanzr-tofacitinib-treatment",0,2020,9,16.5265077457657,0.398483276367188,0.218215942382812,1,0.297605514526367,1,3.88,1.66,"Research",1,2
2020-09-29,34.5635681152344,34.6679306030273,34.1840591430664,34.3168869018555,31.6603412628174,13512491,NA,NA,NA,NA,NA,NA,NA,0,2020,9,16.419125148885,0.483871459960938,-0.246681213378906,0,-0.192569732666016,0,NA,NA,NA,1,NA
2020-09-30,34.4117660522461,35.0664138793945,34.3927879333496,34.8197326660156,32.1242561340332,22629275,NA,NA,NA,NA,NA,NA,NA,0,2020,9,16.9347550241682,0.673625946044922,0.407966613769531,1,0.46391487121582,0,NA,NA,NA,1,NA
2020-10-01,35.0189743041992,35.189754486084,34.3073997497559,34.5066413879395,31.8354110717773,22520396,145,44,0.534391531564066,0.281249999581473,"Research","Pfizer Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Investigational Gene Therapy","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-receives-fda-fast-track-designation-duchenne",0,2020,10,16.9299319898548,0.882354736328125,-0.512332916259766,0,-0.288845062255859,1,1.45,0.44,"Research",1,2
2020-10-02,34.2125244140625,34.7817840576172,34.1840591430664,34.5161285400391,31.8441505432129,21461759,NA,NA,NA,NA,NA,NA,NA,0,2020,10,16.8817833048515,0.597724914550781,0.303604125976562,1,0.00873947143554688,0,NA,NA,NA,1,NA
2020-10-05,34.6584434509277,34.9905128479004,34.4781761169434,34.8671722412109,32.168025970459,19400029,137,45,0.505494502717063,0.234234233932774,"Partnerships","SpringWorks Therapeutics Announces Clinical Collaboration with PfizerInc. to  Evaluate Nirogacestat in Combination with PF‐06863135 in Patients with Relapsed  or Refractory Multiple Myeloma","https://www.pfizer.com//news/press-release/press-release-detail/springworks-therapeutics-announces-clinical-collaboration",0,2020,10,16.7807851704241,0.512336730957031,0.208728790283203,1,0.323875427246094,1,1.37,0.45,"Management",1,1
2020-10-06,35.104362487793,35.1328277587891,34.2409858703613,34.3168869018555,31.6603412628174,25233392,230,56,0.608391606264365,0.267289719376365,"COVID-19","BioNTech and Pfizer Initiate Rolling Submission to European Medicines Agency for SARS-CoV-2 Vaccine Candidate BNT162b2","https://www.pfizer.com//news/press-release/press-release-detail/biontech-and-pfizer-initiate-rolling-submission-european",0,2020,10,17.0436787943339,0.891841888427734,-0.7874755859375,0,-0.507684707641602,1,2.3,0.56,"Pandemic",1,4
2020-10-07,34.4022789001465,34.7153701782227,34.1840591430664,34.6015167236328,31.9229278564453,22160034,254,63,0.602523657405288,0.262200165209098,"Research","Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-sangamo-dose-first-participant-phase-3-study",0,2020,10,16.9138009992645,0.53131103515625,0.199237823486328,1,0.26258659362793,1,2.54,0.63,"Research",1,2
2020-10-08,34.7248573303223,35.2751426696777,34.6394691467285,35,32.2905731201172,17857395,278,126,0.376237622831095,0.273898304899052,"Research","Pfizer Announces Positive Phase 3 Top-line Results for Once-Weekly Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-positive-phase-3-top-line-results-once",0,2020,10,16.6979283221108,0.635673522949219,0.275142669677734,1,0.367645263671875,1,2.78,1.26,"Research",1,2
2020-10-09,34.9430732727051,35.2182159423828,34.7153701782227,34.9051246643066,32.2030372619629,23667465,221,105,0.355828219767398,0.240768094356892,"Medicines","PENELOPE-B Trial of IBRANCE® (palbociclib) in Early Breast Cancer Did Not Meet Primary Endpoint","https://www.pfizer.com//news/press-release/press-release-detail/penelope-b-trial-ibrancer-palbociclib-early-breast-cancer",0,2020,10,16.979611920415,0.502845764160156,-0.0379486083984375,0,-0.0875358581542969,1,2.21,1.05,"Research",1,2
2020-10-12,34.8197326660156,35.2751426696777,34.6015167236328,34.9335861206055,32.229305267334,19413837,NA,NA,NA,NA,NA,NA,NA,0,2020,10,16.7814966687258,0.673625946044922,0.113853454589844,1,0.0262680053710938,0,NA,NA,NA,1,NA
2020-10-13,34.7912712097168,35.2277030944824,34.7533226013184,35.0094871520996,32.29931640625,21543233,NA,NA,NA,NA,NA,NA,NA,0,2020,10,16.8855723576985,0.474380493164062,0.218215942382812,1,0.0700111389160156,0,NA,NA,NA,1,NA
2020-10-14,35.1138534545898,35.3889923095703,34.6963958740234,34.9715385437012,32.2643165588379,22120298,NA,NA,NA,NA,NA,NA,NA,0,2020,10,16.9120062517061,0.692596435546875,-0.142314910888672,0,-0.0349998474121094,0,NA,NA,NA,1,NA
2020-10-15,34.7533226013184,34.8576850891113,34.5445938110352,34.677417755127,31.9929580688477,16089205,NA,NA,NA,NA,NA,NA,NA,0,2020,10,16.5936591703302,0.313091278076172,-0.0759048461914062,0,-0.271358489990234,0,NA,NA,NA,1,NA
2020-10-16,35.1707763671875,36.1669845581055,35.1233406066895,36.0056915283203,33.2184066772461,42993503,NA,NA,NA,NA,NA,NA,NA,0.02,2020,10,17.5765595924782,1.04364395141602,0.834915161132812,1,1.22544860839844,0,NA,NA,NA,1,NA
2020-10-19,36.4516143798828,36.8595848083496,35.7115745544434,35.8633766174316,33.0871124267578,31931352,NA,NA,NA,NA,NA,NA,NA,0.01,2020,10,17.2790989377362,1.14801025390625,-0.588237762451172,0,-0.131294250488281,0,NA,NA,NA,1,NA
2020-10-20,35.9297904968262,35.9487686157227,35.4364318847656,35.5692596435547,32.8157615661621,22384852,NA,NA,NA,NA,NA,NA,NA,0,2020,10,16.9238950827382,0.512336730957031,-0.360530853271484,0,-0.271350860595703,0,NA,NA,NA,1,NA
2020-10-21,35.4364318847656,35.531307220459,35.1612892150879,35.1802673339844,32.4568862915039,18984859,263,119,0.376963349798525,0.207046070348484,"Research","Data From Pfizer’s Adult and Pediatric Clinical Trial Programs for 20-Valent Pneumococcal Conjugate Vaccine Presented at IDWeek 2020","https://www.pfizer.com//news/press-release/press-release-detail/data-pfizers-adult-and-pediatric-clinical-trial-programs-20",0,2020,10,16.759152377378,0.370018005371094,-0.25616455078125,0,-0.358875274658203,1,2.63,1.19,"Research",1,2
2020-10-22,35.1802673339844,35.6451606750488,35.1328277587891,35.5123329162598,32.763240814209,19243616,NA,NA,NA,NA,NA,NA,NA,0,2020,10,16.7726899792962,0.512332916259766,0.332065582275391,1,0.306354522705078,0,NA,NA,NA,1,NA
2020-10-23,35.9867172241211,36.3187866210938,35.721061706543,36.2239074707031,33.419734954834,30557884,NA,NA,NA,NA,NA,NA,NA,0,2020,10,17.2351333117524,0.597724914550781,0.237190246582031,1,0.656494140625,0,NA,NA,NA,1,NA
2020-10-26,35.9297904968262,36.0721054077149,35.5597724914551,35.9772300720215,33.1921501159668,33783124,NA,NA,NA,NA,NA,NA,NA,0,2020,10,17.3354719754263,0.512332916259773,0.0474395751953125,1,-0.227584838867188,0,NA,NA,NA,1,NA
2020-10-27,35.1423149108887,36.1669845581055,34.9810256958008,35.5123329162598,32.763240814209,36851529,204,50,0.60629921021142,0.239622641283375,"Research","FDA Grants Priority Review and EMA Accepts Regulatory Submission for Pfizer’s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe Atopic Dermatitis","https://www.pfizer.com//news/press-release/press-release-detail/fda-grants-priority-review-and-ema-accepts-regulatory",0,2020,10,17.4224076954121,1.18595886230469,0.370018005371094,1,-0.428909301757812,1,2.04,0.5,"Research",1,2
2020-10-28,34.9146118164062,35.2277030944824,33.5104370117188,33.6337776184082,31.0301151275635,33857537,NA,NA,NA,NA,NA,NA,NA,0,2020,10,17.3376722208621,1.71726608276367,-1.28083419799805,0,-1.73312568664551,0,NA,NA,NA,1,NA
2020-10-29,33.662239074707,33.8140411376953,32.8273239135742,33.472484588623,30.8813056945801,27545341,NA,NA,NA,NA,NA,NA,NA,0,2020,10,17.1313440048583,0.986717224121094,-0.189754486083984,0,-0.148809432983395,0,NA,NA,NA,1,NA
2020-10-30,33.4345359802246,33.7096786499023,33.0550270080566,33.662239074707,31.0563659667969,25631067,305,45,0.742857140734694,0.26697177706562,"Finance","Mylan and Pfizer Receive Clearance from the U.S. Federal Trade Commission for Proposed Combination of Mylan and Upjohn","https://www.pfizer.com//news/press-release/press-release-detail/mylan-and-pfizer-receive-clearance-us-federal-trade",0,2020,10,17.0593157673902,0.654651641845703,0.227703094482422,1,0.175060272216793,1,3.05,0.45,"Finance",1,3
2020-11-02,34.089183807373,34.3927879333496,33.719165802002,34.3738136291504,31.7128601074219,21430666,NA,NA,NA,NA,NA,NA,NA,0,2020,11,16.8803334915571,0.673622131347656,0.284629821777344,1,0.656494140625,0,NA,NA,NA,1,NA
2020-11-03,34.5635681152344,34.7438316345215,34.2314987182617,34.3358612060547,31.6778430938721,21636617,NA,NA,NA,NA,NA,NA,NA,0,2020,11,16.8898977150708,0.512332916259766,-0.227706909179688,0,-0.0350170135498047,0,NA,NA,NA,1,NA
2020-11-04,35.1612892150879,36.1669845581055,35.0664138793945,35.4174575805664,32.6757164001465,40870536,NA,NA,NA,NA,NA,NA,NA,0,2020,11,17.5259199946761,1.10057067871094,0.256168365478516,1,0.997873306274414,0,NA,NA,NA,1,NA
2020-11-05,35.3415565490723,35.3889923095703,34.5256156921387,34.5256156921387,32.180492401123,33926995,246,36,0.744680848423118,0.245217391091115,"Finance","Pfizer Announces Details for When-Issued and Ex-Distribution Trading of Viatris and Pfizer Common Stock","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-details-when-issued-and-ex-distribution",0,2020,11,17.3397215976214,0.863376617431641,-0.815940856933594,0,-0.495223999023438,1,2.46,0.36,"Finance",1,3
2020-11-06,34.5256156921387,34.8387107849121,34.2409858703613,34.5351028442383,32.1893348693848,23870676,386,199,0.319658119111696,0.270083102368383,"Medicines","Pfizer Announces Positive Phase 3 Study Results for XELJANZ ® (tofacitinib) in Ankylosing Spondylitis (AS)","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-positive-phase-3-study-results-xeljanz-r",0,2020,11,16.9881613598734,0.597724914550781,0.00948715209960938,1,0.00884246826171875,1,3.86,1.99,"Research",1,2
2020-11-09,39.7153701782227,39.8387107849121,36.4136619567871,37.191650390625,34.6654396057129,230153864,311,79,0.594871793346483,0.279369627307042,"Research","Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against",2,2020,11,19.2542586214821,3.425048828125,-2.52371978759766,0,2.47610473632812,1,3.11,0.79,"Research",1,2
2020-11-10,38.3776092529297,38.4629974365234,36.4895629882812,36.6982917785645,34.2055854797363,80091668,92,28,0.533333328888889,0.29999999925,"Events","Celebrating Our Veterans: A Salute to Their Service","https://www.pfizer.com//news/announcements/celebrating-our-veterans-salute-their-service",1.3,2020,11,18.1986823991388,1.97343444824219,-1.67931747436523,0,-0.459854125976562,1,0.92,0.28,"Management",1,1
2020-11-11,36.8880462646484,38.1404151916504,35.9582557678223,36.527515411377,34.0464134216309,58980997,317,68,0.646753245073368,0.252459016227896,"COVID-19","Pfizer and BioNTech Reach an Agreement to Supply the EU With 200 Million Doses of Their BNT162b2 mRNA-Based Vaccine Candidate Against SARS-CoV-2","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-reach-agreement-supply-eu-200-million",0.6,2020,11,17.8927258821984,2.18215942382812,-0.360530853271484,0,-0.159172058105469,1,3.17,0.68,"Pandemic",1,4
2020-11-12,36.3187866210938,36.3757133483887,35.3320693969727,35.6261863708496,33.2063064575195,46767877,264,70,0.580838321614257,0.261141516605831,"Medicines","Analysis from Phase 3 ATTR-ACT and Its Long-Term Extension Study Demonstrates VYNDAQEL® 80 mg/VYNDAMAX® 61 mg Significantly Improved Survival in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Compared to VYNDAQEL 20 mg","https://www.pfizer.com//news/press-release/press-release-detail/analysis-phase-3-attr-act-and-its-long-term-extension-study",0.4,2020,11,17.6607071577085,1.04364395141602,-0.692600250244141,0,-0.840106964111328,1,2.64,0.7,"Research",1,2
2020-11-13,35.9297904968262,36.6793174743652,35.7779884338379,36.6413650512695,34.1525268554688,40175634,NA,NA,NA,NA,NA,NA,NA,0.3,2020,11,17.5087712753123,0.901329040527344,0.711574554443359,1,0.946220397949219,0,NA,NA,NA,1,NA
2020-11-16,35.9203033447266,36.0056915283203,34.9620475769043,35.4174575805664,33.0117568969727,75530167,109,12,0.801652885936753,0.241516965585794,"Finance","Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-completes-transaction-combine-its-upjohn-business",0.15,2020,11,18.1400427105689,1.04364395141602,-0.502845764160156,0,-1.14076995849609,1,1.09,0.12,"Finance",1,3
2020-11-17,36.4900016784668,36.5,35.8199996948242,36.0400009155273,33.5920104980469,46984500,NA,NA,NA,NA,NA,NA,NA,0.1,2020,11,17.6653283393321,0.680000305175781,-0.450000762939453,0,0.580253601074219,0,NA,NA,NA,1,NA
2020-11-18,36.9300003051758,37.4199981689453,36.2999992370605,36.3199996948242,33.8529891967773,63442700,275,77,0.562499998401989,0.256186317135236,"COVID-19","Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine",0.2,2020,11,17.9656477100466,1.11999893188477,-0.610000610351562,0,0.260978698730469,1,2.75,0.77,"Pandemic",1,4
2020-11-19,36.5999984741211,36.6300010681152,35.8600006103516,36.189998626709,33.7318153381348,43261800,405,165,0.421052630840259,0.25583482932862,"Research","Results from Phase 3 CROWN Trial of Pfizer’s LORBRENA® (lorlatinib) in Previously Untreated ALK-Positive Lung Cancer Published in the New England Journal of Medicine","https://www.pfizer.com//news/press-release/press-release-detail/results-phase-3-crown-trial-pfizers-lorbrenar-lorlatinib",0.1,2020,11,17.5827806096152,0.770000457763672,-0.409999847412109,0,-0.121173858642578,1,4.05,1.65,"Research",1,2
2020-11-20,36.7000007629395,37.310001373291,36.439998626709,36.7000007629395,34.2071876525879,60633800,297,78,0.583999998442667,0.260235947078254,"COVID-19","Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-submit-emergency-use-authorization",0.1,2020,11,17.9203630678196,0.870002746582031,0,0,0.475372314453125,1,2.97,0.78,"Pandemic",1,4
2020-11-23,37.0299987792969,37.0900001525879,36.2099990844727,36.5200004577637,34.0394096374512,43673100,150,55,0.463414631885782,0.248484848183655,"Research","Pfizer Doses First Participant in Phase 3 Study Evaluating anti-TFPI Investigational Therapy, Marstacimab, for People With Severe Hemophilia A and B With or Without Inhibitors","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-doses-first-participant-phase-3-study-evaluating",0.22,2020,11,17.5922429327872,0.880001068115234,-0.509998321533203,0,-0.167778015136719,1,1.5,0.55,"Research",1,2
2020-11-24,36.1300010681152,36.7400016784668,36.0200004577637,36.5999984741211,34.1139678955078,42485300,NA,NA,NA,NA,NA,NA,NA,0.22,2020,11,17.5646687152482,0.720001220703125,0.469997406005859,1,0.0745582580566406,0,NA,NA,NA,1,NA
2020-11-25,36.5299987792969,36.560001373291,36.2400016784668,36.5299987792969,34.0487327575684,26955800,NA,NA,NA,NA,NA,NA,NA,0.11,2020,11,17.10970908262,0.319999694824219,0,0,-0.0652351379394531,0,NA,NA,NA,1,NA
2020-11-27,36.7799987792969,37.2599983215332,36.75,37.2299995422363,34.7011833190918,25277000,NA,NA,NA,NA,NA,NA,NA,0.11,2020,11,17.0454054888766,0.509998321533203,0.450000762939453,1,0.652450561523438,0,NA,NA,NA,1,NA
2020-11-30,37.9500007629395,38.7999992370605,37.5999984741211,38.310001373291,35.7078247070312,65425900,NA,NA,NA,NA,NA,NA,NA,0.34,2020,11,17.9964287777797,1.20000076293945,0.360000610351562,1,1.00664138793945,0,NA,NA,NA,1,NA
2020-12-01,39.4000015258789,40.5,39.0099983215332,39.4099998474121,36.7331047058105,72499700,256,67,0.585139317073872,0.264754098143644,"COVID-19","Pfizer and BioNTech Submitted Application for Conditional Marketing Authorization for COVID-19 Vaccine to the EMA","https://www.pfizer.com//news/announcements/pfizer-and-biontech-submitted-application-conditional-marketing-authorization",0.34,2020,12,18.0990929956785,1.4900016784668,0.00999832153320312,1,1.0252799987793,1,2.56,0.67,"Pandemic",1,4
2020-12-02,40.4700012207031,41.4099998474121,40.2999992370605,40.7999992370605,38.0286865234375,84347500,315,86,0.571072317777874,0.253636938485998,"COVID-19","Pfizer and BioNTech Achieve First Authorization in the World for a Vaccine to Combat COVID-19","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-achieve-first-authorization-world",1.02,2020,12,18.2504557399614,1.11000061035156,0.329998016357422,1,1.29558181762695,1,3.15,0.86,"Pandemic",1,4
2020-12-03,40.9799995422363,41.0299987792969,39.5200004577637,40.0900001525879,37.3669166564941,68570100,NA,NA,NA,NA,NA,NA,NA,0.68,2020,12,18.0433671522068,1.5099983215332,-0.889999389648438,0,-0.661769866943359,0,NA,NA,NA,1,NA
2020-12-04,39.8899993896484,40.4500007629395,39.8899993896484,40.3400001525879,37.5999374389649,35368100,180,39,0.643835613498468,0.33953488319452,"Hiring & Recruitment","Pfizer Gene Therapy - Inspiring a Revolution","https://www.pfizer.com//news/announcements/pfizer-gene-therapy-inspiring-revolution",0.51,2020,12,17.3813208701729,0.560001373291016,0.450000762939453,1,0.23302078247071,1,1.8,0.39,"Management",1,1
2020-12-07,40.6599998474121,41.4000015258789,40.3699989318848,41.25,38.4481239318848,48253700,264,73,0.566765576953218,0.261037954871388,"Research","Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels in 3x10¹³ VG/KG Cohort Through One Year Following Hemophilia A Gene Therapy","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-sangamo-announce-updated-phase-12-results-0",0.28,2020,12,17.6919830874708,1.03000259399414,0.590000152587891,1,0.848186492919915,1,2.64,0.73,"Research",1,2
2020-12-08,41.4000015258789,42.7700004577637,41.3499984741211,42.560001373291,39.6691398620605,87039300,206,74,0.471428569744898,0.216550657218445,"Vaccines","U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer’s Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age and Older","https://www.pfizer.com//news/press-release/press-release-detail/us-fda-accepts-priority-review-biologics-license",0.7,2020,12,18.2818703102492,1.42000198364258,1.15999984741211,1,1.22101593017578,1,2.06,0.74,"Pandemic",1,4
2020-12-09,43.0699996948242,43.0800018310547,41.1300010681152,41.8499984741211,39.0073661804199,86118500,191,49,0.591666664201389,0.26258205660549,"Responsibility","Statement on EMA Cyberattack","https://www.pfizer.com//news/announcements/statement-ema-cyberattack",0.84,2020,12,18.2712348243638,1.95000076293945,-1.22000122070312,0,-0.661773681640625,1,1.91,0.49,"Management",1,1
2020-12-10,41.8199996948242,42.2200012207031,41.4500007629395,41.7299995422363,38.8955230712891,57749200,278,88,0.519125681641733,0.257928118211467,"Research","Pfizer and BioNTech Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in The New England Journal of Medicine","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-publication-results-landmark",0.7,2020,12,17.8716200717726,0.770000457763672,-0.0900001525878906,0,-0.111843109130859,1,2.78,0.88,"Research",1,2
2020-12-11,41.9700012207031,42.0699996948242,40.689998626709,41.1199989318848,38.3269500732422,60737000,383,111,0.550607286334803,0.251655629010873,"Vaccines","Pfizer and BioNTech Celebrate Historic First Authorization in the U.S. of Vaccine to Prevent COVID-19","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-celebrate-historic-first-authorization",0.7,2020,12,17.9220636419803,1.38000106811523,-0.850002288818359,0,-0.568572998046875,1,3.83,1.11,"Pandemic",1,4
2020-12-14,41.6199989318848,41.6599998474121,39.0699996948242,39.2099990844727,36.5466918945312,94809700,322,86,0.578431371131296,0.252319109305925,"COVID-19","Pfizer and BioNTech Provide Data from German Phase 1/2 Study Further Characterizing Immune Response Following Immunization with Lead COVID-19 Vaccine Candidate BNT162b2","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-provide-data-german-phase-12-study",0.55,2020,12,18.3673822932134,2.59000015258789,-2.40999984741211,0,-1.78025817871094,1,3.22,0.86,"Pandemic",1,4
2020-12-15,39.060001373291,39.1800003051758,38.2099990844727,38.7099990844727,36.0806503295898,65712800,45,14,0.525423719908073,0.212996389122757,"Research","Pfizer Doses First Participants as Part of Global Achondroplasia Phase 2 Development Program","https://www.pfizer.com//news/announcements/pfizer-doses-first-participants-part-global-achondroplasia-phase-2-development",0.44,2020,12,18.0008043046586,0.970001220703125,-0.350002288818359,0,-0.466041564941413,1,0.45,0.14,"Research",1,2
2020-12-16,38.1800003051758,38.4700012207031,37.7400016784668,37.8400001525879,35.2697486877441,56515300,NA,NA,NA,NA,NA,NA,NA,0.44,2020,12,17.8500219736124,0.729999542236328,-0.340000152587891,0,-0.810901641845696,0,NA,NA,NA,1,NA
2020-12-17,37.8300018310547,38.1199989318848,37.310001373291,38.0299987792969,35.4468383789062,52036400,58,13,0.633802807974608,0.261029410805039,"COVID-19","Pfizer COVID-19 Vaccine Production and Distribution Working Well","https://www.pfizer.com//news/announcements/pfizer-covid-19-vaccine-production-and-distribution-working-well",0.44,2020,12,17.7674540508773,0.80999755859375,0.199996948242188,1,0.177089691162109,1,0.58,0.13,"Pandemic",1,4
2020-12-18,37.9900016784668,38.0900001525879,37.5,37.6800003051758,35.1206169128418,60259200,NA,NA,NA,NA,NA,NA,NA,0.44,2020,12,17.9141658323684,0.590000152587891,-0.310001373291016,0,-0.326221466064453,0,NA,NA,NA,1,NA
2020-12-21,37.2799987792969,37.4000015258789,36.9099998474121,37.3800010681152,34.840991973877,40891800,432,112,0.588235293036332,0.255999999879529,"COVID-19","Pfizer and BioNTech Receive Authorization in the European Union for COVID-19 Vaccine","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-receive-authorization-european-union",0.44,2020,12,17.5264401363697,0.490001678466797,0.100002288818359,1,-0.279624938964844,1,4.32,1.12,"Pandemic",1,4
2020-12-22,37.2099990844727,37.3300018310547,36.5999984741211,36.7400016784668,34.2444686889648,33634400,88,10,0.795918359225323,0.262032084860877,"Finance","Pfizer Invites Public to View and Listen to Webcast of February 2 Conference Call with Analysts","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-february-2",0.33,2020,12,17.3310599404532,0.730003356933594,-0.469997406005859,0,-0.596523284912109,1,0.88,0.1,"Finance",1,3
2020-12-23,37.0099983215332,37.6500015258789,36.8800010681152,37.439998626709,34.8969192504883,36182000,293,72,0.605479450395947,0.252595155534536,"COVID-19","Pfizer and BioNTech to Supply the U.S. with 100 Million Additional Doses of COVID-19 Vaccine","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-supply-us-100-million-additional-doses",0.33,2020,12,17.4040723432014,0.770000457763672,0.430000305175781,1,0.652450561523438,1,2.93,0.72,"Pandemic",1,4
2020-12-24,37.4000015258789,37.5699996948242,37.1800003051758,37.2700004577637,34.7384605407715,14790100,NA,NA,NA,NA,NA,NA,NA,0.22,2020,12,16.5094686636021,0.389999389648438,-0.130001068115234,0,-0.158458709716797,0,NA,NA,NA,1,NA
2020-12-28,37.3600006103516,37.5800018310547,36.6800003051758,36.8199996948242,34.3190269470215,26993700,416,165,0.432013768619598,0.254378283601411,"Medicines","LORBRENA® (lorlatinib) sNDA in Previously Untreated ALK-Positive Lung Cancer Accepted for Priority Review by U.S. FDA","https://www.pfizer.com//news/press-release/press-release-detail/lorbrenar-lorlatinib-snda-previously-untreated-alk-positive",0.45,2020,12,17.1111141004545,0.900001525878906,-0.540000915527344,0,-0.41943359375,1,4.16,1.65,"Research",1,2
2020-12-29,36.9000015258789,37.2000007629395,36.7900009155273,37.0499992370605,34.5334053039551,23152100,281,72,0.592067986991309,0.253046594800683,"COVID-19","Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY®","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-supply-european-union-100-million",0.45,2020,12,16.957596090318,0.409999847412109,0.149997711181641,1,0.214378356933594,1,2.81,0.72,"Pandemic",1,4
2020-12-30,37.0299987792969,37.2400016784668,36.7000007629395,36.7400016784668,34.2444686889648,24889800,NA,NA,NA,NA,NA,NA,NA,0.45,2020,12,17.029968679133,0.540000915527344,-0.289997100830078,0,-0.288936614990234,0,NA,NA,NA,1,NA
2020-12-31,36.6599998474121,36.9199981689453,36.2900009155273,36.810001373291,34.3097114562988,30796500,NA,NA,NA,NA,NA,NA,NA,0.3,2020,12,17.2429116375943,0.629997253417969,0.150001525878906,1,0.0652427673339844,0,NA,NA,NA,1,NA
2021-01-04,36.8699989318848,36.939998626709,36.2700004577637,36.810001373291,34.3097114562988,33565700,306,130,0.403669723844794,0.269801980031063,"Research","US FDA Accepts Regulatory Submission from Pfizer and OPKO for Review of Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency","https://www.pfizer.com//news/press-release/press-release-detail/us-fda-accepts-regulatory-submission-pfizer-and-opko-review",0.54,2021,1,17.3290152999872,0.669998168945312,-0.05999755859375,0,0,1,3.06,1.3,"Research",0,2
2021-01-05,36.7200012207031,37.3699989318848,36.5999984741211,37.189998626709,34.6638946533203,29909400,79,10,0.775280890165383,0.245856352911999,"Finance","Pfizer Invites Public to Listen to Two Webcasts of Pfizer Discussions at Healthcare Conference","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-listen-two-webcasts-pfizer",0.72,2021,1,17.2136834036587,0.770000457763672,0.469997406005859,1,0.354183197021484,1,0.79,0.1,"Finance",0,3
2021-01-06,36.8300018310547,37.4799995422363,36.7700004577637,36.8699989318848,34.3656349182129,34962500,NA,NA,NA,NA,NA,NA,NA,0.72,2021,1,17.3697866450944,0.709999084472656,0.0399971008300781,1,-0.298259735107422,0,NA,NA,NA,0,NA
2021-01-07,37.0400009155273,37.1500015258789,36.6699981689453,37.060001373291,34.5427284240723,27809500,161,63,0.437499998046875,0.280701754034208,"Research","Pfizer Doses First Participant in Phase 3 Study for Duchenne Muscular Dystrophy Investigational Gene Therapy","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-doses-first-participant-phase-3-study-duchenne",0.72,2021,1,17.1408882828633,0.480003356933594,0.0200004577636719,1,0.177093505859375,1,1.61,0.63,"Research",0,2
2021-01-08,37.1599998474121,37.5299987792969,36.9000015258789,37.1300010681152,34.6079788208008,33462400,287,87,0.534759356858932,0.244924688772151,"COVID-19","An In Vitro Study Shows Pfizer-BioNTech COVID-19 Vaccine Elicits Antibodies that Neutralize SARS-CoV-2 with a Mutation Associated with Rapid Transmission","https://www.pfizer.com//news/announcements/vitro-study-shows-pfizer-biontech-covid-19-vaccine-elicits-antibodies-neutralize",0.9,2021,1,17.3259330082707,0.629997253417969,-0.029998779296875,0,0.0652503967285156,1,2.87,0.87,"Pandemic",0,4
2021-01-11,37.2200012207031,37.8300018310547,37.1500015258789,37.7700004577637,35.2045021057129,47286900,NA,NA,NA,NA,NA,NA,NA,0.72,2021,1,17.6717438806478,0.680000305175781,0.549999237060547,1,0.596523284912109,0,NA,NA,NA,0,NA
2021-01-12,37.7000007629395,37.7900009155273,36.8199996948242,37.1800003051758,34.6545791625977,47831100,127,18,0.75172413274673,0.240863786975309,"Partnerships","Pfizer Invests $120 Million in Biotechnology Innovation Through the Pfizer Breakthrough Growth Initiative","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invests-120-million-biotechnology-innovation-through",0.72,2021,1,17.6831866344173,0.970001220703125,-0.520000457763672,0,-0.549922943115234,1,1.27,0.18,"Management",0,1
2021-01-13,37,37.1699981689453,36.6399993896484,36.8600006103516,34.3563117980957,31027900,NA,NA,NA,NA,NA,NA,NA,0.72,2021,1,17.2503973899213,0.529998779296875,-0.139999389648438,0,-0.298267364501953,0,NA,NA,NA,0,NA
2021-01-14,36.7799987792969,36.9599990844727,36.6100006103516,36.75,34.2537841796875,30272000,473,205,0.395280235405191,0.280513032569089,"Medicines","Pfizer’s XALKORI® (crizotinib) Approved by FDA for ALK-positive Anaplastic Large Cell Lymphoma in Children and Young Adults","https://www.pfizer.com//news/press-release/press-release-detail/pfizers-xalkorir-crizotinib-approved-fda-alk-positive",0.9,2021,1,17.2257337838676,0.349998474121094,-0.029998779296875,0,-0.102527618408203,1,4.73,2.05,"Research",0,2
2021-01-15,36.6800003051758,36.7799987792969,36.4000015258789,36.7000007629395,34.2071876525879,34287800,204,46,0.631999997472,0.244618395063974,"COVID-19","Statement on European Upscaling as well as Impact on Deliveries","https://www.pfizer.com//news/announcements/statement-european-upscaling-well-impact-deliveries",0.9,2021,1,17.3503001928989,0.379997253417969,0.0200004577636719,1,-0.0465965270996094,1,2.04,0.46,"Pandemic",0,4
2021-01-19,36.7599983215332,37,36.6199989318848,36.7299995422363,34.2351417541504,33451300,NA,NA,NA,NA,NA,NA,NA,0.75,2021,1,17.3256012376536,0.380001068115234,-0.029998779296875,0,0.0279541015625,0,NA,NA,NA,0,NA
2021-01-20,36.7900009155273,36.810001373291,36.4599990844727,36.5,34.0207595825195,35400100,293,92,0.522077920721876,0.244289339946517,"COVID-19","Pfizer and BioNTech Publish Results of Study Showing COVID-19  Vaccine Elicits Antibodies that Neutralize Pseudovirus Bearing the  SARS-CoV-2 U.K. Strain Spike Protein in Cell Culture","https://www.pfizer.com//news/announcements/pfizer-and-biontech-publish-results-study-showing-covid-19-vaccine-elicits",0.75,2021,1,17.3822252312073,0.350002288818359,-0.290000915527344,0,-0.214382171630859,1,2.93,0.92,"Pandemic",0,4
2021-01-21,36.3899993896484,36.5900001525879,36.1500015258789,36.4799995422363,34.0021286010742,33829700,NA,NA,NA,NA,NA,NA,NA,0.75,2021,1,17.3368497024086,0.439998626708984,0.0900001525878906,1,-0.0186309814453125,0,NA,NA,NA,0,NA
2021-01-22,36.3199996948242,36.8300018310547,36.25,36.5499992370605,34.0673713684082,26271200,344,80,0.622641507965468,0.276221498191387,"COVID-19","Pfizer and BioNTech Reach Agreement with COVAX for Advance Purchase of Vaccine to Help Combat COVID-19","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-reach-agreement-covax-advance-purchase",0.6,2021,1,17.0839838781652,0.580001831054688,0.229999542236328,1,0.0652427673339844,1,3.44,0.8,"Pandemic",0,4
2021-01-25,36.5499992370605,37.2900009155273,36.3199996948242,37.2799987792969,34.7477836608887,31728500,446,194,0.393749999384766,0.247295208559778,"Medicines","European Commission Approves BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma","https://www.pfizer.com//news/press-release/press-release-detail/european-commission-approves-bavencior-avelumab-first-line",0.56,2021,1,17.272725920086,0.970001220703125,0.729999542236328,1,0.680412292480469,1,4.46,1.94,"Research",0,2
2021-01-26,37.2700004577637,37.5999984741211,37.1599998474121,37.310001373291,34.775749206543,27718700,218,69,0.519163761257269,0.2192513367309,"Research","Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis","https://www.pfizer.com//news/press-release/press-release-detail/myovant-sciences-and-pfizer-announce-positive-one-year-data",0.56,2021,1,17.1376178697161,0.439998626708984,0.0400009155273438,1,0.0279655456542969,1,2.18,0.69,"Research",0,2
2021-01-27,36.9900016784668,37.0400009155273,36.1699981689453,36.2400016784668,33.7784271240234,50561200,332,191,0.269598469847804,0.262814070219691,"Medicines","Pfizer Shares Co-Primary Endpoint Results from Post-Marketing Required Safety Study of XELJANZ® (tofacitinib) in Subjects with Rheumatoid Arthritis (RA)","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-shares-co-primary-endpoint-results-post-marketing",0.56,2021,1,17.7386950614765,0.870002746582031,-0.75,0,-0.997322082519531,1,3.32,1.91,"Research",0,2
2021-01-28,35.9500007629395,36.3300018310547,35.8400001525879,35.8600006103516,33.7878456115723,39466700,NA,NA,NA,NA,NA,NA,NA,0.56,2021,1,17.4909678616781,0.490001678466797,-0.0900001525878906,0,0.00941848754882812,0,NA,NA,NA,0,NA
2021-01-29,36.8800010681152,36.8800010681152,35.6199989318848,35.9000015258789,33.8255424499512,60251900,270,75,0.565217389666037,0.246604717479196,"COVID-19","Pfizer and BioNTech Publish Data on COVID-19 Vaccine-Induced Antibodies’ Ability to Neutralize SARS-CoV-2 U.K. Strain Pseudovirus in Cell Culture in Science","https://www.pfizer.com//news/announcements/pfizer-and-biontech-publish-data-covid-19-vaccine-induced-antibodies-ability",0.56,2021,1,17.9140446817045,1.26000213623047,-0.979999542236328,0,0.0376968383789062,1,2.7,0.75,"Pandemic",0,4
2021-02-01,35.9300003051758,36.189998626709,35.7200012207031,35.7999992370605,33.7313117980957,40395800,281,76,0.574229690268264,0.247058823358437,"COVID-19","Pfizer and BioNTech Publish Preclinical Data from Investigational COVID-19 Vaccine  Program in Nature","https://www.pfizer.com//news/announcements/pfizer-and-biontech-publish-preclinical-data-investigational-covid-19-vaccine",0.39,2021,2,17.5142364018861,0.469997406005859,-0.130001068115234,0,-0.0942306518554688,1,2.81,0.76,"Pandemic",0,4
2021-02-02,35.7599983215332,35.7799987792969,34.2700004577637,34.9900016784668,32.9681205749512,84062400,NA,NA,NA,NA,NA,NA,NA,0.52,2021,2,18.2470699500646,1.5099983215332,-0.769996643066406,0,-0.763191223144531,0,NA,NA,NA,0,NA
2021-02-03,34.9900016784668,35.2900009155273,34.7799987792969,34.8400001525879,32.826789855957,38524200,NA,NA,NA,NA,NA,NA,NA,0.52,2021,2,17.466797199176,0.510002136230469,-0.150001525878906,0,-0.141330718994141,0,NA,NA,NA,0,NA
2021-02-04,34.810001373291,35.0800018310547,34.7000007629395,34.8899993896484,32.8738975524902,34284900,NA,NA,NA,NA,NA,NA,NA,0.52,2021,2,17.3502156111363,0.380001068115234,0.0799980163574219,1,0.0471076965332031,0,NA,NA,NA,0,NA
2021-02-05,34.9199981689453,35.0800018310547,34.7799987792969,34.9199981689453,32.9021682739258,31749600,165,73,0.38655462022456,0.235877105811817,"Medicines","Pfizer Confirms U.S. Patent Term Extension for IBRANCE® (palbociclib) Until March 2027","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-confirms-us-patent-term-extension-ibrancer",0.39,2021,2,17.2733907162949,0.300003051757812,0,0,0.0282707214355469,1,1.65,0.73,"Research",0,2
2021-02-08,34.9599990844727,35.0099983215332,34.7400016784668,34.8199996948242,32.8079414367676,31633900,272,78,0.554285712702041,0.245959240867211,"COVID-19","Pfizer and BioNTech Publish Data from In Vitro Studies in Nature Medicine Demonstrating COVID-19 Vaccine Elicits Antibodies that Neutralize SARS-CoV-2 with Key Mutations Present in U.K. and South African Variants","https://www.pfizer.com//news/announcements/pfizer-and-biontech-publish-data-vitro-studies-nature-medicine-demonstrating",0.42,2021,2,17.2697399199565,0.269996643066406,-0.139999389648438,0,-0.0942268371582031,1,2.72,0.78,"Pandemic",0,4
2021-02-09,34.7999992370605,35.060001373291,34.7599983215332,34.9700012207031,32.949275970459,30170200,161,36,0.63451776327656,0.351785713657526,"Responsibility","Pfizer and IDA Foundation Partner to Expand Access to Essential Cancer Treatments in 70 Low- and Lower-Middle-Income Countries","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-ida-foundation-partner-expand-access-essential",0.42,2021,2,17.2223652733603,0.300003051757812,0.170001983642578,1,0.141334533691406,1,1.61,0.36,"Management",0,1
2021-02-10,35,35.0800018310547,34.7000007629395,34.7400016784668,32.7325744628906,29039900,NA,NA,NA,NA,NA,NA,NA,0.42,2021,2,17.1841813388241,0.380001068115234,-0.259998321533203,0,-0.216701507568359,0,NA,NA,NA,0,NA
2021-02-11,34.7999992370605,34.810001373291,34.2799987792969,34.4300003051758,32.440486907959,30885200,NA,NA,NA,NA,NA,NA,NA,0.42,2021,2,17.2457876951046,0.530002593994141,-0.369998931884766,0,-0.292087554931641,0,NA,NA,NA,0,NA
2021-02-12,34.439998626709,34.9500007629395,34.3600006103516,34.7200012207031,32.7137184143066,25578600,285,73,0.59217876929559,0.251935256684071,"Vaccines","Pfizer and BioNTech to Supply the United States with 100 Million Additional Doses of COVID-19 Vaccine","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-supply-united-states-100-million",0.42,2021,2,17.0572666614544,0.590000152587891,0.280002593994141,1,0.273231506347656,1,2.85,0.73,"Pandemic",0,4
2021-02-16,34.8499984741211,34.8600006103516,34.560001373291,34.689998626709,32.6854515075684,28730300,NA,NA,NA,NA,NA,NA,NA,0.48,2021,2,17.1734629077541,0.299999237060547,-0.159999847412109,0,-0.0282669067382812,0,NA,NA,NA,0,NA
2021-02-17,34.5699996948242,35,34.4599990844727,34.8899993896484,32.8738975524902,26389400,291,85,0.547872338968425,0.23544145257643,"COVID-19","In Vitro Study Published in The New England Journal of Medicine Demonstrates Sera from Individuals Immunized with the Pfizer- BioNTech COVID-19 Vaccine Neutralize SARS-CoV-2 with South African Variant Spike Mutations","https://www.pfizer.com//news/announcements/vitro-study-published-new-england-journal-medicine-demonstrates-sera-individuals",0.48,2021,2,17.0884730102302,0.540000915527344,0.319999694824219,1,0.188446044921875,1,2.91,0.85,"Pandemic",0,4
2021-02-18,34.7799987792969,34.8800010681152,34.5200004577637,34.560001373291,32.5629653930664,24052500,300,91,0.534526852852872,0.251285346882207,"Research","Pfizer and BioNTech Commence Global Clinical Trial to Evaluate COVID-19 Vaccine in Pregnant Women","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-commence-global-clinical-trial-evaluate",0.64,2021,2,16.9957495407933,0.360000610351562,-0.219997406005859,0,-0.310932159423828,1,3,0.91,"Research",0,2
2021-02-19,34.6599998474121,34.6800003051758,34.4000015258789,34.439998626709,32.4499015808105,28145300,329,78,0.616707615192365,0.248929663456312,"COVID-19","Pfizer and BioNTech Submit COVID-19 Vaccine Stability Data at Standard Freezer Temperature to the U.S. FDA","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-submit-covid-19-vaccine-stability-data",0.64,2021,2,17.1528909714402,0.279998779296875,-0.220001220703125,0,-0.113063812255859,1,3.29,0.78,"Pandemic",0,4
2021-02-22,34.3300018310547,34.3699989318848,34.0400009155273,34.2599983215332,32.2803077697754,34322500,88,9,0.814432981294505,0.270949719913548,"Finance","Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-5",0.72,2021,2,17.3513117028893,0.329998016357422,-0.0700035095214844,0,-0.169593811035156,1,0.88,0.09,"Finance",0,3
2021-02-23,34,34.189998626709,33.6800003051758,33.9099998474121,31.9505252838135,37624200,177,60,0.49367088399295,0.236055776657315,"Vaccines","U.S. FDA Accepts for Priority Review Pfizer’s Application for TicoVac™ (Tick-borne Encephalitis Vaccine)","https://www.pfizer.com//news/press-release/press-release-detail/us-fda-accepts-priority-review-pfizers-application",0.72,2021,2,17.4431580449274,0.509998321533203,-0.0900001525878906,0,-0.329782485961914,1,1.77,0.6,"Pandemic",0,4
2021-02-24,33.8699989318848,34.0499992370605,33.6699981689453,33.75,31.7997760772705,30686100,NA,NA,NA,NA,NA,NA,NA,0.72,2021,2,17.2393203738851,0.380001068115234,-0.119998931884766,0,-0.150749206542969,0,NA,NA,NA,0,NA
2021-02-25,33.8199996948242,34.1100006103516,33.5400009155273,33.8199996948242,31.8657264709473,37506100,329,103,0.523148146937157,0.249278707299897,"COVID-19","Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-initiate-study-part-broad-development",0.9,2021,2,17.4400141710408,0.569999694824219,0,0,0.0659503936767578,1,3.29,1.03,"Pandemic",0,4
2021-02-26,33.8400001525879,33.9000015258789,33.3600006103516,33.4900016784668,31.554801940918,41462800,229,76,0.501639342617576,0.262027491183825,"Medicines","EMA Accepts Marketing Application for Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency","https://www.pfizer.com//news/press-release/press-release-detail/ema-accepts-marketing-application-somatrogon-treat",0.9,2021,2,17.540307221783,0.540000915527344,-0.349998474121094,0,-0.310924530029297,1,2.29,0.76,"Research",0,2
2021-03-01,33.5900001525879,33.9300003051758,33.5099983215332,33.689998626709,31.7432422637939,30407800,NA,NA,NA,NA,NA,NA,NA,0.84,2021,3,17.2302097452994,0.420001983642578,0.0999984741210938,1,0.188440322875977,0,NA,NA,NA,0,NA
2021-03-02,33.6800003051758,33.8899993896484,33.5,33.5099983215332,31.5736427307129,27670400,NA,NA,NA,NA,NA,NA,NA,0.84,2021,3,17.1358738438879,0.389999389648438,-0.170001983642578,0,-0.169599533081055,0,NA,NA,NA,0,NA
2021-03-03,33.5099983215332,34.4500007629395,33.439998626709,34.3899993896484,32.4027938842773,46020200,308,135,0.390519186477383,0.256811594054022,"Medicines","U.S. FDA Expands Approval of Pfizer’s LORBRENA® as First-Line Treatment for ALK-Positive Metastatic Lung Cancer","https://www.pfizer.com//news/press-release/press-release-detail/us-fda-expands-approval-pfizers-lorbrenar-first-line",1.05,2021,3,17.6445910102282,1.01000213623047,0.880001068115234,1,0.829151153564453,1,3.08,1.35,"Research",0,2
2021-03-04,34.2599983215332,35.0900001525879,33.8400001525879,34.2000007629395,32.2237739562988,45449600,88,10,0.795918359225323,0.270718231296358,"Finance","Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-6",1.05,2021,3,17.6321145996713,1.25,-0.05999755859375,0,-0.179019927978516,1,0.88,0.1,"Finance",0,3
2021-03-05,34.2900009155273,34.5499992370605,33.9599990844727,34.3899993896484,32.4027938842773,30589900,NA,NA,NA,NA,NA,NA,NA,1.05,2021,3,17.2361804797701,0.590000152587891,0.0999984741210938,1,0.179019927978516,0,NA,NA,NA,0,NA
2021-03-08,34.4799995422363,34.8699989318848,34.3300018310547,34.3499984741211,32.3651008605957,24352300,205,100,0.344262293953238,0.274034141712458,"Research","Valneva and Pfizer Announce Initiation of Phase 2 Study for Lyme Disease Vaccine Candidate","https://www.pfizer.com//news/press-release/press-release-detail/valneva-and-pfizer-announce-initiation-phase-2-study-lyme",0.96,2021,3,17.0081368999482,0.539997100830078,-0.130001068115234,0,-0.0376930236816406,1,2.05,1,"Research",0,2
2021-03-09,34.5400009155273,34.8499984741211,34.439998626709,34.4500007629395,32.4593276977539,25167100,NA,NA,NA,NA,NA,NA,NA,1.2,2021,3,17.0410481836804,0.409999847412109,-0.0900001525878906,0,0.0942268371582031,0,NA,NA,NA,0,NA
2021-03-10,34.6399993896484,35.1399993896484,34.5200004577637,34.9300003051758,32.9115905761719,33501800,NA,NA,NA,NA,NA,NA,NA,1.2,2021,3,17.3271097565442,0.619998931884766,0.290000915527344,1,0.452262878417969,0,NA,NA,NA,0,NA
2021-03-11,35.0699996948242,35.1199989318848,34.6599998474121,34.7099990844727,32.7042999267578,24557900,404,129,0.515947466198973,0.259999999873171,"COVID-19","Real-World Evidence Confirms High Effectiveness of Pfizer-BioNTech COVID-19 Vaccine and Profound Public Health Impact of Vaccination One Year After Pandemic Declared","https://www.pfizer.com//news/press-release/press-release-detail/real-world-evidence-confirms-high-effectiveness-pfizer",1.68,2021,3,17.0165441934216,0.459999084472656,-0.360000610351562,0,-0.207290649414062,1,4.04,1.29,"Pandemic",0,4
2021-03-12,34.560001373291,34.9799995422363,34.5099983215332,34.939998626709,32.921012878418,16342400,NA,NA,NA,NA,NA,NA,NA,1.68,2021,3,16.609273576626,0.470001220703125,0.379997253417969,1,0.216712951660156,0,NA,NA,NA,0,NA
2021-03-15,35.0099983215332,35.4300003051758,34.9599990844727,35.4099998474121,33.3638534545898,21896100,NA,NA,NA,NA,NA,NA,NA,1.61,2021,3,16.9018191424067,0.470001220703125,0.400001525878906,1,0.442840576171875,0,NA,NA,NA,0,NA
2021-03-16,35.4700012207031,35.8600006103516,35.310001373291,35.8300018310547,33.7595825195312,25022400,NA,NA,NA,NA,NA,NA,NA,1.61,2021,3,17.0352820216283,0.549999237060547,0.360000610351562,1,0.395729064941406,0,NA,NA,NA,0,NA
2021-03-17,35.8300018310547,35.9599990844727,35.1199989318848,35.7900009155273,33.7218933105469,42540100,NA,NA,NA,NA,NA,NA,NA,1.38,2021,3,17.5659577419696,0.840000152587891,-0.0400009155273438,0,-0.037689208984375,0,NA,NA,NA,0,NA
2021-03-18,35.5299987792969,35.9700012207031,35.5200004577637,35.7700004577637,33.7030487060547,24729800,NA,NA,NA,NA,NA,NA,NA,1.61,2021,3,17.0235195925586,0.450000762939453,0.240001678466797,1,-0.0188446044921875,0,NA,NA,NA,0,NA
2021-03-19,35.75,35.8199996948242,35.4700012207031,35.5299987792969,33.4769134521484,48348900,NA,NA,NA,NA,NA,NA,NA,1.38,2021,3,17.6939540495122,0.349998474121094,-0.220001220703125,0,-0.22613525390625,0,NA,NA,NA,0,NA
2021-03-22,35.4799995422363,36.0099983215332,35.3600006103516,36,33.9197578430176,25427500,NA,NA,NA,NA,NA,NA,NA,1.62,2021,3,17.0513418628094,0.649997711181641,0.520000457763672,1,0.442844390869141,0,NA,NA,NA,0,NA
2021-03-23,35.8199996948242,35.9300003051758,35.3199996948242,35.3600006103516,33.3167457580566,27970500,137,32,0.621301771471587,0.247076023030591,"COVID-19","Pfizer Initiates Phase 1 Study of Novel Oral Antiviral Therapeutic Agent Against SARS-CoV-2","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-initiates-phase-1-study-novel-oral-antiviral",1.62,2021,3,17.1466609770663,0.610000610351562,-0.459999084472656,0,-0.603012084960938,1,1.37,0.32,"Pandemic",0,4
2021-03-24,35.4799995422363,35.9300003051758,35.3699989318848,35.6100006103516,33.5522956848145,22883400,247,89,0.470238093838577,0.230294722254767,"Research","Myovant Sciences and Pfizer Announce Positive Data from Phase 3 LIBERTY Randomized Withdrawal Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids","https://www.pfizer.com//news/press-release/press-release-detail/myovant-sciences-and-pfizer-announce-positive-data-phase-3",1.89,2021,3,16.9459223585342,0.560001373291016,0.130001068115234,1,0.235549926757812,1,2.47,0.89,"Research",0,2
2021-03-25,35.6500015258789,35.7900009155273,35.25,35.6699981689453,33.608829498291,24875300,241,97,0.42603550169812,0.254326561132937,"Research","Real-World Evidence Supports Effectiveness of First-line IBRANCE® (palbociclib) Combination Therapy in HR+, HER2- Metastatic Breast Cancer","https://www.pfizer.com//news/press-release/press-release-detail/real-world-evidence-supports-effectiveness-first-line",1.89,2021,3,17.0293859414382,0.540000915527344,0.0199966430664062,1,0.0565338134765625,1,2.41,0.97,"Research",0,2
2021-03-26,35.6800003051758,36.2900009155273,35.6399993896484,36.25,34.1553153991699,27944500,314,78,0.602040814790712,0.263263935350394,"Vaccines","EMA Approves New Storage Option for Pfizer-BioNTech Vaccine, Easing Distribution and Storage of Doses Across European Union","https://www.pfizer.com//news/press-release/press-release-detail/ema-approves-new-storage-option-pfizer-biontech-vaccine",1.89,2021,3,17.1457309940227,0.650001525878906,0.569999694824219,1,0.546485900878906,1,3.14,0.78,"Pandemic",0,4
2021-03-29,36.0299987792969,36.7400016784668,35.9000015258789,36.6199989318848,34.5039329528809,27004800,50,8,0.724137918549346,0.263636362438017,"Government","Michigan is Ready for Cures","https://www.pfizer.com//news/announcements/michigan-ready-cures",1.86,2021,3,17.1115252229762,0.840000152587891,0.590000152587891,1,0.348617553710938,1,0.5,0.08,"Management",0,1
2021-03-30,36.5900001525879,36.6300010681152,36.0200004577637,36.1100006103516,34.0234031677246,26303300,NA,NA,NA,NA,NA,NA,NA,2.17,2021,3,17.0852050025798,0.610000610351562,-0.479999542236328,0,-0.48052978515625,0,NA,NA,NA,0,NA
2021-03-31,36.1500015258789,36.4300003051758,36.0400009155273,36.2299995422363,34.1364669799805,26582700,311,88,0.558897241707024,0.24167171396628,"Research","Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-biontech-announce-positive-topline-results-pivotal",2.48,2021,3,17.0957712238444,0.389999389648438,0.0799980163574219,1,0.113063812255859,1,3.11,0.88,"Research",0,2
2021-04-01,36.2999992370605,36.4500007629395,36.0200004577637,36.2999992370605,34.2024269104004,21319900,328,92,0.561904760566893,0.240549828040922,"COVID-19","Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-confirm-high-efficacy-and-no-serious",2.79,2021,4,16.8751515137239,0.430000305175781,0,0,0.0659599304199219,1,3.28,0.92,"Pandemic",0,4
2021-04-05,36.439998626709,36.5699996948242,36.0999984741211,36.2799987792969,34.1835746765137,22096900,NA,NA,NA,NA,NA,NA,NA,2.52,2021,4,16.910947930411,0.470001220703125,-0.159999847412109,0,-0.0188522338867188,0,NA,NA,NA,0,NA
2021-04-06,36.2599983215332,36.4000015258789,36,36.0499992370605,33.966869354248,20722900,NA,NA,NA,NA,NA,NA,NA,2.88,2021,4,16.8467499752076,0.400001525878906,-0.209999084472656,0,-0.216705322265625,0,NA,NA,NA,0,NA
2021-04-07,36.0299987792969,36.2400016784668,35.7599983215332,35.9099998474121,33.8349533081055,21933800,296,135,0.373549883124014,0.259795057106814,"Medicines","Pfizer Announces Extension of Review of New Drug Application of Abrocitinib for the Treatment of Moderate to Severe Atopic Dermatitis","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-extension-review-new-drug-application",3.24,2021,4,16.9035394295886,0.480003356933594,-0.119998931884766,0,-0.131916046142578,1,2.96,1.35,"Research",0,2
2021-04-08,35.9599990844727,36.1500015258789,35.8699989318848,35.9599990844727,33.8820686340332,18129400,NA,NA,NA,NA,NA,NA,NA,3.24,2021,4,16.7130455430236,0.280002593994141,0,0,0.0471153259277344,0,NA,NA,NA,0,NA
2021-04-09,35.9000015258789,36.810001373291,35.9000015258789,36.5999984741211,34.4850845336914,31686700,304,80,0.583333331814236,0.249512670403176,"COVID-19","Pfizer and BioNTech Request Regulatory Agencies Expand  Emergency Use of Their COVID-19 Vaccine to Adolescents","https://www.pfizer.com//news/announcements/pfizer-and-biontech-request-regulatory-agencies-expand-emergency-use-their-covid",2.88,2021,4,17.2714076240076,0.909999847412109,0.699996948242188,1,0.603015899658203,1,3.04,0.8,"Pandemic",0,4
2021-04-12,36.4799995422363,37.0299987792969,36.3300018310547,36.9700012207031,34.8337059020996,29944900,213,59,0.566176468506704,0.245045044824284,"Research","Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating Contraceptive Efficacy of Once-Daily Relugolix Combination Tablet","https://www.pfizer.com//news/press-release/press-release-detail/myovant-sciences-and-pfizer-announce-first-participant",2.7,2021,4,17.2148696176141,0.699996948242188,0.490001678466797,1,0.348621368408203,1,2.13,0.59,"Research",0,2
2021-04-13,37.4099998474121,37.6500015258789,36.8899993896484,37.1599998474121,35.0127258300781,33967400,NA,NA,NA,NA,NA,NA,NA,3.3,2021,4,17.3409118285257,0.760002136230469,-0.25,0,0.179019927978516,0,NA,NA,NA,0,NA
2021-04-14,37.1699981689453,37.3800010681152,36.9599990844727,37.1699981689453,35.0221519470215,23842900,NA,NA,NA,NA,NA,NA,NA,3,2021,4,16.9869970789999,0.420001983642578,0,0,0.00942611694335938,0,NA,NA,NA,0,NA
2021-04-15,37.2599983215332,37.7400016784668,37.2599983215332,37.5999984741211,35.4273071289062,24945800,133,16,0.785234894058826,0.303462321174211,"Finance","Pfizer Invites Shareholders to Attend Virtual-Only 2021 Annual Meeting of Shareholders on April 22","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-shareholders-attend-virtual-only-2021-annual",3,2021,4,17.0322160694052,0.480003356933594,0.340000152587891,1,0.405155181884766,1,1.33,0.16,"Finance",0,3
2021-04-16,37.8699989318848,38.7000007629395,37.810001373291,38.5699996948242,36.341251373291,52829500,NA,NA,NA,NA,NA,NA,NA,3,2021,4,17.782580323705,0.889999389648438,0.700000762939453,1,0.913944244384766,0,NA,NA,NA,0,NA
2021-04-19,38.5999984741211,38.9599990844727,38.3300018310547,38.9300003051758,36.6804504394531,30905100,256,60,0.620253162594136,0.256701868191144,"COVID-19","Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY®","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-supply-european-union-100-million-0",2.64,2021,4,17.2464318091498,0.629997253417969,0.330001831054688,1,0.339199066162109,1,2.56,0.6,"Pandemic",0,4
2021-04-20,38.75,39.2400016784668,38.75,39.0299987792969,36.7746696472168,26459400,NA,NA,NA,NA,NA,NA,NA,2.64,2021,4,17.0911220784508,0.490001678466797,0.279998779296875,1,0.0942192077636719,0,NA,NA,NA,0,NA
2021-04-21,39.1399993896484,39.6699981689453,39.1300010681152,39.5299987792969,37.245777130127,29365000,NA,NA,NA,NA,NA,NA,NA,2.64,2021,4,17.1953140809929,0.539997100830078,0.389999389648438,1,0.471107482910156,0,NA,NA,NA,0,NA
2021-04-22,39.4799995422363,39.5,38.5200004577637,38.6399993896484,36.4072036743164,33373600,161,22,0.759562837379438,0.291401273421336,"Finance","Pfizer Announces 2021 Shareholder Meeting Results","https://www.pfizer.com//news/announcements/pfizer-announces-2021-shareholder-meeting-results",2.64,2021,4,17.3232757562031,0.979999542236328,-0.840000152587891,0,-0.838573455810547,1,1.61,0.22,"Finance",0,3
2021-04-23,38.6300010681152,38.8300018310547,38.4300003051758,38.6599998474121,36.4260559082031,24375000,NA,NA,NA,NA,NA,NA,NA,2.64,2021,4,17.0090686158738,0.400001525878906,0.029998779296875,1,0.0188522338867188,0,NA,NA,NA,0,NA
2021-04-26,38.7299995422363,38.7400016784668,38.4900016784668,38.6800003051758,36.4449005126953,19773400,65,28,0.39784945808764,0.240310076898424,"Breaking News","Calling All Creatives! We need YOU to design for science!","https://www.pfizer.com//news/announcements/calling-all-creatives-we-need-you-design-science",2.64,2021,4,16.7998482086774,0.25,-0.0499992370605469,0,0.0188446044921875,1,0.65,0.28,"Breaking News",0,5
2021-04-27,38.5099983215332,38.6100006103516,38.3499984741211,38.4500007629395,36.2281875610351,19061500,NA,NA,NA,NA,NA,NA,NA,2.97,2021,4,16.7631812044013,0.260002136230469,-0.05999755859375,0,-0.216712951660163,0,NA,NA,NA,0,NA
2021-04-28,38.5400009155273,38.939998626709,38.5200004577637,38.810001373291,36.5673866271973,21963300,172,66,0.445378149389167,0.29059829024347,"Partnerships","Pfizer Acquires Amplyx Pharmaceuticals","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-acquires-amplyx-pharmaceuticals-0",2.97,2021,4,16.9048834820703,0.419998168945312,0.270000457763672,1,0.339199066162116,1,1.72,0.66,"Management",0,1
2021-04-29,38.9900016784668,39,38.310001373291,38.5999984741211,36.3695220947266,23569400,NA,NA,NA,NA,NA,NA,NA,2.97,2021,4,16.9754598609279,0.689998626708984,-0.390003204345703,0,-0.197864532470703,0,NA,NA,NA,0,NA
2021-04-30,38.5,38.9000015258789,38.4900016784668,38.6500015258789,36.4166297912598,28413200,NA,NA,NA,NA,NA,NA,NA,3.3,2021,4,17.1623644190779,0.409999847412109,0.150001525878906,1,0.0471076965332031,0,NA,NA,NA,0,NA
2021-05-03,39.0400009155273,39.8400001525879,38.9599990844727,39.8300018310547,37.5284423828125,46638600,20,4,0.66666663888889,0.224299063324308,"Responsibility","Supporting India in Its Time of Need","https://www.pfizer.com//news/announcements/supporting-india-its-time-need",3.12,2021,5,17.6579391038448,0.880001068115234,0.790000915527344,1,1.11181259155273,1,0.2,0.04,"Management",0,1
2021-05-04,40,40.1699981689453,39.4300003051758,39.9500007629395,37.6415138244629,52802200,87,19,0.641509427910288,0.207843136847366,"Medicines","Hospira Issues A Voluntary Nationwide Recall for One Lot of  0.5% Bupivacaine Hydrochloride Injection, USP and One Lot of 1%  Lidocaine HCl Injection, USP Due to Mislabeling","https://www.pfizer.com//news/announcements/hospira-issues-voluntary-nationwide-recall-one-lot-05-bupivacaine-hydrochloride",3.9,2021,5,17.7820634334137,0.739997863769531,-0.0499992370605469,0,0.113071441650391,1,0.87,0.19,"Research",0,2
2021-05-05,40.1800003051758,41.0900001525879,38.9300003051758,39.9700012207031,37.6603584289551,76627500,NA,NA,NA,NA,NA,NA,NA,3.9,2021,5,18.154466591166,2.15999984741211,-0.209999084472656,0,0.0188446044921875,0,NA,NA,NA,0,NA
2021-05-06,38.4799995422363,39.2299995422363,37.9599990844727,39.189998626709,37.2892646789551,54944900,376,82,0.641921395978338,0.274909963820582,"COVID-19","Pfizer and BioNTech to Provide COVID-19 Vaccine Doses for Olympic Athletes at the 2020 Tokyo Games","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-provide-covid-19-vaccine-doses-olympic",4.29,2021,5,17.8218414410597,1.27000045776367,0.709999084472656,1,-0.37109375,1,3.76,0.82,"Pandemic",0,4
2021-05-07,39.0499992370605,39.8699989318848,39.0499992370605,39.5800018310547,37.6603622436523,33807800,327,87,0.57971014352727,0.253832004749337,"COVID-19","Pfizer and BioNTech Initiate Rolling Submission of Biologics License Application for U.S. FDA Approval of Their COVID 19 Vaccine","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-initiate-rolling-submission-biologics",3.9,2021,5,17.3362021326399,0.819999694824219,0.530002593994141,1,0.371097564697266,1,3.27,0.87,"Pandemic",0,4
2021-05-10,39.8300018310547,40.2799987792969,39.7799987792969,39.8600006103516,37.9267730712891,30831900,329,96,0.548235292827682,0.24781341093422,"COVID-19","Pfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adolescents","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-receive-first-us-authorization",3.5,2021,5,17.2440604586815,0.5,0.029998779296875,1,0.266410827636719,1,3.29,0.96,"Pandemic",0,4
2021-05-11,39.6800003051758,40.0699996948242,39.2299995422363,39.3499984741211,37.4415092468262,30568600,210,59,0.561338287876066,0.315727699159944,"Research","Pfizer’s Novel Prediction Model, Derived from Machine Learning, Shows Robust Performance for Identifying Heart Failure Patients At-Risk for Wild-Type Transthyretin Amyloid Cardiomyopathy, a Rare and Life-Threatening Condition","https://www.pfizer.com//news/announcements/pfizers-novel-prediction-model-derived-machine-learning-shows-robust-performance",3.5,2021,5,17.2354839289991,0.840000152587891,-0.330001831054688,0,-0.485263824462891,1,2.1,0.59,"Research",0,2
2021-05-12,39.439998626709,39.9199981689453,39.310001373291,39.689998626709,37.7650184631348,26208600,NA,NA,NA,NA,NA,NA,NA,3.5,2021,5,17.0815981973012,0.609996795654297,0.25,1,0.323509216308594,0,NA,NA,NA,0,NA
2021-05-13,39.5,40.2799987792969,39.5,40.0999984741211,38.1551322937012,25415000,NA,NA,NA,NA,NA,NA,NA,3.85,2021,5,17.05085014821,0.779998779296875,0.599998474121094,1,0.390113830566406,0,NA,NA,NA,0,NA
2021-05-14,40.2400016784668,40.3199996948242,39.9199981689453,40.0200004577637,38.0790176391602,18041100,NA,NA,NA,NA,NA,NA,NA,3.85,2021,5,16.7081631017786,0.400001525878906,-0.220001220703125,0,-0.0761146545410085,0,NA,NA,NA,0,NA
2021-05-17,40.0699996948242,40.4000015258789,40.0099983215332,40.1100006103516,38.1646461486816,18095000,33,8,0.609756082688876,0.235632182553838,"Breaking News","In Their Words: Five People with Ulcerative Colitis Speak Up about Their Disease Journeys","https://www.pfizer.com//news/announcements/their-words-five-people-ulcerative-colitis-speak-about-their-disease-journeys",2.88,2021,5,16.7111462702439,0.390003204345703,0.0400009155273438,1,0.0856285095214773,1,0.33,0.08,"Breaking News",0,5
2021-05-18,40.1800003051758,40.3499984741211,39.8300018310547,40.0499992370605,38.1075592041016,15805500,NA,NA,NA,NA,NA,NA,NA,3.2,2021,5,16.5758686019589,0.519996643066406,-0.130001068115234,0,-0.0570869445800781,0,NA,NA,NA,0,NA
2021-05-19,39.9000015258789,39.9000015258789,39.4300003051758,39.8300018310547,37.8982315063477,20209500,97,25,0.59016392958882,0.403973508596114,"Events","Making a Global Impact in Breast Cancer Care","https://www.pfizer.com//news/announcements/making-global-impact-breast-cancer-care",2.88,2021,5,16.8216633983278,0.470001220703125,-0.0699996948242188,0,-0.209327697753906,1,0.97,0.25,"Management",0,1
2021-05-20,39.7299995422363,40.25,39.7200012207031,40.1199989318848,38.1741676330566,18621100,320,91,0.557177614216113,0.251376146635244,"COVID-19","Pfizer and BioNTech to Supply the European Union With up to 1.8 Billion Additional Doses of COMIRNATY®","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-supply-european-union-18-billion",3.2,2021,5,16.7398059580329,0.529998779296875,0.389999389648438,1,0.275936126708984,1,3.2,0.91,"Pandemic",0,4
2021-05-21,40.2099990844727,40.5999984741211,39.9099998474121,39.9500007629395,38.0124092102051,21144800,NA,NA,NA,NA,NA,NA,NA,2.88,2021,5,16.8669046176361,0.689998626708984,-0.259998321533203,0,-0.161758422851562,0,NA,NA,NA,0,NA
2021-05-24,40.0800018310547,40.1399993896484,39.7799987792969,39.810001373291,37.8791961669922,16922300,287,114,0.431421445308176,0.224649859818123,"Research","Pfizer Initiates Study Exploring Coadministration of Its 20-valent Pneumococcal Conjugate Vaccine Candidate Along With a Third Dose of the Pfizer-BioNTech COVID-19 Vaccine in Older Adults","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-initiates-study-exploring-coadministration-its-20",2.56,2021,5,16.644142895804,0.360000610351562,-0.270000457763672,0,-0.133213043212891,1,2.87,1.14,"Research",0,2
2021-05-25,39.8199996948242,39.8600006103516,39.2400016784668,39.3300018310547,37.4224853515625,25916300,67,5,0.861111099151235,0.315789472299169,"Employees","Meet The People Of PGS: Maritza","https://www.pfizer.com//news/announcements/meet-people-pgs-maritza",2.88,2021,5,17.0703827109312,0.619998931884766,-0.489997863769531,0,-0.456710815429688,1,0.67,0.05,"Management",0,1
2021-05-26,39.2900009155273,39.2999992370605,38.7799987792969,38.9199981689453,37.0323677062988,28036500,334,132,0.433476393919579,0.248798718500374,"Medicines","Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE®, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids","https://www.pfizer.com//news/press-release/press-release-detail/myovant-sciences-and-pfizer-receive-fda-approval-myfembreer",2.88,2021,5,17.1490178263243,0.520000457763672,-0.370002746582031,0,-0.390117645263672,1,3.34,1.32,"Research",0,2
2021-05-27,38.9700012207031,39.1800003051758,38.5999984741211,38.6500015258789,36.7754592895508,38471200,55,15,0.571428563265306,0.248226949474373,"Employees","Meet the People of PGS: Julie","https://www.pfizer.com//news/announcements/meet-people-pgs-julie",2.88,2021,5,17.465420493373,0.580001831054688,-0.319999694824219,0,-0.256908416748047,1,0.55,0.15,"Management",0,1
2021-05-28,38.75,39.0200004577637,38.6800003051758,38.7299995422363,36.8515777587891,16154100,323,95,0.54545454414963,0.256599140419522,"COVID-19","Pfizer and BioNTech Receive First Authorization in European Union for COVID-19 Vaccine in Adolescents","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-receive-first-authorization-european",2.88,2021,5,16.5976845072862,0.340000152587891,-0.0200004577636719,0,0.0761184692382812,1,3.23,0.95,"Pandemic",0,4
2021-06-01,38.939998626709,39,38.4799995422363,38.5,36.6327362060547,23642400,NA,NA,NA,NA,NA,NA,NA,2.72,2021,6,16.9785523104886,0.520000457763672,-0.439998626708984,0,-0.218841552734375,0,NA,NA,NA,0,NA
2021-06-02,38.6399993896484,38.9300003051758,38.5400009155273,38.7900009155273,36.9086685180664,19629000,NA,NA,NA,NA,NA,NA,NA,3.06,2021,6,16.792518673465,0.389999389648438,0.150001525878906,1,0.275932312011719,0,NA,NA,NA,0,NA
2021-06-03,38.7599983215332,39.0400009155273,38.6300010681152,38.9700012207031,37.0799369812012,17376300,NA,NA,NA,NA,NA,NA,NA,3.06,2021,6,16.6706178243098,0.409999847412109,0.210002899169922,1,0.171268463134766,0,NA,NA,NA,0,NA
2021-06-04,39.0499992370605,39.5,39.0200004577637,39.1500015258789,37.2512092590332,19375300,NA,NA,NA,NA,NA,NA,NA,3.06,2021,6,16.7795096685669,0.479999542236328,0.100002288818359,1,0.171272277832031,0,NA,NA,NA,0,NA
2021-06-07,39.0800018310547,39.5999984741211,38.9700012207031,38.9900016784668,37.0989761352539,24110700,NA,NA,NA,NA,NA,NA,NA,2.72,2021,6,16.9981663248073,0.629997253417969,-0.0900001525878906,0,-0.152233123779297,0,NA,NA,NA,0,NA
2021-06-08,39.0699996948242,39.1100006103516,38.4799995422363,38.8499984741211,36.9657592773438,18880300,266,88,0.502824857336653,0.230769230618794,"Vaccines","U.S. FDA Approves PREVNAR 20™, Pfizer’s Pneumococcal 20-valent Conjugate Vaccine for Adults Ages 18 Years or Older","https://www.pfizer.com//news/press-release/press-release-detail/us-fda-approves-prevnar-20tm-pfizers-pneumococcal-20-valent",3.06,2021,6,16.7536296613512,0.630001068115234,-0.220001220703125,0,-0.133216857910156,1,2.66,0.88,"Pandemic",0,4
2021-06-09,39,39.8400001525879,38.9799995422363,39.810001373291,37.8791961669922,29824000,NA,NA,NA,NA,NA,NA,NA,3.06,2021,6,17.2108240299975,0.860000610351562,0.810001373291016,1,0.913436889648438,0,NA,NA,NA,0,NA
2021-06-10,39.9000015258789,40.7200012207031,39.8899993896484,40.6800003051758,38.7070083618164,42613700,389,96,0.60412371009459,0.255532138959151,"COVID-19","Pfizer and BioNTech to Provide 500 Million Doses of COVID-19 Vaccine to U.S. Government for Donation to Poorest Nations","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-provide-500-million-doses-covid-19",3.4,2021,6,17.5676863792494,0.830001831054688,0.779998779296875,1,0.827812194824219,1,3.89,0.96,"Pandemic",0,4
2021-06-11,40.6599998474121,40.6699981689453,39.9500007629395,40.1500015258789,38.202709197998,21386900,367,163,0.384905659651121,0.261987147670792,"Medicines","XELJANZ® Safety Review Recommendation Issued in the European Union","https://www.pfizer.com//news/announcements/xeljanzr-safety-review-recommendation-issued-european-union",3.74,2021,6,16.8782891897769,0.719997406005859,-0.509998321533203,0,-0.504299163818359,1,3.67,1.63,"Research",0,2
2021-06-14,40.0299987792969,40.0699996948242,39.3800010681152,39.6300010681152,37.7079315185547,23408300,NA,NA,NA,NA,NA,NA,NA,3.06,2021,6,16.968601261011,0.689998626708984,-0.399997711181641,0,-0.494777679443359,0,NA,NA,NA,0,NA
2021-06-15,39.7099990844727,39.8400001525879,39.3899993896484,39.5900001525879,37.6698722839355,20206900,NA,NA,NA,NA,NA,NA,NA,3.06,2021,6,16.8215347376913,0.450000762939453,-0.119998931884766,0,-0.0380592346191406,0,NA,NA,NA,0,NA
2021-06-16,39.6199989318848,39.8400001525879,39.2799987792969,39.2999992370605,37.3939361572266,19177500,418,184,0.388704318291189,0.278832792830555,"Research","Data Published in New England Journal of Medicine Shows Pfizer’s Tofacitinib Meets Primary Endpoint in Brazilian Study in Patients Hospitalized with COVID-19 Pneumonia","https://www.pfizer.com//news/press-release/press-release-detail/data-published-new-england-journal-medicine-shows-pfizers",3.06,2021,6,16.76924832696,0.560001373291016,-0.319999694824219,0,-0.275936126708984,1,4.18,1.84,"Research",0,2
2021-06-17,39.2700004577637,39.5900001525879,39.0699996948242,39.4799995422363,37.5652046203613,19580100,NA,NA,NA,NA,NA,NA,NA,3.4,2021,6,16.7900243533782,0.520000457763672,0.209999084472656,1,0.171268463134766,0,NA,NA,NA,0,NA
2021-06-18,39.2999992370605,39.439998626709,38.7000007629395,38.810001373291,36.9277000427246,37775900,NA,NA,NA,NA,NA,NA,NA,3.06,2021,6,17.4471819175924,0.739997863769531,-0.489997863769531,0,-0.637504577636719,0,NA,NA,NA,0,NA
2021-06-21,38.8800010681152,39.4799995422363,38.8800010681152,39.4199981689453,37.5081100463867,19488100,NA,NA,NA,NA,NA,NA,NA,2.72,2021,6,16.7853146321549,0.599998474121094,0.539997100830078,1,0.580410003662109,0,NA,NA,NA,0,NA
2021-06-22,39.4099998474121,39.689998626709,39.2599983215332,39.6100006103516,37.6888961791992,15975900,NA,NA,NA,NA,NA,NA,NA,3.4,2021,6,16.5865919572634,0.430000305175781,0.200000762939453,1,0.1807861328125,0,NA,NA,NA,0,NA
2021-06-23,39.6300010681152,39.6599998474121,38.9799995422363,39.0499992370605,37.156063079834,22025400,183,85,0.365671640426598,0.262745097781622,"Medicines","First Participant Dosed in Pfizer’s Pivotal Phase 3 TALAPRO-3 Combination Study of Talazoparib and Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer (mCSPC)","https://www.pfizer.com//news/press-release/press-release-detail/first-participant-dosed-pfizers-pivotal-phase-3-talapro-3",3.4,2021,6,16.9077069362042,0.680000305175781,-0.580001831054688,0,-0.532833099365234,1,1.83,0.85,"Research",0,2
2021-06-24,39.1399993896484,39.3499984741211,39.0800018310547,39.189998626709,37.2892646789551,13436500,46,4,0.8399999832,0.306748464375776,"Finance","Pfizer Declares Third-Quarter 2021 Dividend","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-declares-third-quarter-2021-dividend",3.4,2021,6,16.4134855169024,0.269996643066406,0.0499992370605469,1,0.133201599121094,1,0.46,0.04,"Finance",0,3
2021-06-25,39.1199989318848,39.4099998474121,38.8899993896484,38.9799995422363,37.0894546508789,22774300,NA,NA,NA,NA,NA,NA,NA,3.06,2021,6,16.9411433090916,0.520000457763672,-0.139999389648438,0,-0.199810028076172,0,NA,NA,NA,0,NA
2021-06-28,39.0099983215332,39.2099990844727,38.9000015258789,39.1199989318848,37.2226676940918,19225700,NA,NA,NA,NA,NA,NA,NA,3.06,2021,6,16.7717585356301,0.30999755859375,0.110000610351562,1,0.133213043212891,0,NA,NA,NA,0,NA
2021-06-29,39.1300010681152,39.2799987792969,38.9799995422363,39.0999984741211,37.2036323547363,14516600,55,8,0.746031734189972,0.256097559934563,"Employees","Meet The People Of PGS: Craig","https://www.pfizer.com//news/announcements/meet-people-pgs-craig",3.4,2021,6,16.4908034490483,0.299999237060547,-0.0300025939941406,0,-0.0190353393554688,1,0.55,0.08,"Management",0,1
2021-06-30,39.1399993896484,39.2700004577637,38.8199996948242,39.1599998474121,37.2607269287109,21248100,152,49,0.512437808395832,0.256050955087833,"Partnerships","Spero Therapeutics Announces $40 Million Equity Investment from Pfizer Inc. and Licensing Agreement for SPR206","https://www.pfizer.com//news/press-release/press-release-detail/spero-therapeutics-announces-40-million-equity-investment",3.4,2021,6,16.8717780846356,0.450000762939453,0.0200004577636719,1,0.0570945739746094,1,1.52,0.49,"Management",0,1
2021-06-30,39.1399993896484,39.2700004577637,38.8199996948242,39.1599998474121,37.2607269287109,21248100,152,49,0.512437808395832,0.256050955087833,"Partnerships","Spero Therapeutics Announces $40 Million Equity Investment from Pfizer Inc. and Licensing Agreement for SPR206","https://www.pfizer.com//news/press-release/press-release-detail/spero-therapeutics-announces-40-million-equity-investment",11.22,2021,6,16.8717780846356,0.450000762939453,0.0200004577636719,1,0,1,1.52,0.49,"Management",0,1
2021-07-01,39.1699981689453,39.6300010681152,39.1100006103516,39.560001373291,37.6413269042969,20035900,NA,NA,NA,NA,NA,NA,NA,9.86,2021,7,16.8130362723414,0.520000457763672,0.390003204345703,1,0.380599975585938,0,NA,NA,NA,1,NA
2021-07-02,39.4599990844727,39.8300018310547,39.3800010681152,39.7299995422363,37.8030776977539,16592700,NA,NA,NA,NA,NA,NA,NA,9.52,2021,7,16.6244734578357,0.450000762939453,0.270000457763672,1,0.161750793457031,0,NA,NA,NA,1,NA
2021-07-06,39.4799995422363,39.6500015258789,39.0400009155273,39.2900009155273,37.3844223022461,18931900,NA,NA,NA,NA,NA,NA,NA,11.47,2021,7,16.7563589407531,0.610000610351562,-0.189998626708984,0,-0.418655395507812,0,NA,NA,NA,1,NA
2021-07-07,39.2200012207031,39.3600006103516,38.9700012207031,39.3499984741211,37.4415092468262,17665200,NA,NA,NA,NA,NA,NA,NA,10.73,2021,7,16.6871072171426,0.389999389648438,0.129997253417969,1,0.0570869445800781,0,NA,NA,NA,1,NA
2021-07-08,39,39.3199996948242,38.9300003051758,39.25,37.3463592529297,23021200,285,89,0.524064169721754,0.242542152890699,"Vaccines","Pfizer and BioNTech Provide Update on Booster Program in Light of the Delta-Variant","https://www.pfizer.com//news/announcements/pfizer-and-biontech-provide-update-booster-program-light-delta-variant",11.84,2021,7,16.9519261319214,0.389999389648438,0.25,1,-0.0951499938964844,1,2.85,0.89,"Pandemic",1,4
2021-07-09,39.5299987792969,40.0999984741211,39.4599990844727,39.6100006103516,37.6888961791992,21578700,NA,NA,NA,NA,NA,NA,NA,12.58,2021,7,16.8872173213578,0.639999389648438,0.0800018310546875,1,0.342536926269531,0,NA,NA,NA,1,NA
2021-07-12,39.6599998474121,40.25,39.5999984741211,39.7599983215332,37.8316268920898,24513000,NA,NA,NA,NA,NA,NA,NA,11.56,2021,7,17.0147141878296,0.650001525878906,0.0999984741210938,1,0.142730712890618,0,NA,NA,NA,1,NA
2021-07-13,39.7700004577637,39.7999992370605,39.5299987792969,39.6500015258789,37.7269592285156,12222000,NA,NA,NA,NA,NA,NA,NA,11.56,2021,7,16.3187482462567,0.270000457763672,-0.119998931884766,0,-0.104667663574212,0,NA,NA,NA,1,NA
2021-07-14,39.7200012207031,40.0299987792969,39.6599998474121,39.9500007629395,38.0124092102051,15888600,NA,NA,NA,NA,NA,NA,NA,10.54,2021,7,16.5811124918427,0.369998931884766,0.229999542236328,1,0.285449981689453,0,NA,NA,NA,1,NA
2021-07-15,39.9500007629395,40.189998626709,39.8600006103516,40.0900001525879,38.145622253418,20250800,NA,NA,NA,NA,NA,NA,NA,10.88,2021,7,16.8237049062901,0.329998016357422,0.139999389648438,1,0.133213043212891,0,NA,NA,NA,1,NA
2021-07-16,40.1399993896484,40.3499984741211,39.9300003051758,40.3499984741211,38.3930053710938,24270400,296,86,0.549738218456183,0.243777919436006,"COVID-19","U.S. FDA Grants Priority Review for the Biologics License Application for Pfizer-BioNTech COVID-19 Vaccine","https://www.pfizer.com//news/announcements/us-fda-grants-priority-review-biologics-license-application-pfizer-biontech",11.9,2021,7,17.004768100022,0.419998168945312,0.209999084472656,1,0.247383117675781,1,2.96,0.86,"Pandemic",1,4
2021-07-19,40.0699996948242,40.3499984741211,39.6800003051758,40.1500015258789,38.202709197998,29818400,210,87,0.414141412746999,0.269021738886756,"Research","Valneva and Pfizer Complete Recruitment for Phase 2 Trial of Lyme Disease Vaccine Candidate","https://www.pfizer.com//news/press-release/press-release-detail/valneva-and-pfizer-complete-recruitment-phase-2-trial-lyme",11.16,2021,7,17.2106362441328,0.669998168945312,0.0800018310546875,1,-0.190296173095703,1,2.1,0.87,"Research",1,2
2021-07-20,40.25,41.7099990844727,40.2000007629395,41.0499992370605,39.0590629577637,48804100,NA,NA,NA,NA,NA,NA,NA,11.88,2021,7,17.7033249041777,1.5099983215332,0.799999237060547,1,0.856353759765625,0,NA,NA,NA,1,NA
2021-07-21,41.2400016784668,41.2400016784668,40.5200004577637,41.0200004577637,39.0305137634277,27530200,349,94,0.575620766194987,0.249016301152886,"Partnerships","Pfizer and BioNTech Announce Collaboration With Biovac to Manufacture and Distribute COVID-19 Vaccine Doses Within Africa","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-collaboration-biovac",11.16,2021,7,17.1307941782182,0.720001220703125,-0.220001220703125,0,-0.0285491943359375,1,3.49,0.94,"Management",1,1
2021-07-22,41.1199989318848,41.5499992370605,40.9000015258789,41.4700012207031,39.4586906433105,18913300,330,134,0.422413792193074,0.258495821583011,"Medicines","Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein Degrader ARV-471","https://www.pfizer.com//news/press-release/press-release-detail/arvinas-and-pfizer-announce-global-collaboration-develop",11.52,2021,7,16.7553759891231,0.649997711181641,0.350002288818359,1,0.428176879882812,1,3.3,1.34,"Research",1,2
2021-07-23,41.4599990844727,41.8300018310547,41.4199981689453,41.6800003051758,39.6585083007812,21609200,309,91,0.5449999986375,0.24767801842249,"COVID-19","Pfizer and BioNTech to Provide U.S. Government with an Additional 200 Million Doses of COVID-19 Vaccine to Help Meet Continued Need for Vaccine Supply in the U.S.","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-provide-us-government-additional-200",12.6,2021,7,16.8886297541762,0.410003662109375,0.220001220703125,1,0.199817657470703,1,3.09,0.91,"Pandemic",1,4
2021-07-26,41.6199989318848,41.939998626709,41.3899993896484,41.810001373291,39.7822036743164,23720000,NA,NA,NA,NA,NA,NA,NA,10.15,2021,7,16.9818291742523,0.549999237060547,0.19000244140625,1,0.123695373535156,0,NA,NA,NA,1,NA
2021-07-27,41.8199996948242,42.2000007629395,41.5800018310547,42.0999984741211,40.0581321716309,32544100,NA,NA,NA,NA,NA,NA,NA,10.5,2021,7,17.2981066813163,0.619998931884766,0.279998779296875,1,0.275928497314453,0,NA,NA,NA,1,NA
2021-07-28,42.3499984741211,43.7400016784668,42.25,43.4500007629395,41.3426628112793,53822400,250,26,0.811594199957992,0.355212354755196,"Breaking News","Get to Know Our Breakthrough Fellows!","https://www.pfizer.com//news/announcements/get-know-our-breakthrough-fellows",11.9,2021,7,17.8012003139365,1.4900016784668,1.10000228881836,1,1.28453063964844,1,2.5,0.26,"Breaking News",1,5
2021-07-29,43.2299995422363,43.2999992370605,42.6199989318848,42.7900009155273,41.0834274291992,29015000,NA,NA,NA,NA,NA,NA,NA,11.9,2021,7,17.1833235300718,0.680000305175781,-0.439998626708984,0,-0.259235382080078,0,NA,NA,NA,1,NA
2021-07-30,42.8800010681152,43.189998626709,42.689998626709,42.810001373291,41.1026306152344,24763300,NA,NA,NA,NA,NA,NA,NA,10.5,2021,7,17.0248733167651,0.5,-0.0699996948242188,0,0.0192031860351562,0,NA,NA,NA,1,NA
2021-08-02,43.2999992370605,44.1399993896484,43.25,43.9599990844727,42.2067642211914,43066900,NA,NA,NA,NA,NA,NA,NA,9.8,2021,8,17.5782653018063,0.889999389648438,0.659999847412109,1,1.10413360595703,0,NA,NA,NA,1,NA
2021-08-03,44.1699981689453,45.8600006103516,44.0699996948242,45.6800003051758,43.8581657409668,45643300,NA,NA,NA,NA,NA,NA,NA,11.2,2021,8,17.6363674072489,1.79000091552734,1.51000213623047,1,1.65140151977539,0,NA,NA,NA,1,NA
2021-08-04,45.3499984741211,45.7999992370605,45.0099983215332,45.189998626709,43.3877105712891,43391200,135,69,0.323529410178777,0.220540540302118,"Medicines","Pfizer Announces Positive Top-Line Results from Phase 2b/3 Trial of Ritlecitinib in Alopecia Areata","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-phase-2b3-trial",11.55,2021,8,17.5857672365802,0.790000915527344,-0.159999847412109,0,-0.470455169677734,1,1.35,0.69,"Research",1,2
2021-08-05,45,45.1399993896484,44.7000007629395,45.060001373291,43.2629013061523,23505400,NA,NA,NA,NA,NA,NA,NA,11.55,2021,8,16.9727407824948,0.439998626708984,0.0600013732910156,1,-0.124809265136719,0,NA,NA,NA,1,NA
2021-08-06,45.0900001525879,45.310001373291,44.6300010681152,45.0699996948242,43.2724990844727,20413000,NA,NA,NA,NA,NA,NA,NA,11.55,2021,8,16.8316825597441,0.680000305175781,-0.0200004577636719,0,0.0095977783203125,0,NA,NA,NA,1,NA
2021-08-09,45.1100006103516,46.0299987792969,45.1100006103516,45.9799995422363,44.1462059020996,32374300,NA,NA,NA,NA,NA,NA,NA,10.54,2021,8,17.2928754870173,0.919998168945312,0.869998931884766,1,0.873706817626953,0,NA,NA,NA,1,NA
2021-08-10,46.2000007629395,48.5699996948242,45.8899993896484,48.189998626709,46.2680587768555,81189400,NA,NA,NA,NA,NA,NA,NA,10.88,2021,8,18.2122952670555,2.68000030517578,1.98999786376953,1,2.12185287475586,0,NA,NA,NA,1,NA
2021-08-11,47.7799987792969,48.0800018310547,46.2599983215332,46.310001373291,44.4630393981934,50878200,NA,NA,NA,NA,NA,NA,NA,10.54,2021,8,17.7449451186666,1.82000350952148,-1.46999740600586,0,-1.80501937866211,0,NA,NA,NA,1,NA
2021-08-12,46.5,47.4000015258789,46.3400001525879,47.2400016784668,45.35595703125,29676400,170,53,0.524663674777293,0.252548131084317,"Vaccines","VTX-801 Receives U.S. FDA Fast Track Designation for the Treatment of Wilson Disease","https://www.pfizer.com//news/press-release/press-release-detail/vtx-801-receives-us-fda-fast-track-designation-treatment",11.56,2021,8,17.205862708803,1.06000137329102,0.740001678466797,1,0.892917633056641,1,1.7,0.53,"Pandemic",1,4
2021-08-13,47.4099998474121,48.5,47.3199996948242,48.4799995422363,46.5464973449707,35379200,188,68,0.468749998168945,0.252216748519983,"Vaccines","U.S. FDA Approves TICOVAC™, Pfizer’s Tick-Borne Encephalitis (TBE) Vaccine","https://www.pfizer.com//news/press-release/press-release-detail/us-fda-approves-ticovactm-pfizers-tick-borne-encephalitis",10.88,2021,8,17.3816346630605,1.18000030517578,1.06999969482422,1,1.1905403137207,1,1.88,0.68,"Pandemic",1,4
2021-08-16,48.2299995422363,48.9700012207031,47.5099983215332,48.9099998474121,46.9593505859375,38045800,323,102,0.519999998776471,0.236242356733606,"COVID-19","Pfizer and BioNTech Announce Submission of Initial Data to U.S. FDA to Support Booster Dose of COVID-19 Vaccine","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-submission-initial-data-us-fda",11.34,2021,8,17.4543012813861,1.46000289916992,0.680000305175781,1,0.412853240966797,1,3.23,1.02,"Pandemic",1,4
2021-08-17,48.7799987792969,50.4900016784668,48.7099990844727,50.4199981689453,48.409122467041,68817000,NA,NA,NA,NA,NA,NA,NA,12.18,2021,8,18.0469613799357,1.78000259399414,1.63999938964844,1,1.44977188110352,0,NA,NA,NA,1,NA
2021-08-18,50.2299995422363,51.8600006103516,49.1699981689453,49.310001373291,47.3433952331543,88598000,NA,NA,NA,NA,NA,NA,NA,12.6,2021,8,18.299619853244,2.69000244140625,-0.919998168945312,0,-1.06572723388672,0,NA,NA,NA,1,NA
2021-08-19,48.5,49.9599990844727,48.2599983215332,48.7999992370605,46.8537330627441,57741600,NA,NA,NA,NA,NA,NA,NA,13.44,2021,8,17.8714884595597,1.70000076293945,0.299999237060547,1,-0.489662170410156,0,NA,NA,NA,1,NA
2021-08-20,48.9799995422363,49.7299995422363,48.6599998474121,48.7200012207031,46.776927947998,35157500,418,193,0.368248771901393,0.257154882046652,"Medicines","XELJANZ® (tofacitinib citrate) Receives Marketing Authorization in the European Union for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis","https://www.pfizer.com//news/press-release/press-release-detail/xeljanzr-tofacitinib-citrate-receives-marketing",12.18,2021,8,17.37534855317,1.06999969482422,-0.259998321533203,0,-0.0768051147460938,1,4.18,1.93,"Research",1,2
2021-08-23,50.2900009155273,51.3600006103516,49.5999984741211,49.9300003051758,47.9386711120605,88652400,360,98,0.572052400497702,0.259343148211017,"Vaccines","Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives Full U.S. FDA Approval for Individuals 16 Years and Older","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-biontech-covid-19-vaccine-comirnatyr-receives-full",14,2021,8,18.3002336741561,1.76000213623047,-0.360000610351562,0,1.1617431640625,1,3.6,0.98,"Pandemic",1,4
2021-08-24,49.7400016784668,50.0499992370605,48.2400016784668,48.3800010681152,46.4504890441895,52624100,NA,NA,NA,NA,NA,NA,NA,13.72,2021,8,17.7786847666855,1.80999755859375,-1.36000061035156,0,-1.48818206787109,0,NA,NA,NA,1,NA
2021-08-25,48.0400009155273,48.2799987792969,46.9300003051758,47.5099983215332,45.6151809692383,51036800,330,108,0.506849313911303,0.256140350727403,"COVID-19","Pfizer and BioNTech Initiate Rolling Submission of Supplemental Biologics License Application to U.S. FDA for Booster Dose of COMIRNATY® in Individuals 16 and Older","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-initiate-rolling-submission",11.2,2021,8,17.7480575187043,1.34999847412109,-0.530002593994141,0,-0.835308074951172,1,3.3,1.08,"Pandemic",1,4
2021-08-26,47.7000007629395,48.1599998474121,47.2999992370605,47.3800010681152,45.4903717041016,29029300,374,100,0.578059070510424,0.264508928423823,"COVID-19","Pfizer and BioNTech Announce Collaboration With Brazil’s Eurofarma to Manufacture COVID-19 Vaccine Doses for Latin America","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-collaboration-brazils",9.8,2021,8,17.1838162571715,0.860000610351562,-0.319999694824219,0,-0.124809265136719,1,3.74,1,"Pandemic",1,4
2021-08-27,47.3699989318848,47.5,46.5299987792969,46.5999984741211,44.7414741516113,32924500,NA,NA,NA,NA,NA,NA,NA,8.12,2021,8,17.309727649822,0.970001220703125,-0.770000457763672,0,-0.748897552490234,0,NA,NA,NA,1,NA
2021-08-30,46.2000007629395,47.1599998474121,46.1599998474121,46.7599983215332,44.895092010498,25774400,157,51,0.509615382165311,0.27332457257119,"Medicines","Positive Top-Line Results From Pfizer’s Phase 3 JADE DARE Trial Comparing the Efficacy of Abrocitinib and Dupilumab for Moderate to Severe Atopic Dermatitis","https://www.pfizer.com//news/press-release/press-release-detail/positive-top-line-results-pfizers-phase-3-jade-dare-trial",6.44,2021,8,17.064892348024,1,0.55999755859375,1,0.153617858886719,1,1.57,0.51,"Research",1,2
2021-08-31,46.7200012207031,47.1399993896484,45.9300003051758,46.0699996948242,44.2326126098633,34547800,NA,NA,NA,NA,NA,NA,NA,5.98,2021,8,17.3578544592638,1.20999908447266,-0.650001525878906,0,-0.662479400634766,0,NA,NA,NA,1,NA
2021-09-01,46.189998626709,46.2599983215332,45.4199981689453,46.0400009155273,44.2038116455078,32900100,320,146,0.373390557138647,0.262239729734249,"Medicines","FDA Issues Drug Safety Communication Related to Current XELJANZ® Label","https://www.pfizer.com//news/announcements/fda-issues-drug-safety-communication-related-current-xeljanzr-label",5.98,2021,9,17.3089862856397,0.840000152587891,-0.149997711181641,0,-0.0288009643554688,1,3.2,1.46,"Research",1,2
2021-09-02,46.4799995422363,46.8699989318848,46.1300010681152,46.8400001525879,44.9719047546387,26106300,182,72,0.433070864436729,0.298122065377791,"Research","Pfizer Announces Start of Phase 3 Clinical Trial in Adults for Its Investigational Vaccine Against Respiratory Syncytial Virus (RSV)","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-start-phase-3-clinical-trial-adults-its",5.52,2021,9,17.0776872607809,0.739997863769531,0.360000610351562,1,0.768093109130859,1,1.82,0.72,"Research",1,2
2021-09-03,46.9000015258789,47.0299987792969,46.3400001525879,46.8400001525879,44.9719047546387,20817200,106,21,0.669291333312667,0.239171374314178,"Medicines","The Bristol-Myers Squibb-Pfizer Alliance is pleased with the decision by the U.S.  Court of Appeals for the Federal Circuit upholding the Eliquis®Patents","https://www.pfizer.com//news/announcements/bristol-myers-squibb-pfizer-alliance-pleased-decision-us-court-appeals-federal",5.29,2021,9,16.8512901740731,0.689998626708984,-0.0600013732910156,0,0,1,1.06,0.21,"Research",1,2
2021-09-07,46.9900016784668,47.5,46.5400009155273,46.75,44.8854942321777,26236900,90,11,0.782178210077443,0.262337661656266,"Finance","Pfizer Invites Public to Listen to Two Webcasts of Pfizer Discussions at Upcoming Healthcare Conferences","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-listen-two-webcasts-pfizer-0",4.83,2021,9,17.0826774129314,0.959999084472656,-0.240001678466797,0,-0.0864105224609375,1,0.9,0.11,"Finance",1,3
2021-09-08,46.5099983215332,46.7900009155273,46.25,46.5099983215332,44.6550598144531,15839600,NA,NA,NA,NA,NA,NA,NA,4.83,2021,9,16.5780237546394,0.540000915527344,0,0,-0.230434417724609,0,NA,NA,NA,1,NA
2021-09-09,46.4700012207031,46.7200012207031,45.8499984741211,46.0299987792969,44.1942100524902,21695300,302,118,0.438095237052154,0.249554367053147,"Medicines","Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis","https://www.pfizer.com//news/press-release/press-release-detail/myovant-sciences-and-pfizer-announce-fda-acceptance",4.83,2021,9,16.8926062512829,0.870002746582031,-0.44000244140625,0,-0.460849761962891,1,3.02,1.18,"Research",1,2
2021-09-10,46.2700004577637,46.3499984741211,45.5099983215332,45.5900001525879,43.7717590332031,20801500,NA,NA,NA,NA,NA,NA,NA,4.83,2021,9,16.8505357055294,0.840000152587891,-0.680000305175781,0,-0.422451019287109,0,NA,NA,NA,1,NA
2021-09-13,45.7400016784668,45.8300018310547,44.2000007629395,44.5800018310547,42.8020362854004,37086200,NA,NA,NA,NA,NA,NA,NA,5.04,2021,9,17.4287555176898,1.63000106811523,-1.15999984741211,0,-0.969722747802734,0,NA,NA,NA,1,NA
2021-09-14,44.6699981689453,45.2599983215332,44.5499992370605,44.7099990844727,42.9268531799316,24100200,NA,NA,NA,NA,NA,NA,NA,4.8,2021,9,16.9977307386751,0.709999084472656,0.0400009155273438,1,0.12481689453125,0,NA,NA,NA,1,NA
2021-09-15,44.560001373291,45.3699989318848,44.4700012207031,44.7700004577637,42.9844589233398,28674600,NA,NA,NA,NA,NA,NA,NA,4.56,2021,9,17.1715223063232,0.899997711181641,0.209999084472656,1,0.057605743408196,0,NA,NA,NA,1,NA
2021-09-16,44.8800010681152,44.9900016784668,44.0299987792969,44.4700012207031,42.6964263916016,22424200,NA,NA,NA,NA,NA,NA,NA,4.8,2021,9,16.925651335397,0.960002899169922,-0.409999847412109,0,-0.288032531738274,0,NA,NA,NA,1,NA
2021-09-17,44.1699981689453,44.4599990844727,43.310001373291,43.8899993896484,42.1395568847656,56370500,373,113,0.534979422767532,0.245702729906116,"COVID-19","FDA Advisory Committee Votes Unanimously in Favor Of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-risk Populations","https://www.pfizer.com//news/press-release/press-release-detail/fda-advisory-committee-votes-unanimously-favor-comirnatyr",5.04,2021,9,17.8474565477245,1.14999771118164,-0.279998779296875,0,-0.556869506835938,1,3.73,1.13,"Pandemic",1,4
2021-09-20,43.3899993896484,44.6500015258789,43.3899993896484,44.2000007629395,42.4371948242188,41873000,340,108,0.517857141701212,0.249999999860491,"COVID-19","Pfizer and BioNTech Announce Positive Topline Results From Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-positive-topline-results",4.62,2021,9,17.5501518096566,1.26000213623047,0.810001373291016,1,0.297637939453125,1,3.4,1.08,"Pandemic",1,4
2021-09-21,44.25,44.7299995422363,43.8499984741211,43.9199981689453,42.1683578491211,23645600,NA,NA,NA,NA,NA,NA,NA,4.2,2021,9,16.978687651373,0.880001068115234,-0.330001831054688,0,-0.268836975097656,0,NA,NA,NA,1,NA
2021-09-22,43.9900016784668,44.3899993896484,43.8300018310547,43.9500007629395,42.1971626281738,22616700,365,96,0.583514098517323,0.262080727537191,"COVID-19","Pfizer and BioNTech Expand Collaboration with U.S. to Provide 500 Million Additional COVID-19 Vaccine Doses at Not-for-Profit Price for Donation to Poorest Countries","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-expand-collaboration-us-provide-500",3.78,2021,9,16.9341991736304,0.55999755859375,-0.0400009155273438,0,0.0288047790527344,1,3.65,0.96,"Pandemic",1,4
2021-09-23,44.2799987792969,44.7200012207031,44.1500015258789,44.189998626709,42.4275932312012,19719200,46,4,0.8399999832,0.306748464375776,"Finance","Pfizer Declares Fourth-Quarter 2021 Dividend","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-declares-fourth-quarter-2021-dividend",4.41,2021,9,16.7971033890765,0.569999694824219,-0.0900001525878906,0,0.230430603027344,1,0.46,0.04,"Finance",1,3
2021-09-24,44.0699996948242,44.4099998474121,43.810001373291,43.939998626709,42.1875610351562,16150700,152,53,0.482926826912552,0.264857880794757,"Medicines","Pfizer and OPKO Announce Extension of U.S. FDA Review of Biologics License Application of Somatrogon for Pediatric Growth Hormone Deficiency","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-opko-announce-extension-us-fda-review-biologics",4.41,2021,9,16.5974740122637,0.599998474121094,-0.130001068115234,0,-0.240032196044922,1,1.52,0.53,"Research",1,2
2021-09-27,43.9199981689453,44.1300010681152,43.5099983215332,43.5699996948242,41.8323211669922,19955900,177,27,0.735294114042676,0.247873632748635,"Research","Pfizer Starts Study of mRNA-Based Next Generation Flu Vaccine Program","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-starts-study-mrna-based-next-generation-flu-vaccine",3.8,2021,9,16.8090354470367,0.620002746582031,-0.349998474121094,0,-0.355239868164062,1,1.77,0.27,"Research",1,2
2021-09-28,43.0699996948242,43.2799987792969,42.4300003051758,43.0400009155273,41.3234596252441,28512200,325,104,0.515151513950696,0.24855156416654,"COVID-19","Pfizer and BioNTech Submit Initial Data to U.S. FDA From Pivotal Trial of COVID-19 Vaccine in Children 5 to <12 Years of Age","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-submit-initial-data-us-fda-pivotal",4,2021,9,17.1658426588911,0.849998474121094,-0.029998779296875,0,-0.508861541748047,1,3.25,1.04,"Pandemic",1,4
2021-09-29,43.2200012207031,43.689998626709,43.0800018310547,43.5299987792969,41.7939147949219,18037200,337,99,0.545871558381029,0.236827810843657,"Research","Positive Top-line Results of Pfizer’s Phase 3 Study Exploring Coadministration of Prevnar 20™ With Seasonal Flu Vaccine in Older Adults Released","https://www.pfizer.com//news/press-release/press-release-detail/positive-top-line-results-pfizers-phase-3-study-exploring",3.8,2021,9,16.7079469053503,0.609996795654297,0.30999755859375,1,0.470455169677734,1,3.37,0.99,"Research",1,2
2021-09-30,43.7900009155273,44.0499992370605,42.9700012207031,43.0099983215332,41.2946548461914,21103300,137,29,0.650602405719263,0.255778119790789,"Medicines","Japan’s MHLW Approves Pfizer’s CIBINQO® (abrocitinib) for Adults and Adolescents with Moderate to Severe Atopic Dermatitis","https://www.pfizer.com//news/press-release/press-release-detail/japans-mhlw-approves-pfizers-cibinqor-abrocitinib-adults",3.6,2021,9,16.8649400317076,1.07999801635742,-0.780002593994141,0,-0.499259948730469,1,1.37,0.29,"Research",1,2
2021-10-01,42.5200004577637,43.0999984741211,41.7000007629395,42.9300003051758,41.2178497314453,38483000,NA,NA,NA,NA,NA,NA,NA,3.2,2021,10,17.4657271692863,1.39999771118164,0.409999847412109,1,-0.0768051147460938,0,NA,NA,NA,1,NA
2021-10-04,42.9300003051758,43.3499984741211,42.2099990844727,42.4199981689453,40.7281799316406,28906500,NA,NA,NA,NA,NA,NA,NA,2.72,2021,10,17.1795770758825,1.13999938964844,-0.510002136230469,0,-0.489669799804688,0,NA,NA,NA,1,NA
2021-10-05,42.5299987792969,42.7900009155273,42.2799987792969,42.3199996948242,40.6321716308594,19342600,NA,NA,NA,NA,NA,NA,NA,3.4,2021,10,16.7778205270543,0.510002136230469,-0.209999084472656,0,-0.09600830078125,0,NA,NA,NA,1,NA
2021-10-06,42.060001373291,42.2000007629395,41.689998626709,42.0200004577637,40.3441390991211,30483800,NA,NA,NA,NA,NA,NA,NA,3.06,2021,10,17.2327059857321,0.510002136230469,-0.0400009155273438,0,-0.288032531738281,0,NA,NA,NA,1,NA
2021-10-07,42.5200004577637,42.9599990844727,42.2099990844727,42.7400016784668,41.0354194641113,19778300,NA,NA,NA,NA,NA,NA,NA,3.57,2021,10,16.8000959856264,0.75,0.220001220703125,1,0.691280364990234,0,NA,NA,NA,1,NA
2021-10-08,42.7299995422363,42.9099998474121,42.3400001525879,42.4500007629395,40.7569923400879,12778600,NA,NA,NA,NA,NA,NA,NA,3.06,2021,10,16.363282533003,0.569999694824219,-0.279998779296875,0,-0.278427124023438,0,NA,NA,NA,1,NA
2021-10-11,42.4500007629395,42.6199989318848,42.0099983215332,42.060001373291,40.3825454711914,11984200,350,101,0.552106428931028,0.251533742191002,"COVID-19","Pfizer and BioNTech Receive CHMP Positive Opinion for COVID-19 Vaccine Booster in the European Union","https://www.pfizer.com//news/announcements/pfizer-and-biontech-receive-chmp-positive-opinion-covid-19-vaccine-booster",2.52,2021,10,16.2990997569616,0.610000610351562,-0.389999389648438,0,-0.374446868896484,1,3.5,1.01,"Pandemic",1,4
2021-10-12,42.1599998474121,42.2099990844727,41.6599998474121,41.8499984741211,40.1809158325195,16222300,NA,NA,NA,NA,NA,NA,NA,2.52,2021,10,16.601897458489,0.549999237060547,-0.310001373291016,0,-0.201629638671875,0,NA,NA,NA,1,NA
2021-10-13,41.75,41.9099998474121,40.939998626709,41.4199981689453,39.76806640625,28205700,NA,NA,NA,NA,NA,NA,NA,2.88,2021,10,17.1550346785967,0.970001220703125,-0.330001831054688,0,-0.412849426269531,0,NA,NA,NA,1,NA
2021-10-14,41.560001373291,41.9599990844727,41.5200004577637,41.6699981689453,40.0080947875977,17590300,NA,NA,NA,NA,NA,NA,NA,2.88,2021,10,16.6828582285628,0.439998626708984,0.109996795654297,1,0.240028381347656,0,NA,NA,NA,1,NA
2021-10-15,41.9000015258789,42.0299987792969,41.3800010681152,41.4900016784668,39.835277557373,23550300,389,176,0.376991149775237,0.258226690924028,"Medicines","Pfizer’s Abrocitinib Receives Positive CHMP Opinion for the Treatment of Adults with Moderate to Severe Atopic Dermatitis","https://www.pfizer.com//news/press-release/press-release-detail/pfizers-abrocitinib-receives-positive-chmp-opinion",2.7,2021,10,16.9746491596614,0.649997711181641,-0.409999847412109,0,-0.172817230224609,1,3.89,1.76,"Research",1,2
2021-10-18,41.4500007629395,41.7000007629395,41.0400009155273,41.3199996948242,39.6720542907715,21733000,323,96,0.541766108492205,0.256740195921115,"Vaccines","New Formulation of COMIRNATY® Receives Positive Opinion from CHMP","https://www.pfizer.com//news/press-release/press-release-detail/new-formulation-comirnatyr-receives-positive-opinion-chmp",2.38,2021,10,16.8943424467008,0.659999847412109,-0.130001068115234,0,-0.163223266601555,1,3.23,0.96,"Pandemic",1,4
2021-10-19,41.5999984741211,42.2000007629395,41.5400009155273,42.0900001525879,40.4113464355469,17159800,311,120,0.443155451407992,0.234111895581688,"Research","Myovant Sciences and Pfizer Present Data on Relugolix Combination Therapy from Studies in Uterine Fibroids and Endometriosis at the American Society for Reproductive Medicine Congress","https://www.pfizer.com//news/press-release/press-release-detail/myovant-sciences-and-pfizer-present-data-relugolix",2.55,2021,10,16.6580800552202,0.659999847412109,0.490001678466797,1,0.739292144775384,1,3.11,1.2,"Research",1,2
2021-10-20,42.1199989318848,43.1100006103516,42.0999984741211,42.7999992370605,41.0930290222168,22788300,238,59,0.602693600664331,0.235527359051921,"Vaccines","Advisory Committee on Immunization Practices Votes to Recommend Routine Use of Pfizer’s PREVNAR 20™ (Pneumococcal 20-valent Conjugate Vaccine) in Adults","https://www.pfizer.com//news/press-release/press-release-detail/advisory-committee-immunization-practices-votes-recommend",2.55,2021,10,16.9417578482015,1.01000213623047,0.680000305175781,1,0.681682586669922,1,2.38,0.59,"Pandemic",1,4
2021-10-21,43.060001373291,43.0900001525879,42.4300003051758,42.8600006103516,41.1506385803223,22142300,383,108,0.560081465254417,0.252962390390024,"Research","Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-phase-3-trial-data-showing",3.06,2021,10,16.9130004093838,0.659999847412109,-0.200000762939453,0,0.0576095581054688,1,3.83,1.08,"Research",1,2
2021-10-22,42.8199996948242,43.189998626709,42.6300010681152,43.1599998474121,41.4386672973633,17183000,NA,NA,NA,NA,NA,NA,NA,3.06,2021,10,16.6594311391259,0.55999755859375,0.340000152587891,1,0.288028717041016,0,NA,NA,NA,1,NA
2021-10-25,43.2000007629395,43.2400016784668,42.5699996948242,43.1500015258789,41.4290733337402,22846200,NA,NA,NA,NA,NA,NA,NA,3.52,2021,10,16.9442954032764,0.670001983642578,-0.0499992370605469,0,-0.00959396362304688,0,NA,NA,NA,1,NA
2021-10-26,43.3300018310547,43.7599983215332,42.9199981689453,43.560001373291,41.8227233886719,29729100,390,111,0.556886226433361,0.256791388899646,"Vaccines","FDA Advisory Committee Votes in Favor of Granting Emergency Use Authorization for the Pfizer-BioNTech COVID-19 Vaccine in Children 5 to <12 Years","https://www.pfizer.com//news/press-release/press-release-detail/fda-advisory-committee-votes-favor-granting-emergency-use",3.74,2021,10,17.2076369557011,0.840000152587891,0.229999542236328,1,0.393650054931641,1,3.9,1.11,"Pandemic",1,4
2021-10-27,43.4599990844727,43.560001373291,42.6800003051758,42.9700012207031,41.2562484741211,22317500,49,11,0.633333322777778,0.267857141661352,"Hiring & Recruitment","The science behind hiring and interviewing","https://www.pfizer.com//news/announcements/science-behind-hiring-and-interviewing",3.74,2021,10,16.9208817268435,0.880001068115234,-0.489997863769531,0,-0.566474914550781,1,0.49,0.11,"Management",1,1
2021-10-28,42.9500007629395,43.6699981689453,42.939998626709,43.1800003051758,41.4578742980957,18023400,392,104,0.580645160119667,0.252545824718663,"Vaccines","Pfizer and BioNTech to Provide U.S. Government an Additional 50 Million Pediatric Doses of COVID-19 Vaccine to Support Further Preparedness for Future Needs","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-provide-us-government-additional-50",3.52,2021,10,16.7071815270755,0.729999542236328,0.229999542236328,1,0.201625823974609,1,3.92,1.04,"Pandemic",1,4
2021-10-29,43.0900001525879,43.8300018310547,42.8600006103516,43.7400016784668,41.9955406188965,30307500,373,108,0.550935549790155,0.251832460601135,"Vaccines","Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine in Children Ages 5 Through 11 Years","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-receive-first-us-fda-emergency-use",3.52,2021,10,17.226905797598,0.970001220703125,0.650001525878906,1,0.537666320800774,1,3.73,1.08,"Pandemic",1,4
2021-11-01,44.1399993896484,44.2900009155273,43.439998626709,43.6399993896484,41.899528503418,32681500,NA,NA,NA,NA,NA,NA,NA,2.4,2021,11,17.3023197571339,0.850002288818359,-0.5,0,-0.0960121154785085,0,NA,NA,NA,1,NA
2021-11-02,45.0800018310547,46.0400009155273,43.0499992370605,45.4500007629395,43.6373405456543,69248000,1017,358,0.479272726924165,0.247792394981475,"Finance","PFIZER REPORTS THIRD-QUARTER 2021 RESULTS","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-reports-third-quarter-2021-results",3,2021,11,18.0532048361891,2.9900016784668,0.369998931884766,1,1.73781204223633,1,10.17,3.58,"Finance",1,3
2021-11-03,45.5200004577637,45.9900016784668,44.4799995422363,44.8199996948242,43.032470703125,44593100,NA,NA,NA,NA,NA,NA,NA,3.4,2021,11,17.6130897189265,1.51000213623047,-0.700000762939453,0,-0.604869842529297,0,NA,NA,NA,1,NA
2021-11-04,44.2900009155273,44.4700012207031,43.310001373291,43.8499984741211,42.4707069396973,38172500,NA,NA,NA,NA,NA,NA,NA,3.4,2021,11,17.4576259452367,1.15999984741211,-0.44000244140625,0,-0.561763763427734,0,NA,NA,NA,1,NA
2021-11-05,48.0900001525879,48.810001373291,46.5499992370605,48.6100006103516,47.0809860229492,173959100,279,100,0.472295513265711,0.306882590844629,"Research","Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study","https://www.pfizer.com//news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate",5.4,2021,11,18.9743307778257,2.26000213623047,0.520000457763672,1,4.61027908325195,1,2.79,1,"Research",1,2
2021-11-08,48.6100006103516,48.7900009155273,47.5999984741211,48.3300018310547,46.8097915649414,57423300,87,14,0.722772270071562,0.335548171642697,"Employees","Meet the People of PGS: Daniela","https://www.pfizer.com//news/announcements/meet-people-pgs-daniela",3.8,2021,11,17.8659607196847,1.19000244140625,-0.279998779296875,0,-0.271194458007812,1,0.87,0.14,"Management",1,1
2021-11-09,48.3300018310547,48.3800010681152,47.1500015258789,47.2999992370605,45.8121910095215,29920400,371,100,0.575371548672247,0.248942917415992,"COVID-19","Pfizer and BioNTech Submit Request to Amend U.S. FDA Emergency Use Authorization of Their COVID-19 Vaccine Booster to Include All Individuals 18 and Older","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-submit-request-amend-us-fda-emergency",4,2021,11,17.2140511133872,1.22999954223633,-1.03000259399414,0,-0.997600555419915,1,3.71,1,"Pandemic",1,4
2021-11-10,47.4000015258789,49.2099990844727,47.4000015258789,49.0200004577637,47.4780883789062,42696200,89,9,0.816326522282382,0.262032084860877,"Finance","Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-8",3.4,2021,11,17.5696205046858,1.80999755859375,1.61999893188477,1,1.66589736938476,1,0.89,0.09,"Finance",1,3
2021-11-11,49.2299995422363,50.5,48.7299995422363,50.1800003051758,48.6016006469727,42370400,411,101,0.605468748817444,0.256770310804027,"Partnerships","Zipline, Pfizer and BioNTech Collaboration Paves the Way for Automated, On-Demand Delivery of First mRNA COVID-19 Vaccines in Ghana","https://www.pfizer.com//news/press-release/press-release-detail/zipline-pfizer-and-biontech-collaboration-paves-way",3.2,2021,11,17.5619605868015,1.77000045776367,0.950000762939453,1,1.12351226806641,1,4.11,1.01,"Management",1,1
2021-11-12,50.4199981689453,50.4900016784668,49.5699996948242,49.7299995422363,48.1657524108887,27780600,NA,NA,NA,NA,NA,NA,NA,3.2,2021,11,17.1398485293257,0.920001983642578,-0.689998626708984,0,-0.435848236083984,0,NA,NA,NA,1,NA
2021-11-15,49.7299995422363,50.0999984741211,49.3699989318848,49.6500015258789,48.0882682800293,27763200,NA,NA,NA,NA,NA,NA,NA,3.04,2021,11,17.1392219967535,0.729999542236328,-0.0799980163574219,0,-0.077484130859375,0,NA,NA,NA,1,NA
2021-11-16,49.4700012207031,50.1599998474121,48.8899993896484,49.5999984741211,48.0398445129395,31297200,303,73,0.611702126032707,0.297468354195041,"Medicines","Pfizer and The Medicines Patent Pool (MPP) Sign Licensing Agreement for COVID-19 Oral Antiviral Treatment Candidate to Expand Access in Low- and Middle-Income Countries","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-medicines-patent-pool-mpp-sign-licensing",3.23,2021,11,17.2590392265916,1.27000045776367,0.129997253417969,1,-0.0484237670898438,1,3.03,0.73,"Research",1,2
2021-11-17,49.939998626709,51.0900001525879,49.689998626709,50.8699989318848,49.2698936462402,36889800,151,36,0.614973258743459,0.285496182770235,"Finance","Pfizer Completes Acquisition of Trillium Therapeutics","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-completes-acquisition-trillium-therapeutics",3.42,2021,11,17.4234456751425,1.40000152587891,0.930000305175781,1,1.23004913330078,1,1.51,0.36,"Finance",1,3
2021-11-18,51.0999984741211,51.7099990844727,50.6100006103516,51.4099998474121,49.7929077148438,32872600,402,180,0.381443298313671,0.262162162044071,"Medicines","Pfizer’s XELJANZ® (tofacitinib) Receives Marketing Authorization in the European Union for the Treatment of Active Ankylosing Spondylitis","https://www.pfizer.com//news/press-release/press-release-detail/pfizers-xeljanzr-tofacitinib-receives-marketing",3.23,2021,11,17.3081500724155,1.09999847412109,0.310001373291016,1,0.523014068603516,1,4.02,1.8,"Research",1,2
2021-11-19,51.9599990844727,52.8400001525879,50.6800003051758,50.7999992370605,49.2020988464355,47966200,389,106,0.571717170562188,0.253976398022588,"COVID-19","Pfizer and BioNTech Receive Expanded U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster to Include Individuals 18 and Older","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-receive-expanded-us-fda-emergency-use",3.42,2021,11,17.6860071750117,2.15999984741211,-1.15999984741211,0,-0.590808868408203,1,3.89,1.06,"Pandemic",1,4
2021-11-22,50.9500007629395,51.4700012207031,50.3800010681152,51.2000007629395,49.5895118713379,27287900,390,104,0.578947367249094,0.261375661237367,"COVID-19","Follow-Up Data From Phase 3 Trial of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age","https://www.pfizer.com//news/press-release/press-release-detail/follow-data-phase-3-trial-pfizer-biontech-covid-19-vaccine",3,2021,11,17.1219539751057,1.09000015258789,0.25,1,0.387413024902344,1,3.9,1.04,"Pandemic",1,4
2021-11-23,50.5800018310547,51.4500007629395,50.2999992370605,51.0800018310547,49.4732933044434,24946200,82,9,0.802197793382442,0.218225419140946,"Medicines","Important Update on EpiPen® (epinephrine injection, USP) 0.3 mg  Auto-Injectors","https://www.pfizer.com//news/announcements/important-update-epipenr-epinephrine-injection-usp-03-mg-auto-injectors",3,2021,11,17.0322321040393,1.15000152587891,0.5,1,-0.116218566894531,1,0.82,0.09,"Research",1,2
2021-11-24,51.1800003051758,51.3300018310547,50.7099990844727,50.8899993896484,49.2892684936523,18556800,146,43,0.544973542090087,0.244501940175289,"Research","Pfizer Announces Topline Results from Phase 2b Trial of Vupanorsen in Statin-treated Participants with Dyslipidemia","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-topline-results-phase-2b-trial-vupanorsen",3,2021,11,16.7363469105529,0.620002746582031,-0.290000915527344,0,-0.184024810791016,1,1.46,0.43,"Research",1,2
2021-11-26,54.0400009155273,54.939998626709,53.25,54,52.3014450073242,66561300,NA,NA,NA,NA,NA,NA,NA,3.2,2021,11,18.0136339005602,1.68999862670898,-0.0400009155273438,0,3.01217651367188,0,NA,NA,NA,1,NA
2021-11-29,55.1500015258789,55.7000007629395,52.1100006103516,52.4000015258789,50.7517738342285,72660800,NA,NA,NA,NA,NA,NA,NA,3.61,2021,11,18.1013126086437,3.59000015258789,-2.75,0,-1.54967117309571,0,NA,NA,NA,1,NA
2021-11-30,52.310001373291,54.4599990844727,51.9099998474121,53.7299995422363,52.0399360656738,64598400,143,75,0.311926604073731,0.397085609477075,"Breaking News","Supporting Refugee Communities In Africa","https://www.pfizer.com//news/announcements/supporting-refugee-communities-africa",3.61,2021,11,17.9837002161245,2.54999923706055,1.41999816894531,1,1.28816223144532,1,1.43,0.75,"Breaking News",1,5
2021-12-01,52.4700012207031,55.1699981689453,51.8600006103516,54.6800003051758,52.9600563049316,59810400,NA,NA,NA,NA,NA,NA,NA,3.61,2021,12,17.9066901335627,3.30999755859375,2.20999908447266,1,0.920120239257812,0,NA,NA,NA,1,NA
2021-12-02,53.8199996948242,55.0800018310547,52.7700004577637,53.0400009155273,51.371639251709,46361700,205,67,0.507352939311202,0.297267759237959,"Research","AWS Helps Pfizer Accelerate Drug Development And Clinical Manufacturing","https://www.pfizer.com//news/press-release/press-release-detail/aws-helps-pfizer-accelerate-drug-development-and-clinical",3.42,2021,12,17.6519842668758,2.31000137329102,-0.779998779296875,0,-1.58841705322266,1,2.05,0.67,"Research",1,2
2021-12-03,53.7099990844727,54.4099998474121,53.0999984741211,54.2700004577637,52.5629539489746,37574800,376,176,0.362318839923335,0.250340135940889,"Medicines","FDA Issues Update to XELJANZ® Prescribing Information in the United States","https://www.pfizer.com//news/announcements/fda-issues-update-xeljanzr-prescribing-information-united-states",3.42,2021,12,17.4418441975148,1.31000137329102,0.560001373291016,1,1.19131469726562,1,3.76,1.76,"Research",1,2
2021-12-06,53.7799987792969,53.8899993896484,51.25,51.4799995422363,49.860710144043,53724000,NA,NA,NA,NA,NA,NA,NA,3.3,2021,12,17.7993704056248,2.63999938964844,-2.29999923706055,0,-2.70224380493164,0,NA,NA,NA,1,NA
2021-12-07,51.25,52.5,50.4000015258789,51.7200012207031,50.0931625366211,41575400,87,12,0.757575749923477,0.267567566844412,"COVID-19","Pfizer Invites Public to Register for Webcast of Analyst and Investor Call to Discuss Pfizer-BioNTech COVID-19 Vaccine and Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-register-webcast-analyst-and-0",3.3,2021,12,17.5430192282162,2.09999847412109,0.470001220703125,1,0.232452392578125,1,0.87,0.12,"Pandemic",1,4
2021-12-08,52.75,53.0800018310547,51.0299987792969,51.4000015258789,49.7832298278809,37429200,414,122,0.544776118386612,0.245196706200733,"Vaccines","Pfizer and BioNTech Provide Update on Omicron Variant","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-provide-update-omicron-variant",4.62,2021,12,17.4379617331393,2.05000305175781,-1.34999847412109,0,-0.309932708740234,1,4.14,1.22,"Pandemic",1,4
2021-12-09,51.5099983215332,52.8499984741211,51.5099983215332,52.0800018310547,50.441837310791,38325700,406,112,0.567567566471877,0.255298176315772,"COVID-19","Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and Older","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-receive-us-fda-emergency-use",4.18,2021,12,17.4616312734877,1.34000015258789,0.570003509521484,1,0.658607482910156,1,4.06,1.12,"Pandemic",1,4
2021-12-10,51.2000007629395,52.8499984741211,51.1100006103516,52.7799987792969,51.119815826416,26079400,317,144,0.375271148860583,0.251226157901239,"Research","Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer","https://www.pfizer.com//news/press-release/press-release-detail/arvinas-and-pfizer-announce-protacr-protein-degrader-arv",3.74,2021,12,17.0766563269676,1.73999786376953,1.57999801635742,1,0.677978515625,1,3.17,1.44,"Research",1,2
2021-12-13,53.439998626709,55.7299995422363,53.439998626709,55.2000007629395,53.463695526123,54923200,278,62,0.635294115778547,0.278688524361731,"Finance","Pfizer to Acquire Arena Pharmaceuticals","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-acquire-arena-pharmaceuticals",3.57,2021,12,17.8214464219434,2.29000091552734,1.76000213623047,1,2.34387969970703,1,2.78,0.62,"Finance",1,3
2021-12-14,54.7700004577637,55.9500007629395,54.3199996948242,55.5400009155273,53.7930068969727,48685700,420,188,0.381578946740824,0.262862083760111,"Medicines","U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Ankylosing Spondylitis","https://www.pfizer.com//news/press-release/press-release-detail/us-fda-approves-pfizers-xeljanzr-tofacitinib-treatment-0",4.41,2021,12,17.7008959309768,1.63000106811523,0.770000457763672,1,0.329311370849609,1,4.2,1.88,"Research",1,2
2021-12-15,56.1100006103516,58.9199981689453,55.8899993896484,58.7999992370605,56.9504585266113,75202900,100,15,0.739130428355388,0.216981131666073,"Research","Pfizer Invests $68.5 Million in New State-of-the-Art Facility in Durham, North Carolina to Further Advance Gene Therapy Capabilities","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invests-685-million-new-state-art-facility-durham",4.2,2021,12,18.1357003653036,3.02999877929688,2.68999862670898,1,3.15745162963867,1,1,0.15,"Research",1,2
2021-12-16,58.3600006103516,61.4300003051758,57.75,61.25,59.3233947753906,75183600,363,97,0.578260868308129,0.258572231445434,"COVID-19","Pfizer and BioNTech Submit Supplemental Biologics License Application for U.S. FDA Approval of COMIRNATY® in Adolescents 12 Through 15 Years of Age","https://www.pfizer.com//news/announcements/pfizer-and-biontech-submit-supplemental-biologics-license-application-us-fda",4.2,2021,12,18.1354436933304,3.68000030517578,2.88999938964844,1,2.3729362487793,1,3.63,0.97,"Pandemic",1,4
2021-12-17,59.9300003051758,61.189998626709,58.7000007629395,59.4799995422363,57.6090698242188,104192100,370,109,0.54488517631548,0.254516471703232,"Partnerships","Pfizer and BioNTech Provide Update on Ongoing Studies of COVID-19 Vaccine","https://www.pfizer.com//news/announcements/pfizer-and-biontech-provide-update-ongoing-studies-covid-19-vaccine",4.2,2021,12,18.4617468782681,2.48999786376953,-0.450000762939453,0,-1.71432495117188,1,3.7,1.09,"Management",1,1
2021-12-20,60.5999984741211,61.7099990844727,59.8300018310547,61.0200004577637,59.1006317138672,55712200,374,96,0.59148936044364,0.256410256270371,"Partnerships","Pfizer and BioNTech to Provide European Union More Than 200 Million Additional Doses of COMIRNATY® to Help Meet Continued Need for Vaccine Supply","https://www.pfizer.com//news/announcements/pfizer-and-biontech-provide-european-union-more-200-million-additional-doses",3.74,2021,12,17.8357097293839,1.87999725341797,0.420001983642578,1,1.49156188964844,1,3.74,0.96,"Management",1,1
2021-12-21,60.0099983215332,60.0400009155273,57.1599998474121,58.9500007629395,57.0957412719727,63877900,NA,NA,NA,NA,NA,NA,NA,3.74,2021,12,17.9724840222866,2.88000106811523,-1.05999755859375,0,-2.00489044189453,0,NA,NA,NA,1,NA
2021-12-22,59.25,60.5900001525879,58.2200012207031,59.5499992370605,57.6768684387207,62594900,519,199,0.445682450632754,0.287545053949722,"COVID-19","Pfizer Receives U.S. FDA Emergency Use Authorization for Novel COVID-19 Oral Antiviral Treatment","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-receives-us-fda-emergency-use-authorization-novel",3.74,2021,12,17.9521943790787,2.36999893188477,0.299999237060547,1,0.581127166748047,1,5.19,1.99,"Pandemic",1,4
2021-12-23,59.8199996948242,60.0800018310547,58.310001373291,58.7099990844727,56.8632926940918,39203200,NA,NA,NA,NA,NA,NA,NA,3.57,2021,12,17.4842689595901,1.77000045776367,-1.11000061035156,0,-0.813575744628906,0,NA,NA,NA,1,NA
2021-12-27,58.8499984741211,59.3800010681152,58.2299995422363,59.2000007629395,57.3378791809082,27362600,NA,NA,NA,NA,NA,NA,NA,5.4,2021,12,17.1246877119896,1.15000152587891,0.350002288818359,1,0.474586486816406,0,NA,NA,NA,1,NA
2021-12-28,59.0499992370605,59.4500007629395,57.0800018310547,58.0099983215332,56.1853103637695,36901700,89,10,0.797979789919396,0.278089886859298,"Finance","Pfizer Invites Public to View and Listen to Webcast of February 8 Conference Call with Analysts","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-february-8",6.48,2021,12,17.4237682055093,2.36999893188477,-1.04000091552734,0,-1.15256881713867,1,0.89,0.1,"Finance",1,3
2021-12-29,57.310001373291,58.0299987792969,57.0699996948242,57.5800018310547,55.7688369750977,26170200,NA,NA,NA,NA,NA,NA,NA,6.48,2021,12,17.0801319550271,0.959999084472656,0.270000457763672,1,-0.416473388671875,0,NA,NA,NA,1,NA
2021-12-30,57.75,58.7400016784668,57.5299987792969,58.4000015258789,56.5630416870117,24559000,85,9,0.808510629696695,0.277286134875262,"Finance","Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-9",5.76,2021,12,17.0165889845202,1.21000289916992,0.650001525878906,1,0.794204711914062,1,0.85,0.09,"Finance",1,3
2021-12-31,58.5299987792969,59.7999992370605,58.439998626709,59.0499992370605,57.1925926208496,28579600,NA,NA,NA,NA,NA,NA,NA,3.96,2021,12,17.1682037695568,1.36000061035156,0.520000457763672,1,0.629550933837891,0,NA,NA,NA,1,NA
2022-01-03,58.5,58.5499992370605,56.3400001525879,56.6500015258789,54.8680877685547,57219200,429,109,0.594795537927889,0.262311067643924,"COVID-19","Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 12 Years of Age and Older","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-receive-us-fda-emergency-use-0",7.48,2022,1,17.8624000818397,2.20999908447266,-1.84999847412109,0,-2.32450485229492,1,4.29,1.09,"Pandemic",0,4
2022-01-04,56.2200012207031,56.4300003051758,53.939998626709,54.5299987792969,52.8147735595703,66993100,407,127,0.524344568306471,0.272171253683909,"COVID-19","Pfizer to Provide U.S. Government with an Additional 10 Million Treatment Courses of its Oral Therapy to Help Combat COVID-19","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-provide-us-government-additional-10-million",12.58,2022,1,18.0201002019042,2.4900016784668,-1.69000244140625,0,-2.05331420898438,1,4.07,1.27,"Pandemic",0,4
2022-01-05,55.8400001525879,56.439998626709,55.3699989318848,55.6300010681152,53.8801765441895,52956400,264,67,0.595166161343909,0.272652388572774,"Partnerships","Biohaven and Pfizer Complete Collaboration Transaction for Commercialization of Rimegepant and Zavegepant Outside United States","https://www.pfizer.com//news/press-release/press-release-detail/biohaven-and-pfizer-complete-collaboration-transaction",7.82,2022,1,17.7849795103352,1.06999969482422,-0.209999084472656,0,1.06540298461914,1,2.64,0.67,"Management",0,1
2022-01-06,55.1599998474121,55.6300010681152,54.4900016784668,54.8400001525879,53.1150207519531,37000400,NA,NA,NA,NA,NA,NA,NA,7.48,2022,1,17.4264393083876,1.13999938964844,-0.319999694824219,0,-0.765155792236328,0,NA,NA,NA,0,NA
2022-01-07,55.3600006103516,55.7700004577637,54.6300010681152,55.7200012207031,53.9673385620117,27703400,NA,NA,NA,NA,NA,NA,NA,9.18,2022,1,17.1370657434041,1.13999938964844,0.360000610351562,1,0.852317810058594,0,NA,NA,NA,0,NA
2022-01-10,55.7099990844727,56.2599983215332,54.7400016784668,56.2400016784668,54.4709892272949,34044700,243,57,0.619999997933333,0.288461538184172,"Partnerships","Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-beam-enter-exclusive-multi-target-research",6.48,2022,1,17.3431849543669,1.51999664306641,0.530002593994141,1,0.503650665283203,1,2.43,0.57,"Management",0,1
2022-01-11,56.75,57.4300003051758,55.810001373291,56.689998626709,54.9068298339844,33576600,NA,NA,NA,NA,NA,NA,NA,7.02,2022,1,17.3293399835256,1.61999893188477,-0.0600013732910156,0,0.435840606689453,0,NA,NA,NA,0,NA
2022-01-12,56.3400001525879,57.1599998474121,55.9000015258789,56.6500015258789,54.8680877685547,27608500,363,94,0.588621442913301,0.234599589201951,"COVID-19","Positive Top-Line Results of Pfizer’s Phase 3 Study Exploring Coadministration of PREVNAR 20™ With Pfizer-BioNTech COVID-19 Vaccine in Older Adults Released","https://www.pfizer.com//news/press-release/press-release-detail/positive-top-line-results-pfizers-phase-3-study-exploring-0",7.83,2022,1,17.1336342905093,1.2599983215332,0.310001373291016,1,-0.0387420654296875,1,3.63,0.94,"Pandemic",0,4
2022-01-13,56.5299987792969,56.75,55.2200012207031,55.5400009155273,53.7930068969727,28117900,NA,NA,NA,NA,NA,NA,NA,5.94,2022,1,17.1519169777395,1.52999877929688,-0.989997863769531,0,-1.07508087158203,0,NA,NA,NA,0,NA
2022-01-14,54.9799995422363,55.3800010681152,54.5099983215332,54.9500007629395,53.221565246582,27072500,374,141,0.45242718358752,0.267393561647252,"Medicines","U.S. FDA Approves Pfizer’s CIBINQO® (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis","https://www.pfizer.com//news/press-release/press-release-detail/us-fda-approves-pfizers-cibinqor-abrocitinib-adults",4.86,2022,1,17.1140290474225,0.870002746582031,-0.029998779296875,0,-0.571441650390625,1,3.74,1.41,"Research",0,2
2022-01-18,54.5,54.5499992370605,53.4300003051758,54.1100006103516,52.4079818725586,35598000,422,141,0.499111899646338,0.263084112026596,"COVID-19","Pfizer Shares In Vitro Efficacy of Novel COVID-19 Oral Treatment Against Omicron Variant","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-shares-vitro-efficacy-novel-covid-19-oral-treatment",3.74,2022,1,17.3878000425603,1.11999893188477,-0.389999389648438,0,-0.813583374023438,1,4.22,1.41,"Pandemic",0,4
2022-01-19,53.6500015258789,54.4900016784668,53.4500007629395,53.5400009155273,51.8559150695801,27300400,NA,NA,NA,NA,NA,NA,NA,3.96,2022,1,17.122411948692,1.04000091552734,-0.110000610351562,0,-0.552066802978516,0,NA,NA,NA,0,NA
2022-01-20,53.9599990844727,54.5200004577637,53.0699996948242,54.0499992370605,52.3498687744141,35105300,NA,NA,NA,NA,NA,NA,NA,4.18,2022,1,17.3738627026739,1.45000076293945,0.0900001525878906,1,0.493953704833984,0,NA,NA,NA,0,NA
2022-01-21,54.4199981689453,54.8699989318848,52.4599990844727,52.7900009155273,51.1295013427734,41059000,183,59,0.512396692097534,0.285377358154036,"Medicines","Pfizer and OPKO Provide Update on the Biologics License Application for Somatrogon for Pediatric Growth Hormone Deficiency","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-opko-provide-update-biologics-license",3.52,2022,1,17.5305206390107,2.40999984741211,-1.62999725341797,0,-1.22036743164062,1,1.83,0.59,"Research",0,2
2022-01-24,51.75,52.060001373291,49.8199996948242,51.5400009155273,49.9188232421875,59036400,378,124,0.505976094609609,0.241811175220708,"COVID-19","Pfizer and BioNTech Publish Data from Two Laboratory Studies on COVID-19 Vaccine-induced Antibodies Ability to Neutralize SARS-CoV-2 Omicron Variant","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-publish-data-two-laboratory-studies",2.16,2022,1,17.8936647777264,2.2400016784668,-0.209999084472656,0,-1.21067810058594,1,3.78,1.24,"Pandemic",0,4
2022-01-25,51.3600006103516,52.8400001525879,51.2400016784668,52.5400009155273,50.8873672485351,43983200,367,114,0.525987524893997,0.254766949017602,"COVID-19","Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-initiate-study-evaluate-omicron-based",2.52,2022,1,17.5993183235255,1.59999847412109,1.18000030517578,1,0.968544006347649,1,3.67,1.14,"Pandemic",0,4
2022-01-26,52.5699996948242,53.6199989318848,52.4599990844727,53.0099983215332,51.3425788879395,39644800,NA,NA,NA,NA,NA,NA,NA,2.34,2022,1,17.4954703751275,1.15999984741211,0.439998626708984,1,0.455211639404304,0,NA,NA,NA,0,NA
2022-01-27,53.0200004577637,54.5800018310547,53,53.3699989318848,52.0842742919922,36957200,468,176,0.453416148364261,0.288272157435867,"COVID-19","Pfizer Receives CHMP Positive Opinion for Novel COVID-19 Oral Treatment","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-receives-chmp-positive-opinion-novel-covid-19-oral",2.52,2022,1,17.4252710713506,1.58000183105469,0.349998474121094,1,0.741695404052734,1,4.68,1.76,"Pandemic",0,4
2022-01-28,53.7700004577637,54.6699981689453,53.0999984741211,54.3300018310547,53.0211486816406,28590400,307,116,0.451536641958542,0.268060836332027,"Medicines","European Commission Approves LORVIQUA® (lorlatinib) as a First-Line Treatment for ALK-Positive Advanced Lung Cancer","https://www.pfizer.com//news/press-release/press-release-detail/european-commission-approves-lorviquar-lorlatinib-first",2.52,2022,1,17.1685815900833,1.56999969482422,0.560001373291016,1,0.936874389648438,1,3.07,1.16,"Research",0,2
2022-01-31,54,54.1399993896484,52.3899993896484,52.689998626709,51.4206581115723,38644600,164,32,0.673469384319034,0.251604620986387,"Partnerships","Pfizer and Ionis Announce Discontinuation of Vupanorsen Clinical Development Program","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-ionis-announce-discontinuation-vupanorsen",2.04,2022,1,17.4699176337189,1.75,-1.31000137329102,0,-1.60049057006836,1,1.64,0.32,"Management",0,1
2022-02-01,52.7400016784668,53.1599998474121,52.3899993896484,53.0699996948242,51.79150390625,27883300,447,125,0.562937061952907,0.252650176566851,"COVID-19","Pfizer and BioNTech Initiate Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age Following Request From U.S. FDA","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-initiate-rolling-submission-emergency",2.38,2022,2,17.1435385371348,0.770000457763672,0.329998016357422,1,0.370845794677734,1,4.47,1.25,"Pandemic",0,4
2022-02-02,52.8400001525879,54.1300010681152,52.4500007629395,53.8600006103516,52.5624732971191,32039300,NA,NA,NA,NA,NA,NA,NA,2.21,2022,2,17.282473863447,1.68000030517578,1.02000045776367,1,0.770969390869141,0,NA,NA,NA,0,NA
2022-02-03,53.3300018310547,53.8899993896484,53.0900001525879,53.3800010681152,52.0940361022949,22635800,NA,NA,NA,NA,NA,NA,NA,2.04,2022,2,16.9350433259,0.799999237060547,0.0499992370605469,1,-0.468437194824219,0,NA,NA,NA,0,NA
2022-02-04,53.0200004577637,53.4300003051758,52.6300010681152,53,51.7231864929199,24932200,212,81,0.44709897458328,0.2534602073932,"Research","Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate","https://www.pfizer.com//news/press-release/press-release-detail/valneva-and-pfizer-report-further-positive-phase-2-data",1.87,2022,2,17.0316707388068,0.799999237060547,-0.0200004577636719,0,-0.370849609375,1,2.12,0.81,"Research",0,2
2022-02-07,53.2999992370605,53.5800018310547,52.2400016784668,53.2099990844727,51.9281311035156,32358500,NA,NA,NA,NA,NA,NA,NA,1.54,2022,2,17.2923873264611,1.34000015258789,-0.0900001525878906,0,0.204944610595703,0,NA,NA,NA,0,NA
2022-02-08,50.6399993896484,51.7999992370605,49.689998626709,51.7000007629395,50.4545097351074,67922000,51,26,0.324675320458762,0.318181816867017,"Government","Reasons to Reject the Dangerous Medicare Pricing Proposal","https://www.pfizer.com//news/announcements/reasons-reject-dangerous-medicare-pricing-proposal",1.68,2022,2,18.0338705606641,2.11000061035156,1.06000137329102,1,-1.4736213684082,1,0.51,0.26,"Management",0,1
2022-02-09,51.6399993896484,51.7200012207031,50.9000015258789,51.4700012207031,50.2300491333008,38522200,88,9,0.814432981294505,0.266483515751419,"Finance","Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-11",1.54,2022,2,17.4667452824103,0.819999694824219,-0.169998168945312,0,-0.224460601806641,1,0.88,0.09,"Finance",0,3
2022-02-10,51.0400009155273,51.3699989318848,50.3899993896484,50.5999984741211,49.3810043334961,34200600,95,18,0.68141592317331,0.317415729445461,"Hiring & Recruitment","How Pfizer is fostering meaningful growth for every colleague, everywhere","https://www.pfizer.com//news/announcements/how-pfizer-fostering-meaningful-growth-every-colleague-everywhere",1.26,2022,2,17.3477537749778,0.979999542236328,-0.44000244140625,0,-0.849044799804688,1,0.95,0.18,"Management",0,1
2022-02-11,50.3300018310547,51.2400016784668,50.0800018310547,50.7799987792969,49.5566711425781,34997800,407,120,0.54459202932715,0.254589371857686,"COVID-19","Pfizer and BioNTech Provide Update on Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-provide-update-rolling-submission",1.68,2022,2,17.3707957889085,1.15999984741211,0.449996948242188,1,0.175666809082031,1,4.07,1.2,"Pandemic",0,4
2022-02-14,49.8199996948242,50.5,48.4799995422363,49.7999992370605,48.6002807617188,42973100,251,89,0.47647058683391,0.276198212610724,"Research","Biohaven and Pfizer Announce Positive Top-Line Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea","https://www.pfizer.com//news/press-release/press-release-detail/biohaven-and-pfizer-announce-positive-top-line-results",0.9,2022,2,17.5760849197752,2.02000045776367,-0.0200004577636719,0,-0.956390380859375,1,2.51,0.89,"Research",0,2
2022-02-15,49.7999992370605,50.0400009155273,49.2099990844727,49.7900009155273,48.5905227661133,29150000,66,27,0.419354834200486,0.321799306844985,"Government","Reasons To Reject Massachusetts’ Misguided Drug Pricing Bill","https://www.pfizer.com//news/announcements/reasons-reject-massachusetts-misguided-drug-pricing-bill",0.9,2022,2,17.1879655050661,0.830001831054688,-0.00999832153320312,0,-0.00975799560546875,1,0.66,0.27,"Management",0,1
2022-02-16,49.5900001525879,50.7799987792969,49.4300003051758,49.6800003051758,48.4831695556641,27672600,NA,NA,NA,NA,NA,NA,NA,0.9,2022,2,17.1359533480681,1.34999847412109,0.0900001525878906,1,-0.107353210449219,0,NA,NA,NA,0,NA
2022-02-17,49.810001373291,49.9599990844727,48.75,48.9000015258789,47.7219619750977,21231700,NA,NA,NA,NA,NA,NA,NA,0.8,2022,2,16.871005952938,1.20999908447266,-0.909999847412109,0,-0.761207580566406,0,NA,NA,NA,0,NA
2022-02-18,48.7799987792969,49.5200004577637,48.2000007629395,48.5299987792969,47.3608779907227,26955300,NA,NA,NA,NA,NA,NA,NA,0.9,2022,2,17.109690533565,1.31999969482422,-0.25,0,-0.361083984375,0,NA,NA,NA,0,NA
2022-02-22,47.5400009155273,48.310001373291,47.3499984741211,47.5299987792969,46.3849639892578,34814800,158,24,0.736263732218331,0.295934958868398,"Partnerships","Pfizer Statement on Results of Third Annual Pay Equity Study Among Colleagues Worldwide","https://www.pfizer.com//news/announcements/pfizer-statement-results-third-annual-pay-equity-study-among-colleagues",1.04,2022,2,17.3655531704154,0.960002899169922,-0.0100021362304688,0,-0.975914001464844,1,1.58,0.24,"Management",0,1
2022-02-23,47.5900001525879,48.1599998474121,46.7799987792969,46.8699989318848,45.7408638000488,25793000,218,65,0.540636040492452,0.246945898562874,"Vaccines","CDC Advisory Committee on Immunization Practices Votes to Recommend TicoVac™, Pfizer’s Tick-Borne Encephalitis (TBE) Vaccine, For Those at Risk of Virus Exposure","https://www.pfizer.com//news/announcements/cdc-advisory-committee-immunization-practices-votes-recommend-ticovactm-pfizers",1.17,2022,2,17.0656137340193,1.38000106811523,-0.720001220703125,0,-0.644100189208984,1,2.18,0.65,"Pandemic",0,4
2022-02-24,45.8600006103516,46.7599983215332,45.4000015258789,45.9599990844727,44.8527908325195,44227300,393,99,0.597560974395201,0.2502543233722,"Partnerships","Pfizer and BioNTech Receive Positive CHMP Opinion for COVID-19 Vaccine Booster in Adolescents 12 through 17 Years of Age in the European Union","https://www.pfizer.com//news/announcements/pfizer-and-biontech-receive-positive-chmp-opinion-covid-19-vaccine-booster",1.04,2022,2,17.6048528260518,1.3599967956543,0.0999984741210938,1,-0.888072967529297,1,3.93,0.99,"Management",0,1
2022-02-25,45.810001373291,48.0299987792969,45.7400016784668,47.7200012207031,46.5703887939453,31199200,334,137,0.418259022466541,0.289489858457597,"Partnerships","FDA Accepts for Review Pfizer’s Supplemental Application for ABRILADA™ (adalimumab-afzb) InterchangeabilityFDA Accepts for Review Pfizer’s Supplemental Application for ABRILADA™ (adalimumab-afzb) Interchangeability","https://www.pfizer.com//news/announcements/fda-accepts-review-pfizers-supplemental-application-abriladatm-adalimumab-afzb",0.91,2022,2,17.2559030434774,2.28999710083008,1.90999984741211,1,1.71759796142578,1,3.34,1.37,"Management",0,1
2022-02-28,46.8199996948242,47.1699981689453,46.3400001525879,46.939998626709,45.8091773986816,35296100,90,10,0.799999992,0.27027026953981,"Finance","Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-3",0.91,2022,2,17.3792830625453,0.829998016357422,0.119998931884766,1,-0.761211395263672,1,0.9,0.1,"Finance",0,3
2022-03-01,46.689998626709,47.1399993896484,45.439998626709,45.75,44.6478462219238,29854500,NA,NA,NA,NA,NA,NA,NA,1.04,2022,3,17.2118461737053,1.70000076293945,-0.939998626708984,0,-1.16133117675781,0,NA,NA,NA,0,NA
2022-03-02,46.1100006103516,47.9300003051758,46,47.7000007629395,46.5508689880371,36516200,NA,NA,NA,NA,NA,NA,NA,1.43,2022,3,17.4132665830884,1.93000030517578,1.59000015258789,1,1.90302276611328,0,NA,NA,NA,0,NA
2022-03-03,47.6800003051758,48.5900001525879,47.4799995422363,47.8300018310547,46.6777381896973,30553300,NA,NA,NA,NA,NA,NA,NA,1.3,2022,3,17.2349832901178,1.11000061035156,0.150001525878906,1,0.126869201660156,0,NA,NA,NA,0,NA
2022-03-04,47.5,48.7700004577637,47.4099998474121,48.6500015258789,47.4779815673828,33217300,NA,NA,NA,NA,NA,NA,NA,1.3,2022,3,17.3185814126116,1.36000061035156,1.15000152587891,1,0.800243377685547,0,NA,NA,NA,0,NA
2022-03-07,48.25,48.8400001525879,47.5200004577637,47.9799995422363,46.8241233825684,33171300,NA,NA,NA,NA,NA,NA,NA,0.81,2022,3,17.3171956323428,1.31999969482422,-0.270000457763672,0,-0.653858184814453,0,NA,NA,NA,0,NA
2022-03-08,47.5800018310547,48.4199981689453,46.4700012207031,47.439998626709,46.2971343994141,32913300,87,9,0.812499991536458,0.258760107119245,"Finance","Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-4",0.9,2022,3,17.3093874197484,1.94999694824219,-0.140003204345703,0,-0.526988983154297,1,0.87,0.09,"Finance",0,3
2022-03-09,48.1300010681152,49.2200012207031,48,48.75,47.5755729675293,24718900,500,195,0.438848920231872,0.281947261548906,"Vaccines","Pfizer Initiates Phase 2/3 Study of Novel COVID-19 Oral Treatment in Pediatric Participants","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-initiates-phase-23-study-novel-covid-19-oral",0.72,2022,3,17.0230787316367,1.22000122070312,0.619998931884766,1,1.27843856811523,1,5,1.95,"Pandemic",0,4
2022-03-10,48.310001373291,49.2900009155273,48.0499992370605,49.2000007629395,48.0147323608398,24542300,NA,NA,NA,NA,NA,NA,NA,0.72,2022,3,17.0159087581325,1.2400016784668,0.889999389648438,1,0.43915939331054,0,NA,NA,NA,0,NA
2022-03-11,49.1399993896484,50.9000015258789,48.939998626709,50.2700004577637,49.0589561462402,33701900,159,40,0.597989946743769,0.286330934839812,"Financial","Pfizer Completes Acquisition of Arena Pharmaceuticals","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-completes-acquisition-arena-pharmaceuticals",0.81,2022,3,17.3330648032272,1.96000289916992,1.13000106811523,1,1.0442237854004,1,1.59,0.4,"Finance",0,3
2022-03-14,50.7200012207031,52.9099998474121,50.3899993896484,52.25,50.9912605285645,42314500,54,14,0.588235285467128,0.274193547281478,"Responsibility","Pfizer Updates Company Position in Russia","https://www.pfizer.com//news/announcements/pfizer-updates-company-position-russia",0.8,2022,3,17.5606403985082,2.52000045776367,1.52999877929688,1,1.93230438232422,1,0.54,0.14,"Management",0,1
2022-03-15,52.6199989318848,52.9199981689453,51.1800003051758,52.2099990844727,50.9522247314453,30172100,431,134,0.525663715883781,0.239305378975305,"COVID-19","Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of an Additional Booster Dose of their COVID-19 Vaccine for Older Adults","https://www.pfizer.com//news/announcements/pfizer-and-biontech-submit-us-emergency-use-authorization-additional-booster",0.8,2022,3,17.2224282474245,1.73999786376953,-0.409999847412109,0,-0.0390357971191406,1,4.31,1.34,"Pandemic",0,4
2022-03-16,52.5400009155273,53.2700004577637,52.1800003051758,52.9199981689453,51.6451148986816,29891400,NA,NA,NA,NA,NA,NA,NA,0.7,2022,3,17.2130814050252,1.09000015258789,0.379997253417969,1,0.692890167236328,0,NA,NA,NA,0,NA
2022-03-17,52.9199981689453,54.25,52.7900009155273,54.2400016784668,52.9333190917969,30598600,NA,NA,NA,NA,NA,NA,NA,0.6,2022,3,17.2364648469232,1.45999908447266,1.32000350952148,1,1.28820419311523,0,NA,NA,NA,0,NA
2022-03-18,54.3800010681152,55,53.7099990844727,54.5099983215332,53.1968078613281,51815000,NA,NA,NA,NA,NA,NA,NA,0.7,2022,3,17.7631902598999,1.29000091552734,0.129997253417969,1,0.26348876953125,0,NA,NA,NA,0,NA
2022-03-21,54.2400016784668,55.2999992370605,53.9000015258789,54.189998626709,52.884521484375,34592500,111,19,0.707692302248521,0.234234233812191,"Medicines","Pfizer Voluntary Nationwide Recall of Lots of ACCURETIC™ (quinapril HCl/hydrochlorothiazide), quinapril and hydrochlorothiazide Tablets, and quinapril HCl/hydrochlorothiazide Tablets Due to N-Nitroso- Quinapril Content","https://www.pfizer.com//news/announcements/pfizer-voluntary-nationwide-recall-lots-accuretictm-quinapril",0.6,2022,3,17.3591474824337,1.39999771118164,-0.0500030517578125,0,-0.312286376953125,1,1.11,0.19,"Research",0,2
2022-03-22,54.2000007629395,54.3199996948242,52.5,53.0400009155273,51.7622299194336,32253600,398,124,0.524904213553823,0.275898519938743,"COVID-19","Pfizer to Supply UNICEF up to 4 Million Treatment Courses of Novel COVID-19 Oral Treatment for Low- and Middle-Income Countries","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-supply-unicef-4-million-treatment-courses-novel",0.7,2022,3,17.2891402538874,1.81999969482422,-1.15999984741211,0,-1.12229156494141,1,3.98,1.24,"Pandemic",0,4
2022-03-23,53.0200004577637,53.5,52.1599998474121,52.189998626709,50.9327011108398,29183700,168,59,0.480176209338431,0.283749999645313,"Medicines","Pfizer Announces Positive Top-Line Results for Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-phase-3-trial",0.9,2022,3,17.1891209264638,1.34000015258789,-0.830001831054688,0,-0.829528808593757,1,1.68,0.59,"Research",0,2
2022-03-24,52.5400009155273,52.8499984741211,52.2900009155273,52.5900001525879,51.3230667114258,25177500,176,50,0.557522121426893,0.255079006484109,"Vaccines","Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV in Older Adults","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-granted-fda-breakthrough-therapy-designation-0",0.8,2022,3,17.0414613362224,0.55999755859375,0.0499992370605469,1,0.390365600585945,1,1.76,0.5,"Pandemic",0,4
2022-03-25,52.7400016784668,53.25,52.5099983215332,52.7799987792969,51.5084915161133,17429600,NA,NA,NA,NA,NA,NA,NA,0.6,2022,3,16.6736805256679,0.740001678466797,0.0399971008300781,1,0.1854248046875,0,NA,NA,NA,0,NA
2022-03-28,52.5299987792969,53.560001373291,52.5,53.2799987792969,51.9964447021484,21863700,NA,NA,NA,NA,NA,NA,NA,0.48,2022,3,16.9003383310483,1.06000137329102,0.75,1,0.487953186035156,0,NA,NA,NA,0,NA
2022-03-29,54,54.0800018310547,52.6199989318848,52.7400016784668,51.4694557189941,39970000,442,114,0.589928056492935,0.238729068167141,"COVID-19","Pfizer and BioNTech Receive Expanded U.S. Emergency Use Authorization for an Additional COVID-19 Vaccine Booster in Individuals Aged 50 Years and Older","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-receive-expanded-us-emergency-use",0.56,2022,3,17.5036397557063,1.46000289916992,-1.2599983215332,0,-0.526988983154297,1,4.42,1.14,"Pandemic",0,4
2022-03-30,53.2000007629395,53.7200012207031,51.9700012207031,52.439998626709,51.1766777038574,27599600,NA,NA,NA,NA,NA,NA,NA,0.72,2022,3,17.1333118740611,1.75,-0.760002136230469,0,-0.292778015136719,0,NA,NA,NA,0,NA
2022-03-31,52,52.8800010681152,51.7400016784668,51.7700004577637,50.5228233337402,26055200,NA,NA,NA,NA,NA,NA,NA,0.64,2022,3,17.0757279607459,1.13999938964844,-0.229999542236328,0,-0.653854370117188,0,NA,NA,NA,0,NA
2022-04-01,52.1199989318848,52.1599998474121,51.0999984741211,51.5699996948242,50.3276405334473,19073100,NA,NA,NA,NA,NA,NA,NA,0.48,2022,4,16.7637895757884,1.06000137329102,-0.549999237060547,0,-0.195182800292969,0,NA,NA,NA,0,NA
2022-04-04,51.7799987792969,51.8699989318848,50.3699989318848,50.939998626709,49.7128143310547,20462800,NA,NA,NA,NA,NA,NA,NA,0.3,2022,4,16.8341192103884,1.5,-0.840000152587891,0,-0.614826202392578,0,NA,NA,NA,0,NA
2022-04-05,50.810001373291,52.1500015258789,50.75,51.2400016784668,50.0055885314941,21176700,NA,NA,NA,NA,NA,NA,NA,0.3,2022,4,16.8684121258546,1.40000152587891,0.430000305175781,1,0.292774200439453,0,NA,NA,NA,0,NA
2022-04-06,51.1599998474121,53.0900001525879,51.1599998474121,52.8699989318848,51.5963172912598,31717500,NA,NA,NA,NA,NA,NA,NA,0.36,2022,4,17.2723791685252,1.93000030517578,1.70999908447266,1,1.59072875976562,0,NA,NA,NA,0,NA
2022-04-07,52.5,55.4099998474121,52.5,55.1599998474121,53.8311538696289,36305700,228,59,0.588850172164285,0.277294685722421,"Investments","Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-acquire-reviral-and-its-respiratory-syncytial-virus",0.36,2022,4,17.4074853392452,2.90999984741211,2.65999984741211,1,2.23483657836914,1,2.28,0.59,"Finance",0,3
2022-04-08,54.8499984741211,55.5800018310547,54.4599990844727,55.1699981689453,53.8409118652344,24612200,300,108,0.470588234140715,0.24832623235038,"Medicines","Three Year Follow-Up Data from Phase 3 CROWN Trial of Pfizer’s LORBRENA® (lorlatinib) Confirm Prolonged Progression-Free Survival in First-Line ALK-Positive Advanced Lung Cancer","https://www.pfizer.com//news/announcements/three-year-follow-data-phase-3-crown-trial-pfizers-lorbrenar-lorlatinib-confirm",0.3,2022,4,17.0187528535571,1.12000274658203,0.319999694824219,1,0.00975799560546875,1,3,1.08,"Research",0,2
2022-04-11,55.4599990844727,56.3199996948242,53.7799987792969,53.9300003051758,52.6307830810547,22054300,135,25,0.687499995703125,0.280701753893506,"Leadership","Pfizer Names David M. Denton Chief Financial Officer","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-names-david-m-denton-chief-financial-officer",0.3,2022,4,16.9090181975254,2.54000091552734,-1.52999877929688,0,-1.21012878417969,1,1.35,0.25,"Management",0,1
2022-04-12,53.2999992370605,53.9300003051758,52.6500015258789,53.1100006103516,51.8305397033691,22810700,305,106,0.484184913663784,0.259142496684021,"Medicines","Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated with Endometriosis","https://www.pfizer.com//news/press-release/press-release-detail/myovant-sciences-and-pfizer-provide-update-supplemental-new",0.3,2022,4,16.9427403259234,1.27999877929688,-0.189998626708984,0,-0.800243377685547,1,3.05,1.06,"Research",0,2
2022-04-13,53.1300010681152,53.8199996948242,52.7000007629395,53.0999984741211,51.8207778930664,15777800,NA,NA,NA,NA,NA,NA,NA,0.3,2022,4,16.5741145100592,1.11999893188477,-0.0300025939941406,0,-0.00976181030273438,0,NA,NA,NA,0,NA
2022-04-14,53.4000015258789,53.9099998474121,53.0400009155273,53.1199989318848,51.8402976989746,17240100,387,127,0.505836574891369,0.223965141514612,"COVID-19","Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of their COVID-19 Vaccine in Children 5 Through 11 Years of Age","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-data-demonstrating-high-immune",0.3,2022,4,16.6627486816513,0.869998931884766,-0.280002593994141,0,0.0195198059082031,1,3.87,1.27,"Pandemic",0,4
2022-04-18,52.8300018310547,53.1100006103516,51.6300010681152,51.8400001525879,50.591136932373,17065000,NA,NA,NA,NA,NA,NA,NA,0.3,2022,4,16.6525401989224,1.47999954223633,-0.990001678466797,0,-1.24916076660156,0,NA,NA,NA,0,NA
2022-04-19,51.6599998474121,51.8800010681152,49.3699989318848,50.1800003051758,48.9711265563965,33441500,121,15,0.779411758974914,0.2969432307927,"Finance","Pfizer Invites Shareholders to Attend Virtual-Only 2022 Annual Meeting of Shareholders on April 28","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-shareholders-attend-virtual-only-2022-annual",0.3,2022,4,17.325308231537,2.51000213623047,-1.47999954223633,0,-1.62001037597657,1,1.21,0.15,"Finance",0,3
2022-04-20,50,50.1599998474121,49.2099990844727,49.75,48.5514831542969,24751800,NA,NA,NA,NA,NA,NA,NA,0.3,2022,4,17.0244088120083,0.950000762939453,-0.25,0,-0.419643402099602,0,NA,NA,NA,0,NA
2022-04-21,49.9300003051758,50.0099983215332,48.9199981689453,49.1100006103516,47.9269027709961,19105600,NA,NA,NA,NA,NA,NA,NA,0.3,2022,4,16.7654920961019,1.09000015258789,-0.819999694824219,0,-0.624580383300781,0,NA,NA,NA,0,NA
2022-04-22,48.9500007629395,49.0999984741211,47.9000015258789,48.1300010681152,46.9705123901367,22156800,133,20,0.738562086676065,0.287054408467065,"Medicines","Pfizer Voluntary Nationwide Recall of Lots of ACCUPRIL® (Quinapril HCl) Due to N-Nitroso-Quinapril Content","https://www.pfizer.com//news/announcements/pfizer-voluntary-nationwide-recall-lots-accuprilr-quinapril-hcl-due-n-nitroso",0.24,2022,4,16.9136550502168,1.19999694824219,-0.819999694824219,0,-0.956390380859375,1,1.33,0.2,"Research",0,2
2022-04-25,47.8499984741211,49.189998626709,47.1199989318848,48.9500007629395,47.7707595825195,27390600,89,13,0.745098031910804,0.333333332244009,"Employees","Meet The People of PGS: Terrari","https://www.pfizer.com//news/announcements/meet-people-pgs-terrari",0.4,2022,4,17.1257104833132,2.06999969482422,1.10000228881836,1,0.800247192382812,1,0.89,0.13,"Management",0,1
2022-04-26,48.9900016784668,50.25,48.9199981689453,49.0299987792969,47.8488311767578,25366500,385,117,0.533864540769194,0.239275500362595,"COVID-19","Pfizer and BioNTech Submit Application for U.S. Emergency Use Authorization for a COVID-19 Vaccine Booster Dose in Children 5 Through 11 Years of Age","https://www.pfizer.com//news/announcements/pfizer-and-biontech-submit-application-us-emergency-use-authorization-covid-19",0.4,2022,4,17.0489400032621,1.33000183105469,0.0399971008300781,1,0.0780715942382812,1,3.85,1.17,"Pandemic",0,4
2022-04-27,49.1100006103516,49.9099998474121,48.2099990844727,49.7400016784668,48.5417251586914,25819200,201,64,0.5169811301246,0.264471057620288,"Medicines","Pfizer and Biohaven’s VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biohavens-vydurar-rimegepant-granted-first-ever",0.4,2022,4,17.0666289979001,1.70000076293945,0.630001068115234,1,0.692893981933594,1,2.01,0.64,"Research",0,2
2022-04-28,50.439998626709,50.7700004577637,49.4900016784668,50.5099983215332,49.2931709289551,28225400,199,59,0.54263565681149,0.278017241079723,"Research","Pfizer to Open First U.S. Sites in Phase 3 Trial of Investigational Gene Therapy for Ambulatory Patients with Duchenne Muscular Dystrophy","https://www.pfizer.com//news/announcements/pfizer-open-first-us-sites-phase-3-trial-investigational-gene-therapy-ambulatory",0.32,2022,4,17.1557328751621,1.27999877929688,0.0699996948242188,1,0.751445770263672,1,1.99,0.59,"Research",0,2
2022-04-29,49.8699989318848,50.3400001525879,49,49.0699996948242,47.8878631591797,28343300,369,123,0.49999999898374,0.278123233308014,"COVID-19","Pfizer Shares Top-Line Results from Phase 2/3 EPIC-PEP Study of PAXLOVID™ for Post-Exposure Prophylactic Use","https://www.pfizer.com//news/announcements/pfizer-shares-top-line-results-phase-23-epic-pep-study-paxlovidtm-post-exposure",0.32,2022,4,17.1599012639194,1.34000015258789,-0.799999237060547,0,-1.40530776977539,1,3.69,1.23,"Pandemic",0,4
2022-05-02,47.6800003051758,48.7599983215332,47.4599990844727,48.3400001525879,47.1754531860351,36228400,NA,NA,NA,NA,NA,NA,NA,0.28,2022,5,17.4053539272023,1.29999923706055,0.659999847412109,1,-0.712409973144538,0,NA,NA,NA,0,NA
2022-05-03,48.8699989318848,50.0400009155273,47.7000007629395,49.2900009155273,48.1025657653809,33716900,NA,NA,NA,NA,NA,NA,NA,0.35,2022,5,17.3335097829599,2.34000015258789,0.420001983642578,1,0.92711257934571,0,NA,NA,NA,0,NA
2022-05-04,48.8899993896484,49.8699989318848,47.9099998474121,49.6599998474121,48.4636535644531,28613700,251,90,0.472140761078766,0.260106788512504,"Medicines","Pfizer Presents Positive Real-World Evidence for First-Line IBRANCE® (palbociclib) Combination Therapy in HR+, HER2- Metastatic Breast Cancer at ESMO Breast Cancer 2022","https://www.pfizer.com//news/announcements/pfizer-presents-positive-real-world-evidence-first-line-ibrancer-palbociclib",0.42,2022,5,17.1693962170235,1.95999908447266,0.770000457763672,1,0.361087799072266,1,2.51,0.9,"Research",0,2
2022-05-05,49.4599990844727,49.5499992370605,47.5499992370605,48.4500007629395,47.2828063964844,28333000,NA,NA,NA,NA,NA,NA,NA,0.49,2022,5,17.1595377963059,2,-1.0099983215332,0,-1.18084716796875,0,NA,NA,NA,0,NA
2022-05-06,48.0900001525879,49.2200012207031,48.0400009155273,49.0400009155273,47.8585891723633,19891400,283,105,0.45876288541556,0.242803504228533,"Medicines","Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application (sNDA) for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis","https://www.pfizer.com//news/press-release/press-release-detail/myovant-sciences-and-pfizer-provide-update-supplemental-0",0.49,2022,5,16.8057980857553,1.18000030517578,0.950000762939453,1,0.575782775878906,1,2.83,1.05,"Research",0,2
2022-05-09,48.3800010681152,49.1699981689453,47.7700004577637,48.6399993896484,47.4682235717773,25012300,NA,NA,NA,NA,NA,NA,NA,0.3,2022,5,17.0348783018205,1.39999771118164,0.259998321533203,1,-0.390365600585938,0,NA,NA,NA,0,NA
2022-05-10,49.0400009155273,49.9000015258789,48.689998626709,49.4900016784668,48.2977523803711,27335900,349,85,0.608294929473975,0.243273542464533,"Investments","Pfizer to Acquire Biohaven Pharmaceuticals","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-acquire-biohaven-pharmaceuticals",0.36,2022,5,17.1237114511728,1.21000289916992,0.450000762939453,1,0.82952880859375,1,3.49,0.85,"Finance",0,3
2022-05-11,49.0699996948242,50.2400016784668,49.0299987792969,49.4500007629395,48.2587127685547,29699500,NA,NA,NA,NA,NA,NA,NA,0.36,2022,5,17.206640802285,1.21000289916992,0.380001068115234,1,-0.0390396118164062,0,NA,NA,NA,0,NA
2022-05-12,49,50.4300003051758,48.7200012207031,50.3899993896484,49.5770950317383,33468400,NA,NA,NA,NA,NA,NA,NA,0.3,2022,5,17.3261122979202,1.70999908447266,1.38999938964844,1,1.31838226318359,0,NA,NA,NA,0,NA
2022-05-13,50.3800010681152,50.7900009155273,49.6800003051758,49.9199981689453,49.1146774291992,22423700,390,103,0.582150100239046,0.250380903885027,"Vaccines","Pfizer and BioNTech Provide Update on COVID-19 Vaccine Supply Agreement with European Commission","https://www.pfizer.com//news/announcements/pfizer-and-biontech-provide-update-covid-19-vaccine-supply-agreement-european",0.3,2022,5,16.9256290378099,1.11000061035156,-0.460002899169922,0,-0.462417602539062,1,3.9,1.03,"Pandemic",0,4
2022-05-16,49.8699989318848,51.0499992370605,49.8699989318848,50.6699981689453,49.8525772094727,19435600,NA,NA,NA,NA,NA,NA,NA,0.2,2022,5,16.7826170453818,1.18000030517578,0.799999237060547,1,0.737899780273438,0,NA,NA,NA,0,NA
2022-05-17,50.9500007629395,51.5200004577637,50.1800003051758,51.3400001525879,50.5117683410645,19918200,392,115,0.546351083735008,0.232996323422336,"Vaccines","Pfizer and BioNTech Granted U.S. Emergency Use Authorization for Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-granted-us-emergency-use-authorization",0.25,2022,5,16.8071444947974,1.34000015258789,0.389999389648438,1,0.659191131591797,1,3.92,1.15,"Pandemic",0,4
2022-05-18,51.2200012207031,51.4199981689453,50.1599998474121,50.4000015258789,49.5869369506836,22276000,NA,NA,NA,NA,NA,NA,NA,0.25,2022,5,16.9190204685831,1.2599983215332,-0.819999694824219,0,-0.924831390380859,0,NA,NA,NA,0,NA
2022-05-19,50,50.8899993896484,49.5900001525879,50.6500015258789,49.8329010009766,19865500,NA,NA,NA,NA,NA,NA,NA,0.2,2022,5,16.8044951671494,1.29999923706055,0.650001525878906,1,0.245964050292969,0,NA,NA,NA,0,NA
2022-05-20,51.2700004577637,52.7000007629395,51.1300010681152,52.4700012207031,51.6235427856445,31250400,NA,NA,NA,NA,NA,NA,NA,0.2,2022,5,17.2575427660644,1.56999969482422,1.20000076293945,1,1.79064178466797,0,NA,NA,NA,0,NA
2022-05-23,52.5800018310547,53.7000007629395,52.4799995422363,52.8800010681152,52.026927947998,24035800,440,127,0.552028217721291,0.243243243138892,"Vaccines","Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-biontech-covid-19-vaccine-demonstrates-strong-immune",0.2,2022,5,16.9950549851539,1.22000122070312,0.299999237060547,1,0.403385162353516,1,4.4,1.27,"Pandemic",0,4
2022-05-24,52.7099990844727,53.6100006103516,52.7099990844727,53.4099998474121,52.5483741760254,26729800,NA,NA,NA,NA,NA,NA,NA,0.2,2022,5,17.1012896432688,0.900001525878906,0.700000762939453,1,0.521446228027344,0,NA,NA,NA,0,NA
2022-05-25,53.2000007629395,54.0499992370605,53.0499992370605,53.7099990844727,52.8435363769531,24003900,241,32,0.765567762763488,0.33252131506392,"Responsibility","Pfizer Launches ‘An Accord for a Healthier World’ to Improve Health Equity for 1.2 Billion People Living in 45 Lower-Income Countries","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-launches-accord-healthier-world-improve-health",0.2,2022,5,16.9937269167704,1,0.509998321533203,1,0.295162200927734,1,2.41,0.32,"Management",0,1
2022-05-26,54.060001373291,54.9199981689453,53.8800010681152,53.9900016784668,53.1190223693848,23516300,NA,NA,NA,NA,NA,NA,NA,0.2,2022,5,16.9732043982183,1.03999710083008,-0.0699996948242188,0,0.275485992431641,0,NA,NA,NA,0,NA
2022-05-27,53.9199981689453,54.4099998474121,53.5200004577637,53.9099998474121,53.0403099060059,21407500,NA,NA,NA,NA,NA,NA,NA,0.2,2022,5,16.8792519325951,0.889999389648438,-0.00999832153320312,0,-0.0787124633789062,0,NA,NA,NA,0,NA
2022-05-31,53.3199996948242,53.5,51.939998626709,53.0400009155273,52.1843452453613,66058200,72,7,0.822784799711585,0.246874999228516,"Finance","Pfizer Invites Public to View and Listen to a Webcast of Pfizer Discussion on Expanding Access & Affordability","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-6",0.2,2022,5,18.0060467447374,1.56000137329102,-0.279998779296875,0,-0.855964660644531,1,0.72,0.07,"Finance",0,3
2022-06-01,53.25,53.2799987792969,51.8400001525879,52.3699989318848,51.5251502990723,17430600,913,369,0.424336973147943,0.338705416026762,"Events","Thrive with Pride","https://www.pfizer.com//news/announcements/thrive-pride",0.2,2022,6,16.673737897682,1.43999862670898,-0.880001068115234,0,-0.659194946289062,1,9.13,3.69,"Management",0,1
2022-06-02,52.3699989318848,52.7400016784668,51.0400009155273,52.6800003051758,51.8301544189453,21903400,311,152,0.343412526256128,0.234906138896547,"Medicines","Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE®","https://www.pfizer.com//news/press-release/press-release-detail/myovant-sciences-and-pfizer-announce-fda-acceptance-1",0.2,2022,6,16.9021524795331,1.70000076293945,0.310001373291016,1,0.305004119873047,1,3.11,1.52,"Research",0,2
2022-06-03,52.4599990844727,53.5299987792969,52.4599990844727,53.2000007629395,52.3417663574219,18125000,NA,NA,NA,NA,NA,NA,NA,0.15,2022,6,16.7128028138774,1.06999969482422,0.740001678466797,1,0.511611938476562,0,NA,NA,NA,0,NA
2022-06-06,53.189998626709,53.7200012207031,53,53.2599983215332,52.4007949829102,16544400,418,136,0.509025269839305,0.272369714713683,"Financial","Pfizer to Invest $120 Million to Produce COVID-19 Oral Treatment in the U.S.","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invest-120-million-produce-covid-19-oral-treatment",0.15,2022,6,16.6215582943911,0.720001220703125,0.0699996948242188,1,0.0590286254882884,1,4.18,1.36,"Finance",0,3
2022-06-07,53.2799987792969,53.9700012207031,53.0099983215332,53.9599990844727,53.0895042419434,15091200,NA,NA,NA,NA,NA,NA,NA,0.2,2022,6,16.5296224167089,0.960002899169922,0.680000305175781,1,0.688709259033196,0,NA,NA,NA,0,NA
2022-06-08,54.060001373291,54.560001373291,53.4099998474121,53.4700012207031,52.6074104309082,12789800,86,10,0.791666658420139,0.259459458758218,"Finance","Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-7",0.2,2022,6,16.3641586144035,1.15000152587891,-0.590000152587891,0,-0.482093811035156,1,0.86,0.1,"Finance",0,3
2022-06-09,53.2700004577637,53.6500015258789,51.7000007629395,51.7799987792969,50.9446716308594,17572700,167,40,0.613526567084413,0.289106144847617,"Financial","Pfizer Completes Acquisition of ReViral","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-completes-acquisition-reviral",0.2,2022,6,16.6818571762937,1.95000076293945,-1.4900016784668,0,-1.66273880004883,1,1.67,0.4,"Finance",0,3
2022-06-10,51.310001373291,51.3699989318848,49.9500007629395,49.9700012207031,49.163875579834,23826000,NA,NA,NA,NA,NA,NA,NA,0.15,2022,6,16.9862880213124,1.41999816894531,-1.34000015258789,0,-1.78079605102539,0,NA,NA,NA,0,NA
2022-06-13,48.8199996948242,49.2799987792969,47.7099990844727,47.9099998474121,47.1371040344238,26989000,296,72,0.608695650519849,0.251882272243749,"Partnerships","Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47","https://www.pfizer.com//news/announcements/pfizer-morphosys-and-incyte-enter-clinical-trial-collaboration-monjuvir",0.24,2022,6,17.1109399706004,1.56999969482422,-0.909999847412109,0,-2.02677154541016,1,2.96,0.72,"Management",0,1
2022-06-14,47.75,48.4700012207031,47.2200012207031,47.9199981689453,47.1469383239746,23290300,465,169,0.466876970872434,0.280159080742307,"Prescription Medicines","Pfizer Reports Additional Data on PAXLOVID™ Supporting Upcoming New Drug Application Submission to U.S. FDA","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-reports-additional-data-paxlovidtm-supporting",0.24,2022,6,16.9635475657787,1.25,0.169998168945312,1,0.00983428955078125,1,4.65,1.69,"Research",0,2
2022-06-15,47.8800010681152,48.9799995422363,47.1800003051758,48.5099983215332,47.727424621582,25748000,392,111,0.558648110221376,0.249627791439391,"Vaccines","Pfizer and BioNTech Provide Update on Rolling Submission to European Medicines Agency for a Potential Variant-Adapted Vaccine","https://www.pfizer.com//news/announcements/pfizer-and-biontech-provide-update-rolling-submission-european-medicines-agency",0.24,2022,6,17.0638675509926,1.79999923706055,0.629997253417969,1,0.580486297607422,1,3.92,1.11,"Pandemic",0,4
2022-06-16,47.689998626709,48,47.060001373291,47.4799995422363,46.7140426635742,20424500,NA,NA,NA,NA,NA,NA,NA,0.24,2022,6,16.8322457675674,0.939998626708984,-0.209999084472656,0,-1.01338195800781,0,NA,NA,NA,0,NA
2022-06-17,47.3800010681152,48.0299987792969,46.2799987792969,46.5299987792969,45.7793655395508,45047700,442,136,0.529411763789945,0.23524623515049,"Vaccines","Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-biontech-covid-19-vaccine-receives-fda-emergency-use",0.24,2022,6,17.62323250853,1.75,-0.850002288818359,0,-0.934677124023438,1,4.42,1.36,"Pandemic",0,4
2022-06-21,47.3199996948242,48.439998626709,46.9500007629395,48.1100006103516,47.3338775634766,19622100,NA,NA,NA,NA,NA,NA,NA,0.2,2022,6,16.7921670909759,1.48999786376953,0.790000915527344,1,1.55451202392578,0,NA,NA,NA,0,NA
2022-06-22,48.0299987792969,49.5800018310547,47.7700004577637,49.0699996948242,48.2783889770508,20382900,85,13,0.734693870054144,0.346289751426538,"Responsibility","Statement by Pfizer Chairman and CEO Albert Bourla to Pfizer  Colleagues","https://www.pfizer.com//news/announcements/statement-pfizer-chairman-and-ceo-albert-bourla-pfizer-colleagues",0.25,2022,6,16.8302069210654,1.81000137329102,1.04000091552734,1,0.944511413574219,1,0.85,0.13,"Management",0,1
2022-06-23,49.2299995422363,50.1699981689453,48.9799995422363,50.0900001525879,49.2819328308105,20061700,165,33,0.666666663299663,0.296851573767839,"Financial","Valneva and Pfizer Announce Closing of Equity Investment","https://www.pfizer.com//news/press-release/press-release-detail/valneva-and-pfizer-announce-closing-equity-investment",0.2,2022,6,16.8143231325163,1.18999862670898,0.860000610351562,1,1.00354385375977,1,1.65,0.33,"Finance",0,3
2022-06-24,50.6500015258789,51.6399993896484,50.2999992370605,51.5900001525879,50.757740020752,24343200,88,10,0.795918359225323,0.262032084860877,"Financial","Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-july-28-0",0.2,2022,6,17.0077631487913,1.34000015258789,0.939998626708984,1,1.47580718994141,1,0.88,0.1,"Finance",0,3
2022-06-27,51.4799995422363,52.2299995422363,51.2599983215332,51.8800010681152,51.0430564880371,16154300,NA,NA,NA,NA,NA,NA,NA,0.2,2022,6,16.5976968879667,0.970001220703125,0.400001525878906,1,0.285316467285156,0,NA,NA,NA,0,NA
2022-06-28,51.8300018310547,51.9700012207031,50.4099998474121,50.6599998474121,49.8427391052246,16417900,230,77,0.498371333881527,0.263972484725733,"Financial","Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus","https://www.pfizer.com//news/press-release/press-release-detail/roivant-and-pfizer-unveil-priovant-therapeutics-and-ongoing",0.2,2022,6,16.6138828219051,1.56000137329102,-1.17000198364258,0,-1.2003173828125,1,2.3,0.77,"Finance",0,3
2022-06-29,50.7299995422363,51.439998626709,50.6599998474121,50.939998626709,50.118221282959,13925700,457,123,0.575862067972652,0.245554614629316,"Vaccines","Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-new-agreement-us-government",0.2,2022,6,16.4492466836237,0.779998779296875,0.209999084472656,1,0.275482177734375,1,4.57,1.23,"Pandemic",0,4
2022-06-30,51.689998626709,52.8899993896484,51.0900001525879,52.4300003051758,51.5841865539551,33495700,580,228,0.435643563817273,0.290647481909839,"Prescription Medicines","Pfizer Announces Submission of New Drug Application to the U.S. FDA for PAXLOVID™","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-submission-new-drug-application-us-fda",0.2,2022,6,17.3269276602023,1.79999923706055,0.740001678466797,1,1.46596527099609,1,5.8,2.28,"Research",0,2
2022-06-30,51.689998626709,52.8899993896484,51.0900001525879,52.4300003051758,51.5841865539551,33495700,580,228,0.435643563817273,0.290647481909839,"Prescription Medicines","Pfizer Announces Submission of New Drug Application to the U.S. FDA for PAXLOVID™","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-submission-new-drug-application-us-fda",1.85,2022,6,17.3269276602023,1.79999923706055,0.740001678466797,1,0,1,5.8,2.28,"Research",0,2
2022-07-01,52.0400009155273,52.3699989318848,51.25,52.310001373291,51.4661254882812,16143300,NA,NA,NA,NA,NA,NA,NA,1.6,2022,7,16.5970157228185,1.11999893188477,0.270000457763672,1,-0.118061065673828,0,NA,NA,NA,1,NA
2022-07-05,51.75,51.8899993896484,50.4000015258789,51.6399993896484,50.8069305419922,18406800,NA,NA,NA,NA,NA,NA,NA,1.6,2022,7,16.7282307738519,1.48999786376953,-0.110000610351562,0,-0.659194946289062,0,NA,NA,NA,1,NA
2022-07-06,51.6399993896484,52.9599990844727,51.5800018310547,52.75,51.8990211486816,21305500,NA,NA,NA,NA,NA,NA,NA,1.85,2022,7,16.8744758602463,1.37999725341797,1.11000061035156,1,1.09209060668945,0,NA,NA,NA,1,NA
2022-07-07,52.9500007629395,53.5400009155273,52.7900009155273,53.4199981689453,52.5582122802734,17847600,NA,NA,NA,NA,NA,NA,NA,2,2022,7,16.6973796593986,0.75,0.469997406005859,1,0.659191131591797,0,NA,NA,NA,1,NA
2022-07-08,53.0499992370605,53.9199981689453,52.7599983215332,53.1699981689453,52.3122482299805,11322700,425,116,0.571164509110602,0.246020918487485,"Vaccines","Pfizer and BioNTech Announce U.S. FDA Approval of their COVID-19 Vaccine COMIRNATY® For Adolescents 12 through 15 Years of Age","https://www.pfizer.com//news/announcements/pfizer-and-biontech-announce-us-fda-approval-their-covid-19-vaccine-comirnatyr",1.85,2022,7,16.2423202065181,1.15999984741211,0.119998931884766,1,-0.245964050292969,1,4.25,1.16,"Pandemic",1,4
2022-07-11,53,53.7400016784668,52.75,52.8899993896484,52.0367660522461,12921400,NA,NA,NA,NA,NA,NA,NA,1.9,2022,7,16.3743954869724,0.990001678466797,-0.110000610351562,0,-0.275482177734375,0,NA,NA,NA,1,NA
2022-07-12,52.689998626709,52.7799987792969,51.7099990844727,52.0400009155273,51.2004814147949,14633500,NA,NA,NA,NA,NA,NA,NA,1.8,2022,7,16.4988240471704,1.06999969482422,-0.649997711181641,0,-0.836284637451172,0,NA,NA,NA,1,NA
2022-07-13,51.8600006103516,52.310001373291,51.5099983215332,51.7900009155273,50.9545097351074,12927300,81,17,0.653061217825906,0.230588234751557,"Medicines","Hospira Issues A Voluntary Nationwide Recall For One Lot of Propofol Injectable Emulsion, USP (containing benzyl alcohol), Due To The Potential Presence of Visible Particulate.","https://www.pfizer.com//news/announcements/hospira-issues-voluntary-nationwide-recall-one-lot-propofol-injectable-emulsion",1.85,2022,7,16.3748519895931,0.800003051757812,-0.0699996948242188,0,-0.2459716796875,1,0.81,0.17,"Research",1,2
2022-07-14,50.75,51.5900001525879,50.6300010681152,51.3899993896484,50.560962677002,14023800,NA,NA,NA,NA,NA,NA,NA,1.85,2022,7,16.4562665155225,0.959999084472656,0.639999389648438,1,-0.393547058105469,0,NA,NA,NA,1,NA
2022-07-15,51.0400009155273,51.9099998474121,50.4300003051758,51.75,50.9151573181152,19885700,NA,NA,NA,NA,NA,NA,NA,1.75,2022,7,16.8055114887056,1.47999954223633,0.709999084472656,1,0.354194641113281,0,NA,NA,NA,1,NA
2022-07-18,51.9599990844727,51.9700012207031,50.5200004577637,50.75,49.9312858581543,15742900,NA,NA,NA,NA,NA,NA,NA,1.55,2022,7,16.5719000914678,1.45000076293945,-1.20999908447266,0,-0.983871459960938,0,NA,NA,NA,1,NA
2022-07-19,51.0400009155273,51.5099983215332,50.6100006103516,51.3699989318848,50.5412864685059,13402100,430,117,0.572212064767437,0.246618575181867,"COVID-19","Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.1 Adapted Bivalent Vaccine Candidate","https://www.pfizer.com//news/announcements/pfizer-and-biontech-complete-submission-european-medicines-agency-omicron-ba1",1.7,2022,7,16.4109220436755,0.899997711181641,0.329998016357422,1,0.610000610351562,1,4.3,1.17,"Pandemic",1,4
2022-07-20,51.3899993896484,51.4599990844727,50.5099983215332,50.8199996948242,50.0001602172851,12774400,NA,NA,NA,NA,NA,NA,NA,1.65,2022,7,16.3629538045007,0.950000762939453,-0.569999694824219,0,-0.54112625122071,0,NA,NA,NA,1,NA
2022-07-21,50.5699996948242,51.1399993896484,50.1800003051758,51.1199989318848,50.2953147888184,15103800,NA,NA,NA,NA,NA,NA,NA,1.65,2022,7,16.5304569919628,0.959999084472656,0.549999237060547,1,0.29515457153321,0,NA,NA,NA,1,NA
2022-07-22,51.2599983215332,51.5299987792969,50.9500007629395,51.2299995422363,50.4035415649414,10932100,NA,NA,NA,NA,NA,NA,NA,1.65,2022,7,16.207214064919,0.579998016357422,-0.029998779296875,0,0.108226776123047,0,NA,NA,NA,1,NA
2022-07-25,51.3400001525879,51.8800010681152,51.3400001525879,51.7700004577637,50.9348335266113,12995800,NA,NA,NA,NA,NA,NA,NA,1.12,2022,7,16.3801368632501,0.540000915527344,0.430000305175781,1,0.531291961669922,0,NA,NA,NA,1,NA
2022-07-26,51.8400001525879,52.8499984741211,51.7099990844727,52.2999992370605,51.4562835693359,16632500,NA,NA,NA,NA,NA,NA,NA,1.16,2022,7,16.6268692307214,1.13999938964844,0.459999084472656,1,0.521450042724609,0,NA,NA,NA,1,NA
2022-07-27,51.939998626709,52.25,51.189998626709,51.9500007629395,51.111930847168,19203500,466,125,0.576988154692067,0.245024875520305,"COVID-19","Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design","https://www.pfizer.com//news/announcements/pfizer-and-biontech-advance-covid-19-vaccine-strategy-study-start-next",1.24,2022,7,16.7706031641254,1.06000137329102,0.0100021362304688,1,-0.344352722167969,1,4.66,1.25,"Pandemic",1,4
2022-07-28,50.8499984741211,52.3300018310547,49.0999984741211,50.7200012207031,50.2889862060547,38984900,NA,NA,NA,NA,NA,NA,NA,1.32,2022,7,17.4786849752844,3.23000335693359,-0.129997253417969,0,-0.822944641113281,0,NA,NA,NA,1,NA
2022-07-29,50.560001373291,50.7099990844727,49.2799987792969,50.5099983215332,50.0807685852051,25037900,NA,NA,NA,NA,NA,NA,NA,1.2,2022,7,17.035901274804,1.43000030517578,-0.0500030517578125,0,-0.208217620849609,0,NA,NA,NA,1,NA
2022-08-01,50.3199996948242,51.2999992370605,50.1500015258789,50.6100006103516,50.1799201965332,19709900,NA,NA,NA,NA,NA,NA,NA,1.16,2022,8,16.7966316562852,1.14999771118164,0.290000915527344,1,0.099151611328125,0,NA,NA,NA,1,NA
2022-08-02,50.9000015258789,51.4700012207031,49.6300010681152,49.689998626709,49.2677345275879,17802000,NA,NA,NA,NA,NA,NA,NA,1.2,2022,8,16.6948214246745,1.84000015258789,-1.21000289916992,0,-0.912185668945312,0,NA,NA,NA,1,NA
2022-08-03,49.7900009155273,50.0699996948242,49.3400001525879,49.8600006103516,49.4362907409668,16500100,181,47,0.587719295667898,0.296488946298454,"Research","Pfizer to Discontinue Development Program for PF-07265803 for LMNA-Related Dilated Cardiomyopathy","https://www.pfizer.com//news/announcements/pfizer-discontinue-development-program-pf-07265803-lmna-related-dilated",1.16,2022,8,16.6188770600642,0.729999542236328,0.0699996948242188,1,0.168556213378906,1,1.81,0.47,"Research",1,2
2022-08-04,49.9000015258789,50.0499992370605,49.2099990844727,49.8600006103516,49.4362907409668,17026300,NA,NA,NA,NA,NA,NA,NA,1.16,2022,8,16.650269824114,0.840000152587891,-0.0400009155273438,0,0,0,NA,NA,NA,1,NA
2022-08-05,49.6399993896484,49.9700012207031,49.060001373291,49.2700004577637,48.8513069152832,16376600,429,170,0.43238731146513,0.26753014726774,"Prescription Medicines","Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis","https://www.pfizer.com//news/press-release/press-release-detail/myovant-sciences-and-pfizer-receive-us-fda-approval",1.08,2022,8,16.6113641056987,0.909999847412109,-0.369998931884766,0,-0.584983825683594,1,4.29,1.7,"Research",1,2
2022-08-08,49.3899993896484,49.810001373291,48.939998626709,49.5699996948242,49.1487579345703,16071800,340,89,0.585081583717759,0.268124999832422,"Financial","Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-acquire-global-blood-therapeutics-54-billion-enhance",1.16,2022,8,16.5925768036183,0.870002746582031,0.180000305175781,1,0.297451019287109,1,3.4,0.89,"Finance",1,3
2022-08-09,49.75,50.1100006103516,49.5200004577637,49.7799987792969,49.3569717407227,12095600,NA,NA,NA,NA,NA,NA,NA,1.2,2022,8,16.3083523907463,0.590000152587891,0.029998779296875,1,0.208213806152344,0,NA,NA,NA,1,NA
2022-08-10,49.9300003051758,50.0499992370605,49.3800010681152,49.9500007629395,49.5255279541016,17355100,NA,NA,NA,NA,NA,NA,NA,1.2,2022,8,16.6693970269096,0.669998168945312,0.0200004577636719,1,0.168556213378906,0,NA,NA,NA,1,NA
2022-08-11,48.2200012207031,49.1300010681152,47.810001373291,48.2900009155273,47.8796348571777,44048800,56,10,0.69696968640955,0.222222221473999,"Finance","Pfizer Statement on Zantac Litigation","https://www.pfizer.com//news/announcements/pfizer-statement-zantac-litigation",1.08,2022,8,17.6008086909068,1.31999969482422,0.0699996948242188,1,-1.64589309692383,1,0.56,0.1,"Finance",1,3
2022-08-12,48.5499992370605,50.3899993896484,48.5499992370605,50.1100006103516,49.6841697692871,25835500,207,66,0.516483514591635,0.258278145451014,"Vaccines","Pfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Infants","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-phase-3-study-20",0.96,2022,8,17.0672601118127,1.84000015258789,1.56000137329102,1,1.80453491210938,1,2.07,0.66,"Pandemic",1,4
2022-08-15,49.9700012207031,50.0699996948242,49.3899993896484,49.75,49.3272285461426,15797800,246,97,0.434402331095037,0.255970149062709,"COVID-19","Statement from Pfizer Chairman and CEO Albert Bourla on Testing Positive for COVID-19","https://www.pfizer.com//news/announcements/statement-pfizer-chairman-and-ceo-albert-bourla-testing-positive-covid-19",1.35,2022,8,16.575381311096,0.680000305175781,-0.220001220703125,0,-0.356941223144531,1,2.46,0.97,"Pandemic",1,4
2022-08-16,49.3800010681152,50.1800003051758,49.3600006103516,49.8600006103516,49.4362907409668,12874800,NA,NA,NA,NA,NA,NA,NA,1.5,2022,8,16.3707825480839,0.819999694824219,0.479999542236328,1,0.109062194824219,0,NA,NA,NA,1,NA
2022-08-17,49.6500015258789,49.8600006103516,49.25,49.2700004577637,48.8513069152832,13607200,NA,NA,NA,NA,NA,NA,NA,1.5,2022,8,16.4261096958725,0.610000610351562,-0.380001068115234,0,-0.584983825683594,0,NA,NA,NA,1,NA
2022-08-18,49.3899993896484,49.5200004577637,48.3800010681152,48.5800018310547,48.1671714782715,18916300,NA,NA,NA,NA,NA,NA,NA,1.5,2022,8,16.7555345950744,1.13999938964844,-0.80999755859375,0,-0.684135437011712,0,NA,NA,NA,1,NA
2022-08-19,48.8400001525879,49.4500007629395,48.7299995422363,49.1500015258789,48.7323265075684,15350200,86,9,0.810526307257618,0.259562840820867,"Financial","Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-9",1.25,2022,8,16.5466391263743,0.720001220703125,0.310001373291016,1,0.565155029296868,1,0.86,0.09,"Finance",1,3
2022-08-22,49.2099990844727,49.4000015258789,48.7400016784668,48.9000015258789,48.4844512939453,13601200,469,122,0.587140438938849,0.241027732364997,"Vaccines","Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-submit-application-us-fda-emergency-use",1,2022,8,16.4256686556308,0.659999847412109,-0.30999755859375,0,-0.247875213623047,1,4.69,1.22,"Pandemic",1,4
2022-08-23,48.4199981689453,48.5200004577637,47.7599983215332,48.0099983215332,47.6020126342773,16248900,435,125,0.553571427582908,0.23178807937426,"Vaccines","Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-updated-covid-19-vaccine-data",1.08,2022,8,16.6035358336837,0.760002136230469,-0.409999847412109,0,-0.882438659667969,1,4.35,1.25,"Pandemic",1,4
2022-08-24,47.9000015258789,48.0099983215332,47.3800010681152,47.4300003051758,47.0269432067871,15551500,NA,NA,NA,NA,NA,NA,NA,1.04,2022,8,16.5596677192622,0.629997253417969,-0.470001220703125,0,-0.575069427490234,0,NA,NA,NA,1,NA
2022-08-25,47.5200004577637,47.9500007629395,47.2700004577637,47.9000015258789,47.4929504394531,14460000,206,67,0.509157507292463,0.270833333064649,"Vaccines","Pfizer Announces Positive Top-Line Data from Phase 3 Trial of Older Adults for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-positive-top-line-data-phase-3-trial-older",1,2022,8,16.4868968438512,0.680000305175781,0.380001068115234,1,0.466007232666016,1,2.06,0.67,"Pandemic",1,4
2022-08-26,47.6199989318848,47.9599990844727,46.7000007629395,46.8199996948242,46.4221267700195,16546700,437,109,0.600732599632358,0.235446312964447,"Vaccines","Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccine","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-complete-submission-european-medicines",1.56,2022,8,16.62169730457,1.2599983215332,-0.799999237060547,0,-1.07082366943359,1,4.37,1.09,"Pandemic",1,4
2022-08-29,46.3800010681152,46.689998626709,46.1199989318848,46.2299995422363,45.8371391296387,13400500,NA,NA,NA,NA,NA,NA,NA,1,2022,8,16.4108026522819,0.569999694824219,-0.150001525878906,0,-0.584987640380859,0,NA,NA,NA,1,NA
2022-08-30,46.3400001525879,46.3499984741211,45.7999992370605,45.8499984741211,45.4603691101074,16303000,NA,NA,NA,NA,NA,NA,NA,1,2022,8,16.6068597592602,0.549999237060547,-0.490001678466797,0,-0.37677001953125,0,NA,NA,NA,1,NA
2022-08-31,46.0099983215332,46.2900009155273,45.1300010681152,45.2299995422363,44.8456382751465,26416800,438,109,0.601462521752354,0.226970954262668,"Vaccines","Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-granted-fda-emergency-use-authorization",1.04,2022,8,17.0895107672141,1.15999984741211,-0.779998779296875,0,-0.614730834960945,1,4.38,1.09,"Pandemic",1,4
2022-09-01,45.1399993896484,46.6500015258789,45.1399993896484,46.6300010681152,46.2337417602539,19947600,456,108,0.617021275501735,0.234024896168454,"Vaccines","Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-receive-positive-chmp-opinion-omicron",1.04,2022,9,16.8086194434429,1.51000213623047,1.4900016784668,1,1.38810348510743,1,4.56,1.08,"Pandemic",1,4
2022-09-02,46.7400016784668,46.7999992370605,45.5299987792969,45.7000007629395,45.3116455078125,14667700,NA,NA,NA,NA,NA,NA,NA,1.04,2022,9,16.5011584234551,1.27000045776367,-1.04000091552734,0,-0.922096252441406,0,NA,NA,NA,1,NA
2022-09-06,45.9599990844727,46.439998626709,45.5299987792969,45.7599983215332,45.3711318969727,17153500,87,11,0.775510196168263,0.267759562109947,"Financial","Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-11",1.12,2022,9,16.6577128506842,0.909999847412109,-0.200000762939453,0,0.0594863891601562,1,0.87,0.11,"Finance",1,3
2022-09-07,45.7000007629395,46.2099990844727,45.3800010681152,46.1300010681152,45.7379913330078,15378900,172,51,0.542600894427799,0.241865509499061,"Vaccines","FDA Grants Breakthrough Therapy Designation to Pfizer’s Group B Streptococcus Vaccine Candidate to Help Prevent Infection in Infants Via Immunization of Pregnant Women","https://www.pfizer.com//news/press-release/press-release-detail/fda-grants-breakthrough-therapy-designation-pfizers-group-b",1.08,2022,9,16.5485070630517,0.829998016357422,0.430000305175781,1,0.366859436035156,1,1.72,0.51,"Pandemic",1,4
2022-09-08,46.0200004577637,47.1199989318848,45.8699989318848,47.0800018310547,46.6799163818359,18271000,NA,NA,NA,NA,NA,NA,NA,1,2022,9,16.7208257161253,1.25,1.06000137329102,1,0.941925048828125,0,NA,NA,NA,1,NA
2022-09-09,47.2000007629395,47.9900016784668,47.0999984741211,47.8400001525879,47.4334564208984,17501700,140,52,0.458333330946181,0.249999999674479,"Prescription Medicines","FDA and EMA Accept Regulatory Submission for Pfizer’s Ritlecitinib for Individuals 12 Years and Older with Alopecia Areata","https://www.pfizer.com//news/press-release/press-release-detail/fda-and-ema-accept-regulatory-submission-pfizers",1,2022,9,16.6778086341701,0.890003204345703,0.639999389648438,1,0.7535400390625,1,1.4,0.52,"Research",1,2
2022-09-12,48.0800018310547,48.3499984741211,47.689998626709,47.7599983215332,47.3541374206543,13744800,450,108,0.612903224708059,0.232113144662183,"Vaccines","Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in European Union","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-receive-positive-chmp-opinion-omicron-0",1.12,2022,9,16.4361712014847,0.659999847412109,-0.320003509521484,0,-0.0793190002441406,1,4.5,1.08,"Pandemic",1,4
2022-09-13,47.1300010681152,47.3199996948242,46.0200004577637,46.189998626709,45.797477722168,16603200,NA,NA,NA,NA,NA,NA,NA,1.16,2022,9,16.6251060660625,1.29999923706055,-0.94000244140625,0,-1.55665969848633,0,NA,NA,NA,1,NA
2022-09-14,46.2000007629395,46.4099998474121,45.7799987792969,46.1500015258789,45.7578201293945,17162500,200,39,0.673640164545439,0.25978260841328,"Research and Pipeline","Pfizer Initiates Phase 3 Study of mRNA-Based Influenza Vaccine","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-initiates-phase-3-study-mrna-based-influenza-vaccine",1.2,2022,9,16.6582373873249,0.630001068115234,-0.0499992370605469,0,-0.0396575927734375,1,2,0.39,"Research",1,2
2022-09-15,46.1100006103516,46.2900009155273,45.7000007629395,45.939998626709,45.5496025085449,15802000,228,63,0.567010307329861,0.222477064050094,"Vaccines","Pfizer Announces Positive Top-Line Results from Phase 3 Trial of Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-phase-3-trial-0",1.16,2022,9,16.5756471355479,0.590000152587891,-0.170001983642578,0,-0.208217620849609,1,2.28,0.63,"Pandemic",1,4
2022-09-16,46.0900001525879,46.6199989318848,45.6399993896484,46.0299987792969,45.6388397216797,30629500,445,107,0.612318839470437,0.247090420659315,"Vaccines","Pfizer and BioNTech Receive Positive CHMP Opinion for Conversion of COMIRNATY® Conditional Marketing Authorization to Full Marketing Authorization in the European Union","https://www.pfizer.com//news/announcements/pfizer-and-biontech-receive-positive-chmp-opinion-conversion-comirnatyr",1.2,2022,9,17.2374741874585,0.979999542236328,-0.0600013732910156,0,0.0892372131347656,1,4.45,1.07,"Pandemic",1,4
2022-09-19,45.6800003051758,45.8800010681152,44.7799987792969,45.439998626709,45.0538520812988,16256200,210,58,0.567164176988193,0.258188824414076,"Research and Pipeline","Pfizer Announces Positive Top-Line Results from Phase 3 Study in 20-Valent Pneumococcal Conjugate Vaccine in Infants in the European Union","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-phase-3-study-0",1.2,2022,9,16.6039849939493,1.10000228881836,-0.240001678466797,0,-0.584987640380859,1,2.1,0.58,"Research",1,2
2022-09-20,45,45.2700004577637,44.439998626709,44.7700004577637,44.3895454406738,15369000,90,10,0.799999992,0.266666665955556,"Financial","Pfizer Invites Public to View and Listen to Webcast of November 1 Conference Call with Analysts","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-november-1",1.08,2022,9,16.5478631166555,0.830001831054688,-0.229999542236328,0,-0.664306640625,1,0.9,0.1,"Finance",1,3
2022-09-21,44.810001373291,44.9799995422363,43.9000015258789,43.9199981689453,43.5467681884766,17505200,NA,NA,NA,NA,NA,NA,NA,1.12,2022,9,16.6780085947386,1.07999801635742,-0.890003204345703,0,-0.842777252197266,0,NA,NA,NA,1,NA
2022-09-22,43.6699981689453,45,43.5200004577637,44.5699996948242,44.1912460327149,18508100,423,126,0.540983605571979,0.271916790355663,"Prescription Medicines","Pfizer to Supply Global Fund Up to 6 Million PAXLOVID™ Treatment Courses for Low-and-Middle-Income Countries","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-supply-global-fund-6-million-paxlovidtm-treatment",1.08,2022,9,16.7337190860938,1.47999954223633,0.900001525878906,1,0.644477844238288,1,4.23,1.26,"Research",1,2
2022-09-23,44.439998626709,44.560001373291,43.5800018310547,44.0800018310547,43.7054138183594,18871700,NA,NA,NA,NA,NA,NA,NA,1.12,2022,9,16.7531740563664,0.979999542236328,-0.359996795654297,0,-0.485832214355476,0,NA,NA,NA,1,NA
2022-09-26,43.810001373291,44.3300018310547,43.6699981689453,43.8300018310547,43.4575347900391,18680200,421,111,0.58270676582198,0.238672050139672,"Vaccines","Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-submit-application-us-fda-emergency-0",1.2,2022,9,16.7429747508784,0.660003662109375,0.0200004577636719,1,-0.247879028320312,1,4.21,1.11,"Pandemic",1,4
2022-09-27,44.2200012207031,44.5800018310547,43.7400016784668,44.0900001525879,43.7153244018555,21562700,NA,NA,NA,NA,NA,NA,NA,1.12,2022,9,16.8864755744515,0.840000152587891,-0.130001068115234,0,0.257789611816406,0,NA,NA,NA,1,NA
2022-09-28,44.6699981689453,44.810001373291,44.2200012207031,44.4300003051758,44.0524368286133,16532600,429,115,0.577205881291901,0.249541284289201,"COVID-19","Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age","https://www.pfizer.com//news/announcements/pfizer-and-biontech-complete-submission-european-medicines-agency-omicron-ba4ba5",1.16,2022,9,16.6208448076912,0.590000152587891,-0.239997863769531,0,0.337112426757812,1,4.29,1.15,"Pandemic",1,4
2022-09-29,44.4099998474121,44.6199989318848,43.9500007629395,44.1599998474121,43.7847290039062,13559900,NA,NA,NA,NA,NA,NA,NA,1.04,2022,9,16.4226275395649,0.669998168945312,-0.25,0,-0.267707824707031,0,NA,NA,NA,1,NA
2022-09-30,44.1699981689453,44.6100006103516,43.7299995422363,43.7599983215332,43.388126373291,22962300,NA,NA,NA,NA,NA,NA,NA,1,2022,9,16.9493643421642,0.880001068115234,-0.409999847412109,0,-0.396602630615234,0,NA,NA,NA,1,NA
2022-10-03,44.0699996948242,44.2799987792969,43.4900016784668,44.1399993896484,43.7649002075195,22834300,178,52,0.547826084574669,0.245464247336751,"Financial","Pfizer Completes Acquisition of Biohaven Pharmaceuticals","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-completes-acquisition-biohaven-pharmaceuticals",2.16,2022,10,16.9437743932284,0.789997100830078,0.0699996948242188,1,0.376773834228516,1,1.78,0.52,"Finance",1,3
2022-10-04,44.25,44.8400001525879,44.0900001525879,44.4599990844727,44.0821800231934,28198800,307,145,0.358407078853082,0.246724890695019,"Research and Pipeline","Pfizer Announces Positive Topline Results from Phase 3 TALAPRO-2 Trial","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-positive-topline-results-phase-3-talapro-2",2.24,2022,10,17.1547900172739,0.75,0.209999084472656,1,0.317279815673828,1,3.07,1.45,"Research",1,2
2022-10-05,44.1199989318848,44.3699989318848,43.6800003051758,44.1199989318848,43.7450675964355,15673400,225,68,0.53583617564561,0.275894538346615,"Financial","Pfizer Completes Acquisition of Global Blood Therapeutics","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-completes-acquisition-global-blood-therapeutics",2,2022,10,16.5674756297106,0.689998626708984,0,0,-0.337112426757812,1,2.25,0.68,"Finance",1,3
2022-10-06,43.7599983215332,43.7799987792969,43.0400009155273,43.0900001525879,42.7238235473633,22068200,NA,NA,NA,NA,NA,NA,NA,2.24,2022,10,16.909648261544,0.739997863769531,-0.669998168945312,0,-1.02124404907227,0,NA,NA,NA,1,NA
2022-10-07,43.0499992370605,43.0499992370605,41.9199981689453,42.3199996948242,41.9603652954102,20095000,NA,NA,NA,NA,NA,NA,NA,2.48,2022,10,16.8159816356291,1.13000106811523,-0.729999542236328,0,-0.763458251953118,0,NA,NA,NA,1,NA
2022-10-10,42.3499984741211,42.6199989318848,41.75,41.75,41.3952102661133,17888000,NA,NA,NA,NA,NA,NA,NA,1.68,2022,10,16.6996407108404,0.869998931884766,-0.599998474121094,0,-0.565155029296882,0,NA,NA,NA,1,NA
2022-10-11,41.6599998474121,42.5699996948242,41.4500007629395,41.9199981689453,41.5637626647949,20981200,NA,NA,NA,NA,NA,NA,NA,2.16,2022,10,16.8591374042892,1.11999893188477,0.259998321533203,1,0.168552398681641,0,NA,NA,NA,1,NA
2022-10-12,42.0900001525879,43.1399993896484,41.9199981689453,42.0299987792969,41.6728286743164,18803600,423,112,0.581308410128396,0.239802778915373,"Vaccines","Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-receive-us-fda-emergency-use-1",4.32,2022,10,16.7495589520114,1.22000122070312,-0.0600013732910156,0,0.109066009521484,1,4.23,1.12,"Pandemic",1,4
2022-10-13,41.7599983215332,43.1599998474121,41.7000007629395,42.9799995422363,42.6147575378418,23135200,465,111,0.614583332266348,0.233009708643604,"Vaccines","Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-positive-early-data-clinical",4.68,2022,10,16.9568658684204,1.45999908447266,1.22000122070312,1,0.941928863525391,1,4.65,1.11,"Pandemic",1,4
2022-10-14,42.8899993896484,43.3800010681152,42.3600006103516,42.8600006103516,42.495777130127,16980500,NA,NA,NA,NA,NA,NA,NA,3.66,2022,10,16.6475762437126,1.02000045776367,-0.029998779296875,0,-0.118980407714844,0,NA,NA,NA,1,NA
2022-10-17,43.189998626709,43.810001373291,43.189998626709,43.6500015258789,43.2790641784668,16678400,93,13,0.754716974012104,0.260442259802353,"Finance","Pfizer Invites Public to View and Listen to Webcast of Analyst and Investor Call to Review RSV Data Presented at ID Week 2022","https://www.pfizer.com//news/announcements/pfizer-invites-public-view-and-listen-webcast-analyst-and-investor-call-review",2.1,2022,10,16.6296250869903,0.620002746582031,0.460002899169922,1,0.783287048339844,1,0.93,0.13,"Finance",1,3
2022-10-18,44.0499992370605,44.3600006103516,43.6199989318848,44.0900001525879,43.7153244018555,18442800,NA,NA,NA,NA,NA,NA,NA,2.1,2022,10,16.7301846626051,0.740001678466797,0.0400009155273438,1,0.436260223388672,0,NA,NA,NA,1,NA
2022-10-19,43.9099998474121,44.0699996948242,42.7400016784668,43.1100006103516,42.74365234375,23054700,416,113,0.572778826894558,0.240345297482805,"COVID-19","Pfizer and BioNTech Receive Positive CHMP Opinion for COMIRNATY® in Children 6 Months to less than 5 Years in the European Union","https://www.pfizer.com//news/announcements/pfizer-and-biontech-receive-positive-chmp-opinion-comirnatyr-children-6-months",1.95,2022,10,16.9533802545516,1.32999801635742,-0.799999237060547,0,-0.971672058105469,1,4.16,1.13,"Pandemic",1,4
2022-10-20,43.2700004577637,43.4099998474121,42.8199996948242,42.9099998474121,42.545352935791,17715000,255,67,0.583850929863817,0.233502537901739,"Vaccines","Advisory Committee on Immunization Practices Recommends Pfizer’s PREVNAR 20® for Adults Previously Vaccinated with PREVNAR 13®","https://www.pfizer.com//news/announcements/advisory-committee-immunization-practices-recommends-pfizers-prevnar-20r-adults",1.75,2022,10,16.689922352731,0.590000152587891,-0.360000610351562,0,-0.198299407958984,1,2.55,0.67,"Pandemic",1,4
2022-10-21,43.310001373291,45.1599998474121,42.9900016784668,44.9500007629395,44.5680160522461,36575700,NA,NA,NA,NA,NA,NA,NA,1.7,2022,10,17.4148946707839,2.16999816894531,1.63999938964844,1,2.02266311645508,0,NA,NA,NA,1,NA
2022-10-24,45.0800018310547,45.8699989318848,44.9900016784668,45.5400009155273,45.153003692627,24972000,NA,NA,NA,NA,NA,NA,NA,1.48,2022,10,17.0332657952086,0.879997253417969,0.459999084472656,1,0.584987640380859,0,NA,NA,NA,1,NA
2022-10-25,45.2700004577637,45.8199996948242,44.8899993896484,45.5900001525879,45.202579498291,23127000,NA,NA,NA,NA,NA,NA,NA,1.36,2022,10,16.956511367349,0.930000305175781,0.319999694824219,1,0.0495758056640625,0,NA,NA,NA,1,NA
2022-10-26,45.9199981689453,46.6500015258789,45.6199989318848,46.060001373291,45.668586730957,21407900,NA,NA,NA,NA,NA,NA,NA,1.4,2022,10,16.8792706174599,1.03000259399414,0.140003204345703,1,0.466007232666016,0,NA,NA,NA,1,NA
2022-10-27,45.810001373291,46.1100006103516,45.6800003051758,45.7400016784668,45.3513069152832,20377700,36,19,0.309090903471074,0.257009344593414,"Clinical Trials","Listen Now—Science Will Win Season 2 Takes on Breast Cancer","https://www.pfizer.com//news/announcements/listen-now-science-will-win-season-2-takes-breast-cancer",1.36,2022,10,16.8299517727225,0.430000305175781,-0.0699996948242188,0,-0.317279815673828,1,0.36,0.19,"Research",1,2
2022-10-28,45.9799995422363,47.5200004577637,45.9300003051758,47.4300003051758,47.0269432067871,27854000,562,261,0.365735114986956,0.263528658256955,"Medicines","Safety Recommendation on Janus kinase (JAK) Inhibitors Issued in the European Union","https://www.pfizer.com//news/announcements/safety-recommendation-janus-kinase-jak-inhibitors-issued-european-union",1.2,2022,10,17.1424871764967,1.59000015258789,1.45000076293945,1,1.67563629150391,1,5.62,2.61,"Research",1,2
2022-10-31,47.0800018310547,47.3899993896484,46.5400009155273,46.5499992370605,46.1544189453125,29961700,133,49,0.461538459002536,0.371428570670554,"COVID-19","Amid COVID-19 Global Pandemic, The Pfizer Foundation Helps IRC Pursue Urgent Expansion of Health Access in Humanitarian Settings","https://www.pfizer.com//news/announcements/amid-covid-19-global-pandemic-pfizer-foundation-helps-irc-pursue-urgent",1.04,2022,10,17.2154304907025,0.849998474121094,-0.530002593994141,0,-0.872524261474609,1,1.33,0.49,"Pandemic",1,4
2022-11-01,48,48.4199981689453,47.4000015258789,48.0099983215332,47.6020126342773,30614500,244,76,0.524999998359375,0.24902723716029,"Vaccines","Pfizer Announces Positive Top-Line Data of Phase 3 Global Maternal Immunization Trial for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-positive-top-line-data-phase-3-global",1.24,2022,11,17.2369843435616,1.01999664306641,0.00999832153320312,1,1.44759368896484,1,2.44,0.76,"Pandemic",1,4
2022-11-02,47.7700004577637,48.1699981689453,46.9500007629395,47.0699996948242,46.6700019836426,25813100,NA,NA,NA,NA,NA,NA,NA,1.12,2022,11,17.0663927117075,1.21999740600586,-0.700000762939453,0,-0.932010650634766,0,NA,NA,NA,1,NA
2022-11-03,46.3600006103516,46.7999992370605,46.1599998474121,46.5699996948242,46.5699996948242,20124600,464,122,0.583617746444338,0.239281339224467,"COVID-19","Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19","https://www.pfizer.com//news/announcements/pfizer-and-biontech-initiate-phase-1-study-single-dose-mrna-based-combination",1.16,2022,11,16.8174535549854,0.639999389648438,0.209999084472656,1,-0.100002288818359,1,4.64,1.22,"Pandemic",1,4
2022-11-04,47.4700012207031,47.5400009155273,46.6100006103516,47.2200012207031,47.2200012207031,24527300,450,126,0.562499999023438,0.230215827246117,"COVID-19","Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-updated-clinical-data-omicron",1.16,2022,11,17.0152973816446,0.930000305175781,-0.25,0,0.650001525878906,1,4.5,1.26,"Pandemic",1,4
2022-11-07,47.1599998474121,47.6500015258789,46.75,47.0900001525879,47.0900001525879,20304400,NA,NA,NA,NA,NA,NA,NA,1.04,2022,11,16.8263482185443,0.900001525878906,-0.0699996948242188,0,-0.130001068115234,0,NA,NA,NA,1,NA
2022-11-08,47.0400009155273,47.75,46.75,47.3499984741211,47.3499984741211,18054500,NA,NA,NA,NA,NA,NA,NA,1.04,2022,11,16.7089055745383,1,0.30999755859375,1,0.259998321533203,0,NA,NA,NA,1,NA
2022-11-09,47.1599998474121,47.5,46.7000007629395,46.7200012207031,46.7200012207031,15348100,NA,NA,NA,NA,NA,NA,NA,0.96,2022,11,16.5465023109893,0.799999237060547,-0.439998626708984,0,-0.629997253417969,0,NA,NA,NA,1,NA
2022-11-10,47.5299987792969,47.75,46.8499984741211,47.3800010681152,47.3800010681152,20480600,407,108,0.5805825231445,0.245354930802594,"Vaccines","Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-receive-positive-chmp-opinion-omicron-1",1.08,2022,11,16.8349887034081,0.900001525878906,-0.149997711181641,0,0.659999847412109,1,4.07,1.08,"Pandemic",1,4
2022-11-11,47.0699996948242,47.7000007629395,46.310001373291,47.5999984741211,47.5999984741211,20906700,84,10,0.787234034178361,0.262569831668799,"Financial","Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-12",1,2022,11,16.8555802875564,1.38999938964844,0.529998779296875,1,0.219997406005859,1,0.84,0.1,"Finance",1,3
2022-11-14,47.9900016784668,49.8199996948242,47.9300003051758,49.2400016784668,49.2400016784668,26143000,NA,NA,NA,NA,NA,NA,NA,0.78,2022,11,17.0790920644675,1.88999938964844,1.25,1,1.6400032043457,0,NA,NA,NA,1,NA
2022-11-15,49.3400001525879,49.5299987792969,48.1800003051758,48.5699996948242,48.5699996948242,25440500,31,8,0.58974357462196,0.217877093754877,"Maternal Immunization","Listen Now—The Antigen Season 3 Explores Maternal Immunization","https://www.pfizer.com//news/announcements/listen-now-antigen-season-3-explores-maternal-immunization",0.9,2022,11,17.0518529896385,1.34999847412109,-0.770000457763672,0,-0.670001983642578,1,0.31,0.08,"Research",1,2
2022-11-16,48.7999992370605,49.060001373291,48.0499992370605,48.0499992370605,48.0499992370605,15822200,457,113,0.603508770871037,0.24945295393897,"COVID-19","Pfizer and BioNTech Advance Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T cell Responses and Duration of Protection","https://www.pfizer.com//news/announcements/pfizer-and-biontech-advance-next-generation-covid-19-vaccine-strategy-study",0.96,2022,11,16.5769246383129,1.01000213623047,-0.75,0,-0.520000457763672,1,4.57,1.13,"Pandemic",1,4
2022-11-17,47.7999992370605,48.5,47.5299987792969,48.3300018310547,48.3300018310547,13231100,NA,NA,NA,NA,NA,NA,NA,0.87,2022,11,16.3980807525832,0.970001220703125,0.530002593994141,1,0.280002593994141,0,NA,NA,NA,1,NA
2022-11-18,48.6399993896484,48.8300018310547,47.8699989318848,48.2299995422363,48.2299995422363,20664300,400,121,0.535508636208237,0.236603087994277,"Vaccines","Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages","https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-report-new-data-omicron-ba4ba5-adapted",0.81,2022,11,16.8439181800474,0.960002899169922,-0.409999847412109,0,-0.100002288818359,1,4,1.21,"Pandemic",1,4
2022-11-21,48.0999984741211,48.2799987792969,47.7200012207031,48.1800003051758,48.1800003051758,14736000,NA,NA,NA,NA,NA,NA,NA,0.6,2022,11,16.5058041053382,0.55999755859375,0.0800018310546875,1,-0.0499992370605469,0,NA,NA,NA,1,NA
2022-11-22,48.3400001525879,49.25,48.2400016784668,49.0800018310547,49.0800018310547,16358600,NA,NA,NA,NA,NA,NA,NA,0.75,2022,11,16.610264372035,1.0099983215332,0.740001678466797,1,0.900001525878906,0,NA,NA,NA,1,NA
2022-11-23,48.9599990844727,49.2200012207031,48.5200004577637,48.8499984741211,48.8499984741211,10710800,NA,NA,NA,NA,NA,NA,NA,0.75,2022,11,16.1867632295433,0.700000762939453,-0.110000610351562,0,-0.230003356933594,0,NA,NA,NA,1,NA
2022-11-25,48.9300003051758,49.2200012207031,48.8400001525879,49.2099990844727,49.2099990844727,6760200,NA,NA,NA,NA,NA,NA,NA,0.57,2022,11,15.7265631813049,0.380001068115234,0.279998779296875,1,0.360000610351562,0,NA,NA,NA,1,NA
2022-11-28,49.1800003051758,49.7400016784668,49.060001373291,49.5699996948242,49.5699996948242,20704000,NA,NA,NA,NA,NA,NA,NA,NA,2022,11,16.8458375245826,0.680000305175781,0.389999389648438,1,0.360000610351562,0,NA,NA,NA,1,NA
2022-11-29,49.5,49.6699981689453,49.0999984741211,49.4900016784668,49.4900016784668,17160900,NA,NA,NA,NA,NA,NA,NA,NA,2022,11,16.6581441564732,0.569999694824219,-0.00999832153320312,0,-0.0799980163574219,0,NA,NA,NA,1,NA
2022-11-30,49.6399993896484,50.1300010681152,49.0400009155273,50.1300010681152,50.1300010681152,35572700,NA,NA,NA,NA,NA,NA,NA,NA,2022,11,17.3870890758182,1.09000015258789,0.490001678466797,1,0.639999389648438,0,NA,NA,NA,1,NA
2022-12-01,50.310001373291,51.1599998474121,50.2799987792969,51.0800018310547,51.0800018310547,23589800,NA,NA,NA,NA,NA,NA,NA,NA,2022,12,16.9763250155704,0.880001068115234,0.770000457763672,1,0.950000762939453,0,NA,NA,NA,1,NA
2022-12-02,50.560001373291,51.310001373291,50.4799995422363,51.0950012207031,51.0950012207031,4386528,NA,NA,NA,NA,NA,NA,NA,NA,2022,12,15.2940488117222,0.830001831054688,0.534999847412109,1,0.0149993896484375,0,NA,NA,NA,1,NA
